EPICORE Embase Updates

Total documents retrieved: 122

Results Generated From:
Embase <1980 to 2026 Week 13>
Embase Weekly Updates (updates since 2026-03-20) - (122 records)

<1>
Accession Number
2039378011
Title
Intracardiac versus transesophageal echocardiographic guidance for left
atrial appendage occlusion: Design and rationale of the ICE-TEE trial.
Source
Cardiovascular Revascularization Medicine. 84 (pp 82-87), 2026. Date of
Publication: 01 Mar 2026.
Author
Al-Azizi K.; Thomas S.; Hajar M.B.A.; Pickering T.; McCullough K.; Dorton
C.; Moubarak G.; Ma T.-W.; Banwait J.; Hale S.; Gupta S.; DiMaio J.M.;
Szerlip M.; Matar R.; Aqtash O.; Baig I.; Trehan S.; Potluri S.
Institution
(Al-Azizi, Thomas, Szerlip, Matar, Aqtash, Baig, Trehan, Potluri)
Department of Cardiology, Baylor Scott and White The Heart Hospital,
Plano, TX, United States
(Hajar, Pickering, McCullough, Dorton, Moubarak, Ma, Banwait, Hale, Gupta,
DiMaio) Baylor Scott & White Research Institute, Plano, TX, United States
(Moubarak) Department of Internal Medicine, Baylor University Medical
Center, TX, United States
Publisher
Elsevier Inc.
Abstract
Left atrial appendage occlusion (LAAO) has emerged as an alternative to
long-term anticoagulation for stroke prevention in patients with
non-valvular atrial fibrillation deemed high risk for bleeding. LAAO is
performed via a transseptal approach with the placement of an occlusion
device in the left atrial appendage (LAA) to seal it. Intraoperative
imaging with echocardiography is needed to guide and complete the
procedure. Historically, Transesophageal echocardiography (TEE) has been
the most frequently used modality for intraprocedural guidance. Recently,
there has been a growing interest in the use of intracardiac
echocardiography (ICE) as an adjunct to, or even an alternative to,
transesophageal echocardiography (TEE), with several unique advantages and
potential challenges. Several publications have highlighted the safety and
feasibility of ICE in LAAO (Hemam et al., 2019; Morcos et al., 2022; Zhang
et al., 2023 [2, 5, 7]). The most recent SCAI/HRS consensus statement
recommends using TEE or ICE in procedural guidance (Saw et al., 2023 [8]).
To date, no prospective randomized controlled trials have addressed the
safety and feasibility of ICE-guided LAAO, compared to TEE guidance . The
ICE TEE trial is a single-center, prospective, randomized,
parallel-controlled, open-label clinical trial that will assess the
efficacy and safety of ICE-guided LAAO compared to traditional TEE-guided
LAAO. Patients are randomized in a 1:1 fashion. The primary endpoint of
the study is the procedural success of LAAO device implantation, defined
as the appropriate device implantation as per the IFU, without
device-related complications, and no peri-device leaks >5 mm on color
Doppler, according to the Munich consensus. Secondary endpoints include
periprocedural complications, procedural characteristics, and cost of
hospitalization. Patients will be assessed at 45 days with a TEE to
evaluate for any peri-device leak (PDL). The trial aims to assess the
efficacy and potential complications of using ICE to guide the
implantation of percutaneous left atrial appendage occlusion (LAAO)
devices compared to the traditional transesophageal echocardiography
(TEE)- guided LAAO. Copyright © 2025 Elsevier Inc.

<2>
Accession Number
650575558
Title
Sivelestat and Incidence of Acute Respiratory Distress Syndrome After
Cardiovascular Surgery: A Randomized Clinical Trial.
Source
JAMA network open. 9(3) (pp e260390), 2026. Date of Publication: 02 Mar
2026.
Author
Pan T.; Xu C.; Wang Y.-P.; Wang H.-L.; Su W.-X.; Zhang H.-T.; Zhu E.-J.;
Li Y.-T.; Lv Z.-K.; Zhu T.-T.; Xu Z.-W.; Gao Y.; Xu C.-Z.; Shi J.; Ji
W.-J.; Duan Z.-H.; Zhang C.; Xu Z.-J.; Li K.-S.; Chong H.; Zhu X.-Y.; Xue
Y.-X.; Xu W.-Z.; Chen C.; Zhao W.-W.; Ye J.-X.; Ge M.; Xu G.-J.; Wu S.-M.;
Pan J.; Wang D.-J.; Qu J.Z.; Wang Q.
Institution
(Pan, Xu, Zhang, Lv, Shi, Ji, Zhang, Xu, Li, Chong, Zhu, Xue, Xu, Chen,
Zhao, Ye, Ge, Pan, Wang, Wang) Department of Cardiac Surgery, Nanjing Drum
Tower Hospital, Affiliated Hospital of Medical School, Nanjing University,
Nanjing, Jiangsu, China
(Pan, Zhu, Qu) Division of Cardiac Anesthesia, Department of Anesthesia,
Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard
Medical School, Boston, United States
(Wang) Department of Cardiovascular Surgery, First Affiliated Hospital of
Anhui Medical University, Anhui Province, China
(Wang, Su, Ye) Department of Cardiac Surgery, Nanjing Drum Tower Hospital
Clinical College of Nanjing University of Chinese Medicine, Nanjing,
Jiangsu, China
(Zhu, Li) Department of Cardiovascular Surgery, First Affiliated Hospital
of Harbin Medical University, Harbin, China
(Xu, Gao, Xu) Department of Cardiac Surgery, Affiliated Huai'an No.1
People's Hospital of Nanjing Medical University, Northern Jiangsu
Institute of Clinical Medicine, Nanjing Medical University, Huai'an,
Jiangsu, China
(Duan) Department of Thyroid Surgery, Nanjing Drum Tower Hospital,
Affiliated Hospital of Medical School, Nanjing University, Nanjing,
Jiangsu, China
(Xu, Wu) Department of Cardiovascular Surgery, Henan Provincial Chest
Hospital, Chest Hospital of Zhengzhou University, Zhengzhou, Henan, China
Abstract
Importance: Acute respiratory distress syndrome (ARDS) represents a
frequent and serious complication after cardiovascular surgery. Although
sivelestat, a specific neutrophil elastase inhibitor, has demonstrated
therapeutic potential in preliminary studies, the evidence remains limited
by methodological constraints of observational designs and underpowered
studies. Objective(s): To evaluate the efficacy of sivelestat vs
placebo in reducing the incidence of postoperative ARDS and associated
complications among patients undergoing major cardiovascular procedures.
 Design, Setting, and Participant(s): This single-center, randomized,
placebo-controlled clinical trial conducted at a tertiary care academic
medical center om China enrolled 424 participants between February 15,
2024, and April 16, 2025, with a 90-day postoperative follow-up period.
Participants were consecutive patients scheduled for cardiovascular
surgery, including coronary artery bypass grafting, valve surgeries,
ascending aortic reconstruction, combined procedures, congenital heart
defect repairs, and cardiac tumor resections. Intervention(s):
Participants were randomly allocated (1:1) to receive either continuous
intravenous sivelestat (0.2 mg/kg/h), initiated immediately on intensive
care unit (ICU) admission postoperatively and continued for up to 7 days
or until ICU discharge; or volume-matched 0.9% sodium chloride placebo
administered on an identical schedule. Main Outcomes and Measures:
The primary outcome was the incidence of ARDS. Secondary outcomes included
serial measurements of inflammatory biomarkers, including interleukin 6
and interleukin 8, tumor necrosis factor, systemic immune-inflammation
index, and serum neutrophil elastase, on postoperative days 1, 3, 5, and
7, along with ARDS-related clinical outcomes including death, pneumonia,
and reintubation. Analysis was performed on an intention-to-treat basis.
 Result(s): Among 424 randomized patients, 382 completed the trial
(mean [SD] age, 62.9 [6.2] years; 210 male [55.0%]). Adverse events
monitored for safety did not differ between groups. The sivelestat group
had significantly lower rates of ARDS (16.8% [32 of 190] vs 31.2% [60 of
192]; P < .001), and 90-day mortality (1.1% [2 of 190] vs 5.2% [10 of
192]; P = .02). Postoperative inflammatory biomarkers, including
neutrophil elastase and interleukin 6, were significantly reduced in the
sivelestat group. Conclusion and Relevance: In this single-center,
randomized, placebo-controlled clinical trial of patients undergoing
cardiovascular surgery, sivelestat significantly reduced ARDS incidence
and 90-day all-cause mortality. Sivelestat attenuated neutrophil-driven
inflammation by dynamically suppressing neutrophil elastase and reducing
key downstream biomarkers. These preliminary findings suggest sivelestat
may be a pharmacologic option to mitigate ARDS in cardiovascular
procedures. Trial Registration: ClinicalTrials.gov Identifier:
NCT06276569.

<3>
Accession Number
2043911151
Title
Unintended retained surgical items: a systematic review of 743 cases.
Source
International Journal for Quality in Health Care. 38(1) (no pagination),
2026. Article Number: mzag013. Date of Publication: 01 Jan 2026.
Author
Park S.-H.; Cho Y.S.
Institution
(Park) Soonchunhyang University, School of Nusing, Chungnam, Asan, South
Korea
(Cho) Department of Nursing, Seoil University, Seoul, South Korea
Publisher
Oxford University Press
Abstract
Background Despite efforts to count and verify surgical items before skin
closure, retained surgical items (RSIs) continue to be reported in
hospital settings. This study systematically analyzed both the impact and
characteristics of RSI on patients by reviewing relevant studies published
since 2000. Methods MEDLINE, EMBASE, and CINAHL databases were searched.
Case reports or case studies reporting items unintentionally left inside
the patient's body during invasive procedures were included. Two reviewers
independently extracted data and assessed study quality using the Joanna
Briggs Institute's Critical Appraisal Checklist for Case Reports. Results
Data from 634 studies included 743 RSI cases across 78 countries.
Incidence was higher in women aged 20-49 than in men. RSI occurred across
all age groups and surgical sites, with cesarean section, cholecystectomy,
hysterectomy, coronary bypass, and appendectomy accounting for 34.6% of
cases. The time to discovery of RSI was 24.3months (median), with 22.6% of
cases taking over 10years. Most patients (60.0% except not reported)
initially presented to another hospital, with pain (54.9%) as the primary
complaint; symptom duration was 4.1months (median). Computed tomography
was the most frequently used diagnostic method (40.3%), and RSI was
confirmed prior to re-surgery in only 24.9% of patients. Surgical
intervention was performed in 90.8% of cases, although some patients
either declined surgery or did not receive treatment. Most types of RSI
(92.0%) involved surgical items subjected to counting. While 56.3% of
patients recovered well, 2.6% died. The hospital stay after surgery was
5days (median). Conclusion RSI is a socially unacceptable never event, but
it continues to occur worldwide. The symptoms are often common and
nonspecific, making diagnosis difficult without clear information about
prior surgeries. This review highlights the ongoing problem of RSIs and
emphasizes that preventing them requires multiple technical measures and a
strong culture of surgical safety. Copyright © The Author(s)
2026. Published by Oxford University Press on behalf of International
Society for Quality in Health Care. All rights reserved.

<4>
Accession Number
2043577450
Title
Clinical Impact of Diabetes Mellitus After Intravascular Imaging-Guided
PCI vs Coronary Artery Bypass Grafting.
Source
JACC: Cardiovascular Interventions. 19(5) (pp 555-567), 2026. Date of
Publication: 09 Mar 2026.
Author
Gim D.H.; Cho Y.H.; Sung K.; Kim W.S.; Lee S.-J.; Kwon W.; Lee J.-Y.; Lee
S.H.; Shin D.; Lee S.Y.; Kim S.M.; Yun K.H.; Cho J.Y.; Kim C.J.; Ahn
H.-S.; Nam C.-W.; Yoon H.-J.; Park Y.H.; Lee W.S.; Choi K.H.; Park T.K.;
Yang J.H.; Choi S.-H.; Gwon H.-C.; Song Y.B.; Hahn J.-Y.; Jeong D.S.; Lee
J.M.
Institution
(Gim, Lee, Choi, Park, Yang, Choi, Gwon, Song, Hahn, Lee) Division of
Cardiology, Department of Medicine, Heart Vascular Stroke Institute,
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,
South Korea
(Cho, Sung, Kim, Jeong) Department of Thoracic and Cardiovascular Surgery,
Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, South Korea
(Lee, Kwon, Lee) Kangbuk Samsung Hospital, Sungkyunkwan University School
of Medicine, Seoul, South Korea
(Lee) Department of Internal Medicine and Cardiovascular Center, Chonnam
National University Hospital, Gwangju, South Korea
(Shin) Department of Cardiology, St. Francis Hospital and Heart Center,
Roslyn, NY, United States
(Lee, Kim) Chungbuk National University Hospital, Chungbuk National
University College of Medicine, Cheongju, South Korea
(Lee) Chung-Ang University College of Medicine, Chung-Ang University
Gwangmyeong Hospital, Gwangmyeong, South Korea
(Yun, Cho) Wonkwang University Hospital, Iksan, South Korea
(Kim, Ahn) The Catholic University of Korea, Uijeongbu St. Mary's
Hospital, Seoul, South Korea
(Nam, Yoon) Keimyung University Dongsan Hospital, Daegu, South Korea
(Park) Samsung Changwon Hospital, Sungkyunkwan University School of
Medicine, Changwon, South Korea
(Lee) Chung-Ang University College of Medicine, Chung-Ang University
Hospital, Seoul, South Korea
Publisher
Elsevier Inc.
Abstract
Background Coronary artery bypass grafting (CABG) is the standard
revascularization method for patients with diabetes mellitus (DM) and
complex coronary artery disease. However, with significant advances in
percutaneous coronary intervention (PCI), particularly the use of
intravascular imaging (IVI), it is uncertain whether contemporary
IVI-guided PCI can achieve clinical outcomes comparable with those of
CABG. Objectives The aim of this study was to compare the clinical
outcomes of IVI-guided PCI, angiography-guided PCI, and CABG in DM
patients with left main or 3-vessel disease. Methods A total of 3,402 DM
patients with left main or 3-vessel disease were included from individual
patient-level data of the RENOVATE-COMPLEX-PCI (Randomized Controlled
Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on
Clinical Outcomes After Complex Percutaneous Coronary Intervention) trial
and the institutional registries of Samsung Medical Center (n = 6,962).
The primary outcome, which was a composite of all-cause death, nonfatal
myocardial infarction, or stroke at 3 years was compared among IVI-guided
PCI, angiography-guided PCI, and CABG. Results In the DM population, the
cumulative incidence of the primary outcome at 3 years was 20.1% for
angiography-guided PCI, 11.4% for IVI-guided PCI, and 12.4% for CABG. PCI
was associated with a significantly higher risk for primary outcome (17.0%
vs 12.4%; HR: 1.91; 95% CI: 1.50-2.44; P < 0.001). However, the risk for
the primary outcome was comparable between the IVI-guided PCI and CABG
groups (11.4% vs 12.4%; HR: 0.88; 95% CI: 0.58-1.32; P = 0.525). A
propensity score-matched analysis yielded similar results (HR: 0.85; 95%
CI: 0.53-1.36; P = 0.507). Conclusions In this hypothesis-generating
study, PCI was associated with significantly higher risk for all-cause
death, nonfatal myocardial infarction, or stroke at 3 years than CABG in
DM patients with left main or 3-vessel disease. However, IVI-guided PCI
had comparable risk for clinical events compared with CABG in DM patients.
Further randomized controlled trial is needed to confirm this finding.
(Randomized Controlled Trial of Intravascular Imaging Guidance Versus
Angiography-Guidance on Clinical Outcomes After Complex Percutaneous
Coronary Intervention [RENOVATE-COMPLEX-PCI], NCT03381872 ; institutional
cardiovascular catheterization database of Samsung Medical Center
[Long-Term Outcomes and Prognostic Factors in Patient Undergoing CABG or
PCI], NCT03870815 ; institutional CABG database of Samsung Medical Center,
NCT03870815 ) Copyright © 2026 American College of Cardiology
Foundation.

<5>
Accession Number
2043687384
Title
Echocardiographic Indices of Cardiac Remodeling Following Transcatheter
Edge-to-Edge Repair for Secondary Mitral Regurgitation: A Systematic
Review and Meta-Analysis.
Source
Journal of the American Heart Association. 15(4) (pp 1-13), 2026. Article
Number: e045616. Date of Publication: 11 Feb 2026.
Author
Lombardi M.; Basile M.; Jurado-Roman A.; Occhipinti G.; Escaned J.;
Vergallo R.; Porto I.
Institution
(Lombardi, Vergallo, Porto) Department of Internal Medicine and Medical
Specialties (DIMI), Universita di Genova, Genoa, Italy
(Basile, Jurado-Roman) Department of Cardiology, La Paz University
Hospital, Madrid, Spain
(Basile, Jurado-Roman) La Paz University Hospital Research Institute
(IdiPAZ), Madrid, Spain
(Jurado-Roman) Centro de Investigacion Biomedica en Red de Enfermedades
Cardiovasculares (CIBER-CV), Instituto de Salud Carlos III, Madrid, Spain
(Occhipinti) Hospital Clinic, Cardiovascular Clinic Institute, Institut
d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of
Barcelona, Barcelona, Spain
(Escaned) Department of Interventional Cardiology, Hospital Clinico San
Carlos IDISSC, Complutense University of Madrid and CIBER-CV, Madrid,
Spain
(Vergallo, Porto) Cardiothoracic and Vascular Department (DICATOV), IRCCS
Ospedale Policlinico San Martino, Genoa, Italy
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Secondary mitral regurgitation is associated with adverse
clinical outcomes and cardiac remodeling. While transcatheter edge-to-edge
repair (TEER) improves symptoms and prognosis in selected patients, its
effects on cardiac remodeling remain debated. This systematic review and
meta-analysis aimed to evaluate the impact of TEER on echocardiographic
indices of cardiac remodeling. METHOD(S): PubMed, Scopus, and
Cochrane Library were used to identify relevant studies assessing
echocardiographic changes before and after TEER. Outcomes of interest were
left ventricular (LV) ejection fraction, global longitudinal strain, LV
end-diastolic and end-systolic volumes and LV end-diastolic and
end-systolic diameter, tricuspid annular plane systolic excursion,
pulmonary artery systolic pressure, and left atrial end-systolic volume.
 RESULT(S): Forty-two studies (3987 patients) were included. TEER was
associated with a significant increase in LV ejection fraction (mean
difference [MD], 1.51% [95% CI, 0.47-2.55]), without significant
improvement in global longitudinal strain. Significant LV remodeling was
observed, with reductions in LV end-diastolic volume (standardized MD,
-0.26 [95% CI, -0.37 to -0.14]), LV end-systolic volume (standardized MD,
-0.21 [95% CI, -0.30 to -0.12]), LV end-diastolic diameter (MD, -2.35mm
[95% CI, -3.66 to -1.04]) and left ventricular end-systolic diameter (MD,
-2.30mm [95% CI, -3.86 to -0.74). TEER also improved right ventricular
function (tricuspid annular plane systolic excursion [MD, 1.29mm [95% CI,
0.60-1.97]) and reduced pulmonary artery systolic pressure (MD, -6.75mmHg
[95% CI, -8.53 to -4.97). No significant improvement in left atrial
end-systolic volume was detected. CONCLUSION(S): Available evidence
suggests that TEER promotes significant cardiac remodeling in patients
with secondary mitral regurgitation. Copyright © 2026 The
Author(s).

<6>
Accession Number
2043754705
Title
Analgesic efficacy and safety of lidocaine administered by intravenous
route vs erector spinae plane blocks following open heart surgery: An
open-label, randomized clinical trial.
Source
Journal of Clinical Anesthesia. 111 (no pagination), 2026. Article Number:
112166. Date of Publication: 01 Apr 2026.
Author
Selvamani B.J.; Sharma A.; Farhat B.; Sahin L.; Seering M.S.; Parra M.;
Swaran Singh T.S.; Sibenaller Z.A.; Singhal A.K.; Bashir M.A.; Sondekoppam
R.V.
Institution
(Selvamani, Parra) Department of Anesthesia, Mayo Clinic, Rochester, MN,
United States
(Sharma, Seering, Swaran Singh, Sibenaller) Department of Anesthesia,
University of Iowa, Iowa City, IA, United States
(Singhal, Bashir) Department of Cardiothoracic Surgery, University of
Iowa, Iowa City, IA, United States
(Farhat) Department of Anesthesia, University of Mississippi Medical
Center, Jackson, MS, United States
(Sahin) Department of Anesthesia, Washington University School of
Medicine, St. Louis, MO, United States
(Sondekoppam) Department of Anesthesia, Perioperative and Pain Medicine,
Stanford University, Palo Alto, United States
Publisher
Elsevier Inc.
Abstract
Introduction The erector spinae plane (ESP) block is a widely used
regional analgesic technique for truncal analgesia. This randomized,
open-label trial compared intravenous (IV) lidocaine to lidocaine
administered via bilateral continuous ESP blocks for analgesic efficacy in
the context of open heart surgery. Methods Seventy patients (18-80 years)
undergoing primary single procedure elective cardiac surgery via midline
sternotomy were randomized to receive lidocaine infusion via IV or
continuous bilateral ESP block routes. The primary outcomes were
cumulative opioid consumption in the first 48 h postoperatively (Oral
Morphine milligram equivalents- OME) and pain scores at 48 h (Numeric
Rating Scale NRS). Secondary outcomes included additional timepoints for
pain and opioid consumption measures within the first 48 postoperative
hours and plasma lidocaine levels at various timepoints within 24 h of
initiating therapy. Results Sixty patients were analyzed after various
exclusions. Both groups achieved acceptable analgesia, but the ESP group
was not found to be superior to IV lidocaine in reducing opioid
consumption in the first 48 hours (MD = -12.43 [95% CI, -43.7 to 18.8], p
= 0.375) or pain scores at 48 h (MD 0.05 [95% CI, -1.7 to 1.8], p =
0.878). No significant differences were found in secondary outcomes.
Plasma arterial lidocaine levels exceeded 5 mug/mL in 4 patients in the IV
group and 2 in the ESP group at 24 h. Conclusions ESP blocks utilizing
lidocaine did not demonstrate superior postoperative analgesia compared to
intravenous lidocaine in patients undergoing elective primary cardiac
surgery via midline sternotomy. Safety concerns regarding systemic
lidocaine accumulation from both administration routes warrant further
evaluation. Copyright © 2026 Elsevier Inc.

<7>
Accession Number
2039207887
Title
Meta-analysis of transcatheter edge-to-edge repair vs surgery for
secondary mitral regurgitation.
Source
Cardiovascular Revascularization Medicine. 84 (pp 90-95), 2026. Date of
Publication: 01 Mar 2026.
Author
Singh S.; Shabbir M.A.; Tiwari N.; Bliden K.; Tantry U.S.; Gurbel P.A.;
Kanjwal M.Y.; Lundgren S.W.
Institution
(Singh) Department of Medicine, Sinai Hospital of Baltimore, Baltimore,
MD, United States
(Shabbir, Tiwari, Lundgren) Division of Cardiology, University of Nebraska
Medical Center, Omaha, NE, United States
(Bliden, Tantry) Sinai Center for Thrombosis Research, Sinai Hospital of
Baltimore, Baltimore, MD, United States
(Gurbel, Kanjwal) Division of Cardiology, Sinai Hospital of Baltimore,
Baltimore, MD, United States
Publisher
Elsevier Inc.
Abstract
Background Transcatheter edge-to-edge repair (TEER) in patients with
secondary mitral regurgitation (MR) has shown variable outcomes in
clinical studies when compared with mitral valve surgery. We conducted a
meta-analysis to reconcile the data. Methods Online databases were
searched for studies assessing TEER vs surgery for secondary MR. The
outcomes of interest were length of hospital stay, all deaths, heart
failure (HF) rehospitalization, mitral valve reintervention, implantation
of left ventricular assist device (LVAD), stroke and recurrence of grade 3
or 4 MR. Pooled odds ratios (OR) and standardized mean difference (SMD),
with 95 % confidence intervals (CI) were calculated. Results Eight studies
(1 randomized and 7 observational) with a total of 1436 patients (TEER n =
826, surgery n = 610) were included. Length of hospital stay was shorter
in the TEER group (SMD -2.50, 95 % CI -4.65 to -0.35, p = 0.02). No
significant differences were found between the two groups with respect to
all deaths ( p = 0.80), HF rehospitalization, mitral valve reintervention,
implantation of LVAD and stroke. Recurrence of grade 3 or 4 MR was higher
in the TEER group (OR 5.33, 95 % CI 2.57 to 11.03, p < 0.00001).
Conclusions In patients with secondary MR, TEER and surgery have
comparable outcomes such as mortality, except for the lower recurrence of
grade 3 or 4 MR in the surgical group. Thus, TEER may be the first
approach in such patients, except in low surgical risk cases who need
other concomitant cardiac surgeries. Copyright © 2025 Elsevier
Inc.

<8>
Accession Number
2042855681
Title
Contemporary outcomes of lower extremity vein bypass for chronic
limb-threatening ischemia based on a post hoc comparison of the BEST-CLI
and PREVENT III multicenter prospective randomized controlled trials.
Source
Journal of Vascular Surgery. 83(4) (pp 1171-1180), 2026. Date of
Publication: 01 Apr 2026.
Author
Hussain M.A.; Khan A.A.; Menard M.T.; Conte M.S.; Vouyouka A.G.; Doros G.;
Strong M.B.; Kalish J.A.; Chew D.; Gasper W.J.; Tan T.-W.; Darling R.C.;
LaMuraglia G.; Rosenfield K.; Farber A.; Schanzer A.
Institution
(Hussain, Menard, Strong) Division of Vascular and Endovascular Surgery,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United
States
(Hussain) Center for Surgery and Public Health, Brigham and Women's
Hospital, Boston, MA, United States
(Khan) Warren Alpert Medical School of Brown University, Providence, RI,
United States
(Conte, Gasper) Division of Vascular & Endovascular Surgery, University of
California, San Francisco, CA, United States
(Vouyouka) Division of Vascular Surgery, The Icahn School of Medicine at
Mount Sinai, New York, NY, United States
(Doros) Department of Biostatistics, Boston University School of Public
Health, Boston, MA, United States
(Kalish, Farber) Division of Vascular & Endovascular Surgery, Department
of Surgery, Boston University Chobanian & Avedisian School of Medicine,
Boston Medical Center, Boston, MA, United States
(Chew) Division of Vascular Surgery, Iowa Heart Center, West Des Moines,
IA, United States
(Tan) Department of Vascular Surgery, University of Southern California,
Los Angeles, CA, United States
(Darling) Division of Vascular Surgery, Albany Medical Center Hospital,
Albany, NY, United States
(LaMuraglia, Rosenfield) Division of Vascular & Endovascular Surgery,
Massachusetts General Hospital, Boston, MA, United States
(Schanzer) Division of Vascular Surgery, UMass Chan Medical School,
Boston, MA, United States
Publisher
Elsevier Inc.
Abstract
Background: BEST-CLI (Best Endovascular vs Best Surgical Therapy in
Patients with Chronic Limb-Threatening Ischemia [CLTI]) demonstrated the
superiority of single-segment great saphenous vein bypass over
endovascular treatment for patients with CLTI who were candidates for both
treatment strategies. However, with the rise of endovascular techniques
and the subsequent decrease in the number of vein bypass procedures being
performed, concerns have emerged regarding the continued ability to
perform surgical bypass safely and effectively. This study aimed to
evaluate whether outcomes after lower extremity infrainguinal vein bypass
for CLTI have changed over the past two decades by comparing data from two
major randomized controlled trials: BEST-CLI and PREVENT III (Project or
Ex-Vivo vein graft Engineering via Transfection III). Method(s): This
post hoc comparative analysis included patients with CLTI who underwent
lower extremity infrainguinal vein bypass in the multicenter, prospective
BEST-CLI (2014-2019) and PREVENT III (2001-2003) trials. The primary
outcome was a composite of major adverse limb event (MALE) or death at 1
year. Secondary outcomes included perioperative (30-day) rates of major
adverse cardiovascular event (MACE) and MALE. Multivariable Cox and
logistic regression models were used for 1-year and 30-day outcomes,
respectively, to compare outcomes between the two cohorts; confirmatory
analyses were conducted using propensity score methods. Result(s): In
total, 2114 patients underwent infrainguinal vein bypass for CLTI (710
BEST-CLI and 1404 PREVENT III). The mean patient age was 67.9 +/- 11.0
years; 32.8% were female. Patients in BEST-CLI had higher use rates of
aspirin, statins, and single segment great saphenous vein conduit. The
primary end point of 1-year MALE or death was lower in BEST-CLI (21.0%)
compared with PREVENT III (37.8%) (adjusted hazard ratio [HR], 0.50; 95%
confidence interval [CI], 0.40-0.62; P < .0001)-this observation was
consistent across predefined subgroups and in confirmatory analyses using
propensity score methods. Major reinterventions (new bypass, surgical
revision, thrombectomy, or endovascular intervention for graft occlusion)
at 1 year were also lower in BEST-CLI (7.2% vs 18.4%; adjusted HR, 0.40;
95% CI, 0.28-0.57; P < .0001), although rates of any reinterventions were
similar (25.8% vs 29.3%; adjusted HR, 0.90; 95% CI, 0.72-1.14; P = .39).
Perioperative major cardiovascular and limb events were significantly
lower in BEST-CLI: MACE (4.1% vs 7.8%; adjusted OR 0.47; 95% CI,
0.28-0.79; P = .005) and MALE (2.7% vs 6.3%; adjusted OR 0.44; 95% CI,
0.24-0.82; P = .009). Conclusion(s): Over the past two decades,
outcomes after lower extremity infrainguinal vein bypass for CLTI have
improved significantly. These advances likely reflect a combination of
broad improvements in cardiovascular risk management, surgical techniques,
and postoperative care for CLTI patients. Copyright © 2025
Society for Vascular Surgery

<9>
Accession Number
650231802
Title
Predictive and prognostic performance of urinary albumin-to-creatinine
ratio for acute kidney injury: a systematic review and meta-analysis.
Source
Scientific reports. 16(1) (no pagination), 2026. Date of Publication: 12
Feb 2026.
Author
Kitisin N.; Ismail J.; Raykateeraroj N.; Hikasa Y.; Caroli A.; Nubel J.;
Eastwood G.; Bellomo R.; Neto A.S.
Institution
(Kitisin, Ismail, Hikasa, Caroli, Nubel, Eastwood, Bellomo, Neto)
Department of Intensive Care, Austin Hospital, Heidelberg, VIC, Australia
(Kitisin, Raykateeraroj) Department of Anesthesiology, Faculty of
Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
(Raykateeraroj) Department of Anesthesiology, Austin Hospital, Heidelberg,
VIC, Australia
(Caroli) Dipartimento Di Scienze Dell'Emergenza, Anestesiologiche E Della
Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome,
Italy
(Nubel) Department of Cardiology, Brandenburg Medical School (MHB) Theodor
Fontane, University Hospital Heart Centre Brandenburg, Bernau, Germany
(Bellomo, Neto) Australian and New Zealand Intensive Care Research Centre
(ANZIC-RC), School of Public Health and Preventive Medicine, Monash
University, Melbourne, Australia
(Bellomo, Neto) Department of Critical Care, School of Medicine,
University of Melbourne, Parkville, VIC, Australia
(Bellomo, Neto) Data Analytics Research and Evaluation (DARE) Centre,
Austin Hospital, Melbourne, Australia
(Neto) Department of Critical Care Medicine, Hospital Israelita Albert
Einstein, Sao Paulo, Brazil
Abstract
The urine albumin-to-creatinine ratio (UACR) is a well-established marker
for chronic kidney disease, but its utility in predicting acute kidney
injury remains uncertain. This systematic review and meta-analysis aimed
to evaluate predictive performance for AKI development and prognostic
performance for AKI progression in hospitalized adults. A comprehensive
search of Ovid MEDLINE, Embase, and CENTRAL databases identified 13
studies (n = 10,438) on AKI incidence and three studies (n = 1596) on AKI
progression. Elevated UACR was associated with an increased risk of AKI
(pooled OR 1.39; 95% CI 1.08-1.79) and AKI progression (pooled OR 3.76;
95% CI 2.59-5.45). The pooled sensitivity and specificity for AKI
prediction were 0.71 (95% CI 0.59-0.80) and 0.67 (95% CI 0.56-0.76),
respectively, with an area under the curve (AUC) of 0.74. However, there
was high heterogeneity across studies, and UACR thresholds for AKI
prediction varied widely. Despite these limitations, UACR appears to be a
promising, low-cost biomarker for predicting AKI, particularly in
high-risk settings such as cardiac surgery. Standardization of thresholds
and further validation are needed to support its clinical
implementation. Copyright © 2026. The Author(s).

<10>
[Use Link to view the full text]
Accession Number
616768342
Title
A comparison of extraluminal and intraluminal use of the Uniblocker in
left thoracic surgery.
Source
Medicine (United States). 96(21) (no pagination), 2017. Article Number:
e6966. Date of Publication: 01 May 2017.
Author
Liu Z.; He W.; Jia Q.; Yang X.; Liang S.; Wang X.
Institution
(Liu, Wang) Department of Anesthesiology, Third Hospital of Hebei Medical
University, No. 139 Ziqiang Road, Shijiazhuang Hebei, China
(He, Jia, Yang, Liang) Department of Anesthesiology, First Hospital of
Qinhuangdao, Qinhuangdao, Hebei, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The aim of this study was to assess the feasibility and safety
issues concerning extraluminal use of the Uniblocker for one-lung
ventilation (OLV) in the left thoracic surgery. Method(s): Forty
patients undergoing elective left thoracic surgery were included in this
study, and all patients were randomly allocated to extraluminal use of
Uniblocker group (E group, n = 20) or intraluminal use of Uniblocker group
(I group, n = 20). Time for intubation, time for verification of the
correct position of Uniblocker, incidence of Uniblocker displacement,
index of pulmonary collapse, mean arterial pressure, heart rate, peak
airway pressure, oxygen saturation in two-lung ventilation, and 30 minutes
after OLV, bronchial damage after OLV, sore throat, and hoarseness
postoperative were recorded. Result(s): The time for positioning
Uniblocker was 112.6 +/- 31.2 seconds in intraluminal use group, whereas
the time for positioning Uniblocker was significantly shorter in
extraluminal use group (63.4 +/- 15.8 seconds). The incidence of main
bronchial injury, the time of intubation, the incidence of Uniblocker
malposition after initial placement, the time of OLV, the degree of
pulmonary collapse, mean arterial pressure, heart rate, peak airway
pressure, oxygen saturation in two-lung ventilation, and 30 minutes after
OLV, the incidence of sore throat and hoarseness postoperative have no
statistical significance (P > .05). Conclusion(s): Extraluminal use
of the Uniblocker was proved to be a more rapid and more accurate method
than conventional intraluminal use of the Uniblocker for OLV in left
thoracic surgery. Copyright © 2017 the Author(s). Published by
Wolters Kluwer Health, Inc.

<11>
Accession Number
2043685300
Title
The effects of Traditional Chinese Medicine on cardiac function after
percutaneous coronary intervention: a meta-analysis and systematic review.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1619928. Date of Publication: 2026.
Author
Wang M.; Fan S.; Xia L.; Wang Z.; Ren J.
Institution
(Wang, Fan, Wang, Ren) College of Traditional Chinese Medicine, Changchun
University of Chinese Medicine, Jilin, Changchun, China
(Xia) Affiliated Hospital to Changchun University of Chinese Medicine,
Jilin, Changchun, China
Publisher
Frontiers Media SA
Abstract
Objective: This systematic review aimed to synthesize and summarize
current evidence regarding the effects of Traditional Chinese Medicine
(TCM) on cardiac function in patients with coronary heart disease (CHD)
following percutaneous coronary intervention (PCI). Method(s): A
comprehensive search was conducted in PubMed, Embase, the Cochrane
Library, China National Knowledge Infrastructure (CNKI), Wanfang Database,
the Chinese Biomedical Literature Database (CBM), and the Chinese
Scientific and Technological Journal Database (VIP). Relevant conference
papers were also manually screened. Studies evaluating the clinical
efficacy of TCM combined with conventional Western medicine for CHD after
PCI were selected based on predefined inclusion and exclusion criteria.
The methodological quality of the included studies was assessed using the
RoB 2. Data extraction was performed independently, and Stata software was
used for meta-analysis. Result(s): 12 studies involving a total of
6,383 patients were included. Compared with conventional Western medicine
alone, integrated TCM and Western therapy significantly reduced the
incidence of in-stent restenosis (ISR) and non-fatal myocardial infarction
after PCI (p < 0.05). However, no significant differences were observed in
cardiac mortality or the incidence of coronary artery bypass grafting
(CABG) between the two treatment approaches (p > 0.05).
 Conclusion(s): The combination of TCM with conventional Western
therapy may reduce ISR and non-fatal myocardial infarction in CHD patients
after PCI compared with Western medicine alone, suggesting potential
benefits for improving post-PCI clinical outcomes. Copyright 2026
Wang, Fan, Xia, Wang and Ren.

<12>
Accession Number
2043881875
Title
Systematic evaluation and meta-analysis of transcardiac intracavitary and
transesophageal echocardiography-guided left atrial appendage occlusion
surgery.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1701359. Date of Publication: 2026.
Author
Luo B.; Niu Y.; Zhang L.; Cheng Z.
Institution
(Luo, Zhang, Cheng) The First Affiliated Hospital of Hebei North
University, Hebei, Zhangjiakou, China
(Luo, Zhang, Cheng) Department of Ultrasound, The First Affiliated
Hospital of Hebei North University, Hebei, Zhangjiakou, China
(Niu) Hebei North University, Zhangjiakou, China
Publisher
Frontiers Media SA
Abstract
Objective: To systematically evaluate the differences in safety, efficacy,
and economics between intracardiac ultrasound (ICE) and transesophageal
echocardiography (TEE)-guided LAAO (LAAO), and to provide an
evidence-based rationale for the selection of clinical image-guided
modalities. Method(s): PubMed, Embase, Cochrane Library, Web of
Science and Wanfang databases were searched to include randomized
controlled trials and observational studies comparing ICE with TEE-guided
LAAO, strictly following PRISMA guidelines. Two investigators
independently screened the literature, extracted data and assessed the
risk of bias (ROBINS-I and Cochrane tools). Meta-analysis was performed
using RevMan 5.4.1, and the outcome indicators included technical success,
procedure time, contrast dose, fluoroscopy time, complications, and
economic parameters, and subgroup analyses were performed to explore the
effects of factors such as patient characteristics and instrument type.
 Result(s): A total of 16 studies were included.There was no
significant difference between ICE and TEE in terms of technical success
(RR = 1.01,95% CI 1.00-1.02, P = 0.24) and total risk of physical
complications (RR = 0.94,95% CI 0.82-1.09, P = 0.43). Subgroup analysis
showed: Operative efficiency: ICE significantly reduced operative time in
the subgroups of single-center studies (MD = -7.28 min, 95% CI: -9.46 to
-5.10, P < 0.001), with AcuNav catheter (MD = -3.21 min, 95% CI: -6.20 to
-0.19, P = 0.04), and patients aged <75 years (MD = -15.89 min, 95% CI:
-18.95 to -12.82, P < 0.001); the use of multi-seal devices was associated
with a significant reduction in contrast agent volume (MD = -21.69 mL, 95%
CI: -31.44 to -11.94, P < 0.001). Disease characteristics: In the subgroup
with a hypertension proportion <90%, ICE shortened both operative time (MD
= -12.00 min, 95% CI: -15.08 to -8.92, P < 0.001) and fluoroscopic time
(MD = -9.32 min, 95% CI: -14.26 to -4.37, P = 0.003); however, operative
time was prolonged in the ICE group for patients with a proportion of
paroxysmal atrial fibrillation >=50% (MD = 14.20 min, 95% CI: 7.60-20.80,
P < 0.001). Economics: ICE reduced professional/anesthesia-related costs
(MD = -$2,654, P < 0.001) but increased hospitalization costs by
approximately 17.8%, with notable geographic heterogeneity in total costs
(comparable in the United States, but potentially higher for ICE in China
based on existing cost structures). Sensitivity analyses showed good
stability of the results, with heterogeneity (I2 > 90%) mainly
stemming from differences in study design and device type.
 Conclusion(s): The core clinical outcomes (success and safety) of ICE
and TEE in LAAO are equivalent, but operational efficiency is moderated by
patient age, LV morphology, and device design. ICE is recommended for
young, anatomically simple patients at high risk for anesthesia, and
individualized decision-making needs to be optimized with team experience
and health economic assessment. Future multicenter RCTs and cost-utility
analyses are needed to validate long-term benefits. Systematic Review
Registration: PROSPERO CRD42024626272. Copyright 2026 Luo, Niu, Zhang
and Cheng.

<13>
Accession Number
647628209
Title
Prognostic Impact of Prior Percutaneous Coronary Interventions in Patients
Undergoing Coronary Artery Bypass Grafting-A Systematic Review and
Meta-analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Kirov H.; Caldonazo T.; Woehlecke H.; Fischer J.; Runkel A.; Mukharyamov
M.; Doenst T.
Institution
(Kirov, Caldonazo, Woehlecke, Fischer, Runkel, Mukharyamov, Doenst) Jena
University Hospital, Jena, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: There is controversy on the effect of percutaneous coronary
intervention (PCI) on outcomes of patients undergoing coronary artery
bypass grafting (CABG). We meta-analytically assessed the prognostic
impact of prior PCI in patients with coronary artery disease (CAD) who
underwent CABG. Method(s): We performed a systematic review and
meta-analysis of studies comparing patients who underwent CABG and had
prior PCI in the past with patients who underwent CABG as primary
treatment of CAD. Three databases were assessed. The study selection and
data extraction were performed by two independent investigators and
checked by a senior author. The primary endpoint was perioperative
mortality. The secondary outcomes were perioperative myocardial infarction
(MI), neurological events (NE), bleeding, acute renal failure (ARF), and
hospital length of stay (LOS). The overall odds ratio (OR) and standard
mean difference (SMD), as well as the 95% confidence interval (CI) were
calculated using random-effects model. Result(s): After screening of
all records found through the systematic search, 18 studies met the
criteria for inclusion in the final analysis. Risk of perioperative
mortality in patients undergoing direct CABG was lower than in those with
prior PCI (OR: 0.86, 95% CI, 0.77-0.97, p = 0.02). There was no
significant difference between the groups regarding perioperative MI (OR:
0.83, 0.62-1.13, p = 0.24), NE (OR: 0.97, 0.81-1.15, p = 0.71), bleeding
(OR: 0.79, 0.60-1.05, p = 0.10), ARF (OR: 0.83, 0.59-1.16, p = 0.27), and
hospital LOS (SMD: 0.26, -0.18 to 0.70, p = 0.24). Conclusion(s):
CABG in patients with prior PCI appears to be associated with higher rates
of perioperative mortality when compared with patients who underwent CABG
as primary treatment of CAD.

<14>
Accession Number
643690396
Title
Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in
Patients with Chronic Total Occlusion.
Source
Thoracic and Cardiovascular Surgeon. Conference: 53rd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 72(Supplement 1) (no pagination), 2024. Date of Publication: 13
Feb 2024.
Author
Kirov H.; Fischer J.; Caldonazo T.; Tasoudis P.; Soletti G.J.; Cancelli
G.; Dell A.M.; Mukharyamov M.; Doenst T.
Institution
(Kirov, Fischer, Caldonazo, Mukharyamov, Doenst)
Friedrich-Schiller-University, Jena, Germany
(Tasoudis) Division of Cardiothoracic Surgery, Chapel Hill, United States
(Soletti, Cancelli, Dell) Weill Cornell Medicine, New York, United States
Publisher
Georg Thieme Verlag
Abstract
Background: Mechanisms of coronary artery bypass grafting (CABG) and
percutaneous coronary intervention (PCI) differ as CABG provides surgical
collateralization and may prolong life by preventing future myocardial
infarctions (MI). However, CABG benefits are unclear in patients with
chronic total occlusion (CTO), where PCI has been used increasingly as a
lessinvasive alternative. Method(s): We performed a meta-analysis of
studies comparing outcomes in patients with CTO with/without multivessel
disease, who underwent CABG or PCI. Primary outcome was long-term
all-cause mortality (>=5 years). Secondary outcomes were long-term MI,
repeat revascularization, cardiac mortality, major adverse cardiovascular
events, and stroke, as well as short-term mortality (30-days/in-hospital)
and short-term stroke. A pooled Kaplan-Meier survival curve after
reconstruction analysis was generated. Random-effects models were used.
 Result(s): Seven studies with 14,196 patients were included. In the
pooled Kaplan-Meier analysis CABG showed significantly lower risk of death
in the follow-up compared to PCI (HR = 2.08, 95% CI, 1.86-2.34, p <
0.001). CABG was also associated with lower rates of long-term MI (OR:
2.74, CI 95%, 1.96-3.83, p < 0.0001) and long-term repeat
revascularization (OR: 4.88, CI 95%, 1.99-11.91, p < 0.0001). The other
secondary endpoints did not show any significant difference.
 Conclusion(s): CABG appears superior to PCI over time in patients
with CTO. This survival advantage may be associated with fewer events of
MI and repeat revascularization.

<15>
Accession Number
643690458
Title
Genome-Wide Association Study in 2,140 Patients and Subtype Meta-analyses
of Barlow's Disease and Fibroelastic Deficiency Identify Novel Risk Loci
for Mitral Valve Prolapse.
Source
Thoracic and Cardiovascular Surgeon. Conference: 53rd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 72(Supplement 1) (no pagination), 2024. Date of Publication: 13
Feb 2024.
Author
Feirer N.; Weber M.; Knoll K.; Miranda L.; Yu M.; Lahm H.; Kameric M.;
Doppler S.; Neb I.; Lichtner P.; Lek M.; Lange R.; Schunkert H.; Hagege
A.; Bouatia-Naji N.; Muller-Myhsok B.; Trenkwalder T.; Gruber P.; Krane
M.; Dressen M.
Institution
(Feirer, Weber, Knoll, Lahm, Kameric, Doppler, Neb, Lange, Schunkert,
Krane, Dresen) German Heart Center Munich, Munich, Germany
(Feirer, Weber) Institute for Translational Cardiac Surgery (INSURE),
German Heart Center Munich, Munich, Germany
(Miranda) Max Planck Institute of Biochemistry, Munich, Germany
(Yu) Fudan University, Shanghai, China
(Lichtner, Trenkwalder) Helmholtz Center Munich, Munich, Germany
(Lek, Gruber, Dresen) Yale School of Medicine, Division of Cardiac
Surgery, Yale, United States
(Lange, Schunkert, Trenkwalder, Krane) DZHK (German Center for
Cardiovascular Research), Partner Site Munich Heart Alliance, Munich,
Germany
(Hagege) European Hospital Georges Pompidou, Paris, France
(Hagege, Bouatia-Naji) Universite de Paris, Paris, France
(Muller-Myhsok, Krane) Department of Translational Research in Psychiatry,
Max Planck Institute of Psychiatry Munich, Munich, Germany
(Muller-Myhsok) Munich Cluster of Systems Biology, Munich, Germany
(Muller-Myhsok) University of Liverpool, Liverpool, United Kingdom
Publisher
Georg Thieme Verlag
Abstract
Background: Mitral valve prolapse (MVP) is a multifactorial cardiac valve
disease with a strong genetic component. Degenerative MVP subtypes range
from fibroelastic deficiency (FED) to Barlow's Disease (BD). This
genome-wide association study (GWAS) aims to shed light on the
associations of genetic variants with MVP, especially focusing on subtypes
FED and BD. Method(s): The cohort included all consecutive patients
who underwent mitral valve surgery for degenerative MVP at the Department
of Cardiovascular Surgery or presented with symptomatic MVP at the
Department of Cardiology at the German Heart Center Munich between March
2002 and January 2021. Surgery protocols as well as echocardiographic data
in accordance with current ESC/EACTS guidelines were used to identify
degenerative MVP cases. After DNA extraction and genome-wide genotyping,
standard per variant and per individuals quality control was applied. The
imputation of 4.8 million common SNPs was carried out using the 1000
Genomes Project phase 3 haplotype reference panel. Multidimensional
scaling was performed to adjust for population stratification. The GWAS
included 2,140 cases and 9,000 controls. Global meta-analysis included a
publicly available dataset published by Roselli et al. in 2022. For
subgroup analyses, the cohort was subdivided into FED and BD phenotype,
based on clinical and morphological characteristics. Intermediate
phenotypes were excluded from the subgroup analysis. Subgroups were
analyzed via GWAS and investigated in meta-analyses with GWAS datasets
stratified from data from the MVP France study. Result(s): Within
this large cohort of 2,140 MVP patients, 84.5% (n = 1,809) suffered from
severe mitral regurgitation that required surgery. Meta-analysis of this
cohort was performed with 4,884 cases and 434,649 controls from the
Roselli study. For MVP, 40 loci reached genome-wide significance (p < 5 x
10-8). Subgroup analysis included FED (n = 997) and BD (n =
788) cases with 11,439 controls and yielded two loci associated with FED
on chromosome 5q35.2 and 10q26.12. In association with BD, eight highly
significant SNPs all located on chromosome 5q23.3 were identified.
 Conclusion(s): This GWAS comprises the largest single-center cohort
of patients with degenerative MVP to date. Novel risk loci associated with
MVP were identified. For the first time, risk loci for the subtypes FED
and Barlow's Disease were detected and may pave the way towards novel,
patient-specific therapeutic approaches.

<16>
Accession Number
640352431
Title
Five-Year Results of Coronary Artery Bypass Grafting with or without
Carotid Endarterectomy in Patients with Asymptomatic Carotid Artery
Stenosis: CABACS RCT.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Knipp S.C.; Holst T.; Bilbilis K.; Diener H.C.; Jockel K.H.; Jakob H.;
Ruhparwar A.; Weimar C.
Institution
(Knipp, Holst, Bilbilis, Diener, Jockel, Jakob, Ruhparwar) Essen
University Hospital, Essen, Germany
(Weimar) BDH Clinic Elzach GmbH, Elzach, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: In patients with coronary artery disease and concomitant
asymptomatic severe carotid stenosis, combination of simultaneous coronary
artery bypass grafting (CABG) and carotid endarterectomy (CEA) has been
widely performed despite lack of evidence from randomized trials. We
recently showed that the risk of stroke or death within 30 days was higher
following CABG + CEA compared with CABG alone. Here, we report long-term
outcomes following CABG with versus without CEA. Method(s): The
CABACS (Coronary Artery Bypass Graft Surgery in Patients With Asymptomatic
Carotid Stenosis Study) is a randomized, controlled, multicenter, open
trial. Patients with asymptomatic severe (>=70%) carotid stenosis
undergoing CABG were allocated with either CABG + CEA or CABG alone, and
follow-up was 5 years. Major secondary end points included nonfatal stroke
or death, any death, and any nonfatal stroke. Due to low recruitment, the
study was stopped prematurely after randomization of 127 patients in 17
centers. Result(s): By 5 years, the rate of stroke or death did not
significantly differ between groups (CABG + CEA: 40.6% [95% CI,
0.285-0.536], CABG alone: 35.0% [95% CI, 0.231-0.484]; p = 0.58). Higher
albeit statistically nonsignificant rates of nonfatal strokes occurred at
any time following CABG + CEA versus CABG alone (1 year: 19.3 vs. 7.1%, p
= 0.09; 5 years: 29.4 vs. 18.8%, p = 0.25). All-cause mortality up to 5
years was similar in both groups (CABG + CEA: 25.4% vs. CABG alone: 23.3%,
hazard ratio, 1.148 [95% CI, 0.560-2.353]; p = 0.71). Subgroup analyses
did not reveal any significant effect of age, sex, preoperative-modified
Rankin scale and center on outcome events. Conclusion(s): During
5-year follow-up, combined simultaneous CABG + CEA was associated with a
higher albeit statistically nonsignificant rate of stroke or death
compared with CABG alone. This was mainly due to a nonsignificantly higher
perioperative risk following CABG + CEA. Since the power of our study was
not sufficient, no significant effect of either procedure could be
observed at any time during follow-up.

<17>
Accession Number
640352191
Title
Type of Cardioplegia and Its Application May Not Explain Improvements in
Cardiac Surgery Outcomes during the Last Two Decades.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Schneider U.; Mukharyamov M.; Farber G.; Kirov H.; Caldonazo T.; Doenst T.
Institution
(Schneider, Mukharyamov, Farber, Kirov, Caldonazo, Doenst)
Friedrich-Schiller University, Jena, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Cardiac surgery has made tremendous achievements once
cardiopulmonary bypass (CPB) was able to support circulation and
cardioplegia was able to protect the arrested heart during the operative
procedure. Continuous improvements made surgery better and safer until
today, despite significant changes in today's patient profiles (i.e.,
advanced age, higher likelihood of comorbidities). With cardioplegic
arrest being a key component of avoiding ischemic damage to the heart from
the operative procedure, we aimed to assess the role of cardioplegia in
most recent outcomes. Method(s): A systematic literature search was
performed for studies correlating specific cofactors with patient
survival. We searched PubMed, SCOPUS, Embase, Cochrane Database, Google
Scholar, and Ovid for the keywords "cardioplegia," "myocardial
protection," "aortic cross-clamp time," and "mortality." Search terms were
used as key words and in combination as Medical Subject Headings (MeSH)
terms. Result(s): Academic interest in cardioplegia declined in the
past two decades. The number of publications in the time frames of 1990 to
2000 (n = 1,106) and 2010 to 2020 (n = 611) has been cut in half. The
relative percentage of cardioplegia studies related to all cardiac
surgical publications has been reduced to one-fifth (1.3-0.25%). The
youngest cardioplegia solution has been introduced to the market 28 years
ago (del Nido's); the oldest (Bretschneider's) had already been developed
in the 1960s and 1970s. The search for duration of cardioplegic arrest
times and mortality revealed a significant correlation with higher
mortality at higher clamp-times, which was independent of cardioplegia
type or delivery details. Age was qualified as a strong independent risk
factor for mortality. Conclusion(s): Given the results of this
analysis, improved outcomes in cardiac surgery in the past two decades
cannot be attributed to changes in our way to use cardioplegia. However,
there is still a significant relationship between cardioplegic cross-clamp
time and mortality making the field attractive for further investigations
specifically for a changing and often older and sicker patient population.

<18>
Accession Number
647628226
Title
Safety and Efficacy of Contemporary Rapid Deployment Valves-A Comparative
Analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Wilbring M.; Alexiou K.; Matschke K.; Wrobel A.S.; Kappert U.; Arzt S.
Institution
(Wilbring, Alexiou, Matschke, Wrobel, Kappert, Arzt) Department of Cardiac
Surgery, University Heart Center Dresden, Dresden, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Presently two differently designed rapid deployment valves
(RDV) are commercially available-the Edwards INTUITY and the Corcym
Perceval Plus. This study compares valve performances in a large
consecutive cohort. Method(s): All consecutive isolated aortic valve
replacements (AVR) or AVR in combination with CABG were included between
2016 and 2022 using either the INTUITY (n = 309) or the Perceval Plus (n =
338). Multiple valve procedures or non-IFU-conform implantations were
ruled out. The final study group consisted of 647 patients. Preoperative
aortic annular diameter (CT scan and 3D echocardiography), intraoperative
adverse events (AE), predischarge hemodynamic parameters as well as
permanent pacemaker implantation (PPI) rates were analyzed. Predischarge
transthoracic echocardiography was performed by a single examiner between
postoperative day 5 and 6. Result(s): Mean preoperative annular
diameter differed not significantly between both groups (INTUITY 24.7 +/-
2.4 mm versus Perceval Plus 24.2 +/- 2.2 mm; p = 0.06). Intraoperative AE
were likewise counterbalanced by means of valve malpositioning (INTUITY
3.6% versus Perceval Plus 2.4%; p = 0.49), repeated x-clamp (INTUITY 2.9%
versus Perceval Plus 2.4%; p = 0.49), and use of a different prosthesis
(INTUIYT 4.2% versus Perceval Plus 1.8%; p = 0.10). Postoperative mean
effective orifice area generally differed not significantly (INTUITY 1.73
+/- 0.25 cm versus Perceval Plus 1.70 +/- 0.23 cm ; p = 0.15), but was
significantly larger with the Perceval Plus in patients with an aortic
annulus <=23 mm (n = 114; Perceval Plus 1.59 +/- 0.22 cm versus INTUITY
1.44 +/- 0.18 cm ; p = 0.04). Postoperative PVL (>trace) was less frequent
in Perceval Plus (2.4% versus 5.5%; p = 0.04) and PPI rate was comparable
(INTUITY 6.2% versus Perceval Plus 5.9%; p = 1.00). No case of valve
thrombosis was documented. Conclusion(s): Both RDVs are safe and
highly effective with mainly comparable hemodynamic outcomes at a high
safety profile with low rates of permanent pacemaker implantations. The
INTUITY had higher rates of PVL, whereas the Perceval Plus provided larger
EOAs in smaller aortic annulus.

<19>
Accession Number
647628148
Title
Is Negative Pressure Wound Therapy Better for Sternal Wound Healing?.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Taghiyev Z.T.; Sandoval Valderrama J.F.; Niemann B.; Roth P.; Orhan C.;
Haj M.; Grieshaber P.; Boning A.
Institution
(Taghiyev, Sandoval Valderrama, Niemann, Roth, Orhan, Haj, Grieshaber,
Boning) Department of Cardiovascular Surgery, University Hospital Giessen,
Giessen, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: The purpose of this prospective, randomized study is to
determine whether the preventive negative pressure wound therapy with
PICOTM dressing system could reduce wound complications after the standard
median sternotomy in cardiac surgery. Method(s): 256 patients
undergoing open cardiac surgery during the period July 2019 to July 2023
were prospectively randomized in two groups: 108 patients were treated
with PICOTM (Smith and Nephew Ltd, Hull, England) which was applied for 5
to 7 days, whereas 148 patients in control group received conventional
wound dressings. Primary endpoints were superficial and deep sternal wound
healing disorders, as well as the rate of sternal instability within 7,
30, and 180 days after surgery. Inverse probability of treatment weighting
(IPTW) was used to assess the impact of PICOTM on wound complications.
 Result(s): After randomization, baseline and procedural
characteristics were similar in both groups. In the PICO group the
incision was primarily closed in 102 (94.4%) patients and there were seven
cases (95.3%) of superficial dehiscence in the control group after 7 days
of treatment. The overall 30-day incidence of sternal wound healing
disorders was similar in both groups (17 [15.7%] versus 21 [14.2%], p =
0.726). 180 days after surgery, two patients in each group showed a skin
dehiscence, while two patients in the PICO group had an instable sternum.
Statistically, significantly less wound healing problems occurred in the
PICO compared with the conventional group within 7 days after surgery (OR
2.1, 95%CI [1.016 to 4.369], p = 0.045), but not on 30 and 180 days after
surgery, respectively (OR 1.0, 95%CI [0.472 to 2.247], p = 0.942 and OR
6.7, 95%CI [0.685 to 66.098], p = 0.102). Conclusion(s): The initial
superiority of the PICOTM system to prevent wound infections following
open-heart surgery could not be maintained at the 30- and 180-day
follow-up.

<20>
Accession Number
647628166
Title
Survival Trends of Patients After Mitral Valve Repair for Structural
Mitral Regurgitation Compared to the General Population.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Caldonazo T.; Kirov H.; Sakhtianchi B.A.; Tasoudis P.; Fischer J.;
Mukharyamov M.; An K.R.; Doenst T.; Runkel A.
Institution
(Caldonazo, Kirov, Sakhtianchi, Fischer, Mukharyamov, Doenst, Runkel) Jena
University Hospital, Jena, Germany
(Tasoudis) University of North Carolina, Chapel Hill, United States
(An) University of Toronto, Toronto, Canada
Publisher
Georg Thieme Verlag
Abstract
Background: Surgical mitral valve repair (MVr) for structural mitral
regurgitation (MR) restores valve function. Individual studies suggest
that MVr may normalize life expectancy. We performed a systematic review
and a meta-analysis of all studies assessing the impact of MVr for
structural MR on survival. Method(s): Three databases were assessed
searching for studies with survival comparisons to the regional
age-matched general population. The primary and single endpoint was
long-term mortality. Individual patient data (IPD) were reconstructed from
the published Kaplan-Meier curves and was used to calculate overall
survival. The Cox proportional hazards regression model was used to assess
between-group differences. The hazard ratios (HR) and 95% confidence
intervals (CI) of each individual study was calculated. Landmark analysis
was performed to check the robustness of the estimated effect.
 Result(s): Four studies met the criteria for inclusion in the final
analysis. The studies' follow-up ranged from 10 to 26 years. The pooled
Kaplan-Meier curves of reconstructed IPD show that for the entire
follow-up, patients who underwent MVr had higher risk of death compared
with the general age-matched population (HR: 0.62, 95% CI: 0.53-0.72, p <
0.01). Due to violation of the HR proportions, a landmark analysis was
performed splitting the events after 6 years. There was no survival
difference between the groups until 6 years after surgery (HR: 0.83, 95%
CI, 0.68-1.03, p = 0.09). From 6 to 26 years of follow-up, curves diverged
and the MVr group demonstrated significantly higher risk of death compared
with the general age-matched population (HR: 0.45, 95% CI, 0.36-0.56, p <
0.01). The individual studies showed that the decrease in survival after 6
years was associated with an increase in return of MR and need of
reoperation. Conclusion(s): MVr for structural MR has the potential
to restore life expectancy compared with the general population. However,
this effect is limited to the first 6 years after surgery. Risk of death
thereafter correlates with the return of severe regurgitation and/or the
need for reoperation.

<21>
Accession Number
643690388
Title
Does Reduced Forced Expiratory Volume in One Second have an Influence on
Early Postoperative Outcomes after Minimally Invasive Mitral Valve
Surgery?.
Source
Thoracic and Cardiovascular Surgeon. Conference: 53rd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 72(Supplement 1) (no pagination), 2024. Date of Publication: 13
Feb 2024.
Author
Salman J.; Franz M.; Tavil S.; De Manna D.; Ius F.; Aburahma K.; Boethig
D.; Ruhparwar A.; Weymann A.
Institution
(Salman, Franz, Tavil, De Manna, Ius, Aburahma, Boethig, Ruhparwar,
Weymann) Hannover Medical School, Hannover, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Minimally invasive mitral valve surgery is the gold standard
surgical treatment for mitral valve pathologies. However, it is
technically challenging and demands longer surgery time and single lung
ventilation. This might impact the outcome of patients with impaired lung
function. We therefore investigated the early postoperative outcome of
patients with diminished forced expiratory volume in one second.
 Method(s): In a retrospective cohort study, we compared patients with
a forced expiratory volume in one second (FEV1) of <80% and >=80% who
underwent minimally invasive mitral valve surgery. The primary endpoint
was 30-day mortality. Secondary endpoints were overall intubation time,
length of stay on intensive care unit as well as incidences of
postoperative respiratory insufficiency and pneumothorax. Result(s):
Data were collected from January 2011 until December 2022. A study group
(FEV1 <=80%, n = 297) and a control group (FEV1 >80%, n = 443) were
formed. Patients from the study group had a lower incidence of mitral
valve insufficiency (82% vs. 90%; p < 0.001) and a higher rate of mitral
valve stenosis (9% vs. 4%; p = 0.002). The repair rate was lower in the
study group (55% vs. 71%; p < 0.001). No difference was seen in surgery
time (208 vs. 207 minutes; p = 0.74) and time on cardiopulmonary bypass
(137 vs. 138 minutes; p = 0.72). Patients of the study group showed a
slightly higher incidence of postoperative wound healing disorder (10% vs.
5%; p = 0.016). No difference was seen in postoperative respiratory
insufficiency (8% vs. 5%; p = 0.068), arrhythmia (14% vs. 10%; p = 0.11),
pneumothorax (7% vs. 5%; p = 0.2), right ventricular failure (3% vs. 4%; p
= 0.84) and bleeding (10% vs. 6%; p = 0.085). Patients from the study
group had a longer intubation time (12 vs. 10 hours, p < 0.001) and time
on catecholamines (20 vs. 16 hours; p < 0.001). No difference was seen in
the 30-day mortality (2% vs. 2%; p = 1). Conclusion(s): Despite a
slightly longer intubation time and time on ICU, reduced FEV1 does not
affect the early postoperative outcome of patients undergoing minimally
invasive mitral valve surgery.

<22>
Accession Number
640352235
Title
Procedural Success in Transaxillary Transcatheter Aortic Valve
Implantation According to Type of Transcatheter Heart Valve: Results from
the Multicenter TAXI Registry.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Schafer A.; Bhadra O.D.; Conradi L.; Westermann D.; Reichenspurner H.; De
Backer O.; Sondergaard L.; Qureshi W.T.; Kakouros N.; Amat-Santos I.;
Kaneko T.; Teles R.; Nolasco T.; Abecasis M.; Werner N.; Sacha J.; Trani
C.; Mangieri A.; Regueiro A.; Biancari F.; Niemela M.; Giannini F.; Buono
A.; Bruno F.; Savontaus M.; Ielasi A.; Ferraro P.; Biondi-Zoccai G.;
Morello A.; Giordano A.
Institution
(Schafer, Bhadra, Conradi, Westermann, Reichenspurner) University Heart
and Vascular Center Hamburg, Hamburg, Germany
(De Backer) Heart Center - Rigshospitalet, Copenhagen, Denmark
(Sondergaard) Heart Center-Rigshospitalet, Copenhagen, Denmark
(Qureshi, Kakouros) University of Massachusetts, School of Medicine,
Worcester, United States
(Amat-Santos) Hospital Clinico Universitario de Valladolid, Valladolid,
Spain
(Kaneko) Brigham and Women's Hospital, Boston, United States
(Teles, Nolasco, Abecasis) Hospital de Santa Cruz, Lisbon, Portugal
(Werner) Barmherzige Bruder Hospital, Trier, Germany
(Sacha) University of Opole, Opole, Poland
(Trani) Gemelli University Polyclinic Foundation, Rome, Italy
(Mangieri) Humanitas Research Hospital IRCCS, Milan, Italy
(Regueiro) University of Barcelona, Barcelona, Spain
(Biancari) Helsinki University Hospital, Helsinki, Finland
(Niemela) Oulu University Hospital, Oulu, Finland
(Giannini) GVM Care and Research Maria Cecilia Hospital, Cotignola, Italy
(Buono) Fondazione Poliambulanza Institute, Brescia, Italy
(Bruno) Citta Della Salute e della Scienza, Turin, Italy
(Savontaus) Turku University Hospital, Turku, Finland
(Ielasi) Istituto Clinico Sant'Ambrogio, Milan, Italy
(Ferraro) Santa Lucia Clinic, San Giuseppe, Italy
(Biondi-Zoccai) Sapienza University of Rome, Rome, Italy
(Morello, Giordano) Pineta Grande Hospital, Castel Volturno, Italy
Publisher
Georg Thieme Verlag
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an
established therapy. To maintain transvascular access in patients not
eligible for the transfemoral approach, transaxillary (TAx)-TAVI is
increasingly performed. The multicenter retrospective observational TAXI
(Trans-AXillary Intervention) international registry showed that
percutaneous axillary access is superior to surgical access in TAx-TAVI.
In this subanalysis of the TAXI registry, we aimed to compare procedural
success in TAx-TAVI according to different types of transcatheter heart
valves (THV) with a special emphasis on anatomical conditions.
 Method(s): For the TAXI international registry (clinicaltrials.gov
NCT02713932) anonymized data from 18 centers were collected. Follow-up was
based on direct patient visits and echocardiographic controls. Acute
procedural, early clinical and 1-month outcomes were adjudicated in
accordance with standardized VARC-3 definitions. Result(s): From a
total of 432 patients, 368 patients (85.3%, SE group) received a
self-expanding (SE) THV and 64 patients (14.8%, BE group) a
balloon-expandable (BE) THV. Preprocedural imaging revealed lower axillary
artery diameters in SE group (max/min diameter in mm: 8.4/6.6 vs. 9.4/6.8
mm; p < 0.001/p = 0.04) but a higher proportion of axillary tortuosity in
BE group (62/368, 23.6% vs. 26/64, 42.6%; p = 0.004) with steeper
aorta-left ventricle (LV) inflow (55 vs. 51degree; p = 0.002) and left
ventricular outflow tract-LV inflow angle (40.0 vs. 24.5degree; 0.002).
TAx-TAVI was significantly more often conducted by the right sided
axillary artery in BE group (33/368, 9.0% vs. 17/64, 26.6%; p < 0.001).
Device success was higher in SE group (353/368, 95.9% vs. 44/64, 68.8%, p
< 0.001). No significant differences were found regarding other outcomes.
However, in logistic regression analysis, BE THV was a risk factor for
vascular complications and axillary stent implantation.
 Conclusion(s): TAx-TAVI using SE THV leads to a significant higher
rate of device success. However, patients receiving BE THV presented with
significantly more axillary tortuosity, steeper inflow angles and were
more often provided with a right sided access. Advantage of the flexible
delivery catheter of BE THV may be the leading consideration when
utilizing BE THV in more complex anatomy in TAx-TAVI, conversely the
obligatory sheath may adversely impact steerability in hostile vascular
conditions. Based on the herein presented data of this large multicenter
registry, TAx-TAVI with SE-THV should be preferred over utilization of
BE-THV unless specific anatomical considerations occur.

<23>
Accession Number
640352372
Title
Pre-surgery Optimization of Patients' Expectations to Improve Outcome in
Heart Surgery: Study Protocol of the Randomized Controlled Multicenter
PSY-HEART-II Trial.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Salzmann S.; Laferton J.; Shedden-Mora M.; Horn N.; Gartner L.; Schroder
L.; Rau J.; Schade-Brittinger C.; Murmann K.; Rastan A.; Andrasi T.;
Boning A.; Salzmann-Djufri M.; Lowe B.; Brickwedel J.; Albus C.; Wahlers
T.; Hamm A.; Hilker L.; Albert W.; Zimmermann T.; Ismail I.; Strauss B.;
Doenst T.; Schedlowski M.; Moosdorf R.; Rief W.
Institution
(Salzmann, Horn, Gartner, Schroder, Rief) Division of Clinical Psychology
and Psychotherapy, Philipps University of Marburg, Marburg, Germany
(Laferton) Department of Medicine, Health and Medical University, Potsdam,
Germany
(Shedden-Mora) Department of Psychology, Medical School Hamburg, Hamburg,
Germany
(Rau, Schade-Brittinger, Murmann) Coordination Center for Clinical Trials
(KKS), University of Marburg, Marburg, Germany
(Rastan, Andrasi, Moosdorf) Department for Cardiovascular Surgery, Heart
Center, Philipps University of Marburg, Marburg, Germany
(Boning, Salzmann-Djufri) Department of Cardiovascular Surgery, University
Hospital Giessen, Giessen, Germany
(Lowe) Department of Psychosomatic Medicine and Psychotherapy, University
Medical Center Hamburg, Hamburg, Germany
(Brickwedel) Department of Cardiovascular Surgery, University Heart and
Vascular Center Hamburg, Hamburg, Germany
(Albus) Department of Psychosomatics and Psychotherapy, Medical Faculty
and University Hospital, Cologne, Germany
(Wahlers) Department of Cardiothoracic Surgery, University Hospital of
Cologne, Cologne, Germany
(Hamm) Department of Physiological and Clinical Psychology/ Psychotherapy,
University of Greifswald, Greifswald, Germany
(Hilker) Department of Cardiovascular Surgery, Clinic Karlsburg, Heart and
Diabetes Center, Karlsburg, Germany
(Albert) Psychosomatics,German Heart Center Berlin, Berlin, Germany
(Zimmermann) Department of Psychosomatic Medicine and Psychotherapy,
Hannover Medical School, Hanover, Germany
(Ismail) Division of Cardiac,Thoracic,Transplantation and Vascular
Surgery, Hannover Medical School, Hanover, Germany
(Straus) Institute of Psychosocial Medicine,Psychotherapy,and
Psychooncology, University Hospital Jena, Jena, Germany
(Doenst) Jena University Hospital, Friedrich-Schiller-University of Jena,
Jena, Germany
(Schedlowski) Institute of Medical Psychology and Behavioral
Immunobiology, University Clinic Essen, Essen, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Preoperative psychological preparation is gaining importance
for cardiac surgery. The PSY-HEART-I trial indicated that a brief
psychological intervention optimizing patients' expectations before heart
surgery improves disability and quality of life 6 months after coronary
artery bypass graft surgery (CABG). However, to investigate the clinical
utility of such an intervention, a large multi-center trial is needed to
generalize the results and their implications for the health care system.
The PSY-HEART-II study aims to examine whether a preoperative
psychological intervention targeting patients' expectations (EXPECT) can
improve outcomes 6 months after CABG (with or without heart valve
replacement). Method(s): EXPECT will be compared with Standard of
Care (SOC) and an intervention providing emotional support without
targeting expectations (SUPPORT). In a 3-arm multicenter randomized,
controlled, prospective trial (RCT), N = 567 patients scheduled for CABG
surgery will be randomized to either SOC alone or SOC and EXPECT or SOC
and SUPPORT. Patients will be randomized with a fixed unbalanced ratio of
3:3:1 (EXPECT: SUPPORT: SOC) to compare EXPECT to SOC and EXPECT to
SUPPORT. Both psychological interventions consist of 2 in-person sessions
(50 minutes), 2 phone consultations (20 minutes) during the week prior to
surgery, and one booster phone consultation post-surgery 6 weeks later.
Assessment will occur at baseline approximately 3 to 10 days before
surgery, preoperatively the day before surgery, 4 to 6 days later, and 6
months after surgery. This trial is funded by the DFG (German Research
Foundation; PI W. Rief, DFG Ri-574/29-1 and Ri574/29-2). Result(s):
The study's primary endpoint will be patients' illness-related disability
6 months after surgery. Secondary outcomes will be patients' expectations,
subjective illness beliefs, quality of life, anxiety, depression, length
of hospital stay and blood sample parameters (e.g., biomarkers such as
IL-6, IL-8, CRP, NT-proBNP). Conclusion(s): This large multicenter
trial has the potential to corroborate and generalize the promising
results of the PSYHEART-I trial for routine care of cardiac surgery
patients, strengthen the importance of a multi-professional team, and
stimulate revisions of treatment guidelines in heart surgery.

<24>
Accession Number
640352254
Title
Surgeons Learning Curve in Acute Type A Aortic Dissection.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Von Aspern K.; Valencia-Nunez D.M.; Roeschner C.; Schneider M.; Otto K.;
Becker V.; Schmidt T.; Lehmann S.; Garbade J.
Institution
(Von Aspern, Valencia-Nunez, Roeschner, Schneider, Otto, Becker, Schmidt,
Lehmann, Garbade) Klinikum Links der Weser-Herzzentrum Bremen, Bremen,
Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Type A aortic dissection is one of the main emergency
indications for cardiovascular surgery oftentimes operated on after
regular working hours by the on-call surgeon. Due to its heterogeneity in
presentation and surgical strategy involved it is regarded as a challenge
especially for surgeons with less operative experience. The aim of this
study is to investigate the influence of operative experience on outcome.
 Method(s): All emergency surgeries for acute type A aortic dissection
between January 2010 and December 2020 at a single institution were
included. Operative details and outcomes of 12 surgeons (with specialty in
cardiac surgery and at least 1 year of working period in the centers'
operating team) were analyzed. Analyses were stratified according to the
surgeons' operative experience (surgeons' allocation were blinded and
randomized for all analyses). Outcomes included early mortality (30 days
or in-house), early complications, and aortic reoperations during
follow-up. Result(s): A total of 250 patients were operated on.
Surgeons were stratified according to their operative experience at the
time of the operation. Surgeons with up to 5 years of operative experience
did not perform any extended arch procedures compared with 26% (N = 11) of
surgeons with more than 20 years of operative experience (p < 0.05
inter-group significance). Time on cardiopulmonary bypass and aortic
cross-clamp periods gradually decreased for surgeons in their first year
up to 20 years of experience (from 184 +/- 34 and 115 +/- 37 minutes to
129 +/- 35 and 69 +/- 24 minutes, respectively; p < 0.05). No early deaths
were observed for patients operated by surgeons in their first year. A
peak in early mortality was observed for surgeons between their second to
fifth year (20.8%, N = 5), reaching a plateau thereafter at 15.3% (N = 33;
p < 0.05). Conclusion(s): Surgeons in their first year of type A
aortic dissection surgery did not negatively influence outcome. The second
to fifth years seem to be the most vulnerable time frame with regard to
operative complications. Individual attributes might also have an
important effect on outcome irrespective of mere operative experience.
These results might indicate the importance of a functioning aortic team
supervising the early operative learning curve.

<25>
Accession Number
2043885888
Title
Assessment of No-Reflow in Patients With STEMI After Intracoronary
Tirofiban After Opening of the Vessel.
Source
Cardiology Research. 17(1) (pp 23-31), 2026. Date of Publication: 01 Feb
2026.
Author
Hammad M.A.M.; Hassib W.A.E.; Salama M.K.I.; Thalib H.I.; Moanes M.;
Reihan M.
Institution
(Hammad, Hassib, Salama) Cardiology Department, Faculty of Medicine, Kafr
Elsheikh University, Kafr Elsheikh, Egypt
(Thalib) Batterjee Medical College, Jeddah, Saudi Arabia
(Moanes) Cardiology Department, Faculty of Medicine, Al-Azhar University,
Cairo, Egypt
(Moanes) Hayat National Hospitals, Saudi Arabia
(Reihan) Cardiology Department, Faculty of Medicine, Al-Azhar University,
Damietta, Egypt
(Reihan) Department of Internal Medicine, Batterjee Medical College,
Jeddah, Saudi Arabia
(Thalib) Batterjee Medical College, Jeddah, Saudi Arabia
Publisher
Elmer Press
Abstract
Background: No-reflow phenomenon (NRP) following primary percutaneous
coronary intervention (PPCI) remains a critical determinant of adverse
outcomes in ST-segment elevation myocardial infarction (STEMI) cases
despite successful epicardial recanalization. The core purpose of this
study was to establish the value of intracoronary (IC) tirofiban,
delivered via the IC route, in mitigating the occurrence of NRP for STEMI
cases subsequent to successful vessel reopening. Method(s): This
randomized controlled double-blind study enrolled 60 STEMI cases.
Following successful PCI, cases with thrombolysis in myocardial infarction
(TIMI) flow grade less than 3 were randomized to receive either IC
tirofiban (25 mg/kg) or saline 0.9% as placebo, in addition to standard
pre-procedural therapy with aspirin, heparin, and ticagrelor. TIMI flow
grade and incidence of NRP were evaluated. Additionally, ST-T
normalization in electrocardiogram (ECG) was assessed. Bleeding
complications and major adverse cardiac events (MACEs) were recorded
during hospitalization and at 30-day follow-up. Result(s): The
tirofiban group demonstrated notably superior coronary flow restoration
with 80% achieving TIMI 3 flow versus 46.67% in controls (P = 0.007). NRP
occurred in 20% of tirofiban cases compared to 53.33% in controls (P =
0.007). Minor bleeding complications increased in the tirofiban group
(26.67% versus 3.33%, P = 0.026), while major bleeding remained absent in
both groups. Total in-hospital MACEs were notably reduced with tirofiban
treatment compared to controls (3.33% versus 30%, P = 0.012).
 Conclusion(s): In STEMI cases following PPCI, IC tirofiban
administration effectively reduces NRP, improves coronary flow
restoration, and reduces MACE despite increased minor bleeding
risk. Copyright Articles © The authors Journal compilation
© Cardiol Res and Elmer Press IncTM https://cr.elmerpub.com
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (CC BY 4.0), which permits
unrestricted use, distribution, and reproduction in any medium, including
commercial use, provided the original work is properly cited

<26>
Accession Number
2042225968
Title
Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy
associated with mutations in the MYBPC3 gene: Systematic review and
meta-analysis.
Source
Journal of Cardiology. 87(3) (pp 205-211), 2026. Date of Publication: 01
Mar 2026.
Author
Nogueira-Garcia B.; Pinheiro D.; Gregorio C.; Caldeira D.; Pinto F.J.;
Brito D.
Institution
(Nogueira-Garcia, Gregorio, Caldeira, Pinto, Brito) Cardiology Department,
Unidade Local de Saude Santa Maria - Santa Maria Hospital, Lisboa,
Portugal
(Nogueira-Garcia, Pinheiro, Gregorio, Caldeira, Pinto, Brito) Centro
Academico de Medicina de Lisboa (CAML), Universidade de Lisboa, Lisboa,
Portugal
(Nogueira-Garcia, Gregorio, Caldeira, Pinto, Brito) Heart Failure and
Cardiomyopathies Research Unit, CCUL@RISE, Universidade de Lisboa, Lisboa,
Portugal
(Caldeira) Laboratory of Clinical Pharmacology and Therapeutics, Faculdade
de Medicina, Universidade de Lisboa, Lisboa, Portugal
(Caldeira) Centro de Estudos de Medicina Baseada na Evidencia (CEMBE),
Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Background Hypertrophic cardiomyopathy (HCM) is caused by mutations in
sarcomere-related genes, with MYBPC3 being the most common. Documenting
potential genotype-phenotype associations may allow for more personalized
genetic counselling. Methods and results Observational case-control,
cohort, and cross-sectional studies reporting genotype-phenotype
associations and the occurrence of predefined events were selected from
Cochrane and Medline databases. A random- effects meta-analysis was
conducted. Twenty-four studies were included, with 3869 patients enrolled.
The mean age at diagnosis of HCM associated with mutations in the MYBPC3
gene was 39.8 years (95 % CI 32.96 to 46.55), and the mean maximum left
ventricular thickness was 20.4 mm (95 % CI 19.72 to 21.06). Proportion
rates were 12.6 % (95 % CI 5.7 to 21.5 %) for septal reduction therapy,
20.4 % (95 % CI 11.9 to 30.2 %) for the development of heart failure New
York Heart Association (NYHA) III/IV functional class, 16.1 % (95 % CI
10.3 to 22.6 %) for the occurrence of atrial fibrillation, and 26 % (95 %
CI 17.0 to 36.1 %) for ventricular tachycardia.
Cardioverter-defibrillators were implanted in 31.4 % (95 % CI 18.6 to 45.6
%) for secondary prevention, and sudden cardiac arrest occurred in 14.7 %
(95 % CI 7.8 to 23.0 %) of patients. Cardiovascular death occurred in 8.6
% of patients over a median of 73 months of follow-up. Conclusion This is
the largest meta-analysis of MYBPC3 HCM patients to date. We were able to
obtain data on the proportion rates of events in this population, which
allows to answer some questions about the clinical course of HCM disease
associated with mutations in the MYBPC3 gene more clearly. We found not
only a late disease onset and low mortality risk, but importantly, a
non-negligible risk of developing severe heart failure throughout
life. Copyright © 2025 Elsevier Ltd.

<27>
Accession Number
2043645457
Title
Comparison of the efficacy and safety of thoracic epidural and
paravertebral block in postoperative analgesia after thoracic surgery: a
meta-analysis of randomized trials.
Source
Frontiers in Medicine. 13 (no pagination), 2026. Article Number: 1747430.
Date of Publication: 2026.
Author
Qi X.; Li Z.; Zhou L.; Wang J.; Zhang X.
Institution
(Qi) Department of Pancreatic Surgery, Weifang People's Hospital,
Shandong, Weifang, China
(Li, Zhou, Wang, Zhang) Department of Critical Care Medicine, Weifang
People's Hospital, Shandong, Weifang, China
Publisher
Frontiers Media SA
Abstract
Objectives: Paravertebral block (PVB) and thoracic epidural analgesia
(TEA) are commonly used methods for pain relief after open chest surgery.
However, due to their different characteristics, there are still
controversies regarding the analgesic effect and safety of these two
methods after chest surgery. This report represents the latest
meta-analysis on this topic. Method(s): We searched PubMed, Embase,
and Cochrane Library and identified randomized controlled trials on the
use of paravertebral block and thoracic epidural analgesia after thoracic
surgery. Two researchers independently screened the identified studies.
The efficacy and safety of the two different analgesic methods were
compared and analyzed. A meta-analysis was conducted using RevMan 5.4
software. This study has been registered in PROSPERO (CRD420251208232).
 Result(s): Thirty-five trials were included. Compared with
paravertebral block (PVB), thoracic epidural analgesia (TEA) provided
significantly lower pain scores at 24 h postoperatively (Resting: MD 0.41,
P = 0.03; Movement: MD 0.40, P = 0.03). However, no significant
differences were observed at 48 h. PVB was associated with a significantly
lower risk of complications, including hypotension (OR 0.13, P < 0.00001),
postoperative nausea and vomiting (OR 0.38, P = 0.0004), and urinary
retention (OR 0.23, P < 0.0001). Pulmonary complication rates were
comparable between groups (OR 0.61, P = 0.06). Conclusion(s): While
TEA demonstrated slightly superior resting and movement pain control at
the 24-h, these differences were no longer significant by 48 h. Most
notably, PVB was associated with a significantly lower risk of
hypotension, postoperative nausea and vomiting, and urinary retention.
Overall, PVB is a safer and equally effective alternative to TEA for
thoracic surgery. Copyright © 2026 Qi, Li, Zhou, Wang and Zhang.

<28>
Accession Number
2044085007
Title
Effectiveness of adding inspiratory muscle training to a cardiac
rehabilitation program in people with acute myocardial infarction
revascularized by percutaneous coronary intervention (CARDIOINSPIRE):
Study protocol for a randomized controlled trial.
Source
PLOS ONE. 21(3 March) (no pagination), 2026. Article Number: e0343947.
Date of Publication: 01 Mar 2026.
Author
Zuazagoitia-Lama-Noriega J.M.; Gomez-Gonzalez A.M.; Moral-Munoz J.A.
Institution
(Zuazagoitia-Lama-Noriega, Moral-Munoz) Department of Nursing and
Physiotherapy, University of Cadiz, Cadiz, Spain
(Gomez-Gonzalez) Rehabilitation Department, Virgen de la Victoria
University Hospital, Malaga, Spain
(Gomez-Gonzalez) Biomedical Research and Innovation Institute of Malaga
and Nanomedicine Platform (IBIMA-BIONAND Platform), Malaga, Spain
(Moral-Munoz) Biomedical Research and Innovation Institute of Cadiz
(INiBICA), University of Cadiz, Cadiz, Spain
Publisher
Public Library of Science
Abstract
Objectives This study aims to analyze the effectiveness of adding
inspiratory muscle training (IMT) to a cardiac rehabilitation program
(CRP) in people with acute myocardial infarction (AMI) revascularized by
percutaneous coronary intervention (PCI) after 16 sessions. The
biopsychosocial profile and the sex differences of this population will
also be evaluated. Design Triple-blind, parallel-group, low-risk
randomized controlled trial. Methods 72 patients diagnosed with AMI will
be enrolled and randomly assigned to two groups. The control group will
complete the usual CRP with the addition of IMT at 5% of the maximal
inspiratory pressure (MIP) (sham load). The intervention group will
perform the same CRP but will add an IMT program at 70% of MIP. Outcomes
will be collected at baseline and post-intervention. The main outcome will
be cardiorespiratory fitness (CF) measured in metabolic equivalent of task
(MET), secondary outcomes will be MIP, maximal expiratory pressure,
peripheral muscle strength, dyspnea, social support, anxiety, depression,
coping with the disease, sexual dysfunction, quality of life (QoL), sleep
quality, eating habits, and body composition. Descriptive statistics will
summarize baseline data, and influential outliers will be managed via
winsorization or exclusion, confirmed by sensitivity analyses. A
mixed-design ANOVA will evaluate differential changes over time. Depending
on attrition rates, missing data will be addressed using either complete
case analysis (<5%) or multiple imputation with an intention-to-treat
approach (>5%). Discussion According to recent literature, improvements in
CF and MIP are expected. For the rest of the outcomes, data are currently
limited, inconclusive or lacking. We hypothesize that changes in CF may
affect the rest of the outcomes and, in our opinion, IMT at 70% of the MIP
will significantly improve CF. Clinical implications If the expected
benefits are observed, the results may recommend including IMT as a
fundamental component of a CRP in our study population. Copyright
© 2026 Zuazagoitia-Lama-Noriega et al. This is an open access article
distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.

<29>
[Use Link to view the full text]
Accession Number
2043317969
Title
Pre-TAVI CT Angiography for Coronary Artery Disease Assessment: A
Systematic Review and Meta-Analysis of Clinical Outcomes.
Source
Circulation: Cardiovascular Interventions. Publish Ahead of Print (pp
e016074), 2026. Date of Publication: 29 Jan 2026.
Author
Rahmati S.; Nasrollahizadeh A.; Kolte D.; Khalique O.K.; Biering-Sorensen
T.; Hosseini K.
Institution
(Rahmati, Nasrollahizadeh, Hosseini) Tehran Heart Center, Cardiovascular
Diseases Research Institute, Tehran University of Medical Sciences, Iran,
Islamic Republic of
(Kolte) Cardiology Division, Massachusetts General Hospital, Boston
(Khalique) St Francis Hospital and Heart Center, Roslyn, NY
(Biering-Sorensen, Hosseini) Department of Cardiology, Copenhagen
University Hospital-Herlev and Gentofte, Denmark
(Biering-Sorensen, Hosseini) Department of Biomedical Sciences, Center for
Translational Cardiology and Pragmatic Randomized Trials, Faculty of
Health and Medical Sciences, University of Copenhagen, Denmark
(Biering-Sorensen) Department of Cardiology, Copenhagen University
Hospital-Rigshospitalet, Denmark
(Biering-Sorensen) Steno Diabetes Center Copenhagen, Herlev, Denmark
Publisher
Lippincott Williams and Wilkins

<30>
Accession Number
647628297
Title
Survival Trends of Patients after Coronary Artery Bypass Grafting and
Sex-specific Differences-A Meta-analysis of Reconstructed Time-to-event
Data.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Kirov H.; Caldonazo T.; Toshmatov S.; Tasoudis P.; Fischer J.; Runkel A.;
Mukharyamov M.; Doenst T.
Institution
(Kirov, Caldonazo, Toshmatov, Fischer, Runkel, Mukharyamov, Doenst) Jena
University Hospital, Jena, Germany
(Tasoudis) University of North Carolina, Chapel Hill, United States
Publisher
Georg Thieme Verlag
Abstract
Background: Randomized evidence suggest that coronary artery bypass
grafting (CABG) has the potential to improve life expectancy. Women are
considered to have worse outcomes after CABG, but they are generally
underrepresented in randomized trials. Registry data and trial
sub-analyses provide controversial results for CABG in women. We
systematically assessed the survival-improving potential of CABG in both
sexes by analyzing studies that assessed CABG outcomes compared with the
age-matched general population. Method(s): Three databases were
assessed (MEDLINE, ScienceDirect, and Cochrane Library). Primary and
single outcome was long-term all-cause mortality. Reconstruction of
time-to-event data was performed. Sex-specific data from the arms were
separately extracted. Hazard ratios (HR) and 95% confidence intervals (CI)
were calculated. Landmark analysis was performed to check the robustness
of the estimated effect. Result(s): A total of 1,352 studies were
retrieved. Eight studies encompassing 142,165 patients were included in
the analysis. For the entire 19 years observation period, patients who
underwent CABG had worse survival than the general population in both male
(HR = 1.14, 95% CI, 1.05-1.23, p = 0.002) and female patients (HR = 1.21,
95% CI, 1.01-1.47, p = 0.045). However, the curves separated only after
approximately 10 years which coincided with a violation of the
proportional of hazard ratio assumption of the analysis. Performing
landmark analyses suggest that there is no difference in life expectancy
compared with the general population in the first decade. The direct
comparison of men versus women suggests that very long-term survival was
slight better in women (HR: 1.04, 95% CI, 1.01-1.08). Conclusion(s):
Both men and women after CABG for treatment of CAD experience similar life
expectancy in the first decade compared with the general population.
Beyond 10 years, life expectancy becomes worse than the general population
and is the worst in men. It may be speculated that this difference is due
to graft occlusions.

<31>
Accession Number
643690322
Title
Long-Term Survival in Elderly Patients after Coronary Artery Bypass
Grafting Compared to the Age-Matched General Population-A Meta-analysis of
Reconstructed Time-to-event Data.
Source
Thoracic and Cardiovascular Surgeon. Conference: 53rd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 72(Supplement 1) (no pagination), 2024. Date of Publication: 13
Feb 2024.
Author
Kirov H.; Caldonazo T.; Toshmatov S.; Tasoudis P.; Mukharyamov M.; Diab
M.; Doenst T.
Institution
(Kirov) Friedrich-Schiller-University, Jena, Germany
(Caldonazo, Toshmatov, Doenst) Jena University Hospital, Jena, Germany
(Tasoudis) University of North Carolina, Chapel Hill, United States
(Mukharyamov) University Hospital of Friedrich-Schiller, University Jena,
Jena, Germany
(Diab) Herz-Kreislauf-Zentrum Rotenburg a. d. Fulda, Rotenburg an der
Fulda, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Atherosclerotic coronary artery disease (CAD) limits life
expectancy compared to the general population. Myocardial infarctions (MI)
are the primary cause of death. The incidence of MI increases
progressively with age and most MI deaths occur in the population older
than 70 years. Coronary artery bypass grafting (CABG) may prevent the
occurrence of new MIs by bypassing most CAD lesions, providing downstream
"collateralization" to the diseased vessel. We systematically assessed the
survival-improving potential of CABG by comparing elderly CABG patients to
the age-matched general population. Method(s): Three databases were
assessed (MEDLINE, ScienceDirect and Cochrane Library). Primary and single
outcome was long-term all-cause mortality. Reconstruction of individual
patient survival data (IPD) was performed. As a sensitivity analysis,
summary hazard ratios (HR) and 95% confidence intervals (CI) for all
individual studies based on the reconstructed IPD were pooled for a
conventional two-stage meta-analysis. Result(s): A total of 1,352
studies were retrieved. Four studies and 6,917 patients were included in
the analysis. Elderly patients (>70 years) who underwent CABG had
significantly lower risk of death in the follow-up compared to the general
age-matched population in the one-stage (HR: 0.88, 95% CI: 0.83-0.94, p <
0.001) and in the two-stage survival analysis (HR 0.89, 95% CI 0.80-0.99,
p = 0.03). Conclusion(s): Elderly patients (>70 years) who undergo
CABG appear to have significantly better long-term survival compared to
the age-matched general population. This advantage becomes visible after
the first year and underscores the life-prolonging effect of bypass
surgery, which may eliminate the expected reduction in life expectancy
through CAD.

<32>
Accession Number
643690395
Title
3D printing Significantly Improves Procedural Understanding of Elective
Aortic Surgery Patients: A Prospective Randomized Cohort Trial.
Source
Thoracic and Cardiovascular Surgeon. Conference: 53rd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 72(Supplement 1) (no pagination), 2024. Date of Publication: 13
Feb 2024.
Author
Motekallemi A.; Esmaeili F.S.; Peivandi A.D.; Weber R.; Martens S.;
Rukosujew A.
Institution
(Motekallemi) Kassel Clinic, Kassel, Germany
(Motekallemi) Munster University Hospital, Munster, Germany
(Esmaeili, Martens) Klinik fur Herzchirurgie Munster, Munster, Germany
(Peivandi) University Hospital Muenster, Department of Cardiothoracic
Surgery, Muenster, France
(Weber, Rukosujew) Universitatsklinik Munster - Klinik fur Herzchirurgie
Munster, Munster, Germany
(Martens) Albert-Schweitzer-Campus 1, Munster, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: 3D printing is a rapidly evolving new technology with various
applications within cardiac surgery. It is mainly applied for individual
operational planning in complex congenital heart disease. Its impact on
procedural understanding of the patient has not yet been evaluated in a
structured manner. This is the first randomized cohort trial to evaluate
the value of patient-specific 3D printed models on procedural
understanding in patients for elective aortic surgery. Method(s): The
study was planned in collaboration with the Institute of Epidemiology and
Social Medicine and approved by the local ethics committee. Between April
2020 and June 2022 41 patients (21 females) for elective aortic procedures
were included and an intermediate analysis in accordance with the
previously defined power (>0.8) was performed. After randomization,
patients were informed with either conventional forms or with individual
3D models of their own aorta using a commercially available 3D printer.
Beside other factors, procedural understanding and localization of aortic
pathology were evaluated using a validated scoring system (based on the
illness perception questionnaire). General demographic data as well as the
educational and socio-economic background were surveyed separately. The
t-test was applied for comparison of means while the Mann-Whitney U-test
was applied for comparison of independent ordinal-scaled variables using
SPSS version 22.0 (IBM Corp, Armonk, NY). Result(s): This is the
first structured approach evaluating the (additional) value of 3D printing
on procedural understanding in aortic surgery patients. Mean age of the
patients in the 3D and conventional group was 63.6 years and 60.5 years
respectively. Patients informed with a 3D model of their aortic pathology
showed a significantly better understanding regarding their disease (p <
.001), operative procedure (p < 0.001) and localization of their pathology
(p = 0.015). The added value of the 3D model is independent of the
patient's gender, age, level of education or socio-economic background.
 Conclusion(s): Within cardiac surgery, 3D printing has so far been
mainly used for procedure planning in complex (congenital) cases. However,
this study shows the potentials of this innovation for broader
applications beyond the singlecase mentality. This is the first
prospective randomized cohort trial to show a clear benefit of
individualized 3D printed models on patient illness and procedural
perception in aortic pathologies.

<33>
Accession Number
647628294
Title
ERAS in High-risk Patients: Improvement of Clinical Outcomes.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Casper J.; Krey M.; Dolata L.; Gemander C.; Sarwari H.; Yalin Y.; Pecha
S.; Chindris V.; Schulte-Uentrop L.; Girdauskas E.; Reichenspurner H.;
Petersen J.
Institution
(Casper) Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
(Krey) University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Dolata, Sarwari, Yalin) University Heart and Vascular Center Hamburg,
Hamburg, Germany
(Gemander) Uni, Hamburg, Germany
(Pecha, Schulte-Uentrop, Reichenspurner, Petersen) HamburgGermany
(Chindris) Universitatskjlinikum Hamburg-Eppendorf, Martinistrase,
Hamburg- Nord, Germany
(Girdauskas) University Heart Center, Augsburg, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Enhanced Recovery After Surgery (ERAS) uses a
multidisciplinary, evidence-based approach to improve overall outcomes and
length of stay for patients undergoing surgery. Multimorbid patients in
particular could benefit from the ERAS protocol. This study aims to show
the effects of an ERAS routine in patients undergoing high-risk surgery
according to the ERAS guidelines. Method(s): The ERAS protocol with
preoperative appointments and dedicated prehabilitation was applied to a
total of 93 patients from June 2023 to July 2024. According to the ERAS
guidelines, procedures such as root repair/replacement, ascending aortic
replacement, Ross procedure, redo procedures, and combined valve
procedures are defined as high-risk procedures. Of the 93 ERAS patients,
31 patients were considered high risk for ERAS (high risk group) compared
with 62 low-risk patients (low-risk group). Result(s): The high-risk
group was significantly younger (high-risk: 57.5 +/- 7.8 versus low-risk:
60.9 +/- 6.2; p = 0.024) and had a higher EURO-Score II (high-risk: 1.5
+/- 0.89 versus low-risk: 0.87 +/- 45; p = 0.001). Other baseline
characteristics were similar in both groups. Cardiopulmonary bypass time
(p = 0.205) and aortic cross-clamp time (high-risk: 101.9 +/- 46.2 versus
low-risk: 84.3 +/- 23.9; p = 0.088) were similar in both groups.
Extubation in the OR was possible in 35.4% of the high-risk group and 34%
of the low-risk group (p = 0.932). Reintubation was required for
postoperative bleeding in 2/31 patients (high-risk) and 2/62 (low-risk)
patients. Admission to PACU-24 instead of ICU was possible in 32% of
high-risk and 53% of low-risk patients (p = 0.056). One low-risk patient
had postoperative delirium. ICU readmission was required in 2/31
(high-risk) and 2/62 (low-risk) patients (p = 0.470). ICU stay (high-risk:
28.5 +/- 23.4 versus low-risk: 32.9 +/- 30.7; p = 0.481) and postoperative
hospital stay (high-risk: 8.6 +/- 3.8 versus low-risk: 7.2 +/- 2.9; p =
0.084) were similar in both groups. Conclusion(s): ERAS protocols can
also be safely implanted in more complex patients such as combined valve
procedures, Ross procedures, and/or redo procedures. However, a dedicated
multi-professional team with a dedicated ERAS nurse is required to manage
these multimorbid patients within the ERAS protocol.

<34>
Accession Number
647628149
Title
Highlighting Genetic Differences between Barlow's Disease and Fibroelastic
Deficiency via Genome-Wide Association Study Meta-Analyses.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Feirer N.; Weber M.; Knoll K.; Miranda L.; Yu M.; Li L.; Lahm H.; Kameric
M.; Doppler S.; Gottmann I.; Lichtner P.; Berger K.; Lek M.; Lange R.;
Schunkert H.; Hagege A.; Bouatia-Naji N.; Muller-Myhsok B.; Trenkwalder
T.; Gruber P.; Krane M.; Dressen M.
Institution
(Feirer, Knoll, Kameric, Lichtner, Schunkert, Trenkwalder) German Heart
Center Munich, School of Medicine and Health, Technical University of
Munich, Munich, Germany
(Weber) Boehringer Ingelheim, Ulm, Germany
(Miranda) Max Planck Institute of Biochemistry, Munich, Germany
(Yu) Fudan University, Shanghai, China
(Li) Munich Heart Alliance, Munchen, Germany
(Lahm, Doppler, Gottmann, Lange, Krane, Dresen) Department of
Cardiovascular Surgery, Institute Insure, German Heart Center Munich,
Munich, Germany
(Berger) Institut fur Epidemiologie und Sozialmedizin, Munster, Germany
(Lek, Gruber) Yale School of Medicine, Division of Cardiac Surgery, Yale,
United States
(Hagege) European Hospital Georges Pompidou, Paris, France
(Bouatia-Naji) Universite de Paris, Paris, France
(Muller-Myhsok) Department of Translational Research in Psychiatry, Max
Planck Institute of Psychiatry Munich, Munich, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Subtypes of mitral valve prolapse (MVP) show a broad spectrum,
including the phenotypes fibroelastic deficiency (FED) and Barlow's
disease. However, the underlying genetic differences have not yet been
analyzed in detail. This study highlights novel risk loci specific for FED
and Barlow's disease, respectively. Method(s): The cohort included
all consecutive patients who underwent mitral valve surgery for
degenerative MVP at the Department of Cardiovascular Surgery or presented
with symptomatic MVP at the Department of Cardiology at the German Heart
Center Munich between March 2002 and January 2021. The cohort was
subdivided into the phenotypes FED and Barlow's disease, based on clinical
and morphological characteristics. Intermediate phenotypes were excluded
from the subgroup analysis. Subgroups were analyzed via GWAS and
investigated in meta-analyses with GWAS datasets stratified from data from
the MVP France study. Phenome-wide association study (PheWAS) was
performed with datasets from UK Biobank. Result(s): Within our cohort
of 2,140 MVP patients, 84.5% (n = 1,809) suffered from severe mitral
regurgitation that required surgery. The MVP France cohort included 1,412
patients and 2,439 controls, resulting in 3,552 patients and 11,439
controls included in our analyses. GWAS meta-analysis included 997 FED
cases and 788 Barlow's disease cases. Two genome-wide significant loci (p
< 5e-8) associated with Barlow's disease were identified. For Barlow's
disease, 35 further SNPs also showed a significant correlation (p < 5e-5)
in 32 risk loci. In association with FED, one highly significant (p < 5e-
8) locus was identified. Further 35 SNPs showed a significant FED
correlation (p < 5e-5) in 30 risk loci. PheWAS revealed an association
with paroxysmal supraventricular tachycardia for one locus correlating
with FED on chromosome 4 and for one locus correlating with Barlow's
disease on chromosome 10. Also, associations with left ventricular
hypertrophy and ventricular arrhythmia were revealed for risk loci that
correlate with Barlow's disease. Conclusion(s): This study presents
the first GWAS identifying risk loci associated with FED and Barlow's
disease. PheWAS links lead SNPs to several other cardiac conditions. These
findings could initiate a paradigm shift in understanding the genetic
differences between FED and Barlow's disease.

<35>
Accession Number
640352307
Title
Association of Liver Dysfunction with Outcomes after Cardiac Surgery: A
Systematic Review and Meta-analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Kirov H.; Caldonazo T.; Diab M.; Farber G.; Doenst T.
Institution
(Kirov, Caldonazo, Diab, Farber, Doenst) Friedrich-Schiller-University,
Jena, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: To perform a meta-analysis of studies reporting outcomes in
patients with liver dysfunction addressed by the model of end-stage liver
disease (MELD) and Child-Turcotte-Pugh (CTP) scores undergoing cardiac
surgery. Method(s): A systematic literature search was conducted to
identify contemporary studies reporting short- and long-term outcomes in
patients with liver dysfunction compared with patients with no or mild
liver dysfunction undergoing cardiac surgery (stratified in high and low
score group based on the study cutoffs). Primary outcome was perioperative
mortality. Secondary outcomes were perioperative neurological events,
prolonged ventilation, sepsis, bleeding and/or need for transfusion, acute
kidney injury, and long-term mortality. Result(s): A total of 33
studies with 48,891 patients were included. Compared with the low score
group, being in the high score group was associated with significantly
higher risk of perioperative mortality (OR: 3.72, 95% CI: 2.75-5.03, p <
0.001). High score group was also associated with a significantly higher
rate of perioperative neurological events (OR: 1.49, 95% CI: 1.30-1.71, p
< 0.001), prolonged ventilation (OR: 2.45, 95% CI: 1.94-3.09, p < 0.001),
sepsis (OR: 3.88, 95% CI: 2.07-7.26, p < 0.001), bleeding and/or need for
transfusion (OR: 1.95, 95% CI: 1.43-2.64, p < 0.001), acute kidney injury
(OR: 3.84, 95% CI: 2.12-6.98, p < 0.001), and long-term mortality (IRR:
0.78, 95% CI: 0.69-0.88, p < 0.001). At meta-regression, the assessed
variables did not show any significant association with the pooled
estimate for perioperative mortality. Conclusion(s): The analysis
suggests that liver dysfunction in patients undergoing cardiac surgery is
independently associated with higher risk of short and long-term mortality
and also with an increased occurrence of various perioperative adverse
events.

<36>
Accession Number
643690367
Title
Contemporary Surgical Aortic Valve Replacement in Elderly Patients.
Source
Thoracic and Cardiovascular Surgeon. Conference: 53rd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 72(Supplement 1) (no pagination), 2024. Date of Publication: 13
Feb 2024.
Author
Fischer Y.; Bhadra O.D.; Demal T.J.; Von D.H.I.; Hannen L.; Grundmann D.;
Voigtlander L.; Waldschmidt L.; Ludwig S.; Schirmer J.; Schofer N.; Pecha
S.; Blankenberg S.; Conradi L.; Reichenspurner H.; Seiffert M.; Schafer A.
Institution
(Fischer, Bhadra, Demal, Von, Hannen, Grundmann, Voigtlander, Waldschmidt,
Ludwig, Schirmer, Schofer, Pecha, Blankenberg, Conradi, Reichenspurner,
Seiffert, Schafer) University Heart and Vascular Center Hamburg, Hamburg,
Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Surgical Aortic Valve Replacement (SAVR) has steadily declined
in importance due to the increasing use of transcatheter Aortic Valve
Implantation (TAVI) in patients across all risk-strata. Due to large
randomized controlled trials comparing SAVR and TAVI current guidelines
still recommend SAVR for patients <75 years of age and at low surgical
risk. The aim of this study was to compare patients <75 years and >=75
years of age undergoing isolated SAVR in a single center patient cohort.
 Method(s): From 03/2018 to 10/2022, 344 patients undergoing isolated
SAVR were enrolled in Hamburg Harbor registry. Of those, 275 patients were
<75 years of age (group 1, 62.5 +/- 10.9 years) and were compared to 69
patients >=75 years (group 2, 78.9 +/- 2.9 years, p <= 0.01). Acute
procedural and early clinical outcomes were adjudicated in accordance with
standardized VARC-3 definitions. Patients with acute endocarditis were
included. Result(s): Patients >=75 years presented a higher risk
profile according to STS risk stratification (group 1 vs. group 2, 0.9 +/-
1.1 vs. 1.8 +/- 1.6%, p <= 0.01). Aortic regurgitation as leading cause
for SAVR was significantly more present in patients <75 years of age (40.5
vs. 23.9%, p <= 0.01). No significant difference was found regarding
prevalence of infective endocarditis (13 vs. 12.7%, p = 1.0). Procedural
data revealed no differences in cardiopulmonary bypass time (98 +/- 45 vs.
89 +/- 25 minutes, p = 0.11) and cross clamp time (67 +/- 27 vs. 61 +/- 31
minutes, p = 0.18). Rates of stroke (2.17 vs. 1.31%, p = 1.0), acute renal
failure (5.5 vs. 7.0%, p = 0.77), new permanent pacemaker implantation
(PPI) (6.8 vs. 5.6%, p = 1.0) and intensive care unit stay (2 +/- 2.3 vs.
2 +/- 2.1 days, p = 1.0) were comparable between groups. Mean 30-day
aortic valve gradients (11.6 +/- 5.1 mmHg vs. 11.1 +/- 4.4 mmHg, p = 0.44)
and rates of paravalvular leakage >mild (0 vs. 1.4%, p = 0.2) showed
favorable hemodynamic results in both groups. Despite >10% of endocarditis
patients in both groups, rates of 30- day mortality were low (1.8 vs.
1.4%, p = 1.0). Conclusion(s): Both patient cohorts presented
excellent outcomes with low rates of mortality, stroke and PPI despite a
significant proportion of patients with infective endocarditis in both
groups. Decision to provide patients with SAVR or TAVI within a heart team
should be based on a multifactorial decision process including anatomical
parameters, clinical condition and considerations regarding lifetime
management of aortic valve disease.

<37>
Accession Number
640352209
Title
In-Hospital Outcome of Acute Myocardial Infarction: Culprit PCI and
Consecutive CABG versus Emergent Complete Surgical Revascularization.
Source
Thoracic and Cardiovascular Surgeon. Conference: 52nd Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 71(Supplement 1) (no pagination), 2023. Date of Publication: 28
Jan 2023.
Author
Macius E.; Naito S.; Sobik F.; Reichenspurner H.; Sill B.
Institution
(Macius, Naito, Sobik, Reichenspurner, Sill) University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Coronary artery bypass grafting (CABG) and percutaneous
coronary intervention (PCI) are standard therapeutic approaches for
cardiac revascularization. The selection of therapy depends primarily on
the complexity of coronary artery disease and urgency of treatment.
Surgical revascularization guaranties excellent long-term outcomes in
patients with advanced multivessel disease, whereas percutaneous coronary
intervention of the culprit lesion is recommended in the setting of ST
elevation myocardial infarction (STEMI). Still, the outcome of CABG when
compared with PCI in an emergency setting is unclear. Method(s): Data
from January 2010 to February 2020 were used for this survey. A total of
1,062 patients with an acute myocardial infarction (STEMI: n = 229,
NSTEMI: n = 883) were surgically treated (<48 hours after diagnosis) and
retrospectively analyzed. In-hospital outcome (MACCE: myocardial
infarction, surgical revision, stroke, and all causes of death) was
compared between patients with a culprit PCI and consecutive CABG (group
1: n = 138) to patients with emergent complete surgical revascularization
(group 2: n = 924). Outcome parameters were adjusted using regression
analysis. Result(s): There was no significant difference in terms of
MACCE events between the two groups. Patient cohorts were comparable in
terms of 30-day mortality (OR: 0.612, 95% CI: 0.989-1.909; p = 0.379),
rate of prolonged ventilation (>24 hours); (OR: 1.161, 95% CI: 0.507-
2.660; p = 0.724), prolonged catecholamine requirement (>24 hours), (OR:
1.001, 95% CI: 0.427-2.347; p = 0.998), and secondary myocardial
infarctions (OR: 1.537, 95% CI: 0.334-7.073; p = 0.581).
 Conclusion(s): Emergent surgical revascularization is a valid and
safe alternative for patients with an acute myocardial infarction. The
surgical treatment offers complete revascularization with well documented
long-term benefit. Whether or not this is particularly applicable for this
cohort needs to be determined in a longer follow-up period and in
prospective, randomized trials.

<38>
Accession Number
647628181
Title
Sutureless Aortic Valve Replacement Superior to Transcatheter Aortic Valve
Implantation: A State-of-the-Art Systematic Review, Meta-Analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 11
Feb 2025.
Author
Ali-Hasan-Al-Saegh S.; Takemoto S.; Shafiei S.; Yavuz S.; Arjomandi Rad
A.; Amanov L.; Merzah A.; Salman J.; Ius F.; Kaufeld T.; Schmack B.; Popov
A.F.; Sabashnikov A.; Ruhparwar A.; Weymann A.
Institution
(Ali-Hasan-Al-Saegh) MHH, Hannover, Germany
(Takemoto) Harvard Medical School, Boston, United States
(Shafiei) Clinic for Cardiac and Thoracic Vascular Surgery, Marburg,
Germany
(Yavuz) Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
(Arjomandi Rad) Imperial College London, London, United Kingdom
(Amanov, Merzah, Salman, Ius, Kaufeld, Ruhparwar) Hannover Medical School,
Hannover, Germany
(Schmack, Popov, Weymann) Department of Cardiothoracic, Transplant and
Vascular Surgery, Hannover Medical School, Hannover, Germany
(Sabashnikov) Royal Brompton and Harefield NHS Foundation Trust,
Harefield, United Kingdom
Publisher
Georg Thieme Verlag
Abstract
Background: The management of patients with aortic valve pathologies can
sometimes fall into a gray zone, where the optimal treatment approach is
not straightforward. The comparative benefits of sutureless aortic valve
replacement (SUAVR) using the bioprosthesis versus transcatheter aortic
valve implantation (TAVI) for the gray zone of aortic valve replacement
procedures remain a topic of debate. To further explore this issue, we
conducted a study with pairwise, singlearm, and Kaplan-Meier-based
meta-analyses to compare the outcomes of SUAVR with the bioprosthesis
versus TAVI, as well as to evaluate the efficacy, safety, and durability
of SUAVR with the bioprosthesis over mid-term and long-term followup
periods. Method(s): The PubMed, PubMed Central, OVID Medline,
Cochrane Library, Embase, and Web of Science databases were systematically
searched. All study types were included, except study protocols and animal
studies, without time restrictions. The final search was performed in May
2024. Result(s): No statistically significant differences were
observed in permanent pacemaker implantation (PPI) rates between the two
groups. SUAVR showed a lower incidence of new-onset myocardial infarction
but was associated with higher rates of new-onset atrial fibrillation and
major bleeding. TAVI had higher rates of left bundle branch block and
major vascular complications. Conclusion(s): Our findings show that
SUAVR has a lower incidence of complications and a favorable mid-term
overall survival compared with TAVI. SUAVR has more advantages compared
with TAVI and can be considered a valuable and promising option for the
grey zone of aortic valve pathologies.

<39>
Accession Number
643675923
Title
Outcomes of patients with suspected heparin-induced thrombocytopenia in a
contemporary cohort of patients.
Source
Hamostaseologie. Conference: GTH Congress 2024 - 68th Annual Meeting of
the Society of Thrombosis and Haemostasis Research - Building Bridges in
Coagulation. Vienna Austria. 44(Supplement 1) (pp S20-S21), 2024. Date of
Publication: 26 Feb 2024.
Author
Nilius H.; Sinitsa E.; Studt J.-D.; Tsakiris D.A.; Greinacher A.; Mendez
A.; Schmidt A.; Wuillemin W.A.; Gerber B.; Kremer-Hovinga J.A.; Vishnu P.;
Graf L.; Bakchoul T.; Nagler M.
Institution
(Nilius, Sinitsa, Nagler) Inselspital, Bern University Hospital,
Department of Clinical Chemistry, Bern, Switzerland
(Nilius) University of Bern, Graduate School for Health Sciences, Bern,
Switzerland
(Studt) University and University Hospital of Zurich, Division of Medical
Oncology and Hematology, Zurich, Switzerland
(Tsakiris) Basel University Hospital, Diagnostic Haematology, Basel,
Switzerland
(Greinacher) Universitatsmedizin Greifswald, Institut fur Immunologie und
Transfusionsmedizin, Greifswald, Germany
(Mendez) Kantonsspital Aarau, Department of Laboratory Medicine, Aarau,
Switzerland
(Schmidt) Municipal Hospital Zurich Triemli, Clinic of Medical Oncology
and Hematology, Zurich, Switzerland
(Wuillemin) Cantonal Hospital of Lucerne and University of Bern, Division
of Hematology and Central Hematology Laboratory, Lucerne, Switzerland
(Gerber) Oncology Institute of Southern Switzerland, Clinic of Hematology,
Bellinzona, Switzerland
(Kremer-Hovinga) Inselspital, Bern University Hospital, Department of
Hematology and Central Hematology Laboratory, Bern, Switzerland
(Vishnu) CHI Franciscan Medical Group, Division of Hematology, Seattle,
United States
(Graf) Cantonal Hospital St. Gallen, Department of Hematology, St. Gallen,
Switzerland
(Bakchoul) University Hospital Tubingen, Centre for Clinical Transfusion
Medicine, Tubingen, Germany
(Nagler) University of Bern, Medical Faculty, Bern, Switzerland
Publisher
Georg Thieme Verlag
Abstract
Introduction Managing patients with suspected heparin-induced
thrombocytopenia (HIT) remains a major clinical challenge. Knowledge of
the effects of management decisions on clinical outcomes is sparse and
treatment recommendations are often based on low certainty. In a
prospective multicenter cohort study, we studied the treatment and
outcomes of patients with suspected HIT. Method We included consecutive
patients with suspected HIT and report the outcomes of (a) patients with
HIT, (b) patients without HIT but positive heparin/PF4 antibodies, and (c)
patients without HIT. Comprehensive clinical and laboratory data were
collected in detail and the washed-platelet heparininduced platelet
activation test (HIPA) served as the reference standard test defining HIT
Results Among 1393 patients included in 11 study centers (46 % female,
median age of 67), HIT was confirmed in 119 patients (prevalence 8.5 %).
The setting was intensive care unit (37 %) and cardiac surgery (32 %) in
the majority of patients. The predominant treatment was argatroban (70 %),
and complete platelet recovery was observed in 77 % of HIT patients. Of
the patients with HIT, 23 % developed subsequent venous thromboembolism
(TE), 9 % arterial TE, and 18 % died. Major bleeding occurred in 13 % of
HIT patients and did not differ significantly between drugs. Treatment
with argatroban, bivalirudin or DOAC markedly reduced the risk of
subsequent arterial TE. HIT-negative patients with and without H/PF4
antibodies did not differ with regard to any outcome (Graphical abstract)
(.Fig. 1). Conclusion Our results indicate that HIT is still a serious
disease with a high risk of major adverse events. In the absence of
randomized controlled trials, our results add further evidence on the
effectiveness of DOAC, argatroban, and bivalirudin treatment.

<40>
Accession Number
2043982588
Title
Letter to the Editor "Fractional Flow Reserve in Aortic Stenosis:
Pathophysiological Considerations and Clinical Implications" regarding:
"Fractional Flow Reserve Versus Angiography-Guided Revascularisation in
Patients With Severe Aortic Stenosis: A Systematic Review" by Mridha et
al. Heart Lung Circ. 2025;34:556-565.
Source
Heart Lung and Circulation. 35(3) (pp e39-e40), 2026. Date of Publication:
01 Mar 2026.
Author
Skalidis I.; Laforgia P.; Hovasse T.; Garot P.; Akodad M.
Institution
(Skalidis, Laforgia, Hovasse, Garot, Akodad) Institut Cardiovasculaire
Paris-Sud, Hopital Jacques Cartier, Ramsay-Sante, Massy, France
(Skalidis) Department of Cardiology, HFR - Fribourg Kantonal Hospital and
University, Fribourg, Switzerland
Publisher
Elsevier Ltd

<41>
Accession Number
2043612065
Title
Conduction abnormalities after TAVI and their role in patient management:
a systematic review.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1706176. Date of Publication: 2026.
Author
Tudorancea I.; Popa I.P.; Haba M.U.C.; Popa S.; Onofrei V.; Serban D.N.;
Serban I.L.; Costache-Enache I.I.; Iliescu R.; Loghin C.
Institution
(Tudorancea, Popa, Haba, Popa, Onofrei, Serban, Serban, Costache-Enache,
Iliescu) Grigore T. Popa University of Medicine and Pharmacy, Iasi,
Romania
(Tudorancea, Haba, Onofrei, Costache-Enache) Cardiology Clinic, "Saint
Spiridon" County Clinical Emergency Hospital, Iasi, Romania
(Iliescu) Transcend Research Centre, Iasi, Romania
(Loghin) Division of Cardiology, Department of Internal Medicine, UTHealth
McGovern Medical School, Houston, TX, United States
Publisher
Frontiers Media SA
Abstract
Objective: Transcatheter aortic valve implantation (TAVI) is associated
with a relatively high incidence of permanent pacemaker implantation
(PPM-I). We aimed to evaluate the existing literature on
electrocardiographic (ECG) changes before and after TAVI, identify
predictors for PPM-I, and suggest a standardized post-TAVI ECG monitoring
protocol. Method(s): A systematic literature review was conducted
across multiple databases, including PubMed, Web of Science, and JSTOR, to
identify studies published between 2001 and 2024. Result(s): From an
initial pool of 24,170 records, 17 studies met the inclusion criteria.
Pre-existing right bundle branch block and significant prolongation of ECG
intervals were identified as strong predictors of PPM-I. Following TAVI,
new-onset left bundle branch block, prolonged PR interval, and QRS complex
widening were the most common ECG changes. Conclusion(s): Systematic
periprocedural ECG monitoring during TAVI is of paramount importance for
the early recognition of conduction abnormalities (CAs) that predict the
need for PPM-I. Copyright 2026 Tudorancea, Popa, Haba, Popa, Onofrei,
Serban, Serban, Costache-Enache, Iliescu and Loghin.

<42>
[Use Link to view the full text]
Accession Number
2043434164
Title
Transthyretin Stabilizer Therapy in Patients With Transthyretin Amyloid
Cardiomyopathy: A Systematic Review and Meta-Analysis.
Source
Journal of the American College of Surgeons. 32(1) (pp e84-e88), 2025.
Date of Publication: 01 Feb 2025.
Author
Faria H.S.; Peixoto B.P.; Sampaio Sobral M.V.; Alves Ribeiro V.E.;
Patricia de Souza E.; Guimaraes Belchior A.C.
Institution
(Faria) Department of Medicine, Federal University of Santa Maria, Santa
Maria (RS), Brazil
(Peixoto) Department of Medicine, University of Iguacu, Nova Iguacu (RJ),
Brazil
(Sampaio Sobral) Department of Medicine, University of West Sao Paulo,
Presidente Prudente (SP), Brazil
(Alves Ribeiro) Department of Medicine, Federal University of Piaui,
Teresina (PI), Brazil
(Patricia de Souza) Department of Medicine, Federal University of Grande
Dourados, Dourados (MG), Brazil
(Guimaraes Belchior) Department of Medicine, State University of Mato
Grosso do Sul, State Hospital of Mato Grosso do Sul (MS), Brazil
Publisher
Lippincott Williams and Wilkins

<43>
[Use Link to view the full text]
Accession Number
2032793584
Title
Factors Associated With Coronary Angiography Performed Within 6 Months of
Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Source
Circulation: Cardiovascular Interventions. 17(6) (pp 457-473), 2024. Date
of Publication: 01 Jun 2024.
Author
Spertus J.A.; Broderick S.; Rockhold F.W.; Demchenko E.; Grossman G.B.;
Stone G.W.; Mancini G.B.J.; Hochman J.S.; Boden W.E.; Mavromatis K.; Doan
J.; Linefsky J.; Lee R.; Patel R.; Miller T.; Cho S.Y.; Milbrandt S.;
Shelstad D.; Banerjee S.; Kamath P.; Tejani I.; Reynolds H.R.; Newman
J.D.; Bangalore S.; Phillips L.M.; Saric M.; Abdul-Nour K.; Schley A.;
Golden H.; Stone P.H.; Osseni H.; Wiyarand C.; Douglass P.; Pomeroy H.;
Craft A.; Harvey B.; Jang J.J.; Anaya O.; Yee G.; Goold P.; Weitz S.;
Giovannone S.; Pritchard L.; Arnold S.; Gans R.; O'Keefe J.H.; Kennedy P.;
Shapiro M.D.; Ganesan S.; Schlichting D.; Naher A.; Fein S.A.; Stewart
W.L.; Torosoff M.T.; Salmi K.M.; Lyubarova R.; Mookherjee S.; Drzymalski
K.; McFalls E.O.; Garcia S.A.; Bertog S.C.; Johnson D.K.; Siddiqui R.A.;
Herrmann R.R.; Ishani A.; Hansen R.A.; Khouri M.G.; Arges K.; LeFevre M.;
Tomfohr J.; Goldberg J.L.; Byrne K.A.; Zappernick T.; Goldweit R.; Canada
S.; Kakade M.; Mieses P.; Cohen R.A.; Mirrer B.; Navarro V.; Rantinella
M.; Rodriguez J.; Mancilla O.; Winchester D.E.; Stinson S.; Kronenberg M.;
Weyand T.; Crook S.C.; Heitner J.F.; Ho J.; Khan S.; Mohamed M.; Dauber
I.M.; Soltau M.R.; Rose D.K.; Wimmer R.J.; Siegel K.E.; Derbyshire S.;
Cannan C.; Dixon M.; Leonard G.; Sudarshan S.; Heard C.; Gabriel V.;
Desire S.; Mehta P.K.; McDaniel M.; Rashid F.; Lerakis S.; Asier S.;
Quyyumi A.; Patel K.; Wenger N.K.; Hedgepeth C.M.; Gillis J.; Hurlburt H.;
Manocchia M.; Rosen A.; Moore S.; Congdon E.; Sahul Z.; Brandt G.;
Marchelletta N.; Wippler K.; Leung S.; Reda H.; Ziada K.; Setty S.;
Halverson K.E.; Roraff C.; Thorsen J.; Barua R.S.; Ojajuni A.; Olurinde
O.; Surineni K.; Hage F.; Valaiyapathi B.; Davies J.E.; Leesar M.; Heo J.;
Iskandrian A.; Al Solaiman F.; Dajani K.; Kartje C.M.; El-Hajjar M.;
Mesropian P.D.; Sacco J.; Rawlins M.; McCandless B.; Thomson J.; Orgera
M.; Sidhu M.S.; Rogge M.C.; Arif I.; Bunke J.; Kerr H.; Unterbrink K.;
Fannon J.; Burman C.; Trejo J.F.; Dubin M.F.; Fletcher G.; Lane G.E.;
Neeson L.M.; Parikh P.P.; Pollak P.M.; Shapiro B.P.; Landolfo K.;
Gemignani A.; Beaudry S.; O'Rourke D.; Meadows J.L.; Tirado S.A.; Halliday
J.; Julian P.; Call J.T.; Lane S.M.; Stanford J.L.; Hannan J.; Bojar R.;
Arsenault P.; Kumar D.; Sigel P.; Mukai J.; Martin E.T.; Brooks M.;
Vorobiof G.; Douangvila L.; Gevorgyan R.; Moor-Man A.; Ranjbaran F.; Smith
B.; Ohmart C.; Kinlay S.; Hamburger R.J.; Rocco T.P.; Ly S.; Bhatt D.L.;
Quinn M.C.; Croce K.; Temiyasathit S.; Quin J.A.; Do J.; Anumpa J.; Tobin
D.; Zenati M.; Faxon D.P.; Rayos G.; Langdon J.; Bayer M.W.; Seedhom A.;
O'Malley A.; Sullenberger L.; Orvis E.; Kumkumian G.; Murphy M.; Greenberg
A.; Iraola M.; Sedlis S.P.; Maranan L.C.; Donnino R.M.; Lorin J.;
Tamis-Holland J.E.; Malinay A.; Kornberg R.; Leber R.; Saba S.; Edillo
C.P.; Lee M.W.; Small D.R.; Nona W.; Alexander P.B.; Rehman I.; Badami U.;
Ostrander A.; Wasmiller S.; Marzo K.; Drewes W.; Patel D.; Robbins I.H.;
Levite H.A.; White J.M.; Shetty S.; Hallam A.; Patel M.; Hamroff G.S.;
Spooner B.J.; Hollenweger L.M.; Little R.W.; Little H.; Zimbelman B.D.;
Little T.; Lui C.Y.; Eskelson N.A.; Smith B.R.; Vezina D.P.; Khor L.L.;
Abraham J.D.; Bull D.A.; McKellar S.H.; Booth D.; Taul Y.; Kotter J.;
Rodgers C.; Abdel-Latif A.; Isaacs J.; Bulkley V.; Hu B.; Kaneshiro R.;
Labovitz A.J.; Berlowitz M.; Kirby B.J.; Rogal P.; Tran N.N.; McFarren C.;
Jahrsdorfer C.; Matar F.; Caldeira C.; Maron D.J.; Rodriguez F.; Yunis R.;
Schnittger I.; Patro J.; Fearon W.F.; Deedwania P.; Vega A.; Reddy K.;
Sweeny J.; Bloise-Adames H.; Jimenez S.; Vrestil N.S.; Bhandari R.;
Spizzieri C.; Schade D.; Yost R.; Hochberg C.P.; Beardsley P.; Fine D.;
Salerno W.D.; Tancredi J.; Arakelian P.; Mathus S.; O'Neill D.; Wyman R.;
Burkhardt J.; Hosino S.; Lubyanaya O.A.; Salas J.D.; Zarka A.; Aguirre M.;
Shah A.V.; Dhawan M.; Parra D.; Tran T.; Haldis T.; Fowler-Lehman K.;
Spitzer N.; Riedberger C.; Weick C.; Kohn J.A.; Girotra S.; Drum C.;
Miller-Cox K.; Ollinger A.; Almousalli O.; Capasso-Gulve E.; Loehr A.M.;
Mosley M.; Krishnam M.S.; Heydari S.; Mil-Liken J.C.; Lundeen A.M.; Patel
P.M.; Karanjah E.; Seto A.H.; Marfori W.C.; Harley K.T.; Hernandez-Rangel
E.; Gibson M.A.; Singh P.; Allen B.J.; Coram R.; Webb A.M.; Fridell E.;
Wilson H.; Thomas S.; Kim A.; Schwartz R.G.; Wilmot P.; Chen W.; El
Shahawy M.; Stevens R.; Stafford J.; Black L.; Abernethy W.B.; Hull A.B.;
Lim O.J.; Tucker H.C.; Putnam N.C.; Hall L.L.; Cauthren T.; Tucker T.;
Zurick A.; Horton H.; Orga J.; Meyer T.M.; White J.R.; Morford R.G.;
Baumann C.; Rutkin B.; Seeratan V.; Bokhari S.; Jimenez M.; Sokol S.I.;
Schultz C.; Meisner J.; Russo J.; Hamzeh I.; Misra A.; Huda Z.; Wall M.;
Boan A.; De Rosen V.L.; Alam M.; Turner M.C.; Hinton C.R.; Mulhearn T.J.;
Good A.P.; Archer B.A.; Dionne J.S.; Allardyce C.A.; Sikora L.N.; Czerniak
J.H.; Mull J.A.; Ferguson E.; Laube F.; Shammas N.W.; Shammas G.A.;
Christensen L.; Park H.; Chilton R.; Hecht J.; Nguyen P.K.; Vo D.; Hirsch
J.; Jezior M.; Bindeman J.; Salkind S.; Desimone L.-A.; Gordon P.C.;
Felix-Stern L.; Crain T.; Gomes J.; Gordon C.; Stenberg R.; Mann A.;
McCreary T.; Pedalino R.P.; Cobos S.E.; Dwyer R.R.; Espinosa D.; Quiles
K.J.; Wiesel J.; Juang G.J.; Gopaul C.; Hultberg K.; Huk T.; Hussain A.;
Al-Amoodi M.; Zambrano Y.; Rodriguez S.M.; Milner T.; Wohns D.; Mulder A.;
Van Oosterhout S.; Lader E.W.; Meyer M.; Mumma M.; Clapp N.L.; Barrentine
H.; Dharmarajan L.; Jose J.M.; Manchery J.; McGarvey J.F.X.; McKinney V.;
Schwarz L.; Downes T.R.; Kaczkowski S.M.; Luckasen G.J.; Jaskowiak A.J.;
Klitch J.; Cheong B.; Dees D.; Potluri S.; Vasquez P.; Mastouri R.A.;
Breall J.A.; Hannemann E.L.; Revtyak G.E.; Foltz J.M.; Bazeley J.W.;
DeRosa E.; Jorgenson B.; Riestenberg-Smith J.; Giedd K.; Old W.; Bariciano
R.; Burt F.; Sokhon K.; Waldron J.; Mayon M.; Gopal D.; Valeti U.S.;
Peichel G.A.; Kobashigawa J.; Starks B.; Garcia L.; Thottam M.; Anand A.;
Govindan S.C.; Raj J.; Nair R.G.; Ravindran R.; Rajalekshmi V.S.;
Manjunath C.N.; Nataraj N.; Moorthy N.; Nayak S.; Manjunath S.C.;
Mylarappa M.; Narayanappa S.; Pandit N.; Bajaj S.; Nath R.K.; Yadav V.;
Mishra G.; Dwivedi S.K.; Tewari R.; Narain V.S.; Mishra M.; Chandra S.;
Patel S.; Wander G.S.; Tandon R.; Ralhan S.; Kaur B.; Aslam N.; Gupta S.;
Pharmacy B.; Goyal A.; Bhargava B.; Suvarna C.; Karthikeyan G.;
Ramakrishnan S.; Seth S.; Yadav R.; Singh S.; Roy A.; Parakh N.; Verma
S.K.; Narang R.; Mishra S.; Naik N.; Sharma G.; Choudhary S.K.; Patel C.;
Gulati G.; Sharma S.; Bahl V.K.; Mathew A.; Kurian B.M.; Punnoose E.;
Gadkari M.A.; Karwa S.R.; Gadage S.; Kolhe S.; Pillay T.U.; Satheesh S.;
Vindhya R.J.; Jain P.; Seth A.; Meharwal Z.S.; Mathur A.; Verma A.; Bhatia
M.; Sachdeva A.; Devi T.I.; Jungla N.; Rani K.M.; Menon R.; Reddy M.S.;
Oomman A.; Sidh R.R.; Mao R.; Ramakrishnan T.; Solomon H.; Francis R.;
Priya V.P.; Khan S.P.; Preethi K.; Kumar N.; Grant P.; Hande S.; Sonawane
P.; Kachru R.; Dubey A.; Rawat K.; Kumar A.V.K.; Ganapathi S.; Jayakumar
K.; Vineeth C.P.; Sivadasanpillai H.; Chacko M.; Sasidharan B.; Babu S.;
Kapilamoorthy T.R.; Christopher J.; Reddy S.; Polamuri P.; Rani M.; Kaul
U.; Arambam P.; Singh B.; Senior R.; Fox K.A.A.; Carruthers K.; Elghamaz
A.; Gurunathan S.; Karogiannis N.; Young G.M.; Shah B.N.; Kinsey C.;
Trimlett R.H.J.; Kavalakkat R.; Rubens M.B.; Evans J.; Nicol E.D.; Hassan
I.; Mittal T.K.; Hampson R.; Gamma R.A.; Williams S.; Holland K.; Swan K.;
de Belder M.A.; Atkinson B.; Thambyrajah J.; Nageh T.; Kunhunny S.; Davies
J.R.; Lindsay S.J.; Atkinson C.; Kurian J.; Krannila C.; Jamil H.; Vinod
M.; Raheem O.; Hoye A.; Chaytor L.; Cox L.; Morrow J.; Rowe K.; Donnelly
P.; Kelly S.; Valecka B.; Regan S.; Turnbull D.; Chauhan A.; Fleming C.;
Ghosh A.; Gratrix K.; Preston S.; Barr C.; Cartwright A.; Alfakih K.;
Knighton A.; Byrne J.; Martin K.; Webb I.; Henriksen P.; Flint L.;
Harrison J.; OKane P.; Lake-Man N.; Ljubez A.; de Silva R.; Conway D.S.G.;
Wright J.; Exley D.; Sirker A.A.; Andiapen M.; Richards A.J.; Hoole S.P.;
Wong L.; Witherow F.N.; Munro M.J.; Harbinson M.; McEvoy M.; Walsh S.; Bao
B.; Brown C.; Douglas H.; Luckie M.; Charles T.; Kolakaluri L.; Phillips
H.; Sobolewska J.; Morby L.; Hallett K.; Corbett C.; Winstanley L.;
Jeetley P.; Smit A.; Patel N.; Kotecha T.; Travill C.; Gent S.; Karimullah
I.; Hussain N.; Al-Bustami M.; Braganza D.; Haines F.; Taaffe J.;
Henderson R.; Burton J.; Pointon K.; Colton M.; Naik S.; King R.; Mathew
T.; Brown A.; Docherty A.; Berry C.; McCloy L.; Collison D.; Robb K.;
Roditi G.; Paterson C.; Crawford W.; Kelly J.; McGregor L.; Moriarty A.J.;
Mackin A.; Glover J.D.; Knight J.P.; Pradhan J.; Mikhail G.; Bose T.;
Francis D.P.; Dzavik V.; Proietti A.; Brousseau M.; Corfias M.; Blaise P.;
Harvey L.; Diaz A.; Rheault P.; Barrero M.; Gagne C.-E.; Alarie P.;
Pepin-Dubois Y.; Arcand L.; Costa R.; Roy I.; Sia Y.T.; Montpetit E.;
Lemay C.; Gisbert A.; Gervais P.; Rheault A.; Drouin K.; Phaneuf D.C.;
Bergeron C.; Gosselin G.; Shelley C.; Masson C.; Garg P.; Carr S.; Bone
C.; Chow B.J.W.; Moga E.; Hessian R.C.; Kourzenkova J.; Beanlands R.S.;
Walter O.; Davies R.F.; Bainey K.R.; Hogg N.; Welsh S.; Bagai A.; Wald R.;
Goodman S.; Graham J.J.; Peterson M.; Bello O.; Chow C.-M.; Abramson B.;
Cheema A.N.; Syed I.; Vakani M.T.; Hussain M.; Kushniriuk K.; Cha J.; Otis
J.; Otis R.; Howarth A.G.; Seib M.M.; Rivest S.M.; Sandonato R.; Chow J.;
Starovoytov A.; Uchida N.; Meadows N.; Uxa A.; Asif N.; Tavares S.;
Galiwango P.; Bozek B.; Kassam S.; Shier M.; Mukherjee A.; Larmand L.-A.;
Ricci A.J.; Janmohamed A.; Hart B.; Lam A.; Marucci J.; Tai S.; Mehta S.;
Brons S.; Beck C.; Wong G.; Etherington K.; Arumairajah T.; Udell J.;
Aprile M.; Karlsson S.; Webber S.; Genereux P.; Mercure C.; Hameed A.;
Aedy N.; Daba L.; Farquharson F.; Siddiqui A.; Lopes R.D.; Hueb W.;
Takiuti M.E.; Rezende P.C.; Silva E.E.R.; Hueb A.C.; Smanio P.E.P.;
Caetano L.P.; de Quadros A.S.; Kalil R.A.K.; Deiro A.P.; da Costa Vieira
J.L.; Muller A.M.; Grossmann G.; de Moraes M.A.P.; de Oliveira P.P.;
Ascoli B.M.; Bridi L.; Poletti S.Z.; Savaris S.; Vitola J.V.; Cerci R.J.;
Zier S.S.; Farias F.R.; Veiga V.; Fernandes M.M.; Marin-Neto J.A.; Schmidt
A.; de Oliveira Lima Filho M.; da Cunha D.F.; Oliveira R.M.; Chierice
J.R.A.; Polanczyk C.A.; Rucatti G.G.; Furtado M.V.; Igansi F.; Smidt L.F.;
Haeffner M.P.; Carvalho A.C.; Almeida V.; Pucci G.; de Souza G.S.; Lyra
F.; Alves A.R.; Almeida M.; dos Santos V.; Dracoulakis M.D.A.; Oliveira
N.S.; Lima R.G.S.D.; Figueiredo E.; Azevedo B.E.P.; Caramori P.R.; Santos
M.B.; Germann A.; Gomes V.; Homem R.; Magedanz E.; Tumelero R.; Laimer R.;
Tognon A.; Dall'Orto F.; Mesquita C.T.; Santos R.P.; Colafranseschi A.S.;
Oliveira A.C.; Carvalho L.A.; Palazzo I.C.; Sousa A.S.; da Silva E.E.R.;
de Barros e Silva P.G.M.; Okada M.Y.; de Padua Silva Baptista L.; Batista
A.P.; Rodrigues M.J.; Rabaca A.N.; de Resende M.V.C.; Saraiva J.F.; Trama
L.M.; de Souza Ormundo C.T.; Vicente C.; Costantini C.; Pinheiro C.; Komar
D.; Ruzyllo W.; Demkow M.; Pracon R.; Kepka C.; Teresinska A.; Walesiak
O.; Kryczka K.; Malinowska K.; Henzel J.; Solecki M.; Kaczmarska E.;
Mazurek T.; Maksym J.; Wojtera K.; Fojt A.; Szczerba E.; Drozdz J.;
Czarniak B.; Frach M.; Szymczyk K.; Niedzwiecka I.; Sobczak S.; Ciurus T.;
Jakubowski P.; Misztal-Teodorczyk M.; Teodorczyk D.; Swiderek M.; Fratczak
A.; Wojtala E.; Szkopiak M.; Lebioda P.; Wlodarczyk M.; Plachcinska A.;
Kusmierek J.; Miller M.; Marciniak H.; Wojtczak-Soska K.; Luczak K.;
Tarchalski T.; Cichocka-Radwan A.; Szwed H.; Karwowski J.; Szulczyk G.A.;
Witkowski A.; Kukula K.; Celinska-Spodar M.; Zalewska J.; Gajos G.; Bury
K.; Pruszczyk P.; Labyk A.; Roik M.; Szramowska A.; Zdonczyk O.;
Loboz-Grudzien K.; Jaroch J.; Sokalski L.; Brzezinska B.; Lesiak M.;
Lanocha M.; Reczuch K.W.; Kolodziej A.; Kalarus Z.; Swiatkowski A.; Szulik
M.; Musial W.J.; Marcinkiewicz-Siemion M.; Bockeria O.; Bockeria L.;
Petrosyan K.; Kudzoeva Z.; Trifonova T.; Aripova N.; Chernyavskiy A.M.;
Naryshkin I.A.; Kretov E.I.; Kuleshova A.; Grazhdankin I.O.; Malaev D.;
Bershtein L.L.; Sayganov S.A.; Subbotina I.; Kuzmina-Krutetskaya A.M.;
Gumerova V.; Zbyshevskaya E.V.; Katamadze N.O.; Demchenko E.A.; Nikolaeva
O.B.; Kozlov P.S.; Kozulin V.Y.; Lubinskaya E.I.; Lopez-Sendon J.L.;
Lopez-Sendon J.; Fernandez-Figares V.; Castro A.; Salicio E.R.; Guzman G.;
Galeote G.; Valbuena S.; Peteiro J.; Martinez-Ruiz M.D.; Perez-Fernandez
R.; Blanco-Calvo M.; Cuenca-Castillo J.J.; Alonso-Alvarez E.; Flores-Rios
X.; Garcia-Gonzalez P.; Prada-Delgado O.; Barge-Caballero G.; Juanatey
J.R.G.; Amigo J.S.; Bayarri M.S.; Nunez V.P.; Sanchez R.O.; Alvarez B.C.;
Gil C.P.; Monzonis A.M.; Sionis A.; Martinez A.F.; Perales M.V.; Padro
J.M.; Penaranda A.S.; Picart J.G.; Iglesias A.G.; Marimon X.G.-M.; Llado
G.P.; Costa F.C.; Miro V.; Igual B.; Diez J.L.; Calvillo P.; Ortuno F.M.;
Chavarri M.V.; Giner M.Q.; Montolliu A.T.; Aniorte A.I.R.; Bermudez E.P.;
Caravaca J.M.R.; De La Morena G.; Blancas M.G.; Canavate O.; Guerrero S.;
Riera S.; Luena J.E.C.; Lasala M.; Fernandez-Aviles F.; Lorenzo M.;
Sobrino O.; Vazquez A.; Jiang L.; Chen J.; Dong H.; He P.; Xia C.; Yang
J.; Zhong Q.; Wu Y.; Tian Y.; Li D.; Ma Y.; Yang Y.; Ma X.; Yu Z.; Zhao
Q.; Ji Z.; Li C.; Zhu B.; Yang X.; Chen M.; Chi H.; Zhang J.; Lin W.; Jing
R.; Liu J.; Zeng H.; Zhou Q.; Xu C.; Li Z.; Xiong L.; Fu X.; Gao D.; Jiang
D.; Leng R.; Yuan Q.; Zhang L.; Bai Z.; Li J.; Qi J.; Wang F.; Wang H.;
Yang B.; Yue Z.; Zhang Z.; Wang S.; Dong Y.; Mao J.; Zhang B.; Cheng G.;
Li X.; Yao X.; Zhong N.; Zhou N.; Huang Y.; Zhou P.; Fang X.; Su W.; Zeng
Q.; Kunwu Y.; Peng Y.; Su X.; Wang C.; Zhao Y.; Li Q.; Geng Y.; Wang Y.;
Nie S.-P.; Fan J.-Y.; Feng S.-T.; Wang X.; Yan Y.; Zhang H.-M.; Yu Q.; Chi
L.; Liu F.; Chen H.; Jiang J.; Li H.; Wang J.; Han Y.; Xu L.; Zhang S.;
Liu Z.; Chen G.; Hu R.; Perna G.P.; Pietrucci F.; Marini M.; Gabrielli G.;
Provasoli S.; Di Donato A.; Verna E.; Monti L.; Nardi B.; Di Chiara A.;
Pezzetta F.; Mortara A.; Casali V.; Galvani M.; Attanasio C.; Ottani F.;
Sicuro M.; Leone G.; Pisano F.; Bare C.; Calabro P.; Fimiani F.; Formisano
T.; Tarantini G.; Barioli A.; Cucchini U.; Ramani F.; Andres A.L.; Racca
E.; Rolfo F.; Goletto C.; Briguori C.; De Micco F.; Amati R.; Di Marco S.;
Vergoni W.; Tricoli M.; Russo A.; Villella M.; Fanelli R.; Poh K.-K.; Chai
P.; Lau T.; Loh J.P.; Tay E.L.; Teoh K.; Tan S.-Y.V.; Teo L.L.; Sia W.C.;
Ong C.-C.; Leong A.W.; Wong R.C.; Loh P.-H.; Kofidis T.; Chan W.X.; Chan
K.H.; Foo D.; Yan L.H.; Kong J.L.K.; Er C.M.; Jafary F.-H.H.; Chua T.;
Ismail N.; Kyaw M.T.; Yip D.; Doerr R.; Stumpf J.; Grahl D.; Matschke K.;
Guenther F.; Simonis G.; Bonin K.; Kadalie C.T.; Sechtem U.; Wenzelburger
I.; Ong P.; Gruensfelder S.; Schulze P.C.; Goebel B.; Lenk K.; Nickenig
G.; Sinning J.-M.; Weber M.; Werner N.; Schuchlenz H.; Steinmaurer G.;
Weikl S.; Lang I.M.; Winter M.-P.; Andric T.; Huber K.; Maximilian T.;
Gabriele J.-K.; Claudia W.; Bernhard J.; Florian E.; Keltai M.; Vertes A.;
Sebo J.; Davidovits Z.; Matics L.; Varga A.; Agoston G.; Fontos G.; Dekany
G.; Merkely B.; Bartykowszki A.; Maurovich-Horvat P.; Kerecsen G.; Jakal
A.; Hinic S.; Djokic J.; Zdravkovic M.; Mudrenovic V.; Crnokrak B.;
Beleslin B.D.; Boskovic N.N.; Djordjevic-Dikic A.D.; Petrovic M.T.; Giga
V.L.; Dobric M.R.; Stepanovic J.J.; Markovic Z.Z.; Mladenovic A.S.;
Cemerlic-Adjic N.; Velicki L.; Pupic L.; Davidovic G.; Simovic S.M.; Vucic
R.; Dekleva M.N.; Martinovic M.S.; Stevanovic G.; Stankovic G.; Dobric M.;
Apostolovic S.; Martinovic S.S.; Stanojevic D.; Escobedo J.; de
Jesus-Perez R.; Juarez B.; Baleon-Espinosa R.; Campos-Santaolalla A.S.;
Duran-Cortes E.; Flores-Palacios J.M.; Garcia-Rincon A.; Jimenez-Santos
M.; Penafiel J.V.; Ortega-Ramirez J.A.; Valdespino-Estrada A.; Rosas E.A.;
Brassetti M.F.C.; Anaya D.A.V.; Garcia M.P.; Juarez I.E.C.; Rovalo M.M.;
Rodriguez E.D.M.; Selvanayagam J.B.; Rankin J.; Murphy D.; Lee S.; Joseph
M.X.; Thomas P.; Thambar S.T.; Chaplin M.D.; Boer S.C.; Beltrame J.F.;
Stansborough J.K.; Black M.; Hillis G.S.; Bonner M.M.; Ireland K.F.;
Venn-Edmonds C.; Steg P.-G.; Thobois C.; Thuaire C.; Tachot E.; Dutoiu T.;
Laure C.; Vassaliere C.; Steg P.G.; Abergel H.; Juliard J.-M.; Fuentes A.;
Slama M.S.; Eliahou L.; Mahmoud R.E.; Dubourg O.; Michaud P.; Nicollet E.;
Hadjih S.; Goube P.; Brito P.; Barone-Rochette G.; Furber A.; Cornet C.;
Biere L.; Rautureau J.; Juceviciene A.; Kalibataite-Rutkauskiene I.;
Keinaite L.; Laucevicius A.; Laukyte M.; Celutkiene J.; Mikolaitiene G.;
Smigelskaite A.; Tamasauskiene I.; Urboniene A.; Kedhi E.; Timmer J.;
Bouwhuis I.; Hermanides R.; Nijmeijer L.; Kaplan E.; Riezebos R.K.; Samadi
P.; Schoep J.J.M.; van Dongen E.; Janzen E.M.; Niehe S.R.; Suryapranata
H.; Ahoud S.; van Vugt S.; Ramos R.; Cacela D.; Santana A.; Fiarresga A.;
Sousa L.; Marques H.; Patricio L.; Selas M.; Bernanrdes L.; Silva F.; Rio
P.; Freixo C.; Carvalho R.; Ferreira R.; Silva T.; Rodrigues I.; Modas P.;
Portugal G.; Fragata J.; Pinto F.J.; Cabrita I.Z.; Menezes M.N.; Rocha A.;
Lopes G.C.; Figueiras F.P.; Almeida A.G.; Coelho A.; Silva P.C.; Capinha
M.; Nobre A.; Caetano M.I.; Francisco A.R.; Silva S.; Ferreira N.; Lopes
R.L.; Diaz R.; Guzman L.; Tinnirello V.; Figal J.C.; Mungo M.N.; Mendiz
O.; Cortes C.; Favaloro R.R.; Alvarez C.; Garcia M.; Courtis J.; Godoy V.;
Zeballos G.; Schiavi L.; Actis M.V.; Rubio M.; Scaro G.; Devlin G.P.; Low
L.; Fisher R.; Scales J.; Abercrombie K.; Stewart R.A.H.; Howell L.;
Patten C.; Benatar J.; Kedev S.; Mitevska I.P.; Kostovska E.S.; Pejkov H.;
Held C.; Eggers K.; Frostfelt G.; Bjorklund C.; Johnston N.; Andreasson
M.; Olsowka M.; Essermark M.; Akerblom A.; Soveri I.; Aspberg J.; Persson
L.; Beyar R.; Nikolsky E.; Sharir T.; Harel O.; Elian D.; Kerner A.;
Bentzvi M.; Massalha S.; Helmer L.; Fukuda K.; Ueda I.; Kohsaka S.; Fujita
J.; Yasuda S.; Furukawa A.; Nagai T.; Otsuka F.; Nishimura S.; Nakano S.;
Goetschalckx K.; Robesyn V.; Van de Werf F.; Claes K.; Hung C.-L.; Yang
Y.-H.; Yun C.-H.; Hou C.J.-Y.; Kuo J.-Y.; Yeh H.-I.; Hung T.-C.; Li J.-Y.;
Chien C.-Y.; Tsai C.-T.; Liu C.-C.; Yu F.-C.; Lin Y.-H.; Lan W.-R.; Yen
C.-H.; Tsai J.-P.; Sung K.-T.; Ntsekhe M.; Pandie S.; Philander C.;
Viljoen C.A.; Mtana N.; De Andrade M.; Maggioni A.P.; Moccetti T.; Anesini
A.; Rossi M.G.; Maspoli S.; Mombelli M.; Abdelhamid M.; Talaat A.; Adel
A.; Kamal A.; Mahrous H.; El Kaffas S.; El Fishawy H.; Pop C.; Claudia M.;
Popescu B.A.; Ginghina C.; Rosca M.; Deleanu D.; Beladan C.C.; Iliescu
V.A.; Al-Mallah M.H.; Zahrani S.; Aljzeeri A.; Najm H.; Alghamdi A.; Ramos
W.E.M.; Davila M.A.M.; Kuanprasert S.; Prommintikul A.; Nawarawong W.;
Khwakhong S.; Woragidpoonpol S.; Chaiyasri A.; Tepsuwan T.; Mekara W.;
Taksaudom N.; Kulthawong S.; Rimsukcharoenchai C.; Amaritakomol A.;
Euathrongchit J.; Wannasopha Y.; Yamwong S.; Panpunuan P.; Sritara P.;
Aramcharoen S.; Meemuk K.; White H.D.; Alsweiler C.; Khairuddin A.;
Mokhtar N.S.; Hadi H.A.; Basri N.A.; Yahaya S.A.; Yusnida I.; Hashim H.;
Bugiardini R.
Institution
(Pracon, Ruzyllo) National Institute of Cardiology, Warsaw, Poland
(Spertus) Saint Luke's Mid America Heart Institute, University of
Missouri-Kansas City, Durham, NC, United States
(Broderick, Rockhold) Duke Clinical Research Institute, Durham, NC, United
States
(Bangalore, Newman, Reynolds, Hochman) Cardiovascular Clinical Research
Center, New York University Grossman School of Medicine, Durham, NC,
United States
(Rockhold) Department of Biostatistics and Bioinformatics, Duke University
School of Medicine, Durham, NC, United States
(Demchenko) Almazov National Medical Research Centre, Saint Petersburg,
Russian Federation
(Nageh) Southend University Hospital, United Kingdom
(Grossman) Moinhos de Vento Hospital, Porto Alegre, Brazil
(Grossman) Cardionuclear Clinic, Porto Alegre, Brazil
(Mavromatis) Emory University, Atlanta VA Healthcare System, GA, United
States
(Manjunath) Sri Jayadeva Institute of Cardiovascular Sciences and
Research, Bengaluru, India
(Smanio) Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
(Stone) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Mancini) Center for Cardiovascular Innovation, The University of British
Columbia, Vancouver, Canada
(Boden) VA New England Healthcare System, Boston University School of
Medicine, MA, United States
(Maron) Department of Medicine, Stanford University, CA, United States
(Boden, Mavromatis, Doan) Atlanta VA Medical Center, Decatur, GA, United
States
(Linefsky, Lee, Patel, Miller, Cho) Mayo Clinic, Rochester, MN, United
States
(Milbrandt, Shelstad, Banerjee, Kamath) V.A. North Texas Health Care
System, Dallas, TX, United States
(Tejani) NYU Langone Medical Center-Bellevue Hospital, New York, NY,
United States
(Reynolds, Newman, Bangalore, Donnino, Phillips, Saric, Abdul-Nour,
Schley) Henry Ford Health System, Detroit, MI, United States
(Golden, Stone, Osseni) Brigham & Women's Hospital, Harvard Medical
School, Boston, MA, United States
(Wiyarand, Douglass, Pomeroy, Craft, Harvey, Jang, Anaya) Kaiser
Permanente San Jose, San Jose, CA, United States
(Yee, Goold, Weitz, Giovannone) Cardiology Associates of Schenectady P.C.,
Schenectady, NY, United States
(Pritchard, Arnold, Gans) Saint Luke's Hospital, Kansas City, MO, United
States
(O'Keefe, Kennedy, Shapiro, Ganesan) Oregon Health & Science University,
Portland, OR, United States
(Schlichting, Naher) Albany Medical Center Hospital, Albany, NY, United
States
(Fein, Stewart, Torosoff, Salmi, Lyubarova, Mookherjee, Drzymalski,
McFalls) Minneapolis VAMC, Minneapolis, MN, United States
(Garcia, Bertog, Johnson, Siddiqui, Herrmann, Ishani, Hansen, Khouri,
Arges) Duke University Medical Center, Durham, NC, United States
(LeFevre, Tomfohr, Goldberg, Byrne) Louis Stokes Cleveland Veterans
Affairs Medical Center, Cleveland, OH, United States
(Zappernick, Goldweit, Canada) Englewood Hospital and Medical Center,
Englewood, NJ, United States
(Kakade) NYU-HHC Woodhull Hospital, Brooklyn, NY, United States
(Mieses, Cohen, Mirrer, Navarro, Rantinella, Rodriguez, Mancilla,
Winchester, Stinson) Malcom Randall VAMC, Gainesville, FL, United States
(Kronenberg, Weyand) Vanderbilt University Medical Center, Nashville, TN,
United States
(Rogal, Crook, McFarren, Heitner, Ho) New York -Presbyterian/Brooklyn
Methodist Hospital, Brooklyn, NY, United States
(Khan, Mohamed, Dauber, Soltau) South Denver Cardiology Associates, P.C.,
Littleton, CO, United States
(Rose, Wimmer, Siegel, Derbyshire, Cannan, Dixon) Providence Heart and
Vascular Institute, Portland, OR, United States
(Leonard, Sudarshan, Heard) Wichita Falls Heart Clinic, Wichita Falls, TX,
United States
(Gabriel, Desire, Mehta) Emory University, Atlanta, GA, United States
(McDaniel, Rashid, Lerakis, Asier, Quyyumi, Patel, Wenger, Hedgepeth,
Gillis) Kent Hospital, Warwick, RI, United States
(Hurlburt, Manocchia, Rosen, Moore, Congdon, Sahul, Brandt) Michigan
Heart, PC, Ypsilanti, MI, United States
(Marchelletta, Wippler, Booth, Taul) University of Kentucky, Lexington,
KY, United States
(Leung, Isaacs, Abdel-Latif, Bulkley, Reda, Rodgers, Ziada, Setty,
Halverson) Gundersen Lutheran Medical Center, La Crosse, WI, United States
(Roraff, Thorsen, Barua, Ojajuni) Kansas City VA Medical Center, Kansas
City, MO, United States
(Olurinde, Surineni, Hage, Valaiyapathi) UAB Vascular Biology and
Hypertension Program, Birmingham, AL, United States
(Caldeira, Davies, Leesar, Heo, Iskandrian, Al Solaiman, Singh, Dajani,
Kartje) Loyola University Medical Center, Maywood, IL, United States
(El-Hajjar) Samuel Stratton VA Medical Center of Albany NY, Albany, NY,
United States
(Mesropian, Sacco, Rawlins, McCandless, Thomson, Orgera, Sidhu, Rogge)
Cincinnati VA Medical Center, Cincinnati, OH, United States
(Arif, Bunke, Kerr, Unterbrink, Fannon, Burman, Trejo, Dubin) Mayo Clinic
Florida, Jacksonville, FL, United States
(Fletcher, Lane, Neeson, Parikh, Pollak, Shapiro, Landolfo, Gemignani,
Beaudry) VAMC-White River Junction, White River Junction, VT, United
States
(O'Rourke, Meadows, Tirado) VA Connecticut Healthcare System, West Haven,
CT, United States
(Halliday, Julian, Call, Lane) Winchester Cardiology and Vascular
Medicine, PC, Winchester, VA, United States
(Stanford, Hannan) Saint Vincent Hospital, Worcester Medical Center,
Worcester, MA, United States
(Bojar, Arsenault, Kumar, Sigel, Mukai, Martin, Brooks) Oklahoma Heart
Institute, Tulsa, OK, United States
(Vorobiof, Douangvila) Ronald Reagan UCLA Medical Center, Los Angeles, CA,
United States
(Gevorgyan, Moor-Man, Ranjbaran) University of Washington Medical Center,
Seattle, WA, United States
(Smith, Ohmart, Kinlay) VA Boston Healthcare System, West Roxbury, MA,
United States
(Hamburger, Rocco, Ly, Bhatt, Quinn, Croce, Temiyasathit, Quin, Do,
Anumpa, Tobin, Zenati, Faxon, Rayos, Langdon) Daytona Heart Group, Daytona
Beach, FL, United States
(Bayer, Seedhom, O'Malley) Capital Cardiology Associates, Albany, NY,
United States
(Sullenberger, Orvis, Kumkumian, Murphy) NIH Heart Center, Suburban
Hospital, Bethesda, MD, United States
(Greenberg, Iraola, Sedlis, Maranan) VA New York Harbor Health Care
System, New York, NY, United States
(Donnino, Lorin, Tamis-Holland, Malinay) Mount Sinai Saint Luke's
Hospital, Ridgewood, NJ, United States
(Kornberg, Leber, Saba, Edillo) Providence - Providence Park Hospital,
Southfield, MI, United States
(Lee, Small, Nona, Alexander, Rehman, Badami, Ostrander) Covenant Medical
Center, Inc., Saginaw, MI, United States
(Wasmiller, Marzo, Drewes) NYU Winthrop, Mineola, NY, United States
(Patel, Robbins) AtlantiCare Regional Medical Center, Pomona, NJ, United
States
(Levite, White, Shetty, Hallam, Patel, Hamroff, Spooner) NYP Medical
Medical Group Hudson Valley Cardiology, Cortlandt Manor, NY, United States
(Hollenweger, Little, Little) Houston Heart & Vascular Associates,
Houston, TX, United States
(Zimbelman, Little, Lui, Eskelson) Salt Lake City VA Medical Center, Salt
Lake City, UT, United States
(Smith, Vezina, Khor, Abraham, Bull, McKellar, Booth, Taul) Lexington VA
Medical Center, Lexington, KY, United States
(Kotter, Rodgers, Abdel-Latif, Isaacs, Bulkley, Hu, Kaneshiro) Palo Alto
Medical Foundation Research Institute, Palo Alto, CA, United States
(Labovitz) University of South Florida, Tampa, FL, United States
(Berlowitz, Kirby, Rogal, Tran, McFarren, Jahrsdorfer, Matar, Caldeira,
Maron) Stanford University School of Medicine, Stanford, CA, United States
(Rodriguez, Yunis, Schnittger, Patro, Fearon, Deedwania, Vega) UCSF -
Fresno Community Regional Medical Center, Fresno, CA, United States
(Reddy, Sweeny, Bloise-Adames) Icahn School of Medicine at Mount Sinai,
New York, NY, United States
(Jimenez, Vrestil, Bhandari, Spizzieri, Schade) Holy Spirit Hospital
Cardiovascular Institute, Camp Hill, PA, United States
(Yost, Hochberg, Beardsley) Boston Medical Center, Boston, MA, United
States
(Fine, Salerno, Tancredi) Hackensack University Medical Center, Saddle
Brook, NJ, United States
(Arakelian, Mathus, O'Neill, Wyman, Burkhardt) Torrance Memorial Medical
Center, Torrance, CA, United States
(Hosino, Lubyanaya) Coastal Heart Medical Group, Santa Ana, CA, United
States
(Salas, Zarka, Aguirre, Shah, Dhawan, Parra, Tran, Haldis, Weick) Sanford
Health, Fargo, ND, United States
(Fowler-Lehman, Spitzer, Riedberger, Weick, Kohn) NYU New York Medical
Associates, New York, NY, United States
(Cobos, Quiles, Girotra, Drum) University of Iowa Hospitals and Clinics,
Iowa City, IA, United States
(Miller-Cox, Ollinger, Almousalli, Capasso-Gulve) Advanced Heart Care
Group, Fairview Heights, IL, United States
(Loehr, Mosley, Krishnam, Heydari) University of California Irvine Medical
Center, Orange, CA, United States
(Mil-Liken, Lundeen, Patel, Karanjah, Seto, Marfori, Harley,
Hernandez-Rangel, Gibson, Singh, Allen, Coram, Webb) University of
Louisville, Louisville, KY, United States
(Fridell, Wilson, Thomas, Kim) University of Rochester, Rochester, NY,
United States
(Schwartz, Wilmot, Chen, El Shahawy, Stevens) Cardiovascular Center of
Sarasota, Sarasota, FL, United States
(Stafford, Black) University of Maryland Medical Center, Baltimore, MD,
United States
(Abernethy, Hull) Asheville Cardiology Associates, Asheville, NC, United
States
(Lim, Tucker, Putnam, Hall, Cauthren, Tucker, Zurick, Horton) Saint Thomas
Hospital, Nashville, TN, United States
(Orga, Meyer, White) Stroobants Cardiovascular Center, Lynchburg, VA,
United States
(Morford, Baumann, Rutkin, Seeratan) Northwell Health - Manhasset,
Manhasset, NY, United States
(Bokhari, Jimenez) Columbia University Medical Center, New York, NY,
United States
(Sokol, Schultz) Jacobi Medical Center, Bronx, NY, United States
(Meisner, Russo, Hamzeh) Baylor College of Medicine, Houston, TX, United
States
(Misra, Huda, Wall, Boan, De Rosen, Alam, Turner, Hinton) Cardiovascular
Specialists of Southwest Louisiana, Lake Charles, LA, United States
(Mulhearn, Good, Archer) Ohio Health Grant Medical Center, Columbus, OH,
United States
(Dionne, Allardyce, Sikora, Czerniak, Mull, Ferguson, Laube, Shammas,
Shammas) Midwest Cardiovascular Research Foundation, Davenport, IA, United
States
(Christensen, Park, Chilton, Hecht) Audie Murphy V.A., San Antonio, TX,
United States
(Nguyen, Vo) VA Palo Alto Healthcare System, Palo Alto, CA, United States
(Hirsch, Jezior, Bindeman) Walter Reed National Military Medical Center,
Bethesda, MD, United States
(Salkind, Espinosa) Miriam Hospital, Providence, RI, United States
(Desimone, Gordon, Felix-Stern, Crain, Gomes, Gordon, Stenberg, Mann)
Conemaugh Valley Memorial Hospital, Johnstown, PA, United States
(McCreary, Pedalino, Cobos) NYU-HHC Kings County Hospital Center,
Brooklyn, NY, United States
(Dwyer, Espinosa, Quiles, Wiesel) New York University - Langone
Cardiovascular Associates, Flushing, NY, United States
(Juang, Gopaul) Coney Island Hospital, Brooklyn, NY, United States
(Hultberg, Huk, Hussain, Al-Amoodi, Zambrano) Yuma Regional Medical
Center, Yuma, AZ, United States
(Rodriguez, Milner, Wohns, Mulder) Spectrum Health, Grand Rapids, MI,
United States
(Van Oosterhout, Lader, Meyer) Mid Valley Cardiology, Kingston, NY, United
States
(Mumma, Clapp) Sarasota Memorial Hospital, Sarasota, FL, United States
(Barrentine, Dharmarajan, Jose) NYU-HHC Lincoln Medical and Mental Health
Center, Bronx, NY, United States
(Manchery, McGarvey, McKinney) Doylestown Health Cardiology, Doylestown,
PA, United States
(Schwarz, Downes, Kaczkowski) Medical Center of the Rockies, Loveland, CO,
United States
(Luckasen, Jaskowiak, Klitch, Cheong, Dees) Baylor St. Luke's Medical
Center, Houston, TX, United States
(Potluri, Vasquez) Baylor Research Institute, Legacy Heart Center, Plano,
TX, United States
(Mastouri) Indiana University, Krannert Institute of Cardiology,
Indianapolis, IN, United States
(Breall, Hannemann, Revtyak, Foltz, Bazeley, Li, DeRosa) HealthEast Saint
Joseph's Hospital, St. Paul, MN, United States
(Jorgenson, Riestenberg-Smith, Giedd) Beth Israel Medical Center, New
York, NY, United States
(Old, Bariciano) Cardiovascular Associates, Ltd., Chesapeake, VA, United
States
(Burt) Saint Luke's Hospital and Health Network, Bethlehem, PA, United
States
(Sokhon, Waldron) Medicus Alliance Clinical Research Org., Inc., Sugar
land, TX, United States
(Mayon, Gopal) The Heart Hospital Baylor, Plano, TX, United States
(Valeti, Peichel) University of Minnesota, Minneapolis, MN, United States
(Kobashigawa, Starks) Cedars Sinai Medical Center, Beverly Hills, CA,
United States
(Garcia, Thottam, Bhargava, Anand) Government Medical College, Calicut,
India
(Govindan, Raj, Nair, Ravindran, Rajalekshmi, Manjunath, Nataraj) Sri
Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru,
India
(Moorthy, Nayak, Manjunath, Mylarappa, Narayanappa, Pandit, Bajaj) Dr Ram
Manohar Lohia Hospital, New Delhi, India
(Nath, Yadav, Mishra, Dwivedi, Tewari) King George's Medical University,
Department of Cardiology, Lucknow, India
(Narain, Mishra, Chandra, Patel, Singh, Wander) Hero DMC Heart Institute,
Dayanand Medical College and Hospital, Ludhiana, India
(Tandon, Ralhan, Kaur, Aslam, Gupta, Pharmacy, Goyal, Bhargava, Suvarna)
All India Institute of Medical Sciences, New Delhi, India
(Karthikeyan, Ramakrishnan, Seth, Yadav, Singh, Roy, Parakh, Verma,
Narang, Mishra, Naik, Sharma, Choudhary, Patel, Gulati, Sharma, Bahl,
Mathew, Kurian) MOSC Medical College Hospital, Kolenchery, India
(Punnoose, Gadkari, Karwa) KEM Hospital Pune, Pune, India
(Gadage, Kolhe, Pillay, Satheesh, Vindhya) Jawaharlal Institute of
Postgraduate Medical Education & Research (JIPMER), Pondicherry, India
(Jain) Fortis Escort Heart Institute, New Delhi, India
(Seth, Meharwal, Mathur, Verma, Kaul, Bhatia, Sachdeva, Devi, Jungla,
Christopher, Rani) Gurunanak CARE Hospital, Hyderabad, India
(Menon, Reddy, Kumar, Preethi, Oomman, Sidh) Apollo Research and
Innovation, Chennai, India
(Mao, Ramakrishnan, Solomon, Francis, Naik, Priya) Apollo Research &
Innovations, Hyderabad, India
(Khan, Christopher, Preethi) CARE Nampally, Hyderabad, India
(Kumar, Grant, Hande) Ruby Hall Clinic, Grant Medical Foundation, Pune,
India
(Sonawane, Kachru, Dubey) Fortis Healthcare Fl.t Lt. Rajan Dhall Hospital,
New Delhi, India
(Rawat, Kumar) Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Trivandrum, India
(Ganapathi, Jayakumar, Vineeth, Sivadasanpillai, Chacko, Sasidharan, Babu,
Kapilamoorthy, Christopher, Reddy) CARE Hospital, Hyderabad, India
(Polamuri, Rani, Kaul, Arambam) Batra Hospital and Medical Research Centre
(BHMRC), New Delhi, India
(Singh, Senior, Fox, Young, Carruthers) Northwick Park Hospital Harrow,
Royal Brompton Hospital London, Harrow, United Kingdom
(Elghamaz, Gurunathan, Karogiannis, Young, Shah, Kinsey, Trimlett,
Kavalakkat, Rubens, Evans, Nicol, Hassan, Mittal, Hampson, Gamma,
Williams) Broomfield Hospital, Chelmsford, United Kingdom
(Holland, Swan, de Belder, Atkinson) The James Cook University Hospital,
Middlesbrough, Middlesbrough, United Kingdom
(Thambyrajah, Nageh, Kunhunny) Southend University Hospital, Westcliffe on
Sea, United Kingdom
(Davies, Lindsay, Atkinson) Bradford Royal Infirmary, Bradford, United
Kingdom
(Kurian, Krannila, Jamil, Vinod, Raheem, Hoye, Chaytor) The University of
Hull, Castle Hill Hospital, Cottingham, United Kingdom
(Cox, Morrow, Rowe, Donnelly, Kelly) South Eastern Health and Social Care,
Belfast, United Kingdom
(Valecka, Regan, Turnbull, Chauhan, Fleming) Blackpool Teaching Hospitals,
Blackpool, United Kingdom
(Ghosh, Gratrix, Preston, Barr, Cartwright) Russells Hall Hospital,
Dudley, United Kingdom
(Alfakih, Knighton) King's College NHS Foundation Hospital, London, United
Kingdom
(Byrne, Martin, Webb, Henriksen, Flint) Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(Harrison, OKane, Lake-Man) Royal Bournemouth Hospital, Bourneouth, United
Kingdom
(Ljubez, de Silva) Bedford Hospital NHS Trust, Bedford, United Kingdom
(Conway, Wright) Pinderfields Hospital, Wakefield, United Kingdom
(Exley, Sirker, Andiapen) University College London Hospitals NHS
Foundation Trust, London, United Kingdom
(Richards) BartsHealth NHS Trust, United Kingdom
(Hoole, Wong) Papworth Hospital, Cambridge, United Kingdom
(Witherow, Munro) Dorset County Hospital, Dorchester, United Kingdom
(Johnston, Bao) Belfast Trust, Belfast, United Kingdom
(Harbinson, Bao, McEvoy, Walsh, Bao, Brown, Douglas, Luckie, Charles)
Central Manchester University Hospital, Manchester, United Kingdom
(Kolakaluri, Phillips, Sobolewska, Morby) The Pennine Acute Hospitals NHS
Trust, Oldham, United Kingdom
(Hallett, Corbett, Winstanley, Jeetley, Smit) Royal Free London NHS
Foundation Trust, London, United Kingdom
(Patel, Kotecha, Travill, Gent) Luton and Dunstable University Hospital
NHS FT, Luton, United Kingdom
(Karimullah, Hussain, Al-Bustami, Braganza, Haines) Peterborough City
Hospital, Peterborough, United Kingdom
(Taaffe, Henderson, Burton) Nottingham University Hospitals, Nottingham,
United Kingdom
(Pointon, Colton, Naik, King, Mathew, Brown) University of Glasgow,
Clydebank, United Kingdom
(Docherty, Berry, McCloy, Collison, Robb, Roditi, Paterson, Crawford,
Kelly, McGregor, Moriarty, Mackin) Cardiovascular Research Unit, Craigavon
Area Hospital, Craigavon, United Kingdom
(Glover, Knight) Hampshire Hospitals NHS Foundation Trust, Basingstoke,
United Kingdom
(Pradhan, Mikhail, Bose) Imperial College Healthcare NHS Trust, London,
United Kingdom
(Francis, Dzavik, Goodman, Gosselin, Proietti) Montreal Heart Institute,
Montreal, QC, Canada
(Brousseau, Corfias, Blaise, Harvey, Diaz) Centre Hospitalier de Regional
Trois-Rivieres, Trois-Rivieres, QC, Canada
(Rheault, Barrero, Gagne, Alarie, Pepin-Dubois, Arcand, Costa, Roy, Sia,
Montpetit, Lemay, Gisbert, Gervais, Rheault, Drouin) CISSSL - Hopital
Pierre-Le Gardeur, Terrebonne, QC, Canada
(Phaneuf, Bergeron, Gosselin, Shelley, Masson, Garg, Carr) London Health
Sciences Centre, London, ON, Canada
(Bone, Chow, Moga) University of Ottawa Heart Institute, Ottawa, ON,
Canada
(Hessian, Kourzenkova, Beanlands, Walter, Davies, Bainey, Hogg) University
of Alberta, Edmonton, AB, Canada
(Welsh, Cheema) St. Michael's Hospital, Toronto, ON, Canada
(Bagai, Wald, Goodman, Kushniriuk, Graham, Hussain, Peterson, Bello, Chow,
Abramson, Cheema, Syed) Dixie Medical Group, Mississauga, ON, Canada
(Vakani, Hussain, Kushniriuk, Cha, Otis) Dr James Cha, Oshawa, ON, Canada
(Otis, Howarth, Seib) University of Calgary, Calgary, AB, Canada
(Rivest, Sandonato, Wong, Chow) Vancouver General Hospital, Vancouver, BC,
Canada
(Starovoytov, Uchida, Meadows, Uxa, Asif) University Health Network,
Toronto, ON, Canada
(Tavares, Galiwango, Bozek) Scarborough Cardiology Research, Scarborough,
ON, Canada
(Kassam, Shier, Mukherjee, Larmand, Ricci, Janmohamed, Hart, Lam, Marucci)
West Lincoln Memorial Hospital East Grimsby, ON, Canada
(Tai, Mehta, Brons) Hamilton General Hospital, Hamilton, ON, Canada
(Beck, Wong, Etherington, Arumairajah, Udell, Aprile) Women's College
Hospital, Toronto, ON, Canada
(Karlsson, Webber, Genereux, Mercure) Centre Integre Universitaire de
Sante et de Services Sociaux du Montreal, Montreal, QC, Canada
(Hameed, Aedy) Saint Catharines General Hospital, Catharines, ON, Canada
(Daba, Farquharson) Northwest GTA Cardiovascular and Heart Rhythm Program,
Vaughan, ON, Canada
(Siddiqui, Carvalho, Lopes, Hueb, Takiuti) Heart Institute (InCor),
University of Sao Paulo, Sao Paulo, Brazil
(Rezende, Silva, Hueb, Smanio, Caetano) Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
(de Quadros) Instituto de Cardiologia de Porto Alegre, Porto Alegre,
Brazil
(Kalil, Deiro, da Costa Vieira, Muller, Grossmann, de Moraes, de Oliveira,
Ascoli, Bridi, Poletti, Savaris, Vitola) Quanta Diagnostico & Terapia,
Curitiba, Brazil
(Cerci, Zier, Farias, Veiga, Fernandes, Marin-Neto) Hospital das Clinicas
da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo,
Ribeirao Preto, Brazil
(Schmidt, de Oliveira Lima Filho, da Cunha, Oliveira, Chierice, Polanczyk,
Rucatti) Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
(Furtado, Igansi, Smidt, Haeffner, Carvalho, Almeida) Unifesp - Hospital
Sao Paulo, Sao Paulo, Brazil
(Pucci, de Souza, Lyra, Alves, Almeida) Fundacao Bahiana de Cardilogia,
Salvador, Brazil
(dos Santos, Dracoulakis, Oliveira) Hospital da Bahia, Salvador, Brazil
(Lima, Figueiredo, Azevedo) Hospital Lifecenter, Belo Horizonte, Brazil
(Caramori, Santos) Hospital Sao Lucas da Pontificia Universidade Catolica
do Rio Grande do Sol, Porto Alegre, Brazil
(Germann, Gomes, Homem, Magedanz, Tumelero, Laimer) Hospital Sao Vicente
de Paulo Fundo, Brazil
(Tognon, Dall'Orto) Hospital Maternidade e Pronto Socorro Santa Lucia,
Pocos de Caldas, Brazil
(Mesquita, Santos) Hospital Pro-Cardiaco Botafogo, Brazil
(Colafranseschi, Oliveira, Carvalho, Palazzo, Sousa, da Silva) Hospital
TotalCor, Sao Paulo, Brazil
(de Barros e Silva, Okada, de Padua Silva Baptista, Batista, Rodrigues,
Rabaca, de Resende, Saraiva, Trama) Hospital Celso Pierro, Sao Paulo,
Brazil
(Silva, de Souza Ormundo, Vicente, Costantini, Pinheiro, Pracon) Hospital
Cardiologico Costantini, Curitiba, Brazil
(Komar, Ruzyllo, Szwed, Demkow, Pracon) Coronary and Structural Heart
Diseases Department, Institute of Cardiology, Warsaw, Poland
(Kepka, Teresinska, Walesiak, Kryczka, Malinowska, Henzel, Solecki,
Kaczmarska, Mazurek, Maksym) Medical University of Warsaw, Warszawa,
Poland
(Wojtera, Fojt, Szczerba, Drozdz) Cardiology Clinic, Medical University in
Lodz, Lodz, Poland
(Czarniak, Frach, Szymczyk, Niedzwiecka, Sobczak, Ciurus, Jakubowski,
Misztal-Teodorczyk, Teodorczyk, Swiderek, Fratczak, Wojtala, Szkopiak,
Lebioda, Wlodarczyk, Plachcinska, Kusmierek, Miller, Marciniak,
Wojtczak-Soska, Luczak, Tarchalski, Cichocka-Radwan, Szwed, Karwowski)
National Institute of Cardiology, Warsaw, Warsaw, Poland
(Szulczyk, Witkowski) Department of Interventional Cardiology & Angiology,
Institute of Cardiology, Warsaw, Poland
(Kukula, Celinska-Spodar, Zalewska, Gajos) Department of Coronary Disease,
John Paul II Hospital, Jagiellonian University Medical College, Krakow,
Poland
(Bury, Pruszczyk, Labyk) Department of Internal Medicine and Cardiology,
Infant Jesus Teaching Hospital, Medical University of Warsaw, Warszawa,
Poland
(Roik, Szramowska, Zdonczyk, Loboz-Grudzien, Jaroch) T.Marciniak Hospital,
Wroclaw, Poland
(Sokalski, Brzezinska, Lesiak) Szpital Kliniczny Przemienienia Panskiego,
Poznan, Poland
(Lanocha, Reczuch, Kolodziej) Military Hospital, Medical University,
Wroclaw, Poland
(Kalarus) Medical University of Silesia, School of Medicine, The Division
of Dentistry, Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
(Swiatkowski, Szulik, Musial, Marcinkiewicz-Siemion) University Hospital
in Bialystok, Bialystok, Poland
(Bockeria, Bockeria) National Medical Research Center for Cardiovascuar
Surgery, Moscow, Russian Federation
(Petrosyan, Kudzoeva, Trifonova, Aripova, Chernyavskiy, Naryshkin)
E.Meshalkin National Medical Research Center, The Ministry of Health of
the Russian Federation, Novosibirsk, Russian Federation
(Kretov, Kuleshova, Grazhdankin, Malaev, Bershtein) North-Western State
Medical University, Saint Petersburg, Russian Federation
(Sayganov, Subbotina, Kuzmina-Krutetskaya, Gumerova, Zbyshevskaya,
Katamadze, Demchenko, Nikolaeva) Federal Almazov North-West Medical
Research Centre, Saint Petersburg, Russian Federation
(Kozlov, Kozulin, Lubinskaya, Lopez-Sendon, Castro, Lopez-Sendon,
Fernandez-Figares) Hospital La Paz. IdiPaz, Madrid, Spain
(Castro, Salicio, Guzman, Galeote, Valbuena, Peteiro) Complexo
Hospitalario Universitario A Coruna (CHUAC) Sergas, Department of
Cardiology, INIBIC A Coruna. CIBER-CV., Universidad de A Coruna, A Coruna,
Spain
(Martinez-Ruiz, Perez-Fernandez, Blanco-Calvo, Cuenca-Castillo,
Alonso-Alvarez, Flores-Rios, Garcia-Gonzalez, Prada-Delgado,
Barge-Caballero, Juanatey, Amigo) Hospital Clinico Universitario de
Santiago, Santiago de Compostela, Spain
(Bayarri, Nunez, Sanchez, Alvarez, Gil, Monzonis, Sionis, Martinez)
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Perales, Padro, Penaranda, Picart, Iglesias, Marimon, Llado, Costa, Miro,
Igual) Hospital Universitario y Politecnico La Fe, Valencia, Spain
(Diez, Calvillo, Ortuno) HUVA, Hospital Clinico Universitario Virgen De La
Arrixaca, Murcia, Spain
(Chavarri, Giner, Montolliu, Aniorte, Bermudez, Caravaca, De La Morena,
Blancas, Canavate) Hospital De Bellvitge, Barcelona, Spain
(Guerrero, Riera, Luena, Luena) Hospital Universitario Miguel Servet,
Zaragoza, Spain
(Lasala, Fernandez-Aviles, Lorenzo) Hospital General Universitario
Gregorio Maranon, Madrid, Spain
(Sobrino, Vazquez, Jiang, Chen, Dong) Guangdong General Hospital,
Guangzhou, China
(He, Xia, Yang, Zhong, Wu, Tian) Chinese Academy of Medical Sciences,
Fuwai Hospital, Beijing, China
(Li) First Affiliated Hospital of Xinjiang Medical University, Urumqi,
China
(Ma, Li, Yang, Ma, Yu, Zhao, Ji, Li) Tangshan Gongren Hospital, Tangshan,
China
(Zhang, Zhao, Zhu, Yang, Chen) Beijing Chao-yang Hospital, Capital Medical
University, Beijing, China
(Chi, Wang, Zhang, Lin, Jing) TEDA International Cardiovascular Hospital,
Tianjing, China
(Liu, Zeng, Zhou) Tongji Medical College, Wuhan, China
(Xu, Li, Li, Xiong, Fu, Gao) The First Affiliated Hospital of Zhengzhou
University, Zhengzhou, China
(Jiang, Leng, Wang, Yuan, Zhang, Yang, Bai) Shanxi Cardiovascular
Hospital, Taiyuan, China
(Li, Qi, Wang, Wang, Yang, Yue, Zhang, Wang, Dong) Qingdao Fuwai Hospital,
Qingdao, China
(Mao, Zhang, Cheng, Li) Shanxi Provincial People's Hospital, Xian, China
(Yao, Zhong, Zhou, Zhao, Huang) The Second Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Zhou, Fang, Su) Liangxiang Hospital, Beijing, Fangshan District, Beijing,
China
(Zeng, Kunwu) Wuhan Union Hospital, Tongji Medical College, Huazhong
Science and Tech University, Wuhan, China
(Peng, Su, Su, Wang) Wuhan Asia Heart Hospital, Wuhan, China
(Zhao, Li, Geng) Affiliated Hospital of Jining Medical University, Jining,
China
(Wang, Nie, Fan) Beijing Anzhen Hospital, Beijing, China
(Feng, Wang, Yan, Zhang, Yu, Chi) Affiliated Zhongshan Hospital of Dalian
University, Dalian, China
(Liu, Wang, Chen) The Second Affiliated Hospital Zhejiang University
School of Medicine, Hangzhou, China
(Jiang, Li, Wang, Han) Peking Union Medical College Hospital, Beijing,
China
(Xu, Zhang, Liu, Liu, Chen, Hu, Maggioni, Perna, Pietrucci) Cardiology and
CCU - Ospedali Riuniti Ancona, Ancona, Italy
(Marini, Gabrielli, Provasoli, Di Donato) Ospedale di Circolo e Fondazione
Macchi, Varese, Italy
(Verna, Monti) Humanitas Research Hospital, Rozzano (MI), Rozzano, Italy
(Nardi, Di Chiara, Pezzetta) Azienda Servizi Sanitaria n.3 Alto
Friuli-Collinare-Medio Friuli, Tolmezzo, Italy
(Mortara, Casali) Policlinico di Monza, Monza, MB, Monza, Italy
(Galvani, Attanasio) Ospedale "G.B. Morgagni - L. Pierantoni" Forli (AUSL
della Romagna), Forli, Italy
(Ottani, Sicuro, Leone) Ospedale Regionale Umberto Parini, Aosta, Italy
(Pisano, Bare, Calabro, Fimiani) AORN Dei Colli "V. Monaldi" UOC
Cardiologia Universita della Campania "L.Vanvitelli", Napoli, Italy
(Formisano, Tarantini, Barioli) University of Padua- Cardiology Clinic,
Padua, Italy
(Cucchini, Ramani, Andres, Racca, Rolfo) Azienda Ospedaliera S. Croce e
Carle, Cuneo, Italy
(Goletto, Briguori, De Micco) Clinica Mediterranea, Naples, Italy
(Amati, Di Marco) UO Cardiologia Ospedale SS Cosma e Damiano, Pescia,
Italy
(Vergoni, Tricoli, Russo, Villella) IRCCS "Casa Sollievo della
Sofferenza", San Giovanni Rotondo, Italy
(Fanelli, White, Alsweiler, Poh) National University Heart Center
Singapore, Singapore, Singapore
(Chai, Lau, Loh, Tay, Teoh, Tan, Teo, Sia, Ong, Leong, Wong, Loh, Kofidis,
Chan, Chan, Foo, Yan) Tan Tock Seng Hospital, Singapore, Singapore
(Kong, Er, Jafary, Chua, Ismail) National Heart Centre Singapore,
Singapore, Singapore
(Kyaw, Yip, Doerr) Praxisklinik Herz und Gefaesse, Dresden, Germany
(Stumpf, Grahl, Matschke, Guenther, Simonis, Bonin, Kadalie, Sechtem,
Wenzelburger) Robert-Bosch-Krankenhaus, Stuttgart, Germany
(Ong, Gruensfelder, Schulze) University Hospital Jena, Jena, Germany
(Goebel, Lenk, Nickenig, Sinning) Universitatsklinikum Bonn, Bonn, Germany
(Weber, Werner, Lang, Huber, Schuchlenz, Steinmaurer) LKH Graz West, Graz,
Austria
(Weikl, Lang, Winter) Medical University of Vienna, Department of
Cardiology, Vienna, Austria
(Andric) Wilhelminen Hospital Vienna, Vienna, Austria
(Huber, Maximilian, Gabriele, Claudia, Bernhard, Florian, Keltai, Vertes,
Sebo) Eszszk- Szent Istvan Hospital, Budapest, Hungary
(Davidovits, Matics, Varga, Agoston) University of Szeged, Szeged, Hungary
(Fontos, Dekany) George Gottsegen National Institute of Cardiology,
Budapest, Hungary
(Merkely, Bartykowszki) Heart and Vascular Center, Semmelweis University,
Budapest, Hungary
(Maurovich-Horvat, Kerecsen, Jakal) Military Hospital, Budapest, Budapest,
Hungary
(Hinic, Djokic) University Hospital Center Bezanijska Kosa, Belgrade,
Serbia
(Zdravkovic, Mudrenovic, Crnokrak, Beleslin) Faculty of Medicine,
University of Belgrade, Cardiology Clinic, Clinical Center of Serbia,
Belgrade, Serbia
(Boskovic, Djordjevic-Dikic, Petrovic, Giga, Dobric, Stepanovic, Markovic,
Mladenovic, Cemerlic-Adjic, Velicki) Institute of Cardiovascular Diseases
Vojvodina, Sremska Kamenica, Serbia
(Pupic, Davidovic, Simovic) Clinical Center Kragujevac, Kragujevac, Serbia
(Vucic, Dekleva, Martinovic) University Clinical Hospital Zvezdara,
Belgrade, Serbia
(Stevanovic, Stankovic, Dobric) Clinical Center of Serbia, Belgrade,
Serbia
(Apostolovic, Martinovic) Clinic for Cardiovascular Diseases, Clinical
Center Nis, Nis, Serbia
(Stanojevic, Escobedo, de Jesus-Perez, Juarez) Instituto Mexicano del
Seguro Social, Mexico
(Baleon-Espinosa, Campos-Santaolalla, Duran-Cortes, Flores-Palacios,
Garcia-Rincon, Jimenez-Santos, Penafiel, Ortega-Ramirez,
Valdespino-Estrada, Rosas, Brassetti, Selvanayagam) Instituto Nacional de
Cardiologia "Ignacio Chavez", Mexico City, Mexico
(Anaya, Garcia, Juarez, Rovalo, Rodriguez, Selvanayagam, Rankin, Murphy,
Lee) Flinders Medical Centre, Adelaide, Australia
(Joseph, Thomas, Thambar, Chaplin) John Hunter Hospital, New Lambton
Heights, Australia
(Boer, Beltrame, Stansborough) The Queen Elizabeth Hospital, Woodville
South, Australia
(Black, Hillis, Bonner) Royal Perth Hospital, Perth, Australia
(Ireland, Venn-Edmonds, Steg, Abergel, Juliard, Thobois) C.H. Louis
Pasteur, Chartres, France
(Thuaire, Tachot, Dutoiu, Laure, Vassaliere, Steg, Abergel) Bichat
Hospital, Paris, France
(Juliard, Fuentes, Slama, Eliahou) Antoine-Beclere Hospital, Clamart,
France
(Mahmoud, Dubourg) Ambroise Pare Hospital, Boulogne, France
(Michaud, Nicollet, Hadjih) Centre Hospitalier Sud Francilien,
Corbeil-Essonnes, France
(Goube, Brito, Barone-Rochette, Barone-Rochette) Grenoble University
Hospital, Grenoble, France
(Furber, Cornet) Centre Hospitalier Universitaire d'Angers, Angers, France
(Biere, Rautureau, Juceviciene) Vilnius University Hospital Santariskes
Clinic, Vilnius, Lithuania
(Kalibataite-Rutkauskiene, Keinaite, Laucevicius, Laukyte, Celutkiene,
Mikolaitiene, Smigelskaite, Tamasauskiene, Urboniene, Kedhi) Isala
Klinieken, Zwolle, Netherlands
(Timmer, Bouwhuis, Hermanides, Nijmeijer, Kaplan, Riezebos) Cardio
Research Hartcentrum OLVG, Amsterdam, Netherlands
(Samadi, Schoep, van Dongen, Janzen, Niehe, Suryapranata, Ahoud)
Radboudumc, Nijmegen, Netherlands
(van Vugt, Ramos) Hospital de Santa Marta, Lisbon, Portugal
(Cacela, Santana, Fiarresga, Sousa, Marques, Patricio, Selas, Bernanrdes,
Silva, Rio, Freixo, Carvalho, Ferreira, Silva, Rodrigues, Modas, Portugal,
Fragata, Pinto, Cabrita) Santa Maria University Hospital, Cardiology
Department, CHLN, Lisbon, Portugal
(Menezes, Rocha, Lopes, Figueiras, Almeida, Coelho, Silva, Capinha, Nobre,
Caetano, Francisco, Silva, Ferreira) Centro Hospitalar de Vila Nova de
Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal
(Lopes, Diaz, Guzman, Tinnirello) Instituto Medico DAMIC, Cordoba,
Argentina
(Figal, Mungo) Fundacion Favaloro, Ciudad Autonoma de Buenos Aires,
Argentina
(Mendiz, Cortes, Favaloro, Alvarez, Garcia) Hospital Italiano Regional del
Sur Bahia Blanca, Bahia Blanca, Argentina
(Courtis, Godoy) Clinica Romagosa and Clinica De La Familia, Cordoba,
Spain
(Zeballos, Schiavi, Actis) Clinica Del Prado, Cordoba, Spain
(Rubio) Clinica Privada Velez Sarsfield, Cordoba, Spain
(Scaro, Devlin, Low) Waikato Hospital, Hamilton, New Zealand
(Fisher, Scales, Abercrombie, Stewart) Auckland City Hospital, Auckland,
New Zealand
(Howell, Patten, Benatar, Kedev, Held) University Clinic of Cardiology,
Skopje, North Macedonia
(Mitevska, Kostovska, Pejkov, Held) Uppsala University, Uppsala, Sweden
(Eggers, Frostfelt, Bjorklund, Johnston, Andreasson, Olsowka, Essermark,
Akerblom, Soveri, Aspberg, Persson, Sharir) Karolinska Institutet,
Danderyd Hospital, Stockholm, Sweden
(Beyar, Nikolsky, Sharir, Harel) Assuta Medical Centers, Tel-Aviv, Israel
(Elian, Kerner, Bentzvi) Rambam Medical Center, Haifa, Israel
(Massalha, Helmer, Kohsaka, Fukuda, Ueda) Keio University, Shinjuku-ku,
Japan
(Kohsaka, Fujita, Yasuda, Furukawa) National Cerebral and Cardiovascular
Center, Kanae Hirase, RN, -4, Suita-shi, Japan
(Nagai, Otsuka, Nishimura, Nakano) Saitama Medical University, Hidaka,
Japan
(Van de Werf, Goetschalckx, Robesyn) University Hospital Leuven, Leuven,
Belgium
(Van de Werf, Claes, Hung, Yang) Mackay Memorial Hospital, Taipei City,
Taiwan (Republic of China)
(Yun, Hou, Kuo, Yeh, Hung, Li, Chien, Tsai, Liu, Yu, Lin, Lan, Yen, Tsai,
Sung, Ntsekhe) Groote Schuur Hospital, University of Cape Town, Cape Town,
South Africa
(Pandie, Philander, Viljoen, Mtana, De Andrade, Maggioni, Moccetti,
Anesini) Cardiocentro, Lugano, Switzerland
(Rossi, Maspoli, Mombelli, Abdelhamid, Talaat) Cairo University, Cairo,
Egypt
(Adel, Kamal, Mahrous, El Kaffas, El Fishawy, Pop) Emergency County
Hospital Baia Mare, Bucharest, Romania
(Claudia, Popescu) Emergency Institute of Cardiovascular Diseases ''Prof.
Dr. C. C. Iliescu'', Bucharest, Romania
(Ginghina, Rosca, Deleanu, Beladan, Iliescu, Al-Mallah, Zahrani) King
AbdulAziz Cardiac Center, Central Province, Saudi Arabia
(Aljzeeri, Najm, Alghamdi, Ramos) Instituto Neuro Cardiovascular De Las
Americas, Mirafloes, Peru
(Davila, Kuanprasert) Maharaj Nakorn Chiang Mai Hospital, Chiang Mai,
Thailand
(Prommintikul, Nawarawong, Khwakhong, Woragidpoonpol, Chaiyasri, Tepsuwan,
Mekara, Taksaudom, Kulthawong, Rimsukcharoenchai, Amaritakomol,
Euathrongchit, Wannasopha, Yamwong, Panpunuan) Ramathibodi Hospital,
Bangkok, Thailand
(Sritara, Aramcharoen, Meemuk, White, Alsweiler, Khairuddin, Mokhtar)
Institut Jantung Negara, Kuala Lumpur, Malaysia
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: ISCHEMIA (International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches) did not find an
overall reduction in cardiovascular events with an initial invasive versus
conservative management strategy in chronic coronary disease; however,
there were conservative strategy participants who underwent invasive
coronary angiography early postrandomization (within 6 months).
Identifying factors associated with angiography in conservative strategy
participants will inform clinical decision-making in patients with chronic
coronary disease. METHOD(S): Factors independently associated with
angiography performed within 6 months of randomization were identified
using Fine and Gray proportional subdistribution hazard models, including
demographics, region of randomization, medical history, risk factor
control, symptoms, ischemia severity, coronary anatomy based on
protocol-mandated coronary computed tomography angiography, and medication
use. RESULT(S): Among 2591 conservative strategy participants,
angiography within 6 months of randomization occurred in 8.7% (4.7% for a
suspected primary end point event, 1.6% for persistent symptoms, and 2.6%
due to protocol nonadherence) and was associated with the following
baseline characteristics: enrollment in Europe versus Asia (hazard ratio
[HR], 1.81 [95% CI, 1.14-2.86]), daily and weekly versus no angina (HR,
5.97 [95% CI, 2.78-12.86] and 2.63 [95% CI, 1.51-4.58], respectively),
poor to fair versus good to excellent health status (HR, 2.02 [95% CI,
1.23-3.32]) assessed with Seattle Angina Questionnaire, and new/more
frequent angina prerandomization (HR, 1.80 [95% CI, 1.34-2.40]). Baseline
low-density lipoprotein cholesterol <70 mg/dL was associated with a lower
risk of angiography (HR, 0.65 [95% CI, 0.46-0.91) but not baseline
ischemia severity nor the presence of multivessel or proximal left
anterior descending artery stenosis >70% on coronary computed tomography
angiography. CONCLUSION(S): Among ISCHEMIA participants randomized to
the conservative strategy, angiography within 6 months of randomization
was performed in <10% of patients. It was associated with frequent or
increasing baseline angina and poor quality of life but not with objective
markers of disease severity. Well-controlled baseline low-density
lipoprotein cholesterol was associated with a reduced likelihood of
angiography. These findings point to the importance of a comprehensive
assessment of symptoms and a review of guideline-directed medical therapy
goals when deciding the initial treatment strategy for chronic coronary
disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique
identifier: NCT01471522. GRAPHIC ABSTRACT: A graphic abstract is available
for this article. Copyright © 2024 American Heart Association,
Inc.

<44>
[Use Link to view the full text]
Accession Number
2040034705
Title
Tricuspid transcatheter edge-to-edge repair for severe symptomatic
tricuspid regurgitation: a systematic review and meta-analysis.
Source
Journal of Cardiovascular Medicine. 26(9) (pp 519-526), 2025. Date of
Publication: 01 Sep 2025.
Author
Stabile F.; Jaramillo S.; Hakkeem B.; Madaudo C.; Vadala G.; Di Lisi D.;
Sucato V.; Corrado E.; Novo G.; Modi K.; Galassi A.R.
Institution
(Stabile, Madaudo, Vadala, Di Lisi, Sucato, Corrado, Novo, Galassi)
Division of Cardiology, University Hospital P. Giaccone, Department of
ProMISE, University of Palermo, Italy
(Jaramillo) Facultad Ciencias Biomedicas, Universidad Austral, Av.Juan
Domingo Peron, Buenos Aires, Argentina
(Hakkeem) Government Medical College, Kerala, Kozhikode, India
(Modi) Department of Cardiology, Louisiana State University, Shreveport,
LA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background - Severe tricuspid regurgitation is associated with elevated
morbidity and mortality. In recent years, tricuspid transcatheter
edge-to-edge repair (T-TEER) has emerged as a promising procedure for the
treatment of this valvular disease. We conducted a systematic review and
meta-analysis to compare the effectiveness of T-TEER with optimized
medical therapy (OMT) versus OMT alone for the treatment of severe
tricuspid regurgitation. Methods - PubMed, Scopus, and Cochrane databases
were searched for randomized controlled trials (RCTs) and observational
studies comparing T-TEER plus OMT vs. OMT alone. Heterogeneity was
assessed with I2 statistics, and a random-effects model was
used for all the outcomes. Results - We included two RCTs and four
observational studies with a total of 1805 patients, of whom 849 (47%)
underwent T-TEER plus OMT. We found a trend favoring T-TEER for all-cause
mortality [risk ratio 0.87; 95% confidence interval (95% CI) 0.66-1.13; P
= 0.30] and cardiovascular death (risk ratio 0.77; 95% CI 0.36-1.65; P =
0.50), although without statistically significant difference. Heart
failure hospitalizations (risk ratio 0.72; 95% CI 0.61-0.85; P = 0.0001)
were significantly reduced in patients treated with T-TEER compared with
OMT alone. Tricuspid regurgitation severity 2+ or less was also more
frequently achieved in the T-TEER group (risk ratio 6.42; 95% CI
3.08-13.39; P < 0.001). Functional status and quality of life were
significantly improved, with higher KCCQ scores [(mean difference)
+14.01], longer 6MWT distance (MD +29.35 m), and a greater proportion of
patients in NYHA class I-II (risk ratio 1.39; 95% CI 1.27-1.51; P <
0.00001). Conclusion - In patients with severe symptomatic TR, T-TEER is
associated with significant improvements in tricuspid regurgitation
severity, reduction in heart failure hospitalizations, and enhanced
quality of life and functional status, with no apparent effect on
all-cause mortality and cardiovascular death. Copyright © 2025

<45>
Accession Number
2043566347
Title
Association of the Triglyceride-Glucose Index with Major Adverse
Cardiovascular Events in Patients with Acute Coronary Syndromes: A
Systematic Review and Meta-Analysis.
Source
Medicina (Lithuania). 62(2) (no pagination), 2026. Article Number: 360.
Date of Publication: 01 Feb 2026.
Author
Bampali E.; Chiotis S.; Zgouridou A.; Koliastasis L.; Vrachatis D.; Pavlou
D.-O.; Schismenos V.; Chaitidis N.; Antoniadis A.; Pagourelias E.;
Doundoulakis I.; Vassilikos V.P.; Giannopoulos G.
Institution
(Bampali, Chiotis, Zgouridou, Pavlou, Schismenos, Pagourelias, Vassilikos,
Giannopoulos) Third Department of Cardiology, "Hippokration" General
Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
(Koliastasis, Doundoulakis) First University Department of Cardiology,
"Hippokration" General Hospital, National and Kapodistrian University of
Athens, Athens, Greece
(Vrachatis) Department of Interventional Cardiology and Electrophysiology,
Evgenidio Hospital, Athens, Greece
(Chaitidis) First Department of Dermatology and Venereology,
"Hippokration" General Hospital, Aristotle University of Thessaloniki,
Thessaloniki, Greece
(Antoniadis) Second Department of Cardiology, "Hippokration" General
Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
(Doundoulakis) Department of Health Sciences, School of Life and Health
Sciences, University of Nicosia, UNIC Athens, Athens, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background and Objectives: The triglyceride-glucose (TyG) index is an
accessible surrogate marker of insulin resistance and has been
increasingly investigated for its prognostic relevance in cardiovascular
disease. However, evidence regarding its predictive value for major
adverse cardiovascular events (MACEs) in patients with acute coronary
syndromes (ACSs) remains inconsistent. This study systematically assessed
the association between TyG index and the risk of MACEs in individuals
with ACS. Material(s) and Method(s): Following PRISMA 2020
guidelines, PubMed, ScienceDirect, and ClinicalTrials.gov were searched
through October 2025. Ten observational cohort studies including 32,751
ACS patients were analyzed. Studies reporting fully adjusted hazard ratios
(HRs) for the association between TyG index and MACEs were eligible. A
random-effects model was used to pool effect sizes expressed as adjusted
HRs per 1-unit increase in the TyG index. Heterogeneity, sensitivity
analyses, publication bias assessment, and meta-regression were conducted.
 Result(s): Higher TyG index values were significantly associated with
increased MACE risk (pooled adjusted HR 1.45, 95% CI 1.25-1.68,
I2 = 80%). Leave-one-out analysis confirmed robustness.
Meta-regression analysis suggested a stronger association in cohorts
consisting exclusively of patients with type 2 diabetes mellitus, with a
trend toward larger effect estimates in smaller studies, potentially
contributing to the observed heterogeneity. Despite small-study effects,
trim-and-fill-adjusted estimates remained significant (HR 1.26, 95% CI
1.05-1.52). Conclusion(s): An elevated TyG index is independently
associated with higher MACE risk in ACS patients and may be considered as
an additive metabolic risk marker in combination with established risk
stratification tools, pending further prospective
validation. Copyright © 2026 by the authors.

<46>
Accession Number
2041799206
Title
Contemporary and Emerging Therapies in the Management of Refractory
Angina: A Clinical Review.
Source
Catheterization and Cardiovascular Interventions. 107(4) (pp 869-884),
2026. Date of Publication: 01 Mar 2026.
Author
Angers-Goulet A.; Mengi S.; Labbe D.G.; Nguyen C.M.; Paradis J.-M.
Institution
(Angers-Goulet, Mengi, Labbe, Nguyen, Paradis) Quebec Heart and Lung
Institute, Laval University, Quebec City, QC, Canada
(Angers-Goulet) Centre Hospitalier Universitaire de Sherbrooke, Universite
de Sherbrooke, Sherbrooke, QC, Canada
Publisher
John Wiley and Sons Inc
Abstract
Refractory angina (RA) represents a growing challenge in clinical
cardiology, particularly in patients with obstructive coronary artery
disease (CAD) who remain symptomatic despite optimal medical therapy and
who are not candidates for revascularization. Advances in both
device-based and biologic therapies have introduced promising adjunctive
strategies. This review critically appraises current and investigational
treatment modalities for RA in order to give clinicians an informed up to
date picture and to guide them with this difficult to treat population
(Figure 1). Emphasis is placed on evaluating the safety profiles,
therapeutic efficacy, and the strength of clinical evidence supporting
each modality. This review aims to assist clinicians in individualized
decision-making for RA management. Copyright © 2025 The
Author(s). Catheterization and Cardiovascular Interventions published by
Wiley Periodicals LLC.

<47>
Accession Number
2043559800
Title
Erector Spinae Plane Block Versus Thoracic Paravertebral Block for
Postoperative Analgesia in Thoracic Surgery: A Systematic Review and
Meta-Analysis of Randomized and Observational Studies.
Source
Journal of Clinical Medicine. 15(4) (no pagination), 2026. Article Number:
1370. Date of Publication: 01 Feb 2026.
Author
Choi Y.J.; Kang H.; Kim S.H.
Institution
(Choi) Department of Anesthesiology and Pain Medicine, Korea University
Ansan Hospital, Korea University College of Medicine, Ansan, South Korea
(Kang) Department of Anesthesiology and Pain Medicine, Chung-Ang
University College of Medicine, 84 Heukseok-ro, Dongjak-gu, Seoul, South
Korea
(Kim) Department of Anesthesiology and Pain Medicine, Chosun University
Hospital, College of Medicine, Chosun University, 365 Pilmun-daero,
Dong-gu, Gwangju, South Korea
(Kim) Medical Research Institute, Chosun University, 309 Pilmun-daero,
Dong-gu, Gwangju, South Korea
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Both erector spinae plane block (ESPB) and thoracic
paravertebral block (TPVB) are widely used for thoracic surgery analgesia,
but comparative evidence remains inconsistent. This meta-analysis compared
their analgesic efficacy and safety with time-stratified analyses and
trial sequential analysis (TSA). Method(s): We searched MEDLINE,
Embase, Web of Science, and CENTRAL (inception to January 2026) for
randomized controlled trials (RCTs) and observational studies comparing
ESPB with TPVB in adults undergoing thoracic surgery. Primary outcomes
were pain scores at rest and during coughing at 0-6 h, 24 h, and 48 h
postoperatively. Secondary outcomes included opioid consumption and
adverse events. Random-effects meta-analyses were performed. Evidence
certainty was assessed using GRADE. Result(s): Twenty-five studies
(22 RCTs, 3 observational studies; 1847 patients) were included. TPVB
provided superior early analgesia (0-6 h) at rest (SMD 0.25, 95% CI
0.03-0.47) and during coughing (SMD 0.28, 95% CI 0.02-0.54); TSA confirmed
firm evidence for early pain at rest. Pain scores at 24 h and 48 h were
comparable between techniques. TPVB reduced 24 h opioid consumption (SMD
0.42, 95% CI 0.11-0.73), but evidence certainty was low due to
heterogeneity and insufficient information size by TSA. No differences
were observed in postoperative nausea and vomiting or hypotension.
 Conclusion(s): ESPB and TPVB provide comparable analgesia beyond the
early postoperative period. TPVB demonstrates superior early analgesia
(0-6 h) with firm evidence, but opioid-sparing effects remain uncertain.
Both techniques are safe. ESPB represents a practical alternative to TPVB,
particularly where technical simplicity is prioritized. Copyright
© 2026 by the authors.

<48>
Accession Number
2043573113
Title
Early Post-TAVI Physical Activity After Eccentric Training Compared to
Standard Practice-Results of a Feasibility Study.
Source
Clinical Interventions in Aging. 21 (no pagination), 2026. Article Number:
563908. Date of Publication: 2026.
Author
Haase-Fielitz A.; Stoll J.; Engel T.; Beckendorf C.; Haase M.; Kucken T.;
Neuss M.; Butter C.
Institution
(Haase-Fielitz, Kucken, Neus, Butter) Department of Cardiology, University
Hospital Heart Center Brandenburg, Brandenburg Medical School (MHB)
Theodor Fontane, Ladeburger Str. 17, Bernau bei Berlin, Germany
(Haase-Fielitz, Kucken, Neus, Butter) Faculty of Health Sciences
Brandenburg, Neuruppin, Germany
(Haase-Fielitz) Institute of Social Medicine and Health System Research,
Otto von Guericke University Magdeburg, Magdeburg, Germany
(Stoll, Engel, Beckendorf) University Outpatient Clinic, Sports Medicine
and Sports Orthopedics, University of Potsdam, Potsdam, Germany
(Haase) Medical Faculty, Otto-von-Guericke University Magdeburg,
Magdeburg, Germany
(Haase) Diamedikum MVZ, Potsdam, Germany
(Haase) Department of Nephrology and Hypertension, Hannover Medical
School, Hannover, Germany
Publisher
Dove Medical Press Ltd
Abstract
Background: Physical activity after transcatheter aortic valve
implantation (TAVI) can improve cardiovascular outcomes and health-related
quality of life. The aim of the study was to evaluate the functional
status before and shortly after TAVI and to test the feasibility of an
eccentric training program and its effect on functional mobility compared
to standard care. Method(s): In this interventional controlled
feasibility trial, elective TAVI patients without severe mobility
limitations were enrolled. The center of pressure (CoP) measurements in
standing position, the Timed Up & Go test (TUG) to assess functional
mobility and the Chair-Rising test (CRT) for functional lower extremity
muscle strength were assessed before and within five days after TAVI; the
SF-12 test and the EuroQol-5 Dimension test was calculated. The
intervention group performed daily 10-minute guided eccentric training
starting earliest on day two after TAVI; controls received standard care
(no structured or supervised exercise program). Result(s): Of 357
screened patients, 99 met inclusion criteria; 45% declined to participate;
54 patients participated (median age 81 [78-83], 53.7% female). Orthopedic
disorders were common (51.9%), as was chronic joint disease (18.5%).
Before TAVI, most patients in both groups completed CoP testing. Fewer
patients in the eccentric group required handrail support for the two-leg
CoP test than controls (4.2% vs 31.0%, p=0.015). After TAVI, similar
proportions in both groups completed the single-leg COP test (44% vs 51.7,
p=0.389), all needing assistance. After day three, the intervention could
be started in 72% of patients. None of those patients were able to
complete all four exercises within 10 minutes No group differences were
observed for TUG and CRT results (all p>0.15). The physical SF-12 score
improved more in controls (+8.9 points [25.-75. percentiles -2.7-14.9],
p=0.022) compared to patients receiving eccentric training (+1.6
[-4.9-9.5], p=0.463). Conclusion(s): Elderly TAVI patients showed
limited functional mobility pre- and early post-procedure. Initiating
eccentric training within the first few postoperative days was feasible
but associated with considerable barriers and might not provide short-term
functional benefit compared with standard care. Early activity after TAVI
remains challenging within fast-track recovery pathways. Copyright
© 2026 Haase-Fielitz et al.

<49>
Accession Number
2043866873
Title
Global research trends and hotspots in extracorporeal membrane oxygenation
for cardiogenic shock: a bibliometric review and knowledge mapping
approach (1990-2024).
Source
Journal of Thoracic Disease. 18(2) (no pagination), 2026. Article Number:
121. Date of Publication: 28 Feb 2026.
Author
Chen S.; Guo W.; Liu L.; Hu D.; Zhu Y.; Xue H.; Yuan S.; Zhu N.; Li H.;
Liu A.; Yang Y.; Qiu H.; Liu S.
Institution
(Chen, Liu, Hu, Zhu, Xue, Yuan, Liu, Yang, Qiu, Liu) Jiangsu Provincial
Key Laboratory of Critical Care Medicine, Department of Critical Care
Medicine, Trauma Center, Zhongda Hospital, School of Medicine, Southeast
University, Nanjing, China
(Chen, Guo, Zhu, Li) Department of Respiratory and Critical Care Medicine,
Second Affiliated Hospital of Xuzhou Medical University, Xuzhou Mining
Group General Hospital, Xuzhou, China
(Liu) The First People's Hospital of Lianyungang, The Lianyungang Clinical
College of Nanjing Medical University, The First Affiliated Hospital,
Kangda College of Nanjing Medical University, The Affiliated Lianyungang
Hospital of Xuzhou Medical University, Lianyungang, China
(Liu) Department of Critical Care Medicine, Trauma Center, Nanjing Lishui
People's Hospital, Zhongda Hospital Lishui Branch, Nanjing, China
Publisher
AME Publishing Company
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) has emerged as a
promising rescue strategy for patients with refractory cardiogenic shock
(CS). However, comprehensive and quantitative insights into the global
research landscape of ECMO in CS remain limited. This study aimed to
address this gap by systematically mapping the global research landscape
of ECMO in CS through bibliometric analysis and knowledge visualization.
 Method(s): A narrative synthesis was used to provide concise
summaries of the key findings, highlighting emerging research frontiers
and thematic shifts over time. Publications related to ECMO management in
CS from 1990 to 2024 were retrieved from the Web of Science Core
Collection. CiteSpace and VOSviewer were used to analyze publication
patterns, co-authorship networks, keyword clustering, and citation
metrics. High-impact authors, institutions, countries, and emerging
research frontiers were identified. Result(s): A total of 701
publications involving 4,433 authors from 1,105 institutions across 55
countries were analyzed. The United States led in both publication volume
and citations, followed by Germany and China. Four major thematic clusters
were identified: postcardiotomy shock, cardiac arrest, extracorporeal
cardiopulmonary resuscitation (ECPR), acute myocardial infarction
(AMI)-related mechanical circulatory support, and ECMO bridging to
transplantation. Over time, research emphasis has shifted from general
survival and mortality to protocol-driven care, predictive modeling, and
long-term outcomes. Conclusion(s): ECMO for CS is a rapidly expanding
field, with bibliometric patterns suggesting increasing research
consolidation and thematic diversification. Bibliometric analysis revealed
a centralized and collaborative academic ecosystem with evolving themes
suggestive of a shift toward precision support, multidisciplinary
management, and clinical guideline development. These insights provide a
roadmap for future research and health policy planning. Copyright
© AME Publishing Company.

<50>
Accession Number
2043894853
Title
The effectiveness of the AI-based RehabLung mobile rehabilitation system
on cardiopulmonary function and user satisfaction in lung cancer patients
undergoing thoracic surgery: a protocol for a two-arm randomized clinical
trial.
Source
Therapeutic Advances in Respiratory Disease. 20 (no pagination), 2026.
Date of Publication: 01 Jan 2026.
Author
Yang H.-L.; Hung C.-H.; Huang Y.-T.; Cheng H.-C.; Tseng Y.-L.; Su J.-M.;
Tsai K.-L.
Institution
(Yang, Huang, Cheng) Institute of Allied Health Sciences, College of
Medicine, National Cheng Kung University, Tainan City, Taiwan (Republic of
China)
(Tseng) Department of Surgery, National Cheng Kung University Hospital,
College of Medicine, National Cheng Kung University, Tainan City, Taiwan
(Republic of China)
(Su) Department of Information and Learning Technology, National
University of Tainan, Tainan City, Taiwan (Republic of China)
(Tsai) Institute of Allied Health Sciences, College of Medicine, National
Cheng Kung University, Tainan City, Taiwan (Republic of China)
(Tsai) Department of Physical Therapy, College of Medicine, National Cheng
Kung University, Tainan, Taiwan (Republic of China)
Publisher
SAGE Publications Ltd
Abstract
Background: Postoperative recovery following lung cancer surgery can be
challenging owing to various cardiorespiratory complications. Pulmonary
rehabilitation is crucial during both the preoperative and postoperative
periods. However, because of limited resources and accessibility,
innovative approaches are necessary to improve rehabilitation outcomes.
This study aimed to evaluate the effectiveness of the RehabLung App, a
novel AI-based mobile application integrating vision recognition, gamified
feedback, and web-based patient management to support personalized lung
rehabilitation through telerehabilitation and real-time monitoring.
 Objective(s): This study outlines the protocol for a randomized
controlled trial involving patients with lung cancer undergoing thoracic
surgery. Design(s): Assessor-blinded (single-blind), two-arm,
parallel-group randomized controlled trial (1:1 allocation) conducted at a
single medical center. Methods and analysis: The intervention will include
individualized exercise prescriptions delivered five times per week for 8
weeks via the App, which adapts based on weekly assessments of clinical
parameters and real-time performance data. Primary outcomes include forced
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), as
well as cardiopulmonary fitness assessed at baseline and at postoperative
weeks 5 and 8. Secondary outcomes include respiratory muscle strength,
diaphragmatic function, and user satisfaction, which are evaluated using a
custom questionnaire informed by technology acceptance models. In
addition, clinically meaningful endpoints will be collected, including
morbidity, mortality, and length of stay. Frailty will be assessed
preoperatively using the Clinical Frailty Scale, and validated
patient-reported outcomes (EORTC QLQ-C30) will be administered to evaluate
quality of life and symptom burden. Ethics: The study has been approved by
the Institutional Review Board at National Cheng Kung University Hospital
(A-ER-111-055). Discussion(s): We hypothesize that patients using the
RehabLung App may demonstrate improvements in pulmonary function, exercise
tolerance, diaphragmatic function, and rehabilitation adherence compared
with those receiving standard care. The system's real-time feedback and
risk alerts may facilitate timely intervention and could potentially
improve engagement. Conclusion(s): The implementation of the
RehabLung App in lung cancer surgery care may enhance the effectiveness
and accessibility of pulmonary rehabilitation. This protocol describes an
AI-enhanced telerehabilitation system that may support individualized
recovery strategies and could potentially improve both clinical outcomes
and patient engagement. Trial Registration: Registration Date;2024,09,19;
ClinicalTrials.gov (Identifier: NCT06600503). Copyright © The
Author(s), 2026. This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 License
(https://creativecommons.org/licenses/by-nc/4.0/) which permits
non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified
on the SAGE and Open Access pages
(https://us.sagepub.com/en-us/nam/open-access-at-sage).

<51>
[Use Link to view the full text]
Accession Number
2043214812
Title
Anticoagulation and Antiplatelet Therapy Versus Anticoagulation Alone in
Patients With Chronic Coronary Syndrome Receiving Long-Term
Anticoagulation: A Meta-Analysis of Randomized Clinical Trials.
Source
Circulation. 153(4) (pp 294-296), 2026. Date of Publication: 27 Jan 2026.
Author
Lemesle G.; Didier R.; Diallo A.; Dromas H.; Bauters C.; Steg P.G.; Simon
T.; Danchin N.; Ninni S.; Montalescot G.; Vicaut E.; Gilard M.; Cayla G.
Institution
(Lemesle, Diallo, Dromas, Bauters, Ninni) Heart and Lung Institute,
University Hospital of Lille, CHU Lille, Lille, France
(Lemesle, Ninni) Institut Pasteur of Lille, INSERM U1011, Lille, France
(Lemesle, Ninni) Universite de Lille, Lille, France
(Lemesle, Steg, Simon, Danchin) French Alliance for Cardiovascular Trials,
Paris, France
(Didier, Gilard) Cardiology Department, CHU Brest, Brest, France
(Didier, Gilard) INSERM UMR1304-GETBO, Brest, France
(Didier, Gilard) University of Brest, Brest, France
(Diallo, Steg, Montalescot, Vicaut) Assistance Publique - Hopitaux de
Paris, Hopital Fernand Widal, Paris, France
(Diallo, Vicaut) Unite de Recherche Clinique, Statistique, Analyse et
Modelisation Multidisciplinaire, EA4543, Paris, France
(Diallo, Vicaut) Universite Paris 1 Pantheon Sorbonne, Paris, France
(Montalescot, Vicaut, Cayla) ACTION Group, Paris, France
(Steg) Universite Paris-Cite, Paris, France
(Steg, Simon) INSERM U1148, Paris, France
(Simon, Montalescot) Sorbonne Universite, Paris, France
(Simon) Department of Clinical Pharmacology, Unite de Recherche Clinique
de l'EST Parisien (URCEST), Assistance Publique des Hopitaux de Paris,
Hopital Saint Antoine, Paris, France
(Danchin) Department of Cardiology, Saint Joseph Hospital, Paris, France
(Montalescot) INSERM U1166, Paris, France
(Cayla) Universite de Montpellier, Montpellier, France
(Cayla) Centre Hospitalier Universitaire de Nimes, Nimes, France
Publisher
Lippincott Williams and Wilkins

<52>
Accession Number
2042186607
Title
Machine learning models for predicting dosing of oral anticoagulants: a
systematic review.
Source
Journal of Pharmacy Practice and Research. 56(1) (pp 16-46), 2026. Date of
Publication: 01 Feb 2026.
Author
Barras M.; Hanjani L.S.; Scott I.A.; Abdel-Hafez A.; Falconer N.
Institution
(Barras, Falconer) Department of Pharmacy, Princess Alexandra Hospital,
Brisbane, Australia
(Barras, Falconer) School of Pharmacy and Pharmaceutical Sciences, The
University of Queensland, Brisbane, Australia
(Hanjani) Centre for Health Services Research, The University of
Queensland, Brisbane, Australia
(Scott) Metro South Digital Health and Informatics, Metro South Health,
Brisbane, Australia
(Scott) Queensland Digital Health Centre, The University of Queensland,
Brisbane, Australia
(Abdel-Hafez) College of Computing and Information Technology, University
of Doha for Science and Technology, Doha, Qatar
Publisher
John Wiley and Sons Inc
Abstract
Aim: To identify and appraise studies of machine learning (ML)-derived
prediction models for determining the optimal dose of oral anticoagulants
(OACs). Data Sources: PubMed, Embase, International Pharmaceutical
Abstracts (IPA), IEEE Xplore, and Web of Science were searched from
inception to 31 May 2024 using key terms synonymous with 'artificial
intelligence' or 'machine learning', 'prediction', 'dose', and 'oral
anticoagulants'. OACs included vitamin K antagonists (VKAs) - warfarin,
acenocoumarol, phenprocoumon - and direct oral anticoagulants (DOACs) -
apixaban, rivaroxaban, dabigatran. Study Selection: Studies published in
English that used ML methods to develop and/or validate models to predict
optimal OAC doses in adults, in any healthcare setting were included. A
modified checklist, using the Checklist for critical Appraisal and data
extraction for systematic Reviews of prediction Modelling Studies
(CHARMS), guided data extraction and study appraisal was performed
independently by two researchers. This review was conducted and reported
according to the Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) 2020 statement and was registered with the
International Prospective Register of Systematic Reviews (PROSPERO) (Study
registration: PROSPERO CRD42021281150). Result(s): Of 7791 abstracts,
164 underwent full-text review and 53 studies met the inclusion criteria.
All used supervised learning methods; all but one evaluated VKAs. Of the
53 studies, 77% (n = 41) targeted a 'stable therapeutic dose'; and only
one DOAC study evaluated patient outcomes using apixaban, rivaroxaban,
edoxaban, and dabigatran. Nine studies (17%) were prospective and two (4%)
reported external validation. Of 44 retrospective analyses, 15 (34%)
studies used the International Warfarin Pharmacogenetics Consortium (IWPC)
dataset, with 12 (23%) reporting external validation. Only four (8%)
studies satisfied all pre-determined criteria considered essential for
building ML models for OACs. While comparison across studies was
challenging, two of the better performing, externally validated models
were by Li et al. (2020) and Gu et al. (2022) with an accuracy of 63% and
75% and retrospectively. Conclusion(s): Future research should train
models on large datasets, including key genetic and non-genetic
predictors, undertake external validation, and prospectively assess
performance using clinical data. Copyright © 2025 Society of
Hospital Pharmacists of Australia trading as Advanced Pharmacy Australia.

<53>
Accession Number
2043865261
Title
Risk factors for acute kidney injury following transcatheter aortic valve
replacement: a systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1684953. Date of Publication: 2026.
Author
Jiang N.; Liu X.; Huang J.; Jiang Y.; Li D.
Institution
(Jiang, Huang, Jiang, Li) Department of Cardiology, The First People's
Hospital of Zigong, Sichuan, Zigong, China
(Liu) Department of Oncology, The Second People's Hospital of Yibin,
Sichuan, Yibin, China
Publisher
Frontiers Media SA
Abstract
Objective: To delineate risk factors for acute kidney injury (AKI) after
transcatheter aortic valve replacement (TAVR) via a systematic review and
meta-analysis. Method(s): PubMed, Embase, the Cochrane Library, and
Web of Science were searched through February 2025 for case-control
studies reporting post-TAVR AKI. Two reviewers independently performed
study selection, data extraction, and bias assessment. Pooled analyses
were conducted with Stata 15.0. Result(s): Thirty-four studies
(10,353 patients) met the inclusion criteria; 2,250 patients (21.7%)
developed AKI. Univariable meta-analysis implicated multiple comorbid,
hemodynamic, and procedural factors [e.g., hypertension, diabetes,
coronary and peripheral vascular disease, porcelain aorta, prior PCI,
atrial fibrillation, chronic kidney disease (CKD), advanced NYHA class,
left ventricular ejection fraction (LVEF) <40%, anemia, diuretic use,
transapical/transaortic access, general anesthesia, rapid pacing, bleeding
or vascular complications, transfusion, and peri-procedural myocardial
infarction or stroke; all p < 0.05). Multivariable pooling isolated eight
independent predictors: hypertension (OR 2.87), coronary artery disease
(1.46), peripheral vascular disease (1.71), prior stroke (1.61), CKD
(3.27), elevated serum creatinine (2.80), higher STS score (1.06 per
point), and transapical access (3.45). Publication bias was not detected.
 Conclusion(s): Post-TAVR AKI is chiefly driven by cardiovascular
comorbidity and renal impairment, with hypertension, coronary and
peripheral vascular disease, prior stroke, CKD, elevated creatinine, high
STS score, and transapical access displaying the strongest, independent
associations. Awareness of these factors may facilitate peri-procedural
risk stratification and targeted renal-protective
strategies. Copyright 2026 Jiang, Liu, Huang, Jiang and Li.

<54>
Accession Number
2043570799
Title
Near Misses as Signals of System Vulnerability in Thoracic Surgery: A
Narrative Review on Quality Improvement and Patient Safety.
Source
Healthcare (Switzerland). 14(4) (no pagination), 2026. Article Number:
423. Date of Publication: 01 Feb 2026.
Author
Magouliotis D.E.; Androutsopoulou V.; Zotos P.-A.; Xanthopoulos A.; Cioffi
U.; Sicouri N.; Solli P.; Scarci M.
Institution
(Magouliotis) Department of Cardiac Surgery Research, Lankenau Institute
for Medical Research, Wynnewood, PA, United States
(Magouliotis, Xanthopoulos) Department of Cardiology, University of
Thessaly, Biopolis, Larissa, Greece
(Androutsopoulou, Zotos) Department of Cardiothoracic Surgery, University
of Thessaly, Biopolis, Larissa, Greece
(Cioffi) Department of Surgery, University of Milan, Milan, Italy
(Sicouri) Department of Neuroscience Pittsburgh Campus, University of
Pittsburgh, Pittsburgh, PA, United States
(Solli) Department of Thoracic Surgery, Fondazione IRCCS Istituto
Nazionale dei Tumori Milano, Via Giacomo, Venezian 1, Milan, Italy
(Scarci) Department of Cardiothoracic Surgery, Hammersmith Hospital,
Imperial College Healthcare, National Health Service (NHS) Trust, London,
United Kingdom
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Near misses-clinical events that could have resulted in patient harm but
did not-are increasingly recognized as critical yet underutilized sources
of insight in surgical quality improvement. In thoracic surgery, where
procedures are physiologically demanding and care pathways are highly
interdependent, near misses frequently precede major complications and
expose latent system vulnerabilities rather than isolated technical
errors. A structured narrative review methodology was employed, including
a targeted literature search of major biomedical databases and thematic
synthesis of relevant studies. This narrative review synthesizes evidence
from patient safety science, surgical quality literature, and thoracic
surgery-specific outcomes research to examine how near misses can be
systematically leveraged to improve care. We discuss the transition from
individual-centered explanations of adverse events to system-based models
that emphasize human factors, communication, escalation pathways, and
organizational culture. Particular attention is given to contemporary
quality frameworks such as failure to rescue and textbook outcome, which
highlight the importance of early recognition, coordinated response, and
recovery from complications rather than complication avoidance alone. We
further explore the central role of psychological safety and leadership
behaviors in enabling meaningful learning from near misses. By reframing
near misses as actionable data rather than anecdotal "close calls,"
quality improvement emerges as a core professional responsibility in
thoracic surgery. We conclude that excellence in thoracic surgery should
be defined not by the absence of complications, but by the capacity of
surgical systems to learn, adapt, and prevent future harm. Copyright
© 2026 by the authors.

<55>
Accession Number
2037192063
Title
Clinical Outcomes with High- versus Low-Dose Tranexamic Acid Infusion in
Patients Undergoing Cardiac Surgery: A Systematic Review and
Meta-Analysis.
Source
Thoracic and Cardiovascular Surgeon. 73(5) (pp 346-359), 2025. Date of
Publication: 01 Aug 2025.
Author
Rangwala H.S.; Rangwala B.S.; Alotaibi M.; Siddiq M.A.; Qamber A.; Zaidi
S.D.E.Z.; Naveed T.; Naveed H.; Azam S.T.; Hameed I.
Institution
(Rangwala, Rangwala, Siddiq, Qamber, Zaidi, Azam) Department of Medicine,
Jinnah Sindh Medical University, Sindh, Karachi, Pakistan
(Alotaibi) Department of Medicine, Imam Abdulrahman Bin Faisal University,
College of Medicine, Eastern, Dammam, Saudi Arabia
(Naveed, Naveed) Department of Medicine, Ziauddin Medical College, Sindh,
Karachi, Pakistan
(Hameed) Department of Medicine, MedStar Health, Baltimore, MD, United
States
Publisher
Georg Thieme Verlag
Abstract
Objectives Antifibrinolytics, such as tranexamic acid (TXA), are widely
used in cardiac surgery to reduce bleeding risks; however, the optimal
dosage for TXA infusion remains a subject of debate. Hence, this study
aims to evaluate the safety and efficacy of high-dose compared with
low-dose TXA infusion in cardiac surgery patients. Methods PubMed, SCOPUS,
and Cochrane Central Register of Controlled Trials (CENTRAL) were searched
until June 10, 2023, for studies assessing efficacy outcomes (e.g., blood
loss, transfusions) and safety outcomes (e.g., mortality, complications).
Results Results were analyzed via random-effects model, using
Mantel-Haenszel risk ratio (RR) and standard mean difference (SMD). P
-value < 0.05 was considered significant. We analyzed 17 studies involving
93,206 participants (mean age 59.3 years, study duration 3 months to 10
years). Our analysis found significant reductions in total blood loss
(SMD, -0.17 g; CI, -0.34 to -0.01; p = 0.04), 24-hour blood loss (SMD,
-0.23 g; p = 0.005), and the need for fresh frozen plasma (FFP)
transfusions (RR: 0.94; CI, 0.89 to 1.00; p = 0.05) with high-dose TXA.
Chest tube output was also lower (SMD, -0.12 g; p = 0.0006), but
postoperative seizures increased (RR: 2.23; CI, 1.70 to 2.93; p < 0.00001)
with high-dose TXA. For other outcomes like blood transfusions,
hospital/ICU stay, mortality, stroke, myocardial infarction, pulmonary
embolism, renal dysfunction, and reoperation, no significant differences
were found between high-dose and low-dose TXA regimens. Conclusion Our
study showed that high TXA dose effectively reduce postoperative bleeding,
chest tube drainage, and the need for FFP transfusion, but it increases
the risk of seizures. Increasing TXA dose did not affect thromboembolic
events or mortality. This emphasizes the importance of weighing the
benefits and risks when selecting the appropriate TXA regimen for each
patient. Copyright © 2025. Thieme. All rights reserved.

<56>
Accession Number
2030578848
Title
Pericardial Decompression Syndrome: A Comprehensive Review of a
Controversial Entity.
Source
International Journal of Angiology. 33(3) (pp 139-147), 2024. Date of
Publication: 09 Aug 2024.
Author
Sarode K.; Patel A.; Arrington K.; Makhija R.; Mukherjee D.
Institution
(Sarode, Patel, Arrington, Makhija, Mukherjee) Department of
Cardiovascular Medicine, Texas Tech University Health Sciences Center, El
Paso, TX, United States
Publisher
Thieme Medical Publishers, Inc.
Abstract
Pericardial decompression syndrome is an ambiguous clinical entity which
has generated controversy regarding its existence. Following pericardial
decompression, patients experienced clinical deterioration ranging in
complications from pulmonary edema to death that could not be attributed
to any other distinct clinical pathology. Multiple theories have suggested
the pathophysiology behind pericardial decompression syndrome is related
to preload-afterload mismatch following pericardial decompression,
coronary microvascular ischemia, and stress from high adrenergic state.
Our review aims to describe this syndrome by analyzing demographics,
etiology of pericardial effusion, method of drainage, volume of
pericardial fluid removed, time to decompensation, and clinical outcomes.
A systematic review of MEDLINE/PubMed and Google Scholar literature
databases were queried for case reports, case series, review articles, and
abstracts published in English journals between 1983 and December 2022.
Each author's interpretation of echocardiographic and/or pulmonary
arterial catheterization data provided in the case reports was used to
characterize ventricular dysfunction. Based on our inclusion criteria, 72
cases of pericardial decompression syndrome were included in our review.
Our results showed that phenotypic heterogeneity was present based on
echocardiographic findings of right/left or biventricular failure with
similar proportions in each type of ventricular dysfunction. Time to
decompensation was similar between immediate, subacute, and acute cases
with presentation varying between hypoxic respiratory failure and shock.
This review article highlights theories behind the pathophysiology,
clinical outcomes, and therapeutic options in this high mortality
condition. was downloaded for personal use only. Unauthorized distribution
is strictly prohibited. Copyright © 2024. International College
of Angiology. All rights reserved.

<57>
Accession Number
2031446364
Title
A Study of Safety and Effectiveness of Evicel Fibrin Sealant as an
Adjunctive Hemostat in Pediatric Surgery.
Source
European Journal of Pediatric Surgery. 34(6) (pp 512-521), 2024. Date of
Publication: 05 Nov 2024.
Author
Kenny S.; Gabra H.; Hall N.J.; Flageole H.; Illie B.; Barnett E.;
Kocharian R.; Sharif K.
Institution
(Kenny) Department of Paediatric Surgery, Alder Hey Children's Hospital,
Merseyside, Liverpool, United Kingdom
(Gabra) Department of Children's Surgery, Great North Children's Hospital,
Newcastle, United Kingdom
(Hall) Department of Neonatal and Paediatric Surgery, Southampton
Children's Hospital, Southampton, United Kingdom
(Flageole) Department of Pediatric Surgery, McMaster Children's Hospital,
Hamilton, ON, Canada
(Illie, Kocharian) Department of Scientific Affairs, Ethicon Inc, Raritan,
NJ, United States
(Barnett) Department of Scientific Affairs, Ethicon UK, Livingston, United
Kingdom
(Sharif) Department of Paediatric Surgery, Birmingham Children's Hospital
NHS Foundation Trust, Birmingham, United Kingdom
Publisher
Georg Thieme Verlag
Abstract
Introduction Data on the use of fibrin sealants to control intraoperative
bleeding in children are scarce. Evicel Fibrin Sealant (Ethicon Inc.,
Raritan, New Jersey, United States) was found safe and effective in
clinical trials of adults undergoing various surgery types. We evaluated
the safety and efficacy of Evicel versus Surgicel Absorbable Hemostat
(Ethicon Inc.) as adjunctive topical hemostats for mild/moderate
raw-surface bleeding in pediatric surgery. Methods A phase III randomized
clinical trial was designed as required by the European Medicines Agency's
Evicel Pediatric Investigation Plan: 40 pediatric subjects undergoing
abdominal, retroperitoneal, pelvic, or thoracic surgery were randomized to
Evicel or Surgicel, to treat intraoperative mild-to-moderate bleeding.
Descriptive analyses included time-to-hemostasis and rates of treatment
success (4, 7, 10 minutes), intraoperative treatment failure, rebleeding,
and thromboembolic events. Results Forty of 130 screened subjects aged 0.9
to 17 years were randomized 1:1 to Evicel or Surgicel. Surgeries were
predominantly open abdominal procedures. The median bleeding area was 4.0
cm 2 for Evicel and 1.0 cm 2 for Surgicel. The
median time-to-hemostasis was 4.0 minutes for both groups. The 4-, 7-, and
10-minute treatment success rates were 80.0% versus 65.0%, 100.0% versus
80.0%, and 95.0% versus 90.0%, whereas treatment failure rates were 5.0%
versus 25.0%, for Evicel and Surgicel, respectively. No deaths or
thrombotic events occurred. Re-bleeding occurred in 5.0% of Evicel and
10.0% of Surgicel subjects. Conclusions In accordance with adult clinical
trials, this randomized study supports the safety and efficacy of Evicel
for controlling mild-to-moderate surgical bleeding in a broad range of
pediatric surgical procedures. Copyright © 2024. The Author(s).

<58>
Accession Number
2043866689
Title
Research progress on imaging prediction of pleural adhesion: a narrative
review.
Source
Journal of Thoracic Disease. 18(2) (no pagination), 2026. Article Number:
162. Date of Publication: 28 Feb 2026.
Author
Wang Y.; Lyu D.; Tu W.; Zhou X.; Xiao Y.; Fan L.; Liu S.
Institution
(Wang, Lyu, Tu, Zhou, Xiao, Fan, Liu) Department of Radiology, The Second
Affiliated Hospital of Navy Medical University, Shanghai, China
(Fan, Liu) Department of Radiology, The Second Affiliated Hospital of Navy
Medical University, No. 415 Fengyang Road, Huangpu District, Shanghai,
China
Publisher
AME Publishing Company
Abstract
Background and Objective: Pleural adhesion is a significant risk factor
that can lead to a poor prognosis in thoracic surgery. The extent of these
adhesions directly affects the selection of preoperative surgical
approaches, the progress of the intraoperative surgical process, and the
occurrence of serious postoperative complications. Accurate preoperative
judgment of pleural adhesions and their severity is of great significance
for formulating perioperative treatment plans and achieving precision
medicine. This article focuses on summarizing and synthesizing various
imaging methods for preoperative prediction of pleural adhesions and
discusses the challenges and prospects facing future research. The aim is
to improve preoperative diagnostic accuracy and risk stratification,
thereby enhancing surgical safety and efficacy. Method(s): A
comprehensive, non-systematic review of the latest literature was carried
out in order to investigate the progress of predicting pleural adhesions.
PubMed database was being examined, and the last run was on December
17th 2025. Key Content and Findings: This article reviews the
definition, classification, and clinical significance of pleural
adhesions, and summarizes the latest research progress of imaging
prediction of pleural adhesions in the past 10 years. It was found that
ultrasound, chest X-ray, computed tomography (CT), and
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET)/CT can all effectively predict the pleural adhesion
status before the operation. Conclusion(s): Pleural adhesions
influence the survival prognosis of patients with thoracic surgery.
Effective preoperative prediction of the state of pleural adhesions can
help to improve the preoperative surgical plan formulation and reduce the
occurrence of postoperative complications. Ultrasound, chest X-ray, CT,
and 18F-FDG PET/CT have their advantages and disadvantages in
predicting pleural adhesions, and artificial intelligence (AI) may be the
direction of future research. Copyright © AME Publishing Company.

<59>
Accession Number
2043043549
Title
Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy
after percutaneous coronary intervention: an updated meta-analysis of
162,829 patients.
Source
European Journal of Clinical Pharmacology. 82(3) (no pagination), 2026.
Article Number: 64. Date of Publication: 01 Mar 2026.
Author
Elbahloul M.A.; Mansour A.; Galal A.; Moawad W.M.; Khaled M.; Kasem A.W.;
Labeeb E.E.; Elgendy I.Y.
Institution
(Elbahloul) Faculty of Medicine, Kafr El-Shaikh University, Kafr El
Sheikh, Egypt
(Mansour, Galal, Kasem, Labeeb) Faculty of Medicine, Al-Azhar University,
Cairo, Egypt
(Moawad, Khaled) Faculty of Medicine, Fayoum University, El Fayoum, Egypt
(Elgendy) Division of Cardiovascular Medicine, Gill Heart and Vascular
Institute, University of Kentucky, Lexington, KY, United States
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Dual antiplatelet therapy (DAPT) following percutaneous
coronary intervention (PCI) remains a cornerstone for preventing ischemic
events; however, the optimal long-term single antiplatelet therapy after
completion of DAPT remains unclear. We aimed to compare clopidogrel and
aspirin monotherapy after completion of the standard duration of DAPT.
 Method(s): A systematic search was conducted on PubMed, Scopus,
Cochrane Library, and Web of Science from inception to April 2025. We
included randomized clinical trials and observational studies that
compared aspirin versus clopidogrel monotherapy after completion of
standard-duration DAPT. The primary and co-primary outcomes were major
adverse cardiovascular events (MACE) and major bleeding, respectively.
Using random-effects models, outcomes were expressed as risk ratios (RR)
or hazard ratios (HR) with 95% confidence intervals (CI). Result(s):
Ten studies, comprising 162,829 patients, were included. Clopidogrel was
significantly associated with a lower risk of MACE (HR: 0.72, 95% CI:
0.66-0.79) and net adverse clinical events (NACE) (RR: 0.86, 95% CI:
0.73-0.99) at a weighted mean follow-up of 3.2 years. Major bleeding
showed no significant difference between clopidogrel and aspirin (RR:
0.85, 95% CI: 0.60-1.21). Moreover, there was no difference between
clopidogrel and aspirin in all-cause mortality, myocardial infarction,
revascularization, stroke, or all bleeding. Conclusion(s): Among
patients who underwent PCI, clopidogrel monotherapy after standard DAPT
was associated with a lower incidence of MACE and NACE compared with
aspirin monotherapy, without increasing the bleeding risk. Copyright
© The Author(s) 2026.

<60>
Accession Number
618715698
Title
Effects of acupressure on sleep quality after coronary artery bypass
surgery.
Source
Iranian Heart Journal. 18(3) (pp 28-34), 2017. Date of Publication: 2017.
Author
Yaghoubi A.; Golfeshan E.; Azarfarin R.; Nazari A.; Alizadehasl A.; Ehasni
A.
Institution
(Yaghoubi) Rajaie Cardiovascular Medical and Research Center, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Golfeshan) Department of Critical Care Nursing, Qom University of Medical
Sciences, Qom, Iran, Islamic Republic of
(Azarfarin, Alizadehasl) Echocardiography Research Center, Rajaie
Cardiovascular Medical and Research Center, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Nazari) Department of Complementary Medicine, Vali-Asr Hospital, Qom,
Iran, Islamic Republic of
(Ehasni) Department of Medicine, Iran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
Publisher
Iranian Heart Association
Abstract
Background: Sleep disturbances are common following coronary artery bypass
graft surgery (CABG). Nowadays, nonmedical therapies are considered along
with medical therapies for sleep disturbances. The aim of this study was
to evaluate the effects of acupressure on sleep quality in patients after
CABG. Method(s): This randomized controlled trial assigned 60
patients admitted to the intensive care unit after CABG to 2 groups. Each
group comprised 30 patients, with the experimental group receiving
acupressure on 5 different solar points for 5 to 15 minutes during 2
consecutive postoperative days and the control group receiving only
sedative drugs on request. Sleep quality was measured the day before and
after CABG using the St Mary's Hospital Sleep Questionnaire (SMHSQ) in
both groups. An SMHSQ score 9 is normal and 36 is the worst sleep quality.
 Result(s): According to the obtained data, before the intervention,
the median (interquartile range) score for sleep quality was 15 (13-17) in
the experimental group and 14 (13-14) in the control group; therefore,
there was no statistically significant difference between the 2 groups (P
= 0.689). However, following acupressure, the scores changed
significantly: the SMHSQ score rose to 14 (13-14) in the experimental
group, while it remained at 23 (23-25) in the control group suggesting a
reasonable difference in sleep quality between the 2 groups after CABG (P
= 0.001). Also, the average difference in the control group's score (+9
points) before and after the intervention period was more than that of the
acupressure group (-1 point). Conclusion(s): Our findings showed that
acupressure improved sleep quality in patients in the intensive care unit
after CABG surgery. Copyright © 2017, Iranian Heart Association.
All rights reserved.

<61>
Accession Number
641953584
Title
Long-term Outcomes of Low-Risk Patients Treated With Transcatheter Aortic
Valve Replacement Versus Surgical Aortic Valve Replacement: Results from A
Meta-Analysis.
Source
Internal and emergency medicine. 18(7) (pp 2143-2148), 2023. Date of
Publication: 01 Oct 2023.
Author
Tariq M.A.; Amin H.; Malik M.K.
Institution
(Tariq, Malik) Department of Cardiology, Dow University Hospital, Dow
University of Health Sciences, Karachi, Pakistan
(Amin) Dr. Ruth K. M. Pfau, Civil Hospital, Karachi, Pakistan

<62>
Accession Number
2043551331
Title
Multimodality Imaging in Cardiac Metastasis of Cutaneous Melanoma: Case
Report and Systematic Review.
Source
Journal of Cardiovascular Development and Disease. 13(2) (no pagination),
2026. Article Number: 84. Date of Publication: 01 Feb 2026.
Author
Lara-Sampayo K.L.; Ibarrola-Pena J.C.; de la Pena-Tamez M.;
Salinas-Casanova J.A.; Garcia R.; Jerjes-Sanchez C.; Paredes-Vazquez J.G.;
de la Pena-Almaguer E.
Institution
(Lara-Sampayo) Hospital General de Zona y de Medicina Familiar Zona 2 IMSS
Monterrey, Nuevo Leon, Monterrey, Mexico
(Ibarrola-Pena, de la Pena-Tamez, Salinas-Casanova, Garcia,
Jerjes-Sanchez, Paredes-Vazquez, de la Pena-Almaguer) Escuela de Medicina
y Ciencias de la Salud, Tecnologico de Monterrey, Nuevo Leon, Monterrey,
Mexico
(Ibarrola-Pena, Salinas-Casanova, Jerjes-Sanchez, Paredes-Vazquez, de la
Pena-Almaguer) Instituto de Cardiologia y Medicina Vascular, TecSalud,
Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San
Pedro Garza GarciaNuevo Leon, Mexico
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Cardiac metastases from cutaneous melanoma are uncommon and
often underdiagnosed due to their variable and frequently asymptomatic
presentation. To better describe their clinical features, diagnostic
strategies, and outcomes, we performed a systematic review of published
case reports and present an illustrative clinical case. Case presentation:
We report the case of a 67-year-old man with a history of stage IIA
cutaneous melanoma who presented with progressive fatigue and dyspnea.
Disease recurrence was confirmed by skin biopsy. Multimodal imaging,
including echocardiography, FDG PET-CT, and cardiac magnetic resonance
(CMR), demonstrated extensive myocardial infiltration consistent with
cardiac metastases. Despite treatment with immunotherapy, the patient
experienced progressive clinical deterioration and died six months after
diagnosis. Discussion(s): The systematic review encompassed 23
published articles reporting 27 individual cases, with a mean age at
diagnosis of 55.9 years and a clear male predominance. Cardiac involvement
exhibited marked heterogeneity in both clinical presentation and
anatomical distribution, most frequently affecting the left ventricular
free wall and the interventricular septum. Echocardiography consistently
served as the initial diagnostic modality, while cardiac magnetic
resonance and CT/FDG PET-CT were used to refine lesion characterization
and assess extracardiac disease. Notably, a complete multimodal imaging
strategy was reported in fewer than one-third of cases, reflecting
variability in diagnostic approaches. Survival outcomes were highly
heterogeneous, with substantial mortality, underscoring the need for
earlier detection and more accurate diagnostic strategies for cardiac
involvement in melanoma. Conclusion(s): Cardiac metastases from
melanoma represent advanced disease and remain associated with poor and
heterogeneous outcomes. An integrated multimodal imaging approach supports
detailed diagnostic characterization and may aid clinical evaluation and
management in selected cases. Copyright © 2026 by the authors.

<63>
Accession Number
2043386475
Title
Technological advancements for improving preoperative assessment and
precision in cardiovascular surgery.
Source
Expert Review of Cardiovascular Therapy. 24(3) (pp 149-157), 2026. Date of
Publication: 2026.
Author
Galyfos G.; Chamzin A.; Theodorou A.; Sigala F.; Filis K.; Theodorou D.
Institution
(Galyfos, Chamzin, Theodorou, Sigala, Filis, Theodorou) Vascular Surgery
Unit, First Department of Propedeutic Surgery, National and Kapodistrian
University of Athens, Hippocration Hospital, Athens, Greece
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Cardiovascular surgery, including cardiac surgery and
complex endovascular procedure, needs careful preoperative planning as
well as intraoperative precision to improve outcomes and ameliorate
complications. During the last decades, several technological advancements
have been made that could improve preoperative assessment, design of the
surgical procedure, risk prediction as well as surgical precision. Areas
covered: Several areas of technological advancements referring to
cardiovascular surgery are discussed in this review. Data have been
collected using the Pubmed, Scopus, and Google Scholar databases. We
report advancements regarding the utilization of artificial intelligence
in preoperative assessment and risk prediction. We also report on
advancements made in intraoperative imaging including holographic and
fusion imaging techniques. Furthermore, operating techniques such as the
use of novel endovascular tools or robotic surgery are also discussed.
Finally, other novel technologies, such as three-dimentional (3D)
printing, is also presented. Expert opinion: In the next 5 years,
technological advancements in cardiovascular surgery will be definitely
improved and more broadly used. Although these advancements are associated
with a very high cost and a longer learning curve, the associated
healthcare cost benefit is evident. Due to bioethical reasons, this
progress will need to be contained and controlled by humans. Copyright
© 2026 Informa UK Limited, trading as Taylor & Francis Group.

<64>
Accession Number
2043832898
Title
Cardiac Surgery in Cancer Patients: Clinical Dilemmas and Decision-Making
Challenges.
Source
Cancers. 18(5) (no pagination), 2026. Article Number: 748. Date of
Publication: 01 Mar 2026.
Author
Keramida K.; Tsekoura D.; Roubelakis A.; Michalopoulou H.; Androutsopoulou
V.
Institution
(Keramida) General Anticancer Oncological Hospital, Agios Savvas, Athens,
Greece
(Tsekoura) 2nd Department of Surgery, Aretaieio University Hospital,
National and Kapodistrian University of Athens, Athens, Greece
(Roubelakis) 3rd Department of Cardiac Surgery, Athens Medical Center,
Athens, Greece
(Michalopoulou) Department of Cardiology, Laiko General Hospital of
Athens, Athens, Greece
(Androutsopoulou) Department of Cardiothoracic Surgery, University
Hospital of Larissa, Larissa, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Improvements in cancer detection and treatment have led to a
growing population of cancer survivors who subsequently develop
cardiovascular (CV) disease requiring cardiac surgery. Method(s):
This narrative review synthesizes contemporary evidence from observational
studies, registries, meta-analyses, and international guidelines
addressing cardiac surgery in patients with active or prior cancer.
 Result(s): Cancer patients undergoing cardiac surgery face heightened
risks related to hypercoagulability, bleeding, immunosuppression, frailty,
and prior exposure to chemotherapy or radiotherapy. Conventional surgical
risk scores inadequately capture cancer-specific factors such as tumor
biology, prognosis, treatment trajectory, and frailty, often
underestimating operative risk. Timing of surgery must balance CV urgency
against oncologic priorities, with urgent cardiac conditions necessitating
prompt intervention irrespective of cancer status, while stable disease
allows individualized sequencing. Transcatheter and minimally invasive
approaches increasingly play a key role, particularly in patients with
limited life expectancy, hostile thoracic anatomy, or high surgical risk.
Outcomes are heterogeneous and largely driven by cancer stage and
prognosis rather than cardiac pathology alone. Conclusion(s): Cardiac
surgery can be lifesaving and restore eligibility for definitive oncologic
therapy in carefully selected patients, particularly those with
early-stage or potentially curable malignancies. In advanced cancer, the
benefits of invasive intervention must be weighed against perioperative
burden, quality of life impact, and overall prognosis. Multidisciplinary,
patient-centered decision-making within specialized cardio-oncology teams
is essential. Future priorities include the development of cancer-specific
risk prediction models, prospective surgical registries, and greater
integration of quality-of-life outcomes into clinical
decision-making. Copyright © 2026 by the authors.

<65>
Accession Number
2024009250
Title
Glutamate infusion associated with reduced rises of p-Copeptin after
coronary surgery: Substudy of GLUTAMICS II.
Source
Acta Anaesthesiologica Scandinavica. 67(10) (pp 1373-1382), 2023. Date of
Publication: 01 Nov 2023.
Author
Svedjeholm R.; Ferrari G.; Vanky F.; Friberg O.; Holm J.
Institution
(Svedjeholm, Vanky, Holm) Department of Thoracic and Vascular Surgery,
Department of Health, Medicine and Caring Sciences, Unit of Cardiovascular
Medicine, Linkoping University, Linkoping, Sweden
(Ferrari, Friberg) Department of Cardiothoracic and Vascular Surgery,
Faculty of Medicine and Health, Health Care Research Centre, Orebro
University, Orebro, Sweden
Publisher
John Wiley and Sons Inc
Abstract
Background: Glutamate plays a key role for post-ischaemic recovery of
myocardial metabolism. According to post hoc analyses of the two GLUTAMICS
trials, patients without diabetes benefit from glutamate with less
myocardial dysfunction after coronary artery bypass surgery (CABG).
Copeptin reflects activation of the Arginine Vasopressin system and is a
reliable marker of heart failure but available studies in cardiac surgery
are limited. We investigated whether glutamate infusion is associated with
reduced postoperative rises of plasma Copeptin (p-Copeptin) after CABG.
 Method(s): A prespecified randomised double-blind substudy of
GLUTAMICS II. Patients had left ventricular ejection fraction <=0.30 or
EuroSCORE II >=3.0 and underwent CABG +/- valve procedure. Intravenous
infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was
commenced 10-20 min before the release of the aortic cross-clamp and then
continued for another 150 min P-Copeptin was measured preoperatively and
postoperatively on day one (POD1) and day three. The primary endpoint was
an increase in p-Copeptin from the preoperative level to POD1.
Postoperative stroke <=24 h and mortality <=30 days were safety outcomes.
 Result(s): We included 181 patients of whom 48% had diabetes. The
incidence of postoperative mortality <=30 days (0% vs. 2.1%; p =.50) and
stroke <=24 h (0% vs. 3.2%; p =.25) did not differ between the glutamate
group and controls. P-Copeptin increased postoperatively with the highest
values recorded on POD1 without significant inter-group differences. Among
patients without diabetes, p-Copeptin did not differ preoperatively but
postoperative rise from preoperative level to POD1 was significantly
reduced in the glutamate group (73 +/- 66 vs. 115 +/- 102 pmol/L; p =.02).
P-Copeptin was significantly lower in the Glutamate group on POD1 (p =.02)
and POD 3 (p =.02). Conclusion(s): Glutamate did not reduce rises of
p-Copeptin significantly after moderate to high-risk CABG. However,
glutamate was associated with reduced rises of p-Copeptin among patients
without diabetes. These results agree with previous observations
suggesting that glutamate mitigates myocardial dysfunction after CABG in
patients without diabetes. Given the exploratory nature of these findings,
they need to be confirmed in future studies. Copyright © 2023 The
Authors. Acta Anaesthesiologica Scandinavica published by John Wiley &
Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

<66>
Accession Number
2043866703
Title
Perioperative high-dose selenium supplementation in open thoracic aortic
surgery: a post hoc subgroup analysis of the SUSTAIN CSX trial.
Source
Journal of Thoracic Disease. 18(2) (no pagination), 2026. Article Number:
72. Date of Publication: 28 Feb 2026.
Author
Catena D.; Stoppe C.; Mohsen G.; Germinario L.; Kleine-Brueggeney M.;
O'Brien B.; Ott S.; Hagen X.A.; Orsenigo A.; Hellner N.; Landoni G.;
Belletti A.; Ortalda A.; Muller M.; Nersesian G.; Kempfert J.; Pitts L.
Institution
(Catena, Stoppe, Mohsen, Germinario, Kleine-Brueggeney, O'Brien, Ott,
Hagen, Orsenigo, Hellner) Department of Cardiac Anesthesiology and
Intensive Care Medicine, Deutsches Herzzentrum der Charite-Medical Heart
Center of Charite, German Heart Institute Berlin, Berlin, Germany
(Catena, Stoppe, Mohsen, Germinario, Kleine-Brueggeney, O'Brien, Ott,
Hagen, Orsenigo, Hellner, Muller, Nersesian, Kempfert, Pitts) Freie
Universitat Berlin, Humboldt-Universitat zu Berlin,
Charite-Universitatsmedizin Berlin, Berlin, Germany
(Catena, Stoppe, Kleine-Brueggeney, O'Brien, Ott, Nersesian, Kempfert,
Pitts) German Centre for Cardiovascular Research (DZHK), Partner Site
Berlin, Berlin, Germany
(Stoppe) Department of Anesthesiology, Intensive Care, Emergency and Pain
Medicine, University Hospital Wurzburg, Wurzburg, Germany
(O'Brien) Department of Perioperative Medicine, St Bartholomew's Hospital,
Barts Heart Centre, London, United Kingdom
(Ott, Muller, Nersesian, Kempfert, Pitts) Department of Cardiothoracic and
Vascular Surgery, Deutsches Herzzentrum der Charite-Medical Heart Center
of Charite, German Heart Institute Berlin, Berlin, Germany
(Hellner) Department of Anesthesiology, University Hospital Basel, Basel,
Switzerland
(Landoni, Belletti, Ortalda) Department of Anesthesia and Intensive Care,
IRCCS San Raffaele Scientific Institute, Milan, Italy
(Landoni) School of Medicine, Vita-Salute San Raffaele University, Milan,
Italy
Publisher
AME Publishing Company
Abstract
Background: Open surgery on the thoracic aorta is associated with a
variable and often pronounced postoperative inflammatory response, which
contributes to organ injury and prolonged intensive care unit (ICU) stays.
Various anti-inflammatory strategies have been proposed as a way to
modulate this response and therefore improve clinical outcomes. The
SUSTAIN-CSX randomized controlled trial investigated the effect of
perioperative high-dose selenium supplementation on mortality and organ
dysfunction in cardiac surgery patients. In this post hoc analysis, we
examined its effect on 30-day mortality and organ dysfunction in patients
undergoing open thoracic aortic surgery. Method(s): We conducted a
post hoc analysis of patients who underwent open thoracic aortic surgery
within the SUSTAIN-CSX trial, a multicenter randomized controlled trial
evaluating perioperative intravenous high-dose selenium supplementation in
cardiac surgery. The selenium regimen consisted of 2,000 microg sodium
selenite at anesthesia induction, 2,000 microg immediately
postoperatively, and 1,000 microg daily for up to 10 days in the ICU.
Patients treated with endovascular interventions of the thoracic aorta
were excluded. Result(s): A total of 287 patients were included, with
144 randomized to selenium and 143 to placebo. The primary outcome, 30-day
mortality, did not differ significantly between groups (selenium 2.8% vs.
placebo 3.5%; P=0.73). Clinically relevant postoperative atrial
fibrillation (POAF) occurred more frequently in the selenium group
(selenium 18.1% vs. placebo 10.5%; P=0.03). Non-cardiac organ dysfunction,
including acute kidney injury (AKI), postoperative delirium and Sequential
Organ Failure Assessment (SOFA) scores, was comparable between groups.
Postoperative inflammatory and organ injury markers were overall
comparable, although patients receiving selenium showed a non-significant
trend toward lower creatine kinase-myocardial band (CK-MB) levels
(selenium 18.9 microg/L vs. placebo 28.3 microg/L; P=0.07). Six-month
survival, ICU and hospital length of stay, readmission rates, and measures
of functional recovery did not differ between groups. Conclusion(s):
Perioperative intravenous high-dose selenium supplementation did not
improve 30-day mortality and was associated with an increased incidence of
clinically relevant POAF in this exploratory subgroup analysis. Routine
selenium supplementation in this setting cannot be
recommended. Copyright © AME Publishing Company.

<67>
Accession Number
2043704729
Title
The efficacy and safety of cerebral embolic protection devices in patients
undergoing transcatheter aortic valve replacement: a systematic review and
meta-analysis with trial sequential analysis of randomized controlled
trials.
Source
Expert Review of Cardiovascular Therapy. 24(3) (pp 253-271), 2026. Date of
Publication: 2026.
Author
Elazab A.; Hageen A.W.; Elbataa A.; Labeeb E.E.; Najah Q.; Elbahloul M.A.;
Elnady M.I.; Abdelsatar S.M.; Mansour A.; Elkasaby M.H.; Odat R.M.;
Rhabneh L.; Nassar M.; Turkmani M.; Hakim D.
Institution
(Elazab) Faculty of Medicine, South Valley University, Qena, Egypt
(Hageen) Faculty of Medicine, Tanta University, Tanta, Egypt
(Elbataa, Mansour, Labeeb, Mansour, Elkasaby) Faculty of Medicine,
Al-Azhar University, Cairo, Egypt
(Najah) Faculty of Medicine, Elmergib University, Alkhums, Libyan Arab
Jamahiriya
(Elbahloul, Elnady) Faculty of Medicine, Kafr El Sheik University, Kafr El
Sheikh, Egypt
(Abdelsatar) Faculty of Nursing, Beni-Suef National University, Beni-Suef,
Egypt
(Odat) Faculty of Medicine, Jordan University of Science and Technology,
Irbid, Jordan
(Rhabneh) Department of Internal Medicine, HMH Ocean University Medical
Center, Brick, NJ, United States
(Nassar) Division of Endocrinology and Diabetes, Larner College of
Medicine, University of Vermont, Burlington, VT, United States
(Turkmani) Faculty of Medicine, Michigan State University, East Lansing,
MI, United States
(Turkmani) Department of Pulmonary and Critical Care, University of
Toledo, Toledo, OH, United States
(Hakim) Brigham & Women's Hospital/Harvard Medical School, Boston, MA,
United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Transcatheter aortic valve replacement (TAVR) is an
established treatment for severe aortic stenosis but carries a risk of
stroke and cerebral embolism. Cerebral embolic protection devices (CEPD),
including filter-based and deflection-based systems (Sentinel and
TriGUARD), aim to reduce embolic complications; however, their clinical
benefit remains uncertain. This study evaluated the efficacy and safety of
CEPD during TAVR using trial sequential analysis (TSA) and the Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE)
framework. Method(s): Randomized controlled trials (RCTs) comparing
TAVR with and without CEPD were identified through four electronic
databases from inception to April 2025. Primary outcomes were all-cause
mortality, major adverse cardiovascular and cerebrovascular events
(MACCE), stroke, and disabling stroke. Pooled risk ratios (RR) with 95%
confidence intervals (CI) were calculated. TSA was conducted with a 5%
type I error and 80% power. Result(s): Nine RCTs including 11,876
patients were analyzed. CEPD use showed no significant reduction in
mortality, MACCE, stroke, or disabling stroke. Secondary and subgroup
analyses yielded consistent findings. TSA demonstrated that the accrued
evidence was insufficient to confirm a clinical benefit.
 Conclusion(s): Current evidence does not support the routine use of
CEPD during TAVR, given the lack of significant benefit in key clinical
outcomes. Registration: The protocol of this study was registered at
Prospero CRD420251036308. Copyright © 2026 The Author(s).
Published by Informa UK Limited, trading as Taylor & Francis Group.

<68>
Accession Number
2024792744
Title
Confirmation of Safety of Titanium Wire in Sternotomy Closure, A
Randomized Prospective Study.
Source
Thoracic and Cardiovascular Surgeon. 72(1) (pp 70-76), 2022. Date of
Publication: 12 Jan 2024.
Author
Eraqi M.; Diab A.H.; Matschke K.; Alexiou K.
Institution
(Eraqi) Klinikum Bayreuth GmbH, Bayreuth, Germany
(Eraqi, Diab, Matschke, Alexiou) Department of Cardiac Surgery, Heart
Center Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
Publisher
Georg Thieme Verlag
Abstract
Background There are many factors that are known to increase the risk of
sternal wound infection (SWI); some studies have reported that nickel is a
risk factor for SWI. Titanium wires have only been used as an alternative
to steel wires in patients with known allergy to nickel. However, there is
a paucity of literature regarding the safety of using titanium wires
compared to that on the safety of steel wires for sternum closure after
cardiac surgery. Therefore, this study aimed to demonstrate the
noninferiority of titanium wires, even in patients without a known
allergy. Methods A total of 322 patients who underwent elective full
median sternotomy were randomly assigned to sternal closure either by
titanium wires (n = 161) or by stainless steel wires. Results Fourteen
patients had sternal instability, six (3.7%) patients in the titanium
group and eight (5%) patients in the stainless steel group (p = 0.585).
There was no statistically significant difference between both groups in
terms of postoperative wound infection (p = 0.147). Patients in the
titanium group experienced statistically significant lower postoperative
pain than those in the stainless steel group (p = 0.024). The wire type
was not an independent risk factor for SI, as shown by univariate and
logistic regression analyses. Conclusion Titanium wires are a good
alternative and have been proven to be safe and effective for sternal
closure. The surgeon should be aware of the possibility of developing an
allergic reaction to the wires, especially in patients with previous
multiple allergic histories. Copyright © 2022 Georg Thieme
Verlag. All rights reserved.

<69>
Accession Number
2020423582
Title
Inhaled Milrinone via HFNC as a Postextubation Cardiopulmonary Elixir:
Case Series and Review of Literature.
Source
Journal of Cardiac Critical Care. 6(2) (pp 126-130), 2022. Date of
Publication: 21 Sep 2022.
Author
Bansal N.; Magoon R.; Kalaiselvan J.; Shri I.; Kohli J.K.; Kashav R.C.
Institution
(Bansal, Magoon, Kalaiselvan, Shri, Kashav) Department of Cardiac
Anaesthesia, Atal Bihari Vajpayee Institute of Medical Sciences (ABVIMS),
Dr. Ram Manohar Lohia (RML) Hospital, Baba Kharak Singh Marg, New Delhi,
India
(Kohli) Department of Cardiac Anaesthesia, Dr. Ram Manohar Lohia (RML)
Hospital, Baba Kharak Singh Marg, New Delhi, India
Publisher
Thieme Medical and Scientific Publishers Pvt Ltd
Abstract
Pulmonary hypertension (PH) often complicates perioperative course
following pediatric cardiac surgery, often presenting unique challenges to
the attending cardiac anesthesiologist. Apart from difficult weaning from
cardiopulmonary bypass, PH can often compound weaning from mechanical
ventilation in this postoperative subset. From pathophysiological
standpoint, the former can be attributed to concurrent detrimental
cardiopulmonary consequences of PH as a multisystemic syndrome. Therefore,
with an objective to address the affected systems, that is, cardiac and
pulmonary simultaneously, we report combined use of inhaled milrinone (a
pulmonary vasodilator) through high-frequency nasal cannula (oxygen
reservoir and continuous positive airway pressure delivery device),
purported to complement each other's mechanism of action in the management
of PH, thereby hastening postoperative recovery. This article additionally
presents a nuanced perspective on the advantages of combining the
aforementioned therapies and hence proposing the same as a possible
postoperative cardiopulmonary elixir. Copyright © 2022. Official
Publication of The Simulation Society (TSS), accredited by International
Society of Cardiovascular Ultrasound (ISCU). All rights reserved.

<70>
Accession Number
2043747941
Title
Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women
With Type 2 Diabetes and Breast Cancer.
Source
Pharmacotherapy. 46(4) (no pagination), 2026. Article Number: e70130. Date
of Publication: 01 Apr 2026.
Author
Cornelio C.K.; Cowart K.; Perkins J.; Alomar M.E.; Gayoso R.P.; Miranda
A.C.; Phan A.T.; White R.T.
Institution
(Cornelio, Cowart, Perkins, Miranda, White) Department of
Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy,
University of South Florida, Tampa, FL, United States
(Alomar, Gayoso) Department of Malignant Hematology, H. Lee Moffitt Cancer
Center & Research Institute, Tampa, FL, United States
(Phan) Department of Pharmacy, Michigan Medicine, University of Michigan,
Ann Arbor, MI, United States
Publisher
American College of Clinical Pharmacy
Abstract
Introduction: The cardiovascular (CV) benefits of glucagon-like-peptide-1
receptor agonist (GLP-1 RA) therapies are not well-established in women
with breast cancer and type 2 diabetes (T2D). Objective(s): The
primary objective of this study was to compare the incidence of major
adverse cardiovascular events (MACE) in women with T2D and breast cancer
receiving GLP-1 RA therapy versus non-GLP-1 RA diabetes medications.
 Method(s): This retrospective study included women with T2D,
diagnosed with breast cancer at >= 40 years old from December 16, 2014 to
December 16, 2024 and having exposure to diabetes medications of interest
(either GLP-1 RA or non-GLP-1 RA) within 5 years of these diagnoses. The
primary end point, MACE, was a composite of myocardial infarction,
ischemic stroke, coronary revascularization, cardiac arrest, or heart
failure, within 5 years of the index date. Propensity score matching was
performed. Participants were excluded from each individual outcome
analysis if they had the outcome prior to the index date. Incidence rates,
risk ratio (RR), 95% confidence interval (CI), and p-value were reported
for each outcome. Result(s): After matching, 19,608 patients were
included in each cohort (mean age 64 years). Obesity and alkylating agents
were more commonly reported in the GLP-1 RA cohort. Semaglutide was the
most prescribed GLP-1 RA at index (45.1%). MACE occurred in 10.6% of the
GLP-1 RA cohort and 13.4% of the non-GLP-1 cohort (RR 0.80, 95% CI
0.75-0.85, p < 0.001). Individual MACE end points, ischemic heart disease,
and end-stage renal disease were significantly lower in the GLP-1
RA-treated cohort. GLP-1 RA use was also associated with a 61.6% relative
risk reduction in all-cause mortality (RR 0.38, 95% CI 0.36-0.41, p <
0.001). Pancreatitis incidence was similar between groups (p = 0.057),
whereas cholelithiasis was significantly lower with GLP-1 RA therapy (p <
0.001). Conclusion(s): This study demonstrated the potential CV
benefit of GLP-1 RA therapies among a population of female breast cancer
survivors with T2D. Randomized trial data are needed to confirm these
findings. Copyright © 2026 ACCP Foundation, Ltd.

<71>
Accession Number
2023201007
Title
Protocol for a Systematic Review and Individual Participant Data
Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to
Prevent Stroke.
Source
Thrombosis and Haemostasis. 123(3) (pp 366-376), 2023. Date of
Publication: 02 Mar 2023.
Author
McIntyre W.
Publisher
Georg Thieme Verlag
Abstract
Introduction Atrial fibrillation (AF) is a common cause of stroke. Timely
diagnosis of AF and treatment with oral anticoagulation (OAC) can prevent
up to two-thirds of AF-related strokes. Ambulatory electrocardiographic
(ECG) monitoring can identify undiagnosed AF in at-risk individuals, but
the impact of population-based ECG screening on stroke is uncertain, as
ongoing and published randomized controlled trials (RCTs) have generally
been underpowered for stroke. Methods and analysis The AF-SCREEN
Collaboration, with support from AFFECT-EU, have begun a systematic review
and individual participant data meta-analysis of RCTs evaluating ECG
screening for AF. The primary outcome is stroke. Secondary outcomes
include AF detection, OAC prescription, hospitalization, mortality, and
bleeding. After developing a common data dictionary, anonymized data will
be collated from individual trials into a central database. We will assess
risk of bias using the Cochrane Collaboration tool, and overall quality of
evidence with the Grading of Recommendations Assessment, Development and
Evaluation approach.We will pool data using random effects models.
Prespecified subgroup and multilevel meta-regression analyses will explore
heterogeneity. We will perform prespecified trial sequential meta-analyses
of published trials to determine when the optimal information size has
been reached, and account for unpublished trials using the SAMURAI
approach. Impact and Dissemination Individual participant data
meta-analysis will generate adequate power to assess the risks and
benefits of AF screening. Meta-regression will permit exploration of the
specific patient, screening methodology, and health system factors that
influence outcomes. Trial registration number PROSPERO
CRD42022310308. Copyright © 2023 Georg Thieme Verlag. All rights
reserved.

<72>
Accession Number
2043551338
Title
Preventing Postpericardiotomy Syndrome: Current Evidence and Future
Directions.
Source
Journal of Cardiovascular Development and Disease. 13(2) (no pagination),
2026. Article Number: 63. Date of Publication: 01 Feb 2026.
Author
Ballas C.E.; Theologou T.; Samara E.; Barkas F.; Bampali T.;
Kintzoglanakis K.; Diamantis C.; Tzimas P.; Katsouras C.S.; Alexiou C.
Institution
(Ballas, Theologou, Alexiou) Department of Cardiac Surgery, University
Hospital of Ioannina, Ioannina, Greece
(Samara, Tzimas) Department of Anesthesiology and Postoperative Intensive
Care, University Hospital of Ioannina, Ioannina, Greece
(Barkas) Faculty of Medicine, School of Health Sciences, University of
Ioannina, Ioannina, Greece
(Bampali) Cardiology Department, Hatzikosta General Hospital, Ioannina,
Greece
(Kintzoglanakis) Local Health-Team Unit of Thebes, Boeotia, Greece
(Diamantis) Department of Primary Care, General Hospital of Livadeia,
Livadeia, Greece
(Katsouras) First Department of Cardiology, University Hospital of
Ioannina, Ioannina, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Postpericardiotomy syndrome (PPS) is the most frequent inflammatory
after-effect of cardiac surgery and is characterized by high morbidity,
delayed hospitalization, and increased long-term mortality rates. Although
PPS is common, empirical anti-inflammatory therapy has historically been
employed for its prevention, and mechanism-based approaches have not yet
been standardized. In this literature review, which was conducted on the
basis of randomized controlled trials, meta-analyses, cohort studies, and
mechanistic research regarding pharmacologic interventions, surgical
modalities, and biomarker-based preventive strategies, the deficiencies of
a critical synthesis of existing preventive strategies and emerging risk
stratification instruments for PPS are addressed. The review affirms that
the most evidence-based pharmacologic intervention is colchicine, which
demonstrates a consistent reduction in PPS incidence across a range of
randomized trials. Nonsteroidal anti-inflammatory drugs show variable
responses, whereas corticosteroids are no longer recommended for routine
prophylaxis due to relapse. Specific anti-interleukin-1 therapies
represent a promising novel approach for high-risk patients. Surgical
interventions, such as pericardial closure using biomaterials and
posterior pericardiotomy, are important and do not lead to increased
hemodynamic complications, while postoperative effusions, atrial
fibrillation, and tamponade are reduced. Less invasive methods may also be
employed to mitigate inflammatory causes, particularly in valve-sparing
procedures and congenital operations. Emerging biomarker data, including
postoperative neutrophil-to-lymphocyte ratios, C-reactive protein levels,
and pericardial fluid cytokines, enable the identification of high-risk
patients and form the basis for a personalized prevention approach. In
summary, pharmacologic prophylaxis, innovative surgical techniques, and
biomarker-based risk stratification represent a pathway toward reducing
the incidence and burden of PPS in modern cardiac surgery. Copyright
© 2026 by the authors.

<73>
Accession Number
2044099698
Title
Implementation and Results of Intraoperative Methadone in Pediatric
Cardiac Surgery: Early Experiences and Outcomes.
Source
World Journal for Pediatric and Congenital Heart Surgery. (no
pagination), 2026. Date of Publication: 2026.
Author
Gallagher B.; Ghandi D.; Whitley M.; Walker J.
Institution
(Gallagher, Whitley) Department of Anesthesiology and Perioperative
Medicine, Division of Pediatric Anesthesia, Penn State Milton S. Hershey
Medical Center, Hershey, PA, United States
(Ghandi) Penn State College of Medicine, Hershey, PA, United States
(Walker) Department of Anesthesiology and Perioperative Medicine, Division
of Cardiac Anesthesia, Penn State Milton S. Hershey Medical Center,
Hershey, PA, United States
Publisher
SAGE Publications Inc.
Abstract
Postoperative pain continues to be an intense area of research in
pediatric cardiac surgery, and there is a scarcity of information
regarding the use of methadone in this population. We performed a single
center retrospective descriptive cohort analysis of all pediatric cardiac
surgery patients who received intraoperative methadone between January 1,
2020 and December 21, 2024. In total 111 congenital cardiac surgeries were
completed in patients aged 0-18 years during the study period, of which 45
(41%) received intraoperative methadone. In the cohort receiving
methadone, there were 29 male patients (64%), with an average age of 10.3
(SD+/-5.3) year. The average dose of methadone was 0.16mg/kg
(SD+/-0.05mg/kg). With respect to post-operative analgesia, average pain
scores at 6, 12, and 24 hours of 1.8 (SD+/-2.3), 1.95 (SD+/-2.7), and 1.44
(SD+/-2.2), respectively. The median 24-hour opioid requirement was 0.59
Morphine Milligram Equivalents(MME)/kg (IQR 0.25-0.96). In total, 32 of
our 45 patients (71%) were able to be extubated in the operating room with
no reintubations or need for rescue non-invasive positive pressure
ventilation (NIPPV). Our study demonstrates that even a modest dose of
intraoperative methadone in pediatric cardiac surgery can be safe and
effective for intra and postoperative analgesia. Additional randomized
controlled trials are necessary to further evaluate its
effectiveness. Copyright © The Author(s) 2026. This article is
distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License
(https://creativecommons.org/licenses/by-nc/4.0/) which permits
non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified
on the SAGE and Open Access page
(https://us.sagepub.com/en-us/nam/open-access-at-sage).

<74>
Accession Number
2043753648
Title
Fosaprepitant versus Ondansetron for Preventing Postoperative Nausea and
Vomiting After Video-Assisted Thoracoscopic Lung Resection: A Randomized
Controlled Clinical Trial.
Source
Drug Design, Development and Therapy. 20 (no pagination), 2026. Article
Number: 584402. Date of Publication: 2026.
Author
Qi X.; Zhang J.; Sun J.; Wang X.; Chang T.; Yi W.; Zhang Y.; Zhang P.
Institution
(Qi, Zhang, Sun, Yi, Zhang, Zhang) Department of Anesthesiology, Qilu
Hospital of Shandong University, Shandong University, Shandong, Jinan,
China
(Wang) Department of Anesthesiology, The First Affiliated Hospital of
Shandong First Medical University, Shandong, Jinan, China
(Wang) Shandong Institute of Anesthesia and Respiratory Critical Care
Medicine, The First Affiliated Hospital of Shandong First Medical
University, Shandong, Jinan, China
(Wang) Shandong Provincial Clinical Research Center for Anesthesiology,
the First Affiliated Hospital of Shandong First Medical University,
Shandong, Jinan, China
(Chang) Department of Clinical Epidemiology, Qilu Hospital of Shandong
University, Shandong University, Shandong, Jinan, China
Publisher
Dove Medical Press Ltd
Abstract
Purpose: Postoperative nausea and vomiting (PONV) is a frequent
complication after video-assisted thoracoscopic lung resection,
particularly in patients at moderate to high risk, and substantially
hinders recovery. Fosaprepitant, a neurokinin-1 (NK-1) receptor
antagonist, is approved for PONV prevention; however, its efficacy in
video-assisted thoracoscopic lung resection remains uncertain. This
randomized trial evaluated the efficacy of fosaprepitant versus
ondansetron in preventing PONV in high-risk patients undergoing
video-assisted thoracoscopic lung resection. Patients and Methods: In
this prospective, double-blind, randomized controlled clinical trial, 233
adults aged 18-70 years undergoing elective video-assisted thoracoscopic
lung resection with an Apfel score >= 2 were randomized 1:1 to receive
intravenous fosaprepitant 150 mg or ondansetron 8 mg, each combined with
dexamethasone 5 mg. The primary outcome was the incidence of PONV at 24
hours postoperatively. Secondary outcomes included the incidence and
severity of PONV at 6, 12, and 48 hours postoperatively, the use of rescue
antiemetics, adverse events, and recovery outcomes. Result(s): The
24-hour incidence of PONV was 31.0% [36] in the fosaprepitant group and
41.0% [48] in the ondansetron group (OR, 0.76; 95% CI, 0.53 to 1.07;
P=0.112). Fosaprepitant significantly reduced PONV at 48 hours (10.3% [12]
vs 20.5% [24]; OR, 0.51; 95% CI, 0.27 to 0.96; P=0.032), as well as
vomiting at 24 hours (8.6% [10] vs 21.4% [25]; OR, 0.40; 95% CI, 0.20 to
0.80; P=0.006) and 48 hours (0% [0] vs 5.1% [6]; OR, 0.07; 95% CI, 0.00 to
1.32; P=0.040). Conclusion(s): Fosaprepitant was superior to
ondansetron in preventing early postoperative vomiting and delayed-phase
PONV, and it represents an effective antiemetic strategy for high-risk
thoracic surgical patients. Trial Number and Registry Url: Registration
number, NCT05881486; https://clinicaltrials.gov. Copyright © 2026
Qi et al.

<75>
Accession Number
2021637338
Title
Effect of Vitamin D Supplementation on Postoperative Outcomes in Cardiac
Surgery Patients: A Systematic Review.
Source
Journal of Cardiac Critical Care. 6(3) (pp 195-200), 2022. Date of
Publication: 03 Dec 2022.
Author
Das S.; Bej P.
Institution
(Das) Department of Cardiac Anaesthesia and Critical Care, AIIMS, New
Delhi, India
(Bej) Department of Community Medicine, Rama Medical College and Research
Centre, Uttar Pradesh, Hapur, India
Publisher
Thieme Medical and Scientific Publishers Pvt Ltd
Abstract
Background Vitamin D deficiency is a very common occurrence in cardiac
patients. It has been proved that cardiac surgery and cardiopulmonary
bypass accelerate the deficiency further. The postoperative outcomes of
patients deteriorate in the presence of vitamin D deficiency.
Perioperative supplementation of vitamin D is the only solution to the
problem. Hence, the present systematic review was conducted to derive the
efficacy and safety of vitamin D supplementation on postoperative outcomes
in cardiac surgery patients. Method Publications over duration of last 10
years was searched from different database and web sites. The data from
full-text research articles were analyzed for the effect on different
postoperative outcomes and side effects. Result Eight randomized control
trials were retrieved on the effect of perioperative vitamin D
supplementation in cardiac surgery patients and their postoperative
outcomes. Six articles (75%) were found to be in favor of improvement in
postoperative outcome. Two articles (25%) did not find any difference of
outcome between the control and treatment group. All the studies observed
the restoration of vitamin D to normal and no adverse effects from
supplementation. Conclusion Perioperative vitamin D supplementation
improves the postoperative outcomes after cardiac surgery. It is effective
and safe to supplement vitamin D in cardiac surgery
patients. Copyright © 2022 Thieme India. All rights reserved.

<76>
Accession Number
2043566337
Title
Totally Endoscopic Approach for Aortic Valve Replacement: A Systematic
Review and Single-Arm Meta-Analysis.
Source
Medicina (Lithuania). 62(2) (no pagination), 2026. Article Number: 339.
Date of Publication: 01 Feb 2026.
Author
Anghel F.; Bistriceanu M.I.A.; Toma C.V.; Ursu C.G.; Danet A.; Blindaru
A.D.C.; Popescu M.-A.; Paun M.-A.; Parsan V.-I.; Margineanu T.C.; Cristea
D.I.; Cristea C.F.; Ceausu A.-M.; Boboruta R.A.; Udrea V.-N.A.; Andreescu
D.I.; Badiu C.-C.
Institution
(Anghel, Danet, Blindaru, Badiu) Department of Cardiovascular Surgery,
Emergency University Hospital of Bucharest, Bucharest, Romania
(Anghel, Bistriceanu, Toma, Ursu, Danet, Blindaru, Popescu, Paun, Parsan,
Margineanu, Cristea, Cristea, Ceausu, Boboruta, Udrea, Andreescu, Badiu)
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy,
Bucharest, Romania
(Anghel) Curtin Medical School, Curtin University, Perth, Australia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background and Objectives: Totally endoscopic aortic valve replacement
(TE-AVR) is a minimally invasive technique offering potential benefits of
reduced surgical trauma and faster recovery compared with median
sternotomy or other minimally invasive access. While isolated aortic valve
replacement (AVR) is well established through conventional and minimally
invasive access, large-scale evidence for the totally endoscopic approach
remains limited. This meta-analysis aimed to systematically assess the
safety and feasibility of TE-AVR by aggregating perioperative outcomes,
including mortality, stroke, conversion, bleeding, paravalvular leak
(PVL), and atrial fibrillation (AF). Material(s) and Method(s): A
systematic search of PubMed, Embase, and the Cochrane Library was
performed, following PRISMA 2020 guidelines. Observational studies and
randomized controlled trials reporting outcomes of totally endoscopic or
thoracoscopic AVR were eligible. After independent screening and
selection, data were analyzed using a single-arm proportion model.
Leave-one-out sensitivity analyses were performed to evaluate the
influence of individual studies. The protocol was registered in PROSPERO
(CRD42024610128). Result(s): A total of 11 studies comprising 1135
patients were included. The pooled perioperative mortality was 0.00% (95%
CI 0.00-0.23; I2 = 0.0%), indicating highly consistent results
across cohorts. The stroke incidence was 0.69% (95% CI 0.00-2.07;
I2 = 42.7%), confirming the low cerebrovascular risk of this
approach. Conversion to sternotomy occurred in 0.00% of cases (95% CI
0.00-0.17; I2 = 0.0%), with no statistical heterogeneity
observed. Reintervention for bleeding occurred in 1.75% (95% CI 0.34-3.85;
I2 = 43.4%), while PVL was reported in 1.24% (95% CI 0.00-4.22;
I2 = 64.0%). AF incidence was 10.54% (95% CI 3.79-19.70;
I2 = 90.5%), with substantial between-study heterogeneity,
likely related to non-standardized definitions of new-onset AF and
variability in postoperative rhythm monitoring and reporting across
studies. Conclusion(s): TE-AVR is a safe and feasible technique
associated with very low perioperative mortality, bleeding, and stroke
rates, as well as low PVL incidence. The absent conversion rate in our
pooled analysis highlights the technical reliability of the procedure.
Variability in AF reporting underscores the need for future randomized
studies with harmonized definitions. Overall, TE-AVR offers a promising
minimally invasive alternative for aortic valve replacement, with
potential advantages in recovery (pooled ICU stay 1.86 days), hospital
stay (pooled 7.98 days), and aesthetic outcomes. Copyright © 2026
by the authors.

<77>
Accession Number
2019632272
Title
Preliminary Report from a Randomized Controlled Trial Comparing Two Bovine
Pericardial Valves.
Source
Thoracic and Cardiovascular Surgeon. 71(8) (pp 648-655), 2022. Date of
Publication: 04 Dec 2023.
Author
Sohn S.H.; Choi J.W.; Lee J.H.; Kim J.S.; Lim C.; Hwang H.Y.
Institution
(Sohn, Kim, Choi, Hwang) Department of Thoracic and Cardiovascular
Surgery, Seoul National University Hospital, Seoul, South Korea
(Lee, Kim, Lim) Department of Thoracic and Cardiovascular Surgery, Seoul
National University, Bundang Hospital, Seongnam, South Korea
Publisher
Georg Thieme Verlag
Abstract
Background A randomized controlled trial was designed to compare 1-year
hemodynamic profiles and clinical outcomes after bioprosthetic aortic
valve replacement (AVR) using a recently introduced (study group) and
world-widely used (control group) bovine pericardial bioprostheses. This
study evaluated early postoperative outcomes as a preliminary analysis.
Methods The primary end point of the trial was the mean pressure gradient
across the aortic valve (AVMPG) at 1 year after surgery. Patients were
screened to enroll 70 patients in each group based on a noninferiority
design. Early postoperative hemodynamic and clinical outcomes were
compared between the two groups. Results There were no differences in
baseline characteristics, including sex and body surface area (1.64 +/-
0.18 vs. 1.65 +/- 0.15 m 2) between the two groups. The AVMPG
on early postoperative echocardiography was 15.2 +/- 4.6 mm Hg and 16.5
+/- 6.2 mm Hg in the study and control groups, respectively (p = 0.177).
Although AVMPG of the 19 mm prostheses was lower in the study group than
in the control group (17.0 +/- 6.3 mm Hg vs. 22.8 +/- 6.6 mm Hg, p =
0.039), there were no significant differences in the effective orifice
area in all patients (1.57 +/- 0.41 cm 2vs. 1.53 +/- 0.34 cm
2, p = 0.568), and each valve size. The effective orifice area
index was also similar between the two groups in overall (p = 0.352), and
in each valve size. There were no significant differences in clinical
outcomes including operative mortality and postoperative complications
between the two groups. Conclusion Early postoperative hemodynamic and
clinical results after AVR using a recently introduced bovine pericardial
valve were comparable with those using the control valve
(NCT03796442). Copyright © 2022 Georg Thieme Verlag. All rights
reserved.

<78>
Accession Number
2043537941
Title
Extracorporeal Cytokine Adsorption in Acute Cardiovascular Care:
Pathophysiological Insights and Clinical Perspectives.
Source
Biomedicines. 14(2) (no pagination), 2026. Article Number: 360. Date of
Publication: 01 Feb 2026.
Author
Mihali K.; Harbaum L.; Markus B.; Chatzis G.; Patsalis N.; Syntila S.;
Schieffer B.; Kreutz J.
Institution
(Mihali, Harbaum, Markus, Chatzis, Patsalis, Syntila, Schieffer, Kreutz)
Department of Cardiology, Angiology, and Intensive Care Medicine,
Philipps-Universitat Marburg, Marburg, Baldingerstrasse, Germany
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Cardiogenic shock (CS) and post-cardiac arrest syndrome (PCAS)
are frequently associated with a systemic inflammatory response resulting
from ischemia-reperfusion injury, endothelial dysfunction, and
microcirculatory impairment. This inflammatory biology may be further
amplified by temporary mechanical circulatory support (tMCS) through
blood-surface interactions and shear-related hemolysis. Extracorporeal
cytokine adsorption has therefore been proposed as an adjunctive strategy
to attenuate hyperinflammation and facilitate shock reversal in selected
patients. Method(s): We conducted a narrative review, guided by a
targeted PubMed and Scopus search and reference screening, to summarize
the current pathophysiological concepts and clinical evidence on
extracorporeal cytokine adsorption in CS-, PCAS-, and tMCS-supported
states. Result(s): Across porous polymer hemoadsorption cartridges
(e.g., CytoSorb), membrane-based or hybrid filters with
adsorptive properties (e.g., oXiris), and selective approaches
targeting inflammatory mediators (e.g., PentraSorb CRP),
available studies most consistently report short-term physiological
effects, including reduced vasopressor demand, improved metabolic
stabilization, and modulation of inflammatory markers. However, evidence
of benefits to clinically relevant endpoints remains inconsistent in
various clinical settings, and randomized data are limited.
 Conclusion(s): Extracorporeal cytokine adsorption is a biologically
plausible adjunct in inflammation-driven acute cardiovascular syndromes,
but current evidence does not support routine use. Phenotype-guided
patient selection, early timing, and adequately powered,
mechanism-informed randomized trials are required to define clinical
efficacy and safety in defined patient populations. Copyright ©
2026 by the authors.

<79>
Accession Number
2026381307
Title
Inverse Association of Lipoprotein(a) on Long-Term Bleeding Risk in
Patients with Coronary Heart Disease: Insight from a Multicenter Cohort in
Asia.
Source
Thrombosis and Haemostasis. 124(7) (pp 684-694), 2024. Date of
Publication: 25 Jun 2024.
Author
Wang P.; Yuan D.; Zhao X.; Zhu P.; Guo X.; Jiang L.; Xu N.; Wang Z.; Liu
R.; Wang Q.; Chen Y.; Zhang Y.; Xu J.; Liu Z.; Song Y.; Zhang Z.; Yao Y.;
Feng Y.; Tang X.; Wang X.; Gao R.; Han Y.; Yuan J.
Institution
(Wang, Yuan, Zhu, Jiang, Xu, Liu, Chen, Xu, Song, Yao, Tang, Gao, Yuan)
Department of Cardiology, Center for Coronary Heart Disease, Fuwai
Hospital, National Center for Cardiovascular Diseases, Chinese Academy of
Medical Sciences and Peking Union Medical College, Beijing, China
(Zhao) Special Demand Medical Care Center, Chinese Academy of Medical
Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
(Guo) Department of Cardiology, Zhejiang University School of Medicine,
The First Affiliated Hospital, Zhejiang Province, Hangzhou, China
(Wang) Department of Cardiology, Xinxiang Central Hospital, Henan
Province, Xinxiang, China
(Wang) Department of Cardiology, The First Hospital of Qinhuangdao, Hebei
Province, Qinhuangdao, China
(Zhang) Department of Cardiology, Peking University Third Hospital,
Beijing, China
(Liu) Department of Cardiology, Peking Union Medical College Hospital,
Beijing, China
(Zhang) Department of Cardiology, The First Hospital of Lanzhou
University, Gansu Province, Lanzhou, China
(Feng) Department of Cardiology, Guangdong Cardiovascular Institute,
Guangdong Provincial People's Hospital, Guangdong Province, Guangzhou,
China
(Wang, Han) Department of Cardiology, General Hospital of Northern Theater
Command, Liaoning Province, Shenyang, China
(Yuan) National Clinical Research Center for Cardiovascular Diseases,
Chinese Academy of Medical Sciences, Peking Union Medical College, Fuwai
Hospital, National Center for Cardiovascular Diseases, Beijing, China
Publisher
Georg Thieme Verlag
Abstract
Background Lipoprotein(a), or Lp(a), has been recognized as a strong risk
factor for atherosclerotic cardiovascular disease. However, the
relationship between Lp(a) and bleeding remains indistinct, especially in
the secondary prevention population of coronary artery disease (CAD). This
investigation aimed to evaluate the association of Lp(a) with long-term
bleeding among patients with CAD. Methods Based on a prospective
multicenter cohort of patients with CAD consecutively enrolled from
January 2015 to May 2019 in China, the current analysis included 16,150
participants. Thus, according to Lp(a) quintiles, all subjects were
divided into five groups. The primary endpoint was bleeding at 2-year
follow-up, and the secondary endpoint was major bleeding at 2-year
follow-up. Copyright © 2023. The Author(s).

<80>
Accession Number
2022237642
Title
3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal
of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and
Meta-analysis.
Source
Thrombosis and Haemostasis. 123(1) (pp 40-53), 2023. Date of Publication:
10 Jan 2023.
Author
Puchstein D.; Kork F.; Schochl H.; Rayatdoost F.; Grottke O.
Institution
(Puchstein, Kork, Rayatdoost, Grottke) Department of Anaesthesiology, RWTH
Aachen University Hospital, Aachen, Germany
(Schochl) Department for Anaesthesiology and Intensive Care Medicine, AUVA
Trauma Academic Teaching Hospital, Paracelsus Medical University Salzburg,
Salzburg, Austria
Publisher
Georg Thieme Verlag
Abstract
Long-term anticoagulation is used worldwide to prevent or treat thrombotic
events. Anticoagulant therapy using vitamin K antagonists (VKAs) is well
established; however, anticoagulants carry an increased risk of
potentially life-threatening bleeding. In cases of bleeding or need for
surgery, patients require careful management, balancing the need for rapid
anticoagulant reversal with risk of thromboembolic events. Prothrombin
complex concentrates (PCCs) replenish clotting factors and reverse
VKA-associated coagulopathy. Two forms of PCC, 3-factor (3F-PCC) and
4-factor (4F-PCC), are available. Using PRISMA methodology, we
systematically reviewed whether 4F-PCC is superior to 3F-PCC for the
reversal of VKA-associated coagulopathy. Of the 392 articles identified,
48 full texts were reviewed, with 11 articles identified using criteria
based on the PICOS format. Data were captured from 1,155 patients: 3F-PCC,
n=651; 4F-PCC, n=504. ROBINS-I was used to assess bias. Nine studies
showed international normalized ratio (INR) normalization to a predefined
goal, ranging from <=1.5 to <=1.3, following PCC treatment. Meta-analysis
of the data showed that 4F-PCC was favorable compared with 3F-PCC overall
(odds ratio [OR]: 3.50; 95% confidence interval [CI]: 1.88-6.52, p<0.0001)
and for patients with a goal INR of <=1.5 or <=1.3 (OR: 3.45; 95% CI:
1.42-8.39, p=0.006; OR: 3.25; 95% CI: 1.30-8.13, p=0.01, respectively).
However, heterogeneity was substantial (I2=62%, I2=70%, I2=64%). Neither a
significant difference in mortality (OR: 0.72; 95% CI: 0.42-1.24, p=0.23)
nor in thromboembolisms was reported. These data suggest that 4F-PCC is
better suited than 3F-PCC for the treatment of patients with
VKA-associated coagulopathy, but further work is required for a definitive
recommendation. Copyright © 2023. Thieme. All rights reserved.

<81>
Accession Number
2044005376
Title
Safety and efficacy of short-term ventricular assist devices in paediatric
heart transplant candidates: a systematic review and single arm
meta-analysis.
Source
BMC Cardiovascular Disorders. 26(1) (no pagination), 2026. Article Number:
225. Date of Publication: 01 Dec 2026.
Author
Yap N.Q.E.; Nasr J.; Miangul S.; Bitton L.; Seneviratne S.Z.; Farzad A.;
Emil-Inyang J.F.; Nasser M.L.; Sivanathan S.; Than C.A.; Burns J.W.F.
Institution
(Yap, Than) Cambridge University Hospitals NHS Foundation Trust,
Addenbrookes Hospital, Cambridge, United Kingdom
(Nasr) Baim Institute for Clinical Research, 930W Commonwealth Ave,
Boston, MA, United States
(Miangul) Blackpool Victoria Teaching Hospital, Whinney Heys Rd,
Blackpool, United Kingdom
(Bitton, Emil-Inyang) University of Nicosia Medical School, Nicholas St
93, Nicosia, Egkomi, Cyprus
(Seneviratne) Faculty of Medicine, University of Queensland, Herston,
Australia
(Seneviratne) Queensland Health Department, Mackay Base Hospital, Mackay,
Australia
(Farzad) Division of Experimental Medicine, McGill University Montreal,
Quebec, Canada
(Nasser) Department of Internal Medicine, University of Connecticut,
Farmington, CT, United States
(Sivanathan) Oxford University Hospitals NHS Foundation Trust, John
Radcliffe Hospital, Headley Way, Headington, Oxford, United Kingdom
(Than) School of Biomedical Sciences, University of Queensland, St Lucia,
Brisbane, Australia
(Burns) Bolton NHS Foundation Trust, Minerva Road, Farnworth, Bolton,
United Kingdom
Publisher
BioMed Central Ltd
Abstract
Background: Safety and efficacy of short-term ventricular assist devices
(VAD) remains incompletely understood, particularly in younger children.
This systematic review and meta-analysis aims to evaluate outcomes,
including bridging success, complications, and mortality, associated with
short-term VAD support in paediatric heart transplant candidates.
 Method(s): A systematic search of PubMed, EMBASE, CINAHL, Cochrane
Central Register of Controlled Trials, Cochrane Database of Systematic
Reviews, Scopus, and Web of Science was conducted from inception to 2
December 2024. Eligible studies reported patients <= 18 years supported by
short-term VADs. This review was registered in PROSPERO (ID:
CRD42023468125). Result(s): Twelve retrospective studies met the
inclusion criteria, encompassing 532 paediatric patients (mean age 10.0
years, < 0.1-18.3, mean weight 39.5 +/- 30.3 kg). Pooled proportions show
that with a mean support duration of 15.2 days, 50.7% were successfully
bridged to transplant (95% CI 36.4%, 65.0%; I2 = 91.1%) with a
24.8% waitlist mortality (95% CI 17.6%, 31.9%; I2 = 63.8%),
14.0% (95% CI 7.2%, 20.9%; I2 = 97.5%) weaned off support and
5.4% (95% CI 2.6%, 8.3%; I2 = 39.1%) remaining on support.
Complication rates were high with haemorrhage (38.9%), renal impairment
(35.2%), cerebrovascular events (29.5%), infection (17.8%), and
thromboembolism (9.9%) being the most reported. Conclusion(s):
Short-term VADs offer a feasible bridge to transplant in paediatric
patients, with success rates comparable to registry data. However, high
rates of serious complications and waitlist mortality persist,
particularly in these younger children. These findings demonstrate the
need for improved patient selection, standardized outcome reporting, and
development of safer, size-appropriate devices for paediatric
use. Copyright © The Author(s) 2026.

<82>
Accession Number
650582616
Title
Outcome of late-presenter arterial switch operation in TGA-IVS patients: A
meta-Analysis and systematic review.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S154), 2025. Date of Publication: 01
Dec 2025.
Author
Nugraha A.F.; Akbar E.; Soebroto H.; Hakim A.R.; Pagehgiri H.D.;
Hariftyani A.S.; Aulia S.H.
Institution
(Nugraha) Cardiothoracic and Vascular Study Programme, Faculty of
Medicine, University of Airlangga, East Java, Indonesia
(Akbar, Soebroto, Hakim) Department of Cardiothoracic and Vascular
surgery, Dr. Soetomo General Hospital, Surabaya, Indonesia
(Pagehgiri, Hariftyani, Aulia) Faculty of Medicine, University of
Airlangga, East Java, Indonesia
Publisher
Cambridge University Press
Abstract
Introduction: Arterial Switch Operation is recommended treatment for
Neonatal patients with Transposition of the great arteries with Intact
Ventricular Septum (TGA-IVS) with tolerable average surgical mortality
rate of 2-5% if performed from the first few days to three weeks of life.
Ideal timing like that is hard to fulfil in developing countries.
Furthermore, the upper age limit for doing Primary ASO remains
controversial because of LV soon becomes deconditioned. This research was
conducted to compare the outcomes of ASO in Late Presenter TGA-IVS
Patients2 Methods: We searched PubMed, ScienceDirect, BMC, and
Springer for eligible studies with quantitative data on mortality and
complications. The primary outcome analyzed in this study were In-Hospital
Mortality, Length of Hospital Stay and ICU stay, duration of invasive
ventilation usage as well as usage of ECMO Results: 10 journals which
involved 1409 patient with TGA-IVS who underwent the ASO procedure were
reviewed for systematic analysis while 4 studies were analyzed further for
meta-Analysis. Several patient underwent prior interventions mostly
balloon atrial septostomy ranged from 5 to 88%. This meta-Analysis
demonstrated that primary ASO procedure conducted between late and early
presenter TGA-IVS has no significant differences for in-hospital mortality
(OR 0.70, 95% CI [0.33-1.46], I2 = 0%, p = 0.34; Fixed-effects
model), length of hospital stay (MD 1.43, 95% CI [-8.65 to 11.52],
I2 = 91%, p = 0.78; Random-effects model), ICU stay duration
(MD -0.01, 95% CI [-1.59 to 1.58], I2 = 7%, p = 0.99;
Fixed-effects model), invasive ventilator duration (MD 0.14, 95% CI [-2.28
to 2.56], I2 = 77%, p = 0.91; Random-effects model), and ECMO
usage (OR 1.67, 95% CI [0.64-4.35], I2 = 0%, p = 0.29;
Fixed-effects model). Conclusion(s): Our meta-Analysis and systematic
review indicates that there were no significant differences in terms of
in-hospital mortality, length of hospital stay, ICU stay duration and
mechanical support between late and early presenter for TGA-IVS undergoing
primary ASO. Thus, we can conclude that doing ASO in late or early
presenter TGA-IVS is comparable.

<83>
Accession Number
650582496
Title
Trametinib leads to NT-proBNP reduction in children with noonan syndrome
and hypertrophic cardiomyopathy.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S96), 2025. Date of Publication: 01
Dec 2025.
Author
Wozniak K.L.; Kolodziej M.; Werner B.
Institution
(Wozniak, Werner) Department of Pediatric Cardiology and General
Pediatrics, Medical University of Warsaw, Poland
(Kolodziej) Department of Paediatrics, Medical University of Warsaw,
Poland
Publisher
Cambridge University Press
Abstract
Introduction: Noonan syndrome is a RASopathy characterized by abnormal
function of the MAPK/ERK signaling pathway. Trametinib, which influences
this pathway by MEK-inhibition, has been used to experimentally treat
children with different conditions present in patients with Noonan
syndrome, including hypertrophic cardiomyopathy (HCM). NT-proBNP is a
biomarker released mainly by stretching of cardiac myocytes. It is useful
in the diagnosis and prognosis of heart failure. The aim of the study was
to assess the influence of trametinib on NT-proBNP levels in children with
Noonan Syndrome and HCM. Method(s): We applied trametinib treatment
in 2 patients with Noonan syndrome and HCM; additionally through a
systematic review of the literature we identified 8 articles in which
experimental trametinib treatment in children with Noonan syndrome and HCM
was described. In 3 publications the authors included data on NT-proBNP
levels, in total 4 patients met the inclusion criteria. We analyzed
NT-proBNP levels before and after 1-12 months of the treatment (if
multiple NT-proBNP levels were given, the value closest to 1 month of
treatment was used). Result(s): Altogether six children with Noonan
syndrome andHCM who were experimentally treated with trametinib were
identified; 4 cases from the literature and two patients treated at our
center. The median age of the initiation of treatment was 2.1 years (IQR
0.22;7.5). The median NT-proBNP level before the treatment was 17
242.5pg/ml (IQR 1 166.75; 55 671.75), and dropped to a median of 1 323
pg/ml (IQR 120.5; 5 709) after 1-12 months, depending on the data
reported. The levels of NT-proBNP reduced in all patients ranging from
70.6% to 95.6%. All patients except one survived. In the latter, a
decrease in NT-proBNP was seen after the initiation of treatment with
trametinib, however, after a non-cardiac operation deterioration in
pulmonary hypertension was observed and the patient died.
 Conclusion(s): In all the cases of children with Noonan syndrome and
HCM treated with trametinib a great reduction in NT-proBNP levels was
observed after the initiation of treatment. Thus, trametinib appears to
reduce stress on the cardiac myocytes and might improve the prognosis in
this group of patients.

<84>
Accession Number
650582295
Title
Surgical versus catheter treatment for isolated critical and non-critical
aortic stenosis in the neonatal period.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S271-S272), 2025. Date of
Publication: 01 Dec 2025.
Author
Olofsson C.K.; Ystgaard M.B.; Hurskainen M.; Idorn L.; Engholm M.; Hanseus
K.; Holmstrom H.; Rahkonen O.; Sunnegardh J.
Institution
(Olofsson) Department of Paediatrics, Sundsvall Hospital, Sweden
(Ystgaard, Holmstrom) Department of Paediatric Cardiology, Oslo University
Hospital, Oslo, Norway
(Hurskainen, Rahkonen) Department of Pediatric Cardiology, New Children's
Hospital, Helsinki University Hospital and University of Helsinki,
Helsinki, Finland
(Idorn) Department of Pediatrics, Section of Pediatric Cardiology,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
(Engholm) Department of Cardiology, Aarhus University Hospital, Aarhus,
Denmark
(Hanseus) Department of Cardiology, Pediatric Heart Center, Skane
University Hospital, Lund, Sweden
(Sunnegardh) Department of Pediatric Cardiology, Pediatric Heart Centre,
Queen Silvia Children's Hospital, Sahlgrenska University Hospital,
Gothenburg, Sweden
Publisher
Cambridge University Press
Abstract
Introduction: The optimal treatment approach for isolated valvular aortic
stenosis in neonates-whether catheter-based or surgical- remains a subject
of debate. In the absence of a randomised controlled trial, we conducted a
propensity score-matched comparison of outcomes following surgical aortic
valvotomy (SAV) or balloon aortic valvotomy (BAV) during the neonatal
period in the Nordic countries. Method(s): This retrospective,
multicentre study included all neonates with isolated valvular aortic
stenosis, biventricular circulation, and treatment before 30 days of age
in Sweden, Norway, Denmark, and Finland from 2003 to 2023, identified
through local catheter and surgical registries. A strict definition of
critical aortic stenosis-characterised by duct dependency and/or depressed
left ventricular function-or non-critical stenosis, defined by a Doppler
mean gradient of >=50 mmHg, was applied. Data were collected from
echocardiograms and medical records. Outcomes following primary treatment
with SAV and BAV were compared using group statistics and survival
analysis in the complete cohort, in critical and non-critical subgroups,
and within a propensity score-matched model. Result(s): A total of 99
neonates treated with SAV and 102 with BAV were identified. Median
follow-up was 11,3 years. There were no significant differences between
groups in terms of gender, gestational age, birth weight, or distribution
of critical and non-critical aortic stenosis. Median age at intervention
was 6 days for SAV and 4 days for BAV. There were 4 deaths in the SAV
group and 11 in the BAV group (p = 0.13). Reintervention was required in
45 patients following SAV and in 63 following BAV (p = 0.02). Aortic valve
replacement (AVR) was performed in 24 and 35 patients, respectively (p =
0.09). In the critical aortic stenosis subgroup, 29 patients (47%)
underwent reintervention after SAV compared to 38 (68%) after BAV (p =
0.02). AVR was performed in 14 patients (23%) following SAV and in 28
(50%) following BAV (p = 0.002). Kaplan-Meier analysis revealed no
statistically significant differences in mortality, reintervention, or AVR
in the propensity score-matched model. Conclusion(s): Mortality,
reintervention rates andAVRrequirements were similar between patients
treated with SAV or BAV. However, among patients with critical stenosis
outcomes favoured SAV.

<85>
Accession Number
650592080
Title
Efficacy of low-dose nalmefene on recovery from general anaesthesia in
adult patients: a multicentre randomised controlled study.
Source
BMJ open. 16(3) (pp e107754), 2026. Date of Publication: 10 Mar 2026.
Author
Ma X.; Liu J.; Zhang Y.; Li L.; Zhang G.; Xing L.; Huai X.; Tang Y.; Xie
Y.; Su D.
Institution
(Ma, Liu) Department of Anesthesiology, Shanghai Jiao Tong University
School of Medicine Affiliated Renji Hospital, Shanghai, China
(Zhang, Huai) Shanghai Jiao Tong University School of Medicine Affiliated
Renji Hospital, Shanghai, China
(Li) First Affiliated Hospital of Guangxi Medical University, Nanning,
Guangxi, China
(Zhang) Department of Anesthesiology, Shanghai Tongren Hospital, Shanghai,
China
(Xing) First Affiliated Hospital of Zhengzhou University, Zhengzhou,
Henan, China
(Tang) Department of Anaesthesiology, Shanghai Jiaotong University,
Shanghai, China
(Xie) Department of Anesthesiology, Sichuan Clinical Research Center for
Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center,
University of Electronic Science and Technology of China School of
Medicine, Chengdu, Sichuan, China
(Su) Anesthesiology, Zhejiang University School of Medicine First
Affiliated Hospital, Hangzhou, Zhejiang, China
Abstract
OBJECTIVES: This randomised controlled trial aims to evaluate the impact
of low-dose intravenous nalmefene on anaesthesia recovery in adult
patients aged 18-65 undergoing surgery under general anaesthesia. DESIGN:
This was a multicentre, randomised, double-blind trial with two parallel
arms clinical study. SETTING: Four hospitals from China PARTICIPANTS: A
total of 514 patients aged 18-65 who underwent elective orthopaedic,
urologic and thoracic surgeries. INTERVENTIONS: On completion of skin
suturing, the intervention group received a single intravenous dose of
nalmefene (0.25 microg/kg). The control group received an equivalent
volume of normal saline at the same time point. PRIMARY AND SECONDARY
OUTCOME MEASURES: The primary outcome was the interval time between the
end of anaesthesia and the Aldrete score >=9 being achieved in the
postanaesthesia care unit (PACU). The secondary endpoints included the
time interval from the end of operation to extubation; Richmond Agitation
Sedation Scale (RASS) score at extubation; the time at Montreal Cognitive
Assessment Scale (MoCA) orientation score >=5; visual analogue scale (VAS)
score in PACU and 24 hours postoperatively. RESULT(S): 514 patients
were included in the Intention-to-Treat (ITT) analysis. The time interval
between the end of anaesthesia and Aldrete score reached >=9 in PACU was
significantly shorter in the intervention group than in the control group
(mean (SD) 24.8 (11.8) min vs 33.8 (12.5) min; 95% CI -8.8 (-10.8 to
-6.7); p<0.001). Furthermore, the time interval from the end of surgery to
extubation was shorter in the intervention than in the control group (mean
(SD) 20.0 (9.9)min vs 27.6 (11.6) min; 95% CI -7.6 (-9.43 to -5.7),
p<0.001). The time at Montreal cognitive assessment score >=5 was also
shorter in the control than in the intervention group (mean (SD) 20.0
(15.9) min vs 27.0 (20.5) min; 95% CI -7.0 (-10.2 to -3.8); p<0.001).
Compared with the control group, the intervention group had better
analgesic effect at the recovery endpoint (P Aldrete score >=A was
achieved as well as lower 24 hours points postoperatively (p<0.05)).
 CONCLUSION(S): In patients aged 18-65 who underwent elective
orthopaedic, urologic and thoracic surgeries, low-dose nalmefene
administered at the end of surgery can accelerate postanaesthesia recovery
without compromising analgesic effects. TRIAL REGISTRATION NUMBER:
NCT04713358. Copyright © Author(s) (or their employer(s)) 2026.
Re-use permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ Group.

<86>
Accession Number
2044220004
Title
Conduction System vs Biventricular Pacing in Heart Failure: The
PhysioSync-HF Randomized Clinical Trial.
Source
JAMA Cardiology. (no pagination), 2026. Date of Publication: 2026.
Author
Zimerman A.; Dal Forno A.; Rohde L.E.; Ternes C.M.; Alves F.D.; Damiani
L.P.; Martinelli-Filho M.; Costa R.; Fagundes A.A.; Barbosa R.M.; Gadelha
E.B.; Lima C.E.; Silva M.A.; Maldonado J.A.; De Oliveira J.C.; Mallmann
F.; Baggio Junior J.M.; Duarte C.E.; De Souza L.A.; Santos J.S.; Silveira
A.D.; Decker S.R.R.; Zimerman L.I.; Polanczyk C.A.; D'Avila A.
Institution
(Zimerman, Rohde, Alves, De Souza, Santos, Decker, Polanczyk) MOVE
Academic Research Organization, Hospital Moinhos de Vento, Moinhos de
Vento Medical School, Porto Alegre, Brazil
(Zimerman, Rohde, Silveira, Zimerman, Polanczyk, D'Avila) Cardiology
Division, Hospital Moinhos de Vento, Porto Alegre, Brazil
(Zimerman, Rohde, Alves, De Souza, Silveira, Decker, Polanczyk)
Postgraduate Program in Cardiology and Cardiovascular Sciences, Federal
University of Rio Grande, Porto Alegre, Brazil
(Zimerman, Rohde, Ternes, Alves, De Souza, Santos, Silveira, Decker,
Polanczyk) Research Projects Office, Hospital Moinhos de Vento, Porto
Alegre, Brazil
(Dal Forno, Ternes, D'Avila) Hospital SOS Cardio, Florianopolis, Brazil
(Rohde, Silveira, Zimerman, Polanczyk) Cardiology Division, Hospital de
Clinicas de Porto Alegre, Porto Alegre, Brazil
(Damiani) Brazilian Clinical Research Institute, Sao Paulo, Brazil
(Damiani) Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
(Martinelli-Filho) Department of Cardiology, Instituto Do Coracao,
Hospital das Clinicas, Universidade de Sao Paulo, Sao Paulo, Brazil
(Costa) Cardiac Pacing Division, Department of Cardiovascular Surgery,
Instituto Do Coracao, Hospital das Clinicas, Universidade de Sao Paulo,
Sao Paulo, Brazil
(Costa) Discipline of Cardiovascular Surgery, Faculdade de Medicina FMUSP,
Universidade de Sao Paulo, Sao Paulo, Brazil
(Fagundes) Hospital Ana Nery, Salvador, Brazil
(Barbosa) Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil
(Gadelha) Instituto de Medicina Integral Professor Fernando Figueira,
Recife, Brazil
(Lima) Hospital Universitario, Universidade Federal Do Piaui, Teresina,
Brazil
(Silva) Hospital Universitario Cassiano Antonio de Moraes, Vitoria, Brazil
(Maldonado) Fundacao Hospitalar Do Coracao Francisca Mendes, Manaus,
Brazil
(De Oliveira) Hospital Geral Universitario de Cuiaba, Cuiaba, Brazil
(Mallmann) Instituto de Cardiologia de Santa Catarina, Sao Jose, Brazil
(Baggio Junior) Instituto de Cardiologia Do Distrito Federal, Brasilia,
Brazil
(Duarte) Hospital Beneficencia Portuguesa, Sao Paulo, Brazil
(Decker) Internal Medicine Division, Hospital Moinhos de Vento, Porto
Alegre, Brazil
(Decker) Smith Center for Outcomes Research, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA, United States
(D'Avila) Harvard-Thorndike Electrophysiology Institute, Cardiovascular
Division, Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, United States
Publisher
American Medical Association
Abstract
Importance: Conduction system pacing (CSP) is a promising and potentially
cost-effective alternative to biventricular pacing (BiVP) in patients with
heart failure with reduced ejection fraction (HFrEF) and left
bundle-branch block (LBBB), but its impact on heart failure (HF) outcomes
remains uncertain. Objective(s): To compare CSP vs BiVP on an
HF-related outcome in patients with HFrEF and LBBB. Design, Setting,
and Participant(s): PhysioSync-HF (Conduction System Pacing Versus
Biventricular Resynchronization in Patients With Chronic Heart Failure)
was an investigator-initiated, multicenter, noninferiority randomized
clinical trial enrolling participants from November 2022 to December 2023
with 12 months of follow-up at 14 hospitals across all regions of Brazil.
Adults with symptomatic HFrEF (New York Heart Association NYHA] classes II
through III), left ventricular ejection fraction (LVEF) of 35% or less,
and LBBB (QRS duration >=130 milliseconds) were eligible for inclusion.
Data were analyzed from May to August 2025. Intervention(s): Patients
were randomized 1:1 to either CSP (preferentially left bundle-branch area
pacing) or BiVP. Main Outcomes and Measures: The primary outcome was
a hierarchical composite of death, HF hospitalizations, urgent HF visits,
and change in LVEF at 12 months. The prespecified noninferiority margin
for the odds ratio (OR) was 1.2. Result(s): A total of 173 patients
(median [IQR] age, 62 years [56-68]; 86 female patients [49.7%]; 115
(66.5%) with dilated cardiomyopathy; median [IQR] LVEF, 26% [22%-31%];
median [IQR] QRS, 180 milliseconds [170-200]) were included. At 12 months,
CSP failed to meet noninferiority and was inferior to BiVP for the primary
end point (OR, 2.36; 95% CI, 1.37-4.06; P =.99 for noninferiority; P =.002
for between-group difference). The time-to-event composite of death, HF
hospitalizations, or urgent HF visits was higher in CSP (hazard ratio,
2.35; 95% CI, 0.99-5.61). Mean (SD) LVEF increased to 35% (12%) with CSP
and 39% (12%) with BiVP (mean difference, 3.8%; 95% CI, 0.3%-7.3%).
Relative to baseline, both groups had comparable improvements in QRS
duration, Kansas City Cardiomyopathy Questionnaire Overall Summary Score,
NYHA class, and natriuretic peptide levels. Total direct medical cost
related to the procedure and heart failure care was the equivalent of
$7090 (95% CI, $5779-$8648) lower in patients randomized to CSP at 12
months. Conclusions and Relevance: In patients with HFrEF and LBBB,
CSP was inferior to BiVP for a composite of death, HF hospitalizations,
urgent HF visits, and change in LVEF at 12 months. These findings do not
support the routine use of CSP as the first-line resynchronization
strategy in this population. Trial Registration: ClinicalTrials.gov
Identifier: NCT05572736 Copyright © 2026 Zimerman A et al.

<87>
Accession Number
650576890
Title
A pragmatic approach to implement an RCT-proved electronic
patient-reported outcome symptom monitoringalerting- intervening system
(ePRO-SMAI) into surgical practice.
Source
Quality of Life Research. Conference: 30th Annual Conference of the
International Society for Quality of Life Research. Calgary, AB Canada.
32(2 Supplement) (pp S70-S71), 2023. Date of Publication: 01 Nov 2023.
Author
Shi Q.; Deng C.; Yu H.; Wang X.; Guo Q.; Qiao G.
Institution
(Shi, Yu) Chongqing Medical University, Chongqing, China
(Deng, Qiao) Guangdong Provincial People's Hospital, Guangzhou, China
(Wang, Guo) Epro Vision (Beijing) Health Technology Co., Ltd, Beijing,
China
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Aims: Using a multi-center RCT, we evidenced that a symptom monitoring
system with high frequent ePRO assessment and alerttriggered intervention
was able to enhance recovery and reduce the incidence of complications
after lung cancer surgery. The current study aimed at demonstrating the
full process of implementing the RCT-proved ePRO-SMAI (RCT-ver) into the
routine practice in a thoracic surgery unit. Method(s): This study
was conducted in the department of thoracic surgery in a tertiary
hospital. The RCT-ver used the 22-item MDASI-LC to measure patients'
symptoms before surgery, daily during hospitalization after surgery and
bi-weekly after discharge. If patients reported scores reached the preset
threshold (C 5 on a 0-10 scale) on any of the five symptoms (pain,
fatigue, disturbed sleep, coughing and shortness of breath), an alert was
sent to the clinician team who would contact patients within 24 h. We used
the PDCA (plan-do-check-act) cycle for the implementation. In the pilot
phase, the need of optimization was evaluated every 2 weeks. The necessary
modifications were specified (plan), programmed, tested and released (do).
Afterwards the changes were evaluated (check) and, if necessary, further
optimizations were implemented (act). An RWS-version was developed after
the 2-month pilot. Analysis of recruitment, compliance, and response to
alerts were carried out. Result(s): The RCT-ver was applied from
April to June 2022 (n = 338) and RWS-ver from July to December 2022 (n =
257). Barriers and corresponding solutions were listed in Table 1.
Compared with the RCT-ver, the recruitment rates were significantly
increased using the RWS-ver (98.83% vs. 93.79%, P = 0.002). Among all
alerts generated, 57.06% (574/1006) were responded within 103 min. The
compliance rates were statistically higher for the RWS-ver, on
postoperative day 2 (94.9% vs. 76.9%, P = 0.021), the day of discharge
(90.65% vs. 83.09%, P = 0.011) and end of the third month (61.23% vs.
50.74%, P = 0.039). Conclusion(s): The RCT-proved ePRO-SMAI can be
transferred to the surgical practice, by shortening PRO instruments,
simplifying operating procedure, and upgrading hardware and software. The
modifications reduced workloads on clinicians and increased responding to
patients. The pragmatic and robust approach will facilitate the
integration of ePROs into routine clinic workflow making them more usable
and acceptable to end users. (Table present).

<88>
Accession Number
650576202
Title
Pre- Existing and New- Onset AF on All- Cause Mortality in Patients
Undergoing TAVI- Meta- Analysis Study.
Source
Annals of Noninvasive Electrocardiology. Conference: 50th International
Congress on Electrocardiology. Thessaloniki Greece. 30(Supplement 1) (no
pagination), 2025. Date of Publication: 01 Jul 2025.
Author
Saplaouras A.; Bazoukis G.; Mililis P.; Kariki O.; Dragasis S.; Koskina
S.; Efremidis T.; Makris A.; Letsas K.; Efremidis M.
Institution
(Saplaouras, Mililis, Kariki, Dragasis, Koskina, Efremidis, Makris,
Letsas, Efremidis) Arrhythmia Unit, Onassis Cardiac Surgery Center,
Athens, Greece
(Bazoukis) Department of Cardiology, Larnaca General Hospital, Larnaca,
Cyprus
Publisher
John Wiley and Sons Inc
Abstract
Introduction: Atrial fibrillation (AF) is a common comorbidity in patients
with severe AS who are planning to undergo TAVI, while new- onset AF can
complicate the clinical course of these patients. This meta- analysis aims
to evaluate the impact ofpre- existing and new- onset AF on all- cause
mortality in patients undergoing TAVI. Method(s): This meta- analysis
has been prepared in adherence to the Preferred Reporting Items for
Systematic Review and Meta- Analyses (PRISMA) guidelines. Result(s):
Finally, 30 studies provided data regarding the association between pre-
existing (18 studies) and/or new- onset AF (12 studies) with all- cause
mortality and were therefore included in the quantitative analysis.
Patients with new- onset AF had a 67% higher risk of all- cause mortality
compared to patients without new- onset AF (HR: 1.67, 95% CI [1.39-2.00],
p < 0.001, I2 72%). Similarly, patients with pre- existing AF had a 67%
higher risk of all- cause mortality compared to patients without pre-
existing AF (HR: 1.64, 95% CI [1.53-1.77], p < 0.001, I 2 28%).
 Conclusion(s): Pre- existing and new- onset AF is associated with an
increased risk of all- cause mortality in patients undergoing TAVI
procedures. Further research is needed to evaluate the beneficial role of
sinus rhythm maintenance and antiarrhythmic medication, especially in
patients who develop new- onset AF.

<89>
Accession Number
650577466
Title
Associations of health-related quality of life with major adverse
cardiovascular and cerebrovascular events for individuals with ischemic
heart disease: Systematic review, meta-analysis and evidence mapping.
Source
Quality of Life Research. Conference: 30th Annual Conference of the
International Society for Quality of Life Research. Calgary, AB Canada.
32(2 Supplement) (pp S138), 2023. Date of Publication: 01 Nov 2023.
Author
Soloveva A.; Gale C.; Tun H.N.; Palin V.; Hurdus B.; Mebrahtu T.; Van
Spall H.; Batra G.; Dondo T.; Maria B.; Aktaa S.; Munyombwe T.
Institution
(Soloveva) Almazov National Medical Research Centre, Department of
Cardiology, Saint Petersburg, Russian Federation
(Gale, Dondo, Munyombwe) Leeds Institute of Cardiovascular and Metabolic
Medicine, University of Leeds, Leeds, United Kingdom
(Tun) Larner College of Medicine, University of Vermont, Burlington,
Vermont, United States
(Palin, Hurdus, Aktaa) Department of Cardiology Leeds General Infirmary,
Leeds, United Kingdom
(Mebrahtu) Bradford Institute for Health Research, Bradford Teaching
Hospitals Nhs Foundation Trust, Bradford, United Kingdom
(Van Spall) McMaster University, Division of Cardiology, Hamilton, ON,
Canada
(Batra) Department of Medical Sciences, Cardiology and Uppsala Clinical
Research Center, Uppsala University, Uppasala, Sweden
(Maria) Linkoping University, Department of Health, Medicine and Caring
Sciences, Linkoping, Sweden
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Aims: To investigate associations of health-related quality of life
(HRQoL) with major adverse cardiovascular and cerebrovascular events
(MACCE) in individuals with ischemic heart disease (IHD). Method(s):
We conducted a systematic review, meta-analysis and evidence mapping.
Information sources include Medline(R), Embase Classic and Embase, APA
PsycINFO and CINAHL (EBSCO) from inception to 30th June 2022. Main outcome
was MACCE comprising death (all-cause death, cardiovascular death),
myocardial infarction, stroke, heart failure hospitalisation,
hospitalization with unstable angina, percutaneous coronary intervention,
coronary artery bypass graft surgery. Risk of bias was assessed using the
Newcastle- Ottawa Quality Assessment Scale. Random effects meta-analysis
was performed stratified by HRQoL measures. Between-study heterogeneity
was assessed using the Higgins I2 statistic. Result(s): Of 8387
articles identified, 46 were eligible for inclusion, reporting on 39
unique cohorts with a total of 123,619 participants from 52 countries.
Studies varied with respect to HRQoL measures, population characteristics,
follow-up durations and data analysis; thus, data about the predictive
value of HRQoL were synthesised descriptively and mapped by main outcome
measures. The majority of studies (43, 93.5%) reported that poor baseline
HRQoL as overall score or domain, and a decline in HRQoL were associated
with increased risk of MACCE. Of 22 studies included in the stratified
meta-analysis, lower HRQoL score was associated with an increased risk of
all-cause mortality [HeartQoL hazard ratio (HR) 1.64, 95% CI 1.34 to 2.01;
EuroQoL 5-dimension HR 1.17, 95% CI 1.12 to 1.22; 36-Item Short Form
Survey (SF-36) physical component summary score (PCS) HR 1.29, 95% CI 1.19
to 1.41; SF-36 mental component summary score (MCS) HR 1.18, 95% CI 1.08
to 1.30; SF-12 PCS HR 1.45, 95% CI 1.32 to 1.61; SF-12 MCS HR 1.21, 95% CI
1.07 to 1.37], and composite outcome (HeartQoL score HR 1.49, 95% CI 1.16
to 1.93; SF- 12 PCS HR 1.39, 95% CI 1.28 to 1.51). Conclusion(s):
This study found an inverse association between HRQoL and MACCE in
individuals with IHD, albeit with between study heterogeneity.
Standardised and routine use of HRQoL measurement in clinical practice may
help risk stratify individuals with IHD for tailored interventions. (Table
present).

<90>
Accession Number
650582257
Title
Imaging based risk factors for heart failure death in childhood dilated
cardiomyopathy: A systematic review and meta-Analysis.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S191-S192), 2025. Date of
Publication: 01 Dec 2025.
Author
De Palma C.S.; Lim Z.; Field E.; Kaski J.P.; Norrish G.
Institution
(De Palma) Institute of Cardiovascular Sciences, University College
London, London, United Kingdom
(Lim, Field, Kaski, Norrish) Centre for Inherited Cardiovascular Diseases,
Great Ormond Street Hospital, London, United Kingdom
Publisher
Cambridge University Press
Abstract
Introduction: Dilated cardiomyopathy (DCM) is the most common heart muscle
disease presenting in childhood and is associated with an increased risk
of heart failure related death. In adult cohorts, imaging characteristics
such as left ventricular dimensions or the presence of fibrosis on cardiac
magnetic resonance imaging (MRI) have been shown to be associated with
adverse outcomes. In contrast, the prognostic relevance of imaging
characteristics in childhood cohorts remains unclear and predicting
disease progression is challenging. The aim of this study was to perform a
systematic literature review and meta-Analysis of imaging characteristics
associated with adverse outcomes in childhood DCM. Method(s): PubMed,
Embase, and Scopus databases were searched for original articles published
in English from 1946 to July 2024 that included patients under 21 years
with a confirmed diagnosis ofDCMand primary or secondary end-point of
heart failure death or equivalent event (heart transplantation or
ventricular assist device implantation). Studies were excluded if imaging
characteristics were not described Results: Thirteen studies (1348
patients) met the inclusion criteria. All but one study was retrospective
and only one had a patient cohort of more than 100 patients. We identified
three imaging risk factors that were evaluated in at least four studies
and significantly associated with a heart failure end point in at least
two; left ventricular end-diastolic diameter Z score (LVEDD) (pooled
hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.13-1.81, p =
0.003), left ventricular ejection fraction (LVEF) (HR 0.8, 95% CI
0.65-0.99, p = 0.04) and severe mitral regurgitation (MR) (pooled odds
ratio [OR] 5.12, 95% CI 1.18-22.19, p = 0.004). 'Minor' risk factors
included measures of LV diastolic function and changes in LV geometry. Two
small studies (n=32) investigated the role of fibrosis on CMRI and did not
report an association with adverse outcomes. Conclusion(s): A
systematic review and meta-Analysis of imaging risk factors predicting
heart failure adverse events in childhood DCM was performed identifying
three 'major' risk factors; higher LVEDD, lower LVEF and severe MR.
Well-designed multicentre studies are required to investigate the role of
imaging characteristics in predicting outcome.

<91>
Accession Number
650582354
Title
Interventional cardiac catheterization in low weight newborns: Results and
early outcomes in a single-center experience.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S325), 2025. Date of Publication: 01
Dec 2025.
Author
Giordano M.; Gaio G.; Marzullo R.; Palladino M.T.; Gaudieri G.; Esposito
R.; Del Gaizo F.; Fratta F.; Santoro G.; Russo M.G.
Institution
(Giordano, Gaio, Marzullo, Palladino, Gaudieri, Esposito, Del Gaizo,
Fratta, Russo) Paediatric Cardiology, Monaldi Hospital, University of
Campania Luigi Vanvitelli, Naples, Italy
(Santoro) Paediatric Cardiology and GUCH, Heart Hospital G. Pasquinucci,
Tuscany Foundation CNR G. Monasterio, Massa, Italy
Publisher
Cambridge University Press
Abstract
Introduction: Interventional cardiac catheterization in low-weight (<=2.50
kg) newborns is a challenging therapeutic option. However, technical
advances and improvement of cardiologist's expertise widened indications
and complexity of this approach in these patients. Method(s):
Interventional cardiac catheterization procedures performed in low-weight
newborns in the catheterization laboratory of the Paediatric Cardiology
Unit of Monaldi Hospital (Naples) were analysed in terms of proce-dural
mortality and morbidity. Result(s): From January 2000 to December
2024, 476 newborns underwent 552 percutaneous cardiac interventional
procedures. One-hundred-thirteen pts were low-weight (<=2.50 kg). Among
low-weight pts, 7 (6.1%) pts were very low-weight (VLW) (<=1.50 kg). The
mean weight was 2.15+/-0.34 kg (range 1.10- 2.50 kg) and median age was
7.71 days (range 0-59 days). Overall, mortality and morbidity of this
approach were 15.9% and 12.4%, re-spectively. TheVLWgroup had high risk of
mortality (42.8% vs 14.2%, p- 0.04). At multi-variate analysis,
in-hospital mortality was significantly related to procedural failure
(p<0.01), uni-ventricular physiology (p<0.01) and genetic syndromes
(p<0.01). The most represented procedures were pulmonary (29, 27.4%) and
aortic (15, 14.2%) balloon valvuloplasty, Rashkind atrioseptecomy (28,
26.4%), and arterial duct stenting (28, 26.4%). Arterial duct stenting
(mortality 5.6% and morbidity 6.6%) and aortic balloon valvuloplasty
(mortality 13.3% and morbidity 13.3%) were the most hazardous procedures.
 Conclusion(s): Interventional cardiac catheterization is a safe and
feasible alternative to surgery in low-weight newborns, even if still
challenging despite recent technical advances. However, future
improvements in techniques and operator skills as well as a more accurate
selection of patients and peri-procedural care might hopefully fur-ther
improve results and early outcome of this approach in this high-risk
subset of patients.

<92>
Accession Number
650582384
Title
Transannular patch repair and smaller bioprosthetic valve at revalving are
associated with risk of supraventricular tachycardia in tetralogy of
fallot.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S63), 2025. Date of Publication: 01
Dec 2025.
Author
Nerst D.; Groning M.; Jorgensen T.H.; Jensen A.S.; Campens L.; Schmidt
M.R.; Jons C.
Institution
(Nerst, Groning, Jorgensen, Jensen, Campens, Schmidt, Jons) Department of
Cardiology, Rigshospitalet, Copenhagen, Denmark
Publisher
Cambridge University Press
Abstract
Introduction: Residual lesions following repair of Tetralogy of Fallot
(TOF) are common and mainly related to the correction of pulmonal
stenosis. Residual lesions may, according to guidelines, indicate
pulmonary valve replacement (PVR) in these patients. No solid evidence
proves that PVR decreases arrhythmic burden or delays arrythmia in these
patients. This study aims to evaluate the effect of PVR on arrythmia onset
and arrhythmic burden in patients with TOF. Method(s): In a
retrospective study, patients with TOF were followed from birth until
death or 31st December 2018 for the onset of SVT (first mention) and
related admissions lasting longer than 24 hours. Patients were stratified
by method used to correct PS. Pulmonary valve replacement was a time
varying covariate in all analyses. Result(s): A total of 850 patients
were included. Patients repaired with transannular patches (TAP) were the
largest group (n = 368, 43%). SVT developed in 67 patients (8%) resulting
in 216 admissions. The SVT-free survival at 40 years was 0.83 (95% CI:
0.79-0.87, p <0.05). Repair with a TAP was associated with risk of
developing SVT (HR 2.58, 95% CI: 1.28-5.20, p < 0.01). PVR had no
significant effect on the risk of arrythmia onset (HR 1.21, 95% CI 0,67-
2.3, p=0.5). Bioprosthetic pulmonary valves (BPV) smaller than 19 mm at
PVR were associated with increased post-PVR SVT risk (HR 21.56, 95% CI:
2.08-224.0, p < 0.01). Additionally, BPV smaller than 15 mm were
associated with development of SVT (HR 45.28, 95% CI: 3.52 - 836.7, p
<0.01). Arrhythmic burden increased significantly with bioprosthetic
valves older than 8 years (HR 3.67, 95% CI 1.16 - 11.7, p<0.05).
 Conclusion(s): Repair with the use of TAP was associated with
increased risk of SVT. Valve Replacement did not decrease the risk of
arrythmia onset or arrhythmic burden. Valvular prostheses smaller than 19
mm was associated with elevated risk of SVT post PVR and PVR older than
eight years was associated with increased arrythmia burden. There is a
need for randomised controlled studies evaluating the effect of PVR and
its timing on risk of SVT.

<93>
Accession Number
650582327
Title
Modifications in substrates with advanced physiology; an intentional asd
in left to right shunts and substrates at risk of restrictive physiology.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S273), 2025. Date of Publication: 01
Dec 2025.
Author
Shidhika F.; Mureko A.; Feris N.; Simelane S.
Institution
(Shidhika) Division of Paediatric and Congenital Cardiology, Windhoek
Central Hospital, Ministry of Health and Social Services, Namibia
(Mureko) Division of Paediatric and Congenital Heart Surgery, Windhoek
Central Hospital, Ministry of Health and Social Services, Namibia
(Feris) Division of Cardiac Anaesthesia, Windhoek Central Hospital,
Ministry of Health and Social Services, Namibia
(Simelane) Division of Cardiovascular Perfusion, Ministry of Health and
Social Services, Namibia
Publisher
Cambridge University Press
Abstract
Introduction: Advanced age for patients undergoing palliative and
definitive CHD surgery is a common phenomenon in emerging economies.
Advanced PHT albeit absent fixed pulmonary obstructive vascular disease is
associated with postoperative morbidity and mortality. Obstructive right
heart lesions (negative RV remodelling) present a similar challenge. The
morphologic RV has reduced inherent adaptive capacity to volume - pressure
load, attributable to geometrical and fibres' architectural arrangement.
We developed an individual-tailored bundle for these cohorts e.g
anaesthesia, routine use of Del Nido cardioplegia, zerobalance
ultrafiltration to haematocrit (HCT) 40-45%, intentional ASD, prophylactic
PHT and restrictive RV manouevres (Milrinone +/- Noradrenaline, alkalosis,
CVP 12-14 (preload), Dextometomedine (fast-tracking + tachyarrythmias
propylaxis.). Herein, we describe its impact on immediate and longitudinal
postoperative outcomes. Method(s): PICOS (Population, Intervention,
Comparator, Outcomes, Setting) is applied for description. The population
has CHD with mean PAP > 20 mmHg (+ ACHD), and obstructive right heart
phenotypes; > 1 year chronological age. Intervention represents the bundle
under 'introduction'. Comparators are < 1 year chronological age. Outcomes
represent morbidity; 1. prolonged average length of stay (ALoS) > 10 -14
days, effusive drainage (pleural), arrythmias (JET)), 2. acute (<30 days)
and long-term mortality. Setting is Namibia (UMIC). Timeline is 2018 -
2024. Variables sourced from the PROTEA database were demographics,
diagnoses, syndromes/associations, RACHS scores, baseline Hb, HCT,
oximetry, mean and end-diastolic PAP, PVRi etc., and analysed with
command-driven STATA 17. Result(s): The cohort constituted 400
patients, mean age 5 years; ACHD 12.5% (18 - 62 years). Baseline oximetry
was 60 -80%, HCT 50- 72%, in 25% patients (Tetralogy), and PVRi were 3- 9
iWu, pre-vasoreactivity. ALoS was 7 days (5 -14). Tachyarrythmias were
observed in 4%. Pleural effusions occured particularly in 7,5%, with ACHD.
Acute mortality was observed in 1 patient, and long-term was observed in 1
patient with Tetralogy, 3 PHT (1 ACHD). RV remodelling and decremental PHT
are observed in the remaining cohort. Conclusion(s): We conclude that
our modified advanced physiology care bundle (+ an intentional ASD)
positively impacted acute and longitudinal postoperative outcomes.
Research constituting systematic reviews and meta-Analyses is needed for
guidelines' recommendation, for developing countries.

<94>
Accession Number
650582856
Title
Prophylactic pulmonary artery banding versus medical therapy for
peadiatric heart failure: A propensity score- matched comparison.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S26), 2025. Date of Publication: 01
Dec 2025.
Author
Panaioli E.; Pontailler M.; Bonnet D.; Khraiche D.
Institution
(Panaioli, Pontailler, Bonnet, Khraiche) Necker Hospital, France
Publisher
Cambridge University Press
Abstract
Introduction: Dilated cardiomyopathy (DCM) in neonates and toddlers is a
severe condition often leading to severe heart failure (HF) and requiring
advanced treatments such as heart transplantation (HTx). Pulmonary artery
banding (PAB) has been proposed as a promising surgical approach for left
ventricular (LV) remodeling in pediatric patients with preserved right
ventricular function. In our experience Prophylactic PAB has been
successfully performed inDCMpatients with no mortality related to surgical
procedure.In the absence of results from randomized controlled trials, we
sought to provide exploratory data on the potential benefit of PAB
compared with good medical therapy (GDMT) alone in toddlers with DCM.
Using data from the our registry, we performed a propensity score
(PS)-matched comparison of DCM patients undergoing PAB versus GDMT
focusing on clinical, functional, and echocardiographic outcome.
 Method(s): This is a retrospective cohort study(2014 and 2024). The
study include neonates and toddlers (aged 0-3 years) treated at a single
tertiary care center. Patients will be divided into two groups based on
the primary therapeutic approach: PAB group and GDMT group. Using
propensity score matching, clinical, echocardiographic, and functional
data from 22 patients (11 in each group) were analyzed (flow chart study)
Results: PAB was associated with a significant reduction in LV
enddiastolic diameter Z-scores (from 7.28 +/- 2.79 to -0.87 +/- 2.87 at 1-
year follow-up, p = 0.020) and improved left ventricular ejection fraction
(LVEF) compared to GDMT alone (51.14% +/- 8.17% vs. 37.75% +/- 9.54%, p =
0.036). The variation of LVEDD Zscore in time was reduced in GDMT group
-0.62 (1.46) when compared to PAB group -5.72 (3.39, p= 0.015).
Kaplan-Meier analysis revealed improved survival in the PAB group over a
10-year follow- up period. Conclusion(s): These findings highlight
the potential of PAB as a viable strategy to favorise LV remodeling and
improve survival in toddlers with severe DCM. Waiting for a spontaneous
recovery might be not the right strategy in case of severe LV dilatation
with a the distinct left-right displacement of the interventricular septum
shift by the 'apple-shaped' dilated LV. Our study shows that the
protective and regenerative, aspects of HF treatment in infancy should be
considered.

<95>
Accession Number
650582705
Title
Digital interventions for facilitating the transition of young people with
congenital heart disease to adult healthcare: A systematic review.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S183), 2025. Date of Publication: 01
Dec 2025.
Author
Menke M.A.S.; Farquharson B.; Maxwell M.; Moons P.
Institution
(Menke, Farquharson, Maxwell) Faculty of Health Sciences and Sport,
University of Stirling, Stirling, United Kingdom
(Moons) Department of Public Health and Primary Care, University of
Leuven, Leuven, Belgium
Publisher
Cambridge University Press
Abstract
Introduction: Transitioning to adult care can present significant
challenges for young people with congenital heart disease (CHD), often
resulting in disrupted cardiac follow-up, engagement in risky health
behaviours, difficulties with self-management, and increased psychosocial
pressures. Suboptimal transition can lead to serious consequences, such as
worsened cardiac health, unplanned hospitalisations, adverse health
events, and reduced quality of life. This systematic review examined the
potential of digital technology interventions as tools to improve the
transition and transfer to adult cardiac services. Method(s):
Comprehensive searches were conducted across multiple databases, including
CINAHL, MEDLINE, EMBASE, Cochrane Library, PsycINFO, Web of Science,
Scopus, ProQuest, IEEE Xplore, and ACM Digital Library. Result(s):
Five studies involving 269 participants met the inclusion criteria. The
studies comprised three randomised controlled trials (RCTs), a pre-post
study, and a qualitative study that incorporated quantitative data. The
digital tools used in interventions included mobile health application,
Short Message Service (SMS), online health platform, and tele-education.
The systematic review showed mixed results in improving transition
outcomes through digital interventions. One RCT reported digital
intervention enhanced patient health self-efficacy (p=0.003) and
psychological well-being related to CHD (p=0.013), reduced weekday
sedentary behaviour (p=0.042) and weekend leisure-time sedentary behaviour
(p=0.035), increased step counts (p=0.011) and participation in
moderate-to-vigorous physical activities (p=0.027). The pre- post study
found that digital intervention improved participants' knowledge of the
disease (p<0.01) and cardiac surgeries (p<0.01). Two RCTs reported no
impact of digital interventions on improving transition readiness, disease
knowledge, or physical activity levels (p>0.05). The studies highlighted
the frequent use of features like cameras, calendars, and notes in mobile
apps, and showed the success of establishing contact with health
professionals via SMS. Importantly, only a few digital interventions
included individuals with learning disabilities. No studies were found
that compared the outcomes of nurse-led versus digital technology
transition interventions. Conclusion(s): This systematic review
highlights the potential of digital technology to improve transition
outcomes for young people with CHD. Customising digital interventions to
individual needs and ensuring inclusivity for diverse groups, such as
those with learning disabilities, remains crucial. Evidence comparing the
effectiveness of nurse-led transition programs to digital interventions is
necessary in the future.

<96>
Accession Number
650582328
Title
Research activity of nurses working in congenital and inherited cardiac
services in uk and ireland. a scoping review.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S116), 2025. Date of Publication: 01
Dec 2025.
Author
Gaskin K.L.
Institution
(Gaskin) Birmingham City University, United Kingdom
Publisher
Cambridge University Press
Abstract
Introduction: Whilst we know that nurses are working in roles that have a
research focus, the extent of publication and research activity in the UK
and Ireland is currently unknown. The aim of this scoping review was to
establish the baseline of publication and research activity in the UK or
Ireland, by exploring the extent to which nurses working in congenital and
inherited cardiac services, are writing for publication, engaged in or
leading research. Method(s): A scoping review was conducted (October
to November 2024) following PRISMA-ScR guidance, to identify, review and
clarify the breadth and nature of the evidence relating to the research
question: 'What is known about how nurses working in congenital and
inherited cardiac services in the United Kingdom and Ireland, write for
publication, engage in or lead research?' Bibliographic databases CINAHL
Ultimate, PsycINFO, Medline, along with websites (for example Royal
College of Nursing, Congenital Cardiac Nurses Association, British Adult
Congenital Cardiac Nurses Association) to inform the search. Eligibility
criteria included congenital heart disease (paediatric and adult) or
inherited conditions, paediatric heart disease cardiac, heart surgery,
UK/Irish nurses as first author, UK/Irish nurses as co-Author, all types
of paper/publication - theoretical, conceptual and empirical articles,
grey literature, 2015-2024, UK and Ireland. Result(s): N=193 papers
were identified through database searches. After reviewing the full text,
duplicates and additional non-eligible papers were removed leaving n=96
papers. Four national guidance documents were identified through the
websites. For n=61 (64%) papers a nurse was the first author and in n=23
(24%) they were the only nurse in the authorship, n=32 papers (33%) had
nurses as both first and co-Authors, n=32 (33%) a nurse was a co-Author.
The type of paper ranged from research (n=52, 54%), literature reviews
(n=6, 6%) protocols (n=2, 2%) service evaluations (n=6, 2%) to papers
including commentaries, reflections, case studies or opinion pieces (n=30,
31%). Conclusion(s): This is the first literature review to identify
the breadth and nature of nurses writing for publication in the UK and
Ireland. It is promising to find that nurses are engaged in research as
research nurses or PhD supervisors, or leading research as nurse
researchers.

<97>
Accession Number
650582408
Title
Filamin c associated cardiomyopathy in pediatric patients: A belgian case
series and literature review.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S93), 2025. Date of Publication: 01
Dec 2025.
Author
Renders W.; Cansse E.; Bruyndonckx L.; Salaets T.; Callewaert B.; De
Groote K.; Mosquera L.M.
Institution
(Renders, Cansse, De Groote, Mosquera) Department of pediatrics, Ghent
University Hospital, Ghent, Belgium
(Bruyndonckx) Department of pediatrics, Antwerp University Hospital,
Antwerp, Belgium
(Salaets) Department of pediatrics, Leuven University Hospital, Leuven,
Belgium
(Callewaert) Center for Medical Genetics, Ghent University Hospital,
Ghent, Belgium
Publisher
Cambridge University Press
Abstract
Introduction: In recent years, there is increasing interest in the role of
the Filamin C (FLNC) in cardiomyopathy. FLNC, a member of the filamin
family of actin-binding proteins, plays a vital role in maintaining the
structural integrity, signaling and mechanotransduction of sarcomeres in
cardiac and skeletal muscles. Variants in the FLNC gene are extensively
described in skeletal myopathies and all types of cardiomyopathies, mostly
in adults. But increasing literature discussing an early-onset, often
isolated form of cardiomyopathy is being published. The contribution of
FLNC variants in different CMP subtypes is reported to be between 1- 8%.
 Aim(s): To study the cardiovascular outcome of children carrying a
(likely) pathogenic variant in FLNC and evaluate genotype-phenotype
correlations. Method(s): Children up to 18yrs, either found via
literature search or under follow-up in one of the participating Belgian
centers, were included in the study. The FLNC main transcript (NM-01458.5)
was used as reference. Demographic, genetic and cardiovascular data were
collected. Result(s): A total of 70 children (61.4% male, mean age
7.6+/-6.1 yrs) were included (8 in Belgium). A summary of FLNC variants
involved is shown in the figure. 31.4% of patients presented with
associated extracardiac manifestations - such as myopathy or orthopedic
anomalies. Missense variants were most frequent (65.7%), followed by
nonsense variants (15.7%). Truncating variants - caused by nonsense,
frameshift or splice-site mutations - were mostly associated with DCM and
ACM (P<0.001). Missense variants can result in allCMPsubtypes, with an
important proportion of RCM (60.4%). 40% of the children suffered a major
cardiac event (mean age 10.5+/-8.6 yrs, time to event 3+/-4.2 yrs): 18
patients (25.7%) underwent a heart transplantation, 4 received an ICD
(5.7%), and 4 patients (5.7%) suffered from sudden cardiac death (SCD) at
presentation. RCM had the worst outcome accounting for >45% of cardiac
events. Conclusion(s): FLNC-related cardiovascular phenotype can
present at an early age and is associated with important morbidity and
mortality. Truncating variants are mostly associated with DCM and ACM,
while missense variants with RCM. Early screening and follow-up are
necessary to identify those children at risk.

<98>
Accession Number
650582804
Title
Exercise capacity, endothelial function, and muscle mass in pediatric
fontan patients, does biological sex matter?.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S161), 2025. Date of Publication: 01
Dec 2025.
Author
Lui M.; Bernstein D.; Long J.; Leonard M.; Myers J.; Cooke J.; Palaniappan
L.; Tierney S.
Institution
(Lui, Bernstein, Palaniappan, Tierney) Department of Pediatrics, Division
of Pediatric Cardiology, Stanford University, School of Medicine, United
States
(Long, Leonard) Department of Biomedical Data Science, Stanford
University, School of Medicine, United States
(Cooke) Department of Cardiovascular Sciences, Houston Methodist Hospital,
Research Institute, United States
(Myers) Department of Medicine, Health Research Science, Palo Alto VA
Health Care System, United States
Publisher
Cambridge University Press
Abstract
Introduction: Fontan procedure has improved the life expectancy of
children with congenital heart disease, and the focus has shifted toward
understanding various factors that influence their health. Here, we
present baseline data on pediatric patients with Fontan circulation prior
to their participation in a controlled randomized exercise intervention
(RE-ENERGIZE FONTAN) and examine how biological sex influences their
health measures. Method(s): This randomized controlled trial utilizes
live video conferencing to deliver a supervised exercise intervention.
Patients aged 8-19 years with Fontan circulation who have been cleared to
exercise are included. Patients with NYHA Class IV, recent illness, active
protein-losing enteropathy, pacemaker, and/or cognitive delay are
excluded. At baseline, patients undergo a cardiopulmonary exercise test
(peak VO2), endothelial function testing, an echocardiogram (strain and 3D
EF), a DXA scan (lean muscle mass), isokinetic dynamometry (handgrip and
leg strength), and functional movement screening (injury risk).
 Result(s): 114 patients with Fontan circulation (median age 12.7
years [IQR, 10.2, 15.6]) completed the baseline visit. Median time from
Fontan operation was 8.8 years [IQR 6.2, 12.0]; 68 (60%) were male. When
compared to female patients, male patients had higher peak VO2 (1386+/-542
vs. 1153+/-405 ml/min, p=0.01), indexed peak VO2 (29.4+/-6.9 vs.
25.6+/-5.0 ml/min/ kg, p<0.001), percent predicted VO2 (65.3+/-17.0 vs.
71.4 +/-12.7%, p=0.03), O2 pulse (8.4+/-3.2 vs. 6.9+/-2.3 mL/beat,
p=0.004), handgrip strength (18.9+/-8.4 vs. 15.9+/-6.1kg, p=0.03), leg
flexion (26.8+/-15.0 vs. 21.3+/-12.4 ft/lbs., p=0.04) and lower functional
movement screening score (11.5+/-3.2 vs. 12.6+/-2.7, p=0.04). There were
no differences in endothelial function, ventricular function, and muscle
mass. Conclusion(s): In our cohort, female patients have decreased
aerobic capacity, reduced efficiency of oxygen delivery and utilization,
and diminished strength compared to male patients. However, female
patients have better functional movement and lower injury risk. Our
results showcase the complexity of outcomes post-Fontan operation,
highlighting the benefits of developing individualized management to
address specific needs to optimize overall health.

<99>
Accession Number
650582602
Title
Outcome of arterial switch operation in patients with TGA-IVS vs TGA-VSD:
A meta-Analysis and systematic review.
Source
Cardiology in the Young. Conference: 58th Annual Meeting of the
Association for European Paediatric and Congenital Cardiology, AEPC 2025.
Hamburg Germany. 35(Supplement 2) (pp S153-S154), 2025. Date of
Publication: 01 Dec 2025.
Author
Nugraha A.F.; Akbar E.; Soebroto H.; Pagehgiri H.D.; Hakim A.R.;
Hariftyani A.S.; Aulia S.H.
Institution
(Nugraha) Cardiothoracic and vascular surgery resident, Faculty of
Medicine, University of Airlangga, East Java, Indonesia
(Akbar, Soebroto, Pagehgiri, Hakim) Department of Cardiothoracic and
Vascular surgery, Dr. Soetomo General Hospital, Surabaya, Indonesia
(Hariftyani, Aulia) Faculty of Medicine, University of Airlangga, East
Java, Indonesia
Publisher
Cambridge University Press
Abstract
Introduction: The arterial switch operation (ASO) remains the goldstandard
surgical intervention for transposition of the great arteries (TGA). TGA
is broadly classified into two subtypes, whether the ventricular septum
intact or not (TGA IVS or TGA VSD). These subtypes present distinct
anatomical and physiological challenges, potentially influencing
perioperative risks, post-operative complications, and long-term outcomes.
This meta-Analysis and systematic review aim to comprehensively compare
surgical outcomes following ASO in patients with TGA-IVS and TGA-VSD,
focusing on mortality, re-intervention, morbidity profiles, and factors
impacting prognosis. The findings seek to inform surgical strategy and
optimize patient management. Method(s): A PRISMA-guided search of
PubMed, ScienceDirect, BMC, and Springer included studies with
quantitative data on mortality and complications. Pooled outcomes were
analyzed using random-effects models. Result(s): Five of the 2,125
journals that were reviewed were selected for inclusion. These journals
encompassed 397 patients diagnosed with TGA-IVS and 183 patients diagnosed
with TGA-VSD who underwent the ASO procedure. PA banding,
Systemic-to-pulmonary shunt, Coarctation repair, Repair of aortic arch
hypoplasia, Repair of interrupted aortic arch, and balloon atrial
septostomy were performed on a number of patients prior to ASO, accounted
for 15.87% of the TGA-IVS group and 28.96% of the TGA-VSD population. This
meta-Analysis demonstrated that patients with TGA-IVS undergoing ASO have
significantly lower mortality compared to patients with TGAVSD (OR 0.46,
95% CI 0.29-0.73, I2=0%, p=0.001; fixed-effect model).
Furthermore, patients with TGA-IVS undergoing ASO are significantly less
likely to require re-intervention compared to those with TGA-VSD (OR 0.34,
95% CI 0.20-0.58, I2=65%, p<0.0001; random-effects model).
 Conclusion(s): Our meta-Analysis and systematic review indicates that
patients with TGA-IVS undergoing ASO have significant better outcomes
compared to patients with TGA-VSD.

<100>
Accession Number
2043958550
Title
Assessing preoperative bleeding risk using international normalized ratio
and activated partial thromboplastin time: a systematic review.
Source
Journal of Thrombosis and Haemostasis. (no pagination), 2026. Date of
Publication: 2026.
Author
Rahhal H.; Sampat R.; Tse B.; Liontos L.; Hicks L.K.; Tang G.H.; Sholzberg
M.
Institution
(Rahhal) Departamento de Clinica Medica, Instituto Central, Hospital das
Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao
Paulo, Brazil
(Rahhal) Faculdade de Medicina, Universidade de Sao Caetano do Sul, Sao
Paulo, Brazil
(Sampat, Tse, Tang) Hematology-Oncology Clinical Research Group, St.
Michael's Hospital, Toronto, ON, Canada
(Tse, Sholzberg) Department of Laboratory Medicine and Pathobiology,
University of Toronto, Toronto, ON, Canada
(Liontos) Department of Laboratory Medicine and Molecular Diagnostics,
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
(Hicks, Sholzberg) Department of Medicine, St. Michael's Hospital, Li Ka
Shing Knowledge Institute, Toronto, ON, Canada
Publisher
Elsevier B.V.
Abstract
Background The prothrombin time (PT) and activated partial thromboplastin
time (APTT) are often considered routine tests in the assessment of
perioperative bleeding risk. Physicians continue to order these tests, and
major medical societies guidelines exhibit significant heterogeneity
regarding the utility of coagulation tests as a general screening tool,
despite many advocating for a risk-stratified approach over routine
testing. Objectives This study aimed to assess for association between
preoperative coagulation tests and bleeding events around elective
surgery. Methods We conducted a systematic review of the literature. Three
electronic databases were consulted MEDLINE, EMBASE, and EBM Reviews.
Randomized trials and observational studies that assessed the predictive
accuracy of preprocedural PT and APTT test results for perioperative
bleeding were deemed eligible for inclusion. Outcomes included any
bleeding events in the postoperative period. Results In total, 100 studies
were included in our qualitative synthesis: otolaryngology (n = 15), minor
surgeries and procedures (n = 15), neurosurgery (n = 17), orthopedic
surgeries (n = 6), cardiac surgeries (n = 16), liver transplantation or
hepatectomy (n = 20), general surgery, and other types of major surgery (n
= 11). Qualitative synthesis demonstrated a weak or inconsistent
association between PT or APTT and bleeding events. Associations were more
frequently reported in studies involving patients with cirrhosis and/or
neoplastic disease of the liver undergoing liver resection,
transplantation, or major abdominal cancer debulking surgery. Conclusion
Our findings confirm that coagulation testing results are not consistently
associated with bleeding in minor surgeries and nearly all major elective
surgeries. However, PT results might be associated with bleeding outcomes
in patients with advanced liver disease undergoing major abdominal
surgeries. Copyright © 2026 International Society on Thrombosis
and Haemostasis.

<101>
Accession Number
2043929079
Title
The Effect of White and Pink Noise on Dental Anxiety in Children Aged 6-9
Years During Pulpotomy Procedures: A Randomized Controlled Clinical Study.
Source
International Journal of Dentistry. 2026(1) (no pagination), 2026. Article
Number: 3330992. Date of Publication: 2026.
Author
Araman D.; Laflouf M.; Al-Shiekh M.N.
Institution
(Araman, Laflouf, Al-Shiekh) Department of Pediatric Dentistry, Faculty of
Dentistry, Damascus University, Damascus, Syrian Arab Republic
Publisher
John Wiley and Sons Ltd
Abstract
Background: In recent years, white and pink noise have emerged as
nonpharmacological methods that may make dental visits less stressful and
more comfortable for children. This study aimed to evaluate the effect of
white and pink noise on anxiety levels in children undergoing pulpotomy.
 Material(s) and Method(s): A randomized controlled clinical trial was
conducted involving 75 children aged 6-9 years. Participants were randomly
assigned to three equal groups: Group A (Tell-Show-Do [TSD] combined with
white noise during the pulpotomy), Group B (TSD combined with pink noise
during the pulpotomy), and Group C (control group without audio
distraction during the pulpotomy). Anxiety levels were evaluated using the
Facial Image Scale (FIS) at three time points: at baseline, following the
administration of local anesthesia, and after completion of the pulpotomy
procedure. Heart rate was also recorded at these same intervals, as well
as after 10 min of noise exposure, following rubber dam placement, and
during access preparation of the pulp chamber. Statistical analysis was
performed using SPSS version 25, with a significance level set at p-value
< 0.05. Result(s): This study showed that at baseline and subsequent
time points, no significant differences were observed in FIS anxiety
scores among the three groups (p-value = 0.825, 0.178, 0.792,
respectively). In terms of heart rate, there was a significant difference
just during pulp chamber access (p-value = 0.014), where Group A (white
noise) showed lower heart rates (93.80 +/- 14.64) than Groups B (pink
noise) (100.36 +/- 10.98 and C (control) (103.80 +/- 12.20).
 Conclusion(s): Although no significant differences were found between
groups, music intervention may help reduce anxiety and enhance comfort.
Notably, white noise significantly lowered heart rate during pulp chamber
access, suggesting a mild physiological calming effect. Trial
Registration: ISRCTN Registry: ISRCTN11867479. Copyright © 2026
Dana Araman et al. International Journal of Dentistry published by John
Wiley & Sons Ltd.

<102>
Accession Number
650591712
Title
Intraoperative text messaging to reduce parental stress during outpatient
pediatric surgery: a randomized trial.
Source
Pediatric research. (no pagination), 2026. Date of Publication: 10 Mar
2026.
Author
Linke R.; Mayer S.; Suttkus A.; Thiery J.; Hoehne C.; Laufs U.; Wachter
R.; Treml J.; Mende M.; Pfaeffle R.; Lacher M.; Gosemann J.-H.
Institution
(Linke, Mayer, Suttkus, Lacher, Gosemann) Department of Pediatric Surgery,
University of Leipzig Medical Center, Leipzig, Germany
(Thiery) Institute of Laboratory Medicine, Clinical Chemistry and
Molecular Diagnostics, University of Leipzig Medical Center, Leipzig,
Germany; Faculty of Medicine, Deanship, University of Kiel, Kiel, Germany
(Hoehne) Department of Anesthesiology, University of Leipzig Medical
Center, Leipzig, Germany; Department of Anesthesiology, Intensive Care
Medicine and Pain Therapy, DRK Hospital Berlin-Koepenick, Berlin, Germany
(Laufs, Wachter) Department of Cardiology, University of Leipzig Medical
Center, Leipzig, Germany
(Treml) Department of Psychosomatic Medicine and Psychotherapy, University
of Leipzig Medical Center, Leipzig, Germany
(Mende) Clinical Trial Centre (ZKS Leipzig) and Institute of Medical
Informatics, Statistics and Epidemiology, Leipzig University, Faculty of
Medicine, Leipzig, Germany
(Pfaeffle) Department of Pediatrics, Pediatric Endocrinology, University
of Leipzig Medical Center, Leipzig, Germany
Abstract
BACKGROUND: This study examined parental stress indicators during
outpatient pediatric surgery and whether intraoperative text messaging
could alleviate stress. METHOD(S): This randomized trial assigned
parents of children aged 6 months to 6 years undergoing minor outpatient
surgery to an intervention group, receiving standardized intraoperative
text messages, or a control group without messages. Both groups received a
postoperative phone call. Stress was assessed using salivary cortisol,
heart rate, heart rate variability, and subjective ratings at multiple
perioperative time points. RESULT(S): Fifty-one families
participated, predominantly mothers (71%). Cortisol and heart rate
variability peaked preoperatively, while heart rate and subjective stress
were elevated pre- and intraoperatively regardless of messaging. Fathers
had lower cortisol at the end of surgery, heart rate pre- and
postoperative and subjective stress at pre-treatment consultation compared
to mothers, who exhibited lower heart rate variability the evening before
surgery. Messaging reduced postoperative cortisol and intraoperative
subjective stress among fathers but increased subjective stress at surgery
onset within mothers and had no significant effect on stress indicators
across the full cohort. CONCLUSION(S): Intraoperative text messaging
reduced stress in fathers but not in mothers or the full cohort. The
preoperative period remained the most stressful. Future research should
explore gender-specific strategies to improve perioperative parental
support. IMPACT: This study assessed parental stress during outpatient
pediatric surgery and the impact of intraoperative text messaging as a
supportive intervention. Text messages reduced stress in fathers but
showed minimal benefit and potential adverse effects in mothers, with
increased subjective stress at surgery onset; no overall stress reduction
was observed in the full cohort. The preoperative phase was identified as
the most stressful for parents. These findings inform pediatric surgical
teams that text-based interventions may support fathers' perioperative
coping and postoperative compliance but may be ineffective or
counterproductive for mothers, highlighting the need in future research
for gender-sensitive stress-reduction strategies. Copyright ©
2026. The Author(s).

<103>
Accession Number
2043996470
Title
The prognostic value of systemic inflammatory response index (SIRI) in
acute coronary syndrome patients treated with primary percutaneous
coronary intervention: a meta-analysis and systematic review.
Source
Clinical Research in Cardiology. (no pagination), 2026. Date of
Publication: 2026.
Author
Hu C.; Ye Q.; You S.; Li S.; Dostal C.; Ernst M.; Paneni F.; Pokreisz P.;
Szabo G.T.; Kiss A.; Podesser B.K.
Institution
(Hu, Ye, Dostal, Ernst, Pokreisz, Szabo, Kiss, Podesser) Center for
Biomedical Research and Translational Surgery, Medical University of
Vienna, Wahringer Gurtel 18-20, Leitstelle 1Q, Vienna, Austria
(You) Department of Plastic and Burn Surgery, National Key Clinical
Construction Specialty, The Affiliated Hospital of Southwest Medical
University, Luzhou, China
(Li) Department of Dermatology, Meishan People's Hospital, Meishan, China
(Paneni) Center for Translational and Experimental Cardiology (CTEC),
Department of Cardiology, University Hospital Zurich and University of
Zurich, Wagistrasse 12, Schlieren, Switzerland
(Paneni) Department of Cardiology, University Heart Center, University
Hospital Zurich, Zurich, Switzerland
(Szabo) Faculty of Medicine, Department of Cardiology, University of
Debrecen, Debrecen, Hungary
(Hu, Ye, Ernst, Kiss, Podesser) Ludwig Boltzmann Institute for
Cardiovascular Research, 1090, Waehringer Guertel 18-20, Vienna, Austria
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: The systemic inflammatory response index (SIRI)-an
inflammatory index derived from neutrophil, monocyte, and lymphocyte
counts-has shown potential in predicting cardiovascular risk. However, its
prognostic value in patients with acute coronary syndrome (ACS) treated
with primary percutaneous coronary intervention (pPCI) remains unclear.
This study was aimed at evaluating the prognostic significance of SIRI in
this specific high-risk population. Method(s): We conducted a
systematic search of PubMed, Embase, and The Cochrane Library up to June
2025 to identify all relevant studies about SIRI applied to patients with
ACS after pPCI. The primary outcome was all-cause mortality. Among major
adverse cardiovascular events (MACE), new-onset acute myocardial
infarction (AMI), revascularization, and stroke were included as secondary
outcomes. Risk estimates were pooled as odds ratios (OR) with 95%
confidence intervals (CI). Result(s): A total of nine studies
involving 7679 patients were included. The pooled analysis demonstrated
that an elevated SIRI was a significant predictor for both all-cause
mortality (OR 3.32; 95% CI 1.29 to 8.54; p = 0.01), MACE (OR 2.45; 95% CI
1.74 to 3.45; p = 0.001), new-onset AMI (OR 1.86; 95% CI 1.25 to 2.77; p =
0.001), and myocardial revascularization (OR 1.64; 95% CI 1.35 to 1.98; p
= 0.001). Conclusion(s): Our meta-analysis demonstrates that an
elevated SIRI is a useful predictor of all-cause mortality, MACE,
new-onset AMI, and revascularization in patients with ACS undergoing PCI.
As a simple and cost-effective index, SIRI shows significant potential for
early risk stratification and may help guide clinical management in this
patient population. Copyright © The Author(s) 2026.

<104>
Accession Number
2044198298
Title
Early Versus Late Extubation After Pediatric Cardiac Surgery: A Systematic
Review and Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2026.
Date of Publication: 2026.
Author
Alkhatip A.A.A.M.M.; Mills K.E.; Akram A.; Farag E.; Hamza M.K.;
Abdelkader M.; Bahr M.; ELEmady M.F.M.; Hosny H.; Sallam A.; Farag A.M.G.;
Wagih M.
Institution
(Alkhatip) Department of Anaesthesia, Birmingham Children's Hospital,
Birmingham, United Kingdom
(Alkhatip, Farag, Abdelkader, Bahr) Department of Anesthesia, Pain
Management and Surgical Intensive Care, Beni-Suef University Hospital and
Faculty of Medicine, Beni Suef University, Beni Suef, Egypt
(Mills) Department of Science and Technology, University of Canberra,
Canberra, ACT, Australia
(Akram) Dow Medical College, Dow University of Health Sciences, Karachi,
Pakistan
(Hamza, ELEmady, Hosny, Wagih) Department of Anesthesia, Kasr Al Ainy
Faculty of Medicine and Cairo University Hospitals, Cairo University,
Cairo, Egypt
(Hosny) Department of Cardiothoracic Anaesthesia and Intensive Care
Medicine, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust,
Newcastle upon Tyne, United Kingdom
(Sallam) Department of Anaesthesia, St. Vincent's University Hospital,
Dublin, Ireland
(Farag) Department of Cardiac Anaesthesia, King Abdullah Medical City,
Makkah Mukarramah, Saudi Arabia
Publisher
W.B. Saunders
Abstract
Early extubation after pediatric cardiac surgery has been increasingly
adopted as part of fast-track and enhanced recovery pathways, but its
association with postoperative outcomes remains uncertain. The authors
conducted a systematic review and meta-analysis of studies comparing early
extubation (defined as extubation in the operating room or within 24 hours
postoperatively) versus delayed extubation after pediatric cardiac
surgery. Electronic databases were searched from inception through April
2024. Random-effects models were used to pool effect estimates for
mortality, reintubation, and length-of-stay outcomes. Prespecified
subgroup and sensitivity analyses were performed. Twenty-eight studies,
including 37,995 children, were analyzed. Early extubation was associated
with lower in-hospital mortality (odds ratio, 0.19; 95% confidence
interval, 0.14-0.25); however, absolute mortality rates were low, and this
association was vulnerable to confounding by indication and preferential
selection of clinically stable patients for early extubation. Early
extubation was also associated with lower reintubation rates and shorter
intensive care unit and hospital lengths of stay. Associations were more
consistent among older children than among neonates. In this predominantly
observational evidence base, early extubation should be interpreted
primarily as a marker of patient stability and institutional practice
rather than a proven intervention that reduces mortality. Given the low to
very low certainty of evidence, these findings are hypothesis-generating
and may inform quality-improvement initiatives and future prospective
studies, rather than definitive clinical guidance. Copyright ©
2026 Elsevier Inc.

<105>
Accession Number
2043934339
Title
The influence of lipoprotein(a) on coronary revascularization after
percutaneous coronary intervention.
Source
Acta Cardiologica. (no pagination), 2026. Date of Publication: 2026.
Author
Srikulmontri T.; Pantarote S.; Kulthamrongsri N.; Wattanachayakul P.;
Vutthikraivit W.; Amanullah A.
Institution
(Srikulmontri, Wattanachayakul) Department of Internal Medicine, Jefferson
Einstein Hospital, Philadelphia, PA, United States
(Srikulmontri, Wattanachayakul, Amanullah) Department of Medicine, Sidney
Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA,
United States
(Pantarote) Department of Medicine, College of Medicine, Rangsit
University, Bangkok, Thailand
(Kulthamrongsri) Department of Internal Medicine, University of Hawai'i,
Honolulu, HI, United States
(Vutthikraivit) Department of Cardiology, Intermountain Health Saint
George Regional Hospital, Saint George, UT, United States
(Amanullah) Department of Cardiology, Jefferson Einstein Hospital,
Philadelphia, PA, United States
Publisher
Taylor and Francis Ltd.
Abstract
Background: Lipoprotein(a) (Lp(a)) is a proatherogenic lipoprotein
associated with increased cardiovascular risk and is minimally responsive
to statins or lifestyle changes. While Lp(a) is linked to adverse
cardiovascular events, its role in predicting repeat revascularization
after percutaneous coronary intervention (PCI) remains unclear. This
review evaluates the relationship between Lp(a) levels and coronary
revascularization outcomes. Method(s): A systematic review and
meta-analysis of studies from MEDLINE and EMBASE through June 18, 2025,
evaluated the association between elevated Lp(a) and revascularization
outcomes post-PCI. Random-effects models using the DerSimonian-Laird
method were used to pool odds (ORs) and hazard ratios (HRs). Heterogeneity
was assessed using the I2 statistic and Cochran's Q test, and
publication bias was evaluated with Egger's regression test.
 Result(s): Twenty studies were included in the systematic review, of
which eighteen were included in the meta-analysis. Elevated Lp(a) levels
were associated with a higher risk of any repeat revascularization, with
pooled OR 1.33 (95% CI: 1.17-1.52) and HR 1.15 (95% CI: 1.05-1.25). High
Lp(a) was also linked to increased risk of target vessel revascularization
(TVR) (OR 1.42; 95% CI: 1.12-1.81). A non-significant trend towards
increased target lesion revascularization (TLR) was observed (OR 1.25; 95%
CI: 0.96-1.64). Conclusion(s): Elevated Lp(a) levels were associated
with a higher risk of repeat revascularization and TVR, with a
non-significant trend towards increased TLR. Further studies are warranted
to confirm these findings and explore the potential benefit of
Lp(a)-lowering strategies. Copyright © 2026 Belgian Society of
Cardiology.

<106>
Accession Number
2043911553
Title
Natural products targeting the gut-brain axis for the treatment of
post-cardiac procedures anxiety or depression.
Source
Phytomedicine. 155 (no pagination), 2026. Article Number: 158061. Date of
Publication: 01 Jun 2026.
Author
Ning B.; Wei Y.; Luo C.; Yang L.; Zheng Z.; Fang P.; Ge T.; Wang C.; Hu
J.; Zhao Q.; Bo J.; Dong Y.; Lei Y.; He L.; Zhang Z.; Zhao M.; Peng J.;
Zou R.; Fan X.
Institution
(Ning, Yang, Zheng, Ge, Wang, Hu, Zhao, Bo, Zou, Fan) The Second Clinical
College of Guangzhou University of Chinese Medicine, Guangzhou, China
(Wei) The Fourth Clinical Medical College of Guangzhou University of
Chinese Medicine, Shenzhen, China
(Luo) The Clinical Medical College of Chengdu University of Traditional
Chinese Medicine, Chengdu, China
(Fang) The First Clinical College of Guangzhou University of Chinese
Medicine, Guangzhou, China
(Wang, Peng, Zou, Fan) Guangdong Provincial Hospital of Chinese Medicine,
the Second Affiliated Hospital of Guangzhou University of Chinese
Medicine, Guangzhou, China
(Dong) The First Clinical Medical College of Yunnan University of Chinese
Medicine, Kunming, China
(Lei, He, Zhang) The First Clinical Medical College of Shaanxi University
of Chinese Medicine, Xianyang, China
(Zhao) Affiliated Hospital of Shaanxi University of Chinese Medicine,
Xianyang, China
(Zou, Fan) State Key Laboratory of Traditional Chinese Medicine Syndrome,
State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong
Provincial Key Laboratory of TCM Emergency Research, Guangzhou, China
Publisher
Elsevier GmbH
Abstract
Background Post-cardiac surgery anxiety or depression (PCPAD) is a common
neuropsychiatric complication following cardiovascular interventional
procedures, which significantly increases the risk of adverse
cardiovascular events and long-term mortality. Existing treatment
strategies have limitations, and clinical needs remain unmet. The
gut-brain axis (GBA) serves as a core network regulating neuroimmune and
endocrine responses, and its imbalance involves key links such as
intestinal flora dysbiosis and neuroimmune crosstalk disorders. It is
closely related to the pathogenesis of this complication, providing a
novel perspective for targeted interventions. Objective This review aims
to systematically clarify the mechanism of GBA in PCPAD, comprehensively
explore therapeutic strategies targeting this axis, and focus on the
intervention value and application potential of natural products. Methods
The study was designed and conducted in strict accordance with the PRISMA
2020 guidelines. Relevant literatures were searched from PubMed, Web of
Science Core Collection, ScienceDirect, Embase, Cochrane Library, and CNKI
databases from their inception to December 2025. Literatures focusing on
GBA-related mechanisms of PCPAD or investigating the mechanisms and
clinical applications of natural products targeting GBA for PCPAD
treatment were included. Conference abstracts, case reports, duplicate
publications, and other ineligible literatures were excluded. Through
quality control strategies including double independent screening and
verification, priority inclusion of high-credibility evidence, and data
cross-validation, 168 eligible literatures were finally included. The
composition and functions of GBA, its imbalance mechanisms, and the basic
and clinical evidence of natural product-based interventions were
systematically analyzed. Results Studies have shown that GBA imbalance is
the core pathogenesis of PCPAD, among which the inflammatory cascade
initiated by intestinal flora dysbiosis, abnormal activation of the
neuroendocrine axis, disorder of immune-nerve crosstalk, and abnormal gene
and epigenetic regulation are key pathological links. In summary, GBA
imbalance, especially gut microbiota dysbiosis and neuroimmune
interactions, plays a critical role in the pathogenesis of PCPAD. Natural
products (including traditional Chinese medicine (TCM) monomers, TCM
compound prescriptions, patented TCM drugs, and natural products from
other plant sources worldwide) can exert therapeutic effects by
synergistically regulating GBA homeostasis through multiple targets.
Specifically, they include increasing the abundance of beneficial bacteria
such as Bifidobacterium and Lactobacillus, promoting the production of
anti-inflammatory metabolites such as short-chain fatty acids, repairing
intestinal barrier function, inhibiting pro-inflammatory pathways such as
NF-kappaB and NLRP3 inflammasome, and regulating the levels of
neurotransmitters and neurotrophic factors such as 5-HT and BDNF. Basic
and clinical studies have confirmed that these natural products have high
biocompatibility and low toxic side effects, and are compatible with the
safe medication needs of patients during the organ function recovery
period after cardiac surgery. Several natural products have been proven to
modulate GBA dysfunction, with potential for clinical therapeutic
application. Conclusions This review systematically elucidates a new
paradigm of precise intervention for PCPAD via natural products that
regulate GBA through multiple targets, addressing the limitation of
traditional single-target therapies and providing a low-cost, easily
promotable solution for clinical translation. Additionally, natural
product-based interventions offer a novel approach for treating
post-cardiac surgery complications. In the future, it is necessary to
further conduct large-sample, multicenter clinical trials to clarify their
mechanisms of action and standardized dosage regimens, strengthen
toxicological research, facilitate the translation from basic research to
clinical practice, and provide more precise therapeutic strategies for
patients. Copyright © 2026 Elsevier GmbH.

<107>
Accession Number
2043911445
Title
Angiography-derived fractional flow reserve versus coronary angiography to
guide coronary artery bypass grafting in patients undergoing surgical
valve procedures with concomitant coronary artery disease in China (FAVOR
IV-QVAS): a multicentre, triple-blind, randomised trial.
Source
The Lancet. 407(10534) (pp 1161-1170), 2026. Date of Publication: 21 Mar
2026.
Author
Zhu Y.; Cheng Z.; Zhao Y.; Han L.; Zhang W.; Zhang C.; Yang S.; Ma L.;
Qiao C.; Guo Z.; Zhu D.; Zhang X.; Chen L.; Wang Z.; Ye X.; Zhou M.; Li
H.; Qiu J.; Xu H.; Sun Y.; Zhu J.; Xu Z.; Qin G.; Wijns W.; Redfors B.;
Sandner S.; Gaudino M.; Tu S.; Zhao Q.
Institution
(Zhu, Wang, Ye, Zhou, Li, Qiu, Xu, Sun, Zhu, Zhao) Department of
Cardiovascular Surgery, Ruijin Hospital Shanghai Jiao Tong University
School of Medicine, Shanghai, China
(Cheng) Department of Cardiac Surgery, Fuwai Central China Cardiovascular
Hospital, Zhengzhou, China
(Zhao) Department of Cardiovascular Surgery, The Second XiangYa Hospital
of Central South University, Changsha, China
(Han, Xu) Department of Cardiovascular Surgery, Changhai Hospital of
Shanghai, Shanghai, China
(Zhang, Qin) Department of Biostatistics, School of Public Health, Fudan
University, Shanghai, China
(Zhang) Department of Cardiovascular Surgery, The First Affiliated
Hospital of Anhui Medical University, Hefei, China
(Yang) Department of Cardiovascular Surgery, The Affiliated Hospital of
Qingdao University, Qingdao, China
(Ma) Department of Cardiovascular Surgery, The First Affiliated Hospital
Zhejiang University School of Medicine, Hangzhou, China
(Qiao) Department of Cardiovascular Surgery, The First Affiliated Hospital
of Zhengzhou University, Zhengzhou, China
(Guo) Department of Cardiovascular Surgery, Tianjin Chest Hospital,
Tianjin, China
(Zhu) Department of Cardiovascular Surgery, Shanghai Chest Hospital,
Shanghai, China
(Zhang) Department of Cardiovascular Surgery, Qilu Hospital of Shandong
University, Jinan, China
(Chen) Department of Cardiovascular Surgery, Fujian Medical University
Union Hospital, Fuzhou, China
(Wijns) Lambe Institute for Translational Research, Smart Sensors
Laboratory and CURAM, University of Galway, Galway, Ireland
(Redfors) Department of Population Health Sciences, Weill Cornell
Medicine, New York, NY, United States
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Sandner) Department of Cardiac and Thoracic Aortic Surgery, Medical
University of Vienna, Vienna, Austria
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York, NY, United States
(Tu) Biomedical Instrument Institute, School of Biomedical Engineering,
Shanghai Jiao Tong University, Shanghai, China
Publisher
Elsevier B.V.
Abstract
Background For patients undergoing surgical valve procedures with
concomitant coronary artery disease, current guidelines recommend that
coronary artery bypass grafting (CABG) should be anatomically guided on
the basis of stenosis severity, as assessed by coronary angiography. We
aimed to test whether a physiologically guided strategy using
angiography-derived fractional flow reserve (FFR) could improve clinical
outcomes in this population. Methods FAVOR IV-QVAS is an
investigator-initiated, multicentre, randomised, triple-blind trial done
at 12 tertiary hospitals in China. Eligible patients were aged 18 years or
older and were scheduled for valve surgery, with at least one clinically
significant stenosis in a major coronary artery. Patients were randomly
assigned (1:1) to undergo physiologically guided CABG (for lesions with an
angiography-derived FFR value <=0.80) or anatomically guided CABG (for
lesions with a stenosis diameter >=50% on coronary angiography).
Randomisation was done using a web-based program and stratified by site
with fixed blocks of four. Patients, surgeons, follow-up physicians, and
outcome assessors were masked to treatment allocation. The primary outcome
was a composite of death, myocardial infarction, stroke, unplanned
coronary revascularisation, and new renal failure requiring dialysis
within 30 days after surgery. The key secondary outcome was a composite of
death, myocardial infarction, stroke, unplanned coronary
revascularisation, and hospitalisation for unstable angina or heart
failure at a minimum follow-up of 1 year. The primary analysis of the
primary and key secondary outcomes was done in a modified
intention-to-treat population that included all randomly assigned patients
who underwent surgery and had available data for the primary outcome.
Missing data for the primary outcome were planned to be analysed using
complete-case analysis or multiple imputation, with a proportion of
missing data of 2% as the threshold. This trial is registered at
ClinicalTrials.gov (NCT03977129); extended follow-up is ongoing. Findings
Between Aug 4, 2019, and Aug 13, 2024, 793 patients were enrolled. 396
were randomly assigned to the angiography-derived FFR group and 397 to the
coronary angiography group; one patient in the coronary angiography group
declined surgery and was excluded from the modified intention-to-treat
population. The median age was 65 years (IQR 59-70), 221 (28%) patients
were female, and 571 (72%) were male. Concomitant CABG was done in 223
(56%) patients in the angiography-derived FFR group and in 388 (98%)
patients in the coronary angiography group. The primary outcome occurred
in 31 (7.8%) patients in the angiography-derived FFR group and 53 (13.4%)
in the coronary angiography group (absolute difference -5.6 percentage
points [95% CI -9.9 to -1.3]; risk ratio 0.58 [95% CI 0.38 to 0.89];
p=0.011). Death within 30 days occurred in 11 (2.8%) patients in the
angiography-derived FFR group and 17 (4.3%) patients in the coronary
angiography group. At a median follow-up of 27 months (28 months [IQR
18-44] in the angiography-derived FFR group and 27 months [18-42] in the
coronary angiography group), the key secondary outcome occurred in 82
(20.7%) patients in the angiography-derived FFR group and in 106 (26.8%)
patients in the coronary angiography group (hazard ratio 0.74 [95% CI
0.55-0.98]; p=0.036). Interpretation Among patients undergoing valve
surgery with concomitant coronary artery disease, physiologically guided
CABG using angiography-derived FFR reduced the incidence of the composite
perioperative outcome compared with anatomically guided CABG. These
findings support a selective approach to surgical coronary
revascularisation guided by physiological assessment in patients
undergoing valve procedures. Funding Shanghai Hospital Development Center,
Shanghai Municipal Science and Technology Commission, and Ministry of
Science and Technology of the People's Republic of
China. Copyright © 2026 Elsevier Ltd.

<108>
Accession Number
2043907468
Title
Efficacy and safety of transcatheter aortic valve replacement for the
treatment of pure severe native aortic valve regurgitation: a single-arm
meta-analysis.
Source
Frontiers in Medicine. 13 (no pagination), 2026. Article Number: 1735206.
Date of Publication: 2026.
Author
Zhu F.; Zhai G.; He S.; Liu Z.; He Z.
Institution
(Zhu, Zhai, He, Liu, He) Department of Cardiology, Beijing Luhe Hospital,
Capital Medical University, Beijing, China
Publisher
Frontiers Media SA
Abstract
Objective: Numerous studies have reported the efficacy and safety of
transcatheter aortic valve replacement (TAVR) for pure severe native
aortic valve regurgitation (psNAVR) in recent years; however, these
studies show considerable variability in outcomes such as success rate and
mortality. Therefore, this meta-analysis was conducted to evaluate the
efficacy and safety of TAVR in patients with psNAVR based on the latest
research evidence. Method(s): Relevant studies were searched in four
databases-PubMed, Embase, Web of Science, and the Cochrane Library-up to
August 27, 2025. The primary outcomes were device success, all-cause
mortality, and cardiovascular mortality during the perioperative period.
Secondary outcomes included perioperative and 1-year post-operative
adverse events, such as stroke, acute kidney injury (AKI), new-onset
myocardial infarction, major vascular complications, major bleeding
events, readmission due to heart failure (HF), and new permanent pacemaker
(PPM) implantation. Statistical analyses were performed using Stata 14.0
software. Result(s): A total of 29 articles involving 2,773 patients
with psNAVR undergoing TAVR were included in the meta-analysis. The device
success rate was 87.5% [95% confidence interval (CI): 83.3%-91.2%].
Perioperative all-cause mortality was 3.1% (95% CI: 1.6%-5.1%), and
perioperative cardiovascular mortality was 1.4% (95% CI: 0.2%-3.5%).
During the perioperative period, the incidence of adverse events was as
follows: stroke, 0.7%; AKI, 4.5%; new-onset myocardial infarction, 0.0%;
major vascular complications, 3.3%; major bleeding events, 4.4%; and new
PPM implantation, 11.4%. At 1 year, the incidence rates were 9.3% for
all-cause mortality, 4.3% for cardiovascular mortality, 2.6% for stroke,
9.1% for AKI, 0.0% for new-onset myocardial infarction, 1.6% for major
bleeding events, 19.0% for readmission due to HF, and 10.0% for new PPM
implantation. Subgroup analysis indicated that geographic location,
surgical risk, valve type, and procedural approach influenced the
incidence of post-operative adverse events. Conclusion(s): TAVR is a
valuable therapeutic option for patients with psNAVR at high surgical
risk. However, geographic location, surgical risk, valve type, and
procedural approach appear to influence the incidence of adverse events
after TAVR. Copyright © 2026 Zhu, Zhai, He, Liu and He.

<109>
Accession Number
2044221491
Title
Ketamine as a Neuroprotective Intervention to Prevent Early Post-CABG
Delirium: A Triple-Blind Randomized Clinical Trial.
Source
Journal of Cellular and Molecular Anesthesia. 11(1) (no pagination), 2026.
Article Number: e168850. Date of Publication: 01 Mar 2026.
Author
Aligholizadeh M.; Kiaei M.M.; Dolatabadi M.R.M.; Moshki A.; Rajabzadeh R.;
Ghorbanlo M.; Sangi S.
Institution
(Aligholizadeh, Sangi) Department of Anesthesia and Operating Room,
Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Kiaei, Moshki, Ghorbanlo) Department of Anesthesiology and Pain Medicine,
Hasheminejad Kidney Center, School of Medicine, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Dolatabadi) Department of Anesthesiology and Pain Management, Health
Management Research Institute, School of Medicine and Hospital Management,
Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Rajabzadeh) Department of Community Medicine, School of Medicine,
Sabzevar University of Medical Sciences, Sabzevar, Iran, Islamic Republic
of
Publisher
Brieflands
Abstract
Background: Postoperative delirium frequently occurs after coronary artery
bypass graft (CABG) surgery, negatively impacting patient recovery and
outcomes. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist
with analgesic and anti-inflammatory effects, is considered a potential
strategy for delirium prevention. Objective(s): This study examines
the efficacy of intravenous ketamine administered during anesthesia
induction in reducing postoperativee delirium among CABG patients.
 Method(s): A triple-blind, randomized, placebo-controlled clinical
trial was performed on 92 patients scheduled for elective CABG surgery.
Participants were randomly allocated to receive either ketamine (0.5
mg/kg, n = 46) or an equivalent placebo dose at anesthesia induction (n =
46). Delirium was assessed at 24 and 48 hours postoperatively using the
Intensive Care Delirium Screening Checklist (ICDSC), covering the peak
period of delirium incidence after CABG. Due to clinical workflow and
resource constraints, long-term follow-up beyond 48 hours was not
conducted. Statistical analyses included chi-square tests and t-tests,
conducted using SPSS version 19, with a two-sided significance level of
0.05. Result(s): Baseline demographic and surgical characteristics
were similar between groups. Delirium incidence at 24 hours was
significantly lower in the ketamine group (2.2%) compared to the control
group (17.4%) (P = 0.045). At 48 hours, the rates were 4.4% in the
ketamine group versus 26.1% in controls (P = 0.038). These preliminary
findings suggest a possible association between ketamine and reduced early
delirium, though small event numbers and short follow-up limit definitive
conclusions. Conclusion(s): Ketamine was associated with a lower
incidence of early postoperative delirium; however, the small number of
delirium events limits the strength of this conclusion. Larger trials with
extended follow-up and comprehensive safety monitoring are essential
before clinical implementation. Copyright © 2026, Aligholizadeh
et al.

<110>
Accession Number
2044195579
Title
Comprehensive Options for Pediatric Donation After Circulatory Death
Donors.
Source
Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery
Annual. (no pagination), 2026. Date of Publication: 2026.
Author
Kucera J.A.; Wolf S.E.M.; Skalla L.; Turek J.W.; Overbey D.M.
Institution
(Kucera, Wolf, Turek, Overbey) Congenital Heart Surgery Research and
Training Laboratory, Duke University, Durham, North Carolina, United
States
(Skalla) Duke University Medical Center Library & Archives, Duke
University School of Medicine, Duke University, Durham, North Carolina,
United States
(Turek, Overbey) Duke Children's Pediatric and Congenital Heart Center,
Durham, North Carolina, United States
Publisher
W.B. Saunders
Abstract
Cardiac transplant represents the only definitive strategy for children
with end-stage heart failure. Pediatric patients face significant
wait-list times and resultant mortality due to a worsening shortage of
hearts available for transplant. Donation after circulatory death (DCD)
represents an opportunity to increase the number of hearts available to
pediatric recipients by 30%. DCD donation has been historically limited in
application due to logistical challenges and ethical concerns. A
systematic review was carried out using the Cochrane Handbook. Eligible
studies were identified using MEDLINE (via OVID), Embase (Elsevier),
Cochrane Library/Cochrane Central Register of Controlled Trials (CENTRAL;
Wiley), and Web of Science Core Collection (Clarivate). This search was
conducted by a professional medical librarian in consultation with the
author team and validated against a set of pre-selected articles. This
resulted in 438 articles, which were screened based on title and abstract
by 2 independent authors. Full-text review was subsequently performed,
resulting in 21 articles. Agreement for inclusion included pediatric DCD,
published in English, and complete manuscript availability. Four principal
techniques were identified for pediatric DCD: rapid procurement and static
cold storage, organ care systems, normothermic regional perfusion, and
on-table reanimation. These all portend unique advantages and
disadvantages and have largely evolved due to limitations of prior
techniques. Providing a comprehensive approach to pediatric cardiac DCD is
the most effective method to ensure organ stewardship, minimize wait list
mortality, and mitigate ethical concerns associated with pediatric
DCD. Copyright © 2025

<111>
Accession Number
650559227
Title
Perioperative Antibiotic Prophylaxis in Paediatric Cardiac Surgery - Is
One Day Sufficient to Prevent Surgical Site Infections?.
Source
Clinical Pharmacology in Drug Development. Conference: American College of
Clinical Pharmacology Annual Meeting, CPDD 2024. Bethesda, MD United
States. 13(Supplement 1) (pp 53-54), 2024. Date of Publication: 01 Sep
2024.
Author
Zuern C.; Paul L.; Beckschulte K.; Hoehn R.; Kroll J.; Grieshaber P.;
Loukanov T.; Stiller B.; Gorenflo M.; Ziesenitz V.
Institution
(Zuern, Beckschulte, Hoehn, Kroll, Stiller) Freiburg Univ Hosp,
Baden-Wurttemberg, Germany
(Paul, Grieshaber, Loukanov, Gorenflo) Heidelberg Univ Hosp,
Baden-Wurttemberg, Germany
(Ziesenitz) Ctr for Child and Adolescent Health, Heidelberg,
Baden-Wurttemberg, Germany
Publisher
John Wiley and Sons Inc
Abstract
Statement of Purpose, Innovation or Hypothesis: Perioperative antibiotic
prophylaxis (PAbP) is a standard practice in paediatric cardiac surgery to
prevent surgical site infections (SSI). Current prophylactic regimens in
Germany include cefuroxime (secondgeneration cephalosporin). The duration
of its administration is debated, due to the lack of randomised controlled
trials. The target of antibiotic stewardship is to effectively treat
infections, prevent antibiotic resistance and to protect patients from
unnecessary harm. This study aims at comparing the efficacy of PAbP with
cefuroxime during one vs five days perioperatively in children undergoing
congenital heart surgery. Description of Methods and Materials: This
retrospective, bi-centre study included patients <18 yrs of age undergoing
congenital cardiac surgery with cardiopulmonary bypass (CBP) and primary
chest closure (Figure present) from 2015 to 2019. Patients with
preoperative antibiotic treatment or signs of infection and cases of prior
surgeries with CBP during the same admission were excluded. PAbP consisted
of cefuroxime, which was administered according to two different regimens
based on local guidelines: one day (centre 1) vs five days (centre 2).
Patients were stratified according to age and procedural risk (STAT
score). The endpoints were the duration of invasive ventilation and the
duration of postoperative hospitalisation. Data and Results: A total
number of 305 patients could be included in this analysis so far.
Bodyweight (mean 14, 0 vs 16, 7 kg, p = 0.074) and STAT score (median 2 vs
2, p = 0.14) were similar, but the patients were older in centre 2 (median
1, 3 vs 2, 5 yrs, p = 0.04) and mechanical ventilation was longer in
center 1 (mean 1, 8 vs 1, 7 days, p <0, 01). Mean duration of cefuroxime
administration was 3, 1 days in centre 1 and 6, 3 days in centre 2 (p
<0.01). These results show that the shorter use of cefuroxime is
non-inferior and does not cause a significant difference in the duration
of postoperative hospitalisation (median 10 vs 10 days, p = 0.1414).
Interpretation, Conclusion or Significance: According to this
retrospective bi-centre study, a one-day PAbP regimen is sufficient to
prevent SSI around congenital cardiac surgical procedures. Prospective
data should be obtained in a multicentre study to confirm these results.

<112>
Accession Number
650545322
Title
Surgical Versus Transcatheter Aortic Valve Replacement in Patients Aged
>60Years With Bicuspid Valve Stenosis: A Time-to-Event Data Meta-Analysis.
Source
Journal of the American Heart Association. (pp e046556D), 2026. Date of
Publication: 10 Mar 2026.
Author
Moscarelli M.; Lancellotti P.; Athanasiou T.; Casula R.; Pernice V.;
Zaccone G.; Nguyen Trung M.-L.; Giannini F.; Speziale G.; Gaudino M.;
Fattouch K.
Institution
(Moscarelli, Pernice, Zaccone) Department of Cardiovascular Surgery Maria
Eleonora Hospital, GVM Care and Research Palermo Italy, Italy
(Moscarelli, Athanasiou) Imperial College, Department of Surgery and
Cancer-Faculty of Medicine London UK
(Lancellotti, Nguyen Trung) University of Liege Hospital, Cardiovascular
Sciences and Metabolism, Department of Cardiology CHU Sart Tilman Liege
Belgium, Belgium
(Athanasiou, Casula) Department of Cardiothoracic Surgery, Hammersmith
Hospital Imperial College Healthcare NHS Trust London UK
(Giannini) Division of Cardiology IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan Italy, Italy
(Speziale) Department of Cardiovascular Surgery Santa Maria Hospital, GVM
Care and Research Bari Italy, Italy
(Gaudino) Department of Cardiothoracic Surgery Weill Cornell Medicine New
York NY USA
(Fattouch) Kore University of Medicine Enna Italy, Italy
Abstract
BACKGROUND: The role of transcatheter aortic valve implantation (TAVI) in
bicuspid aortic valve stenosis requires further evaluation, particularly
as its use has become comparable to surgical aortic valve replacement. We
sought to compare midterm outcomes of TAVI and surgical aortic valve
replacement in patients with bicuspid aortic valve stenosis.
 METHOD(S): Systematic searches of MEDLINE, EMBASE, and Cochrane
Central Register of Controlled Trials identified studies reporting TAVI
and surgical aortic valve replacement outcomes in patients aged >=60 years
with bicuspid aortic valve stenosis. The primary analysis included only
comparative studies with interpretable Kaplan-Meier curves. Individual
patient data were reconstructed for time-to-event analysis. Sensitivity
analyses incorporated noncomparative single-arm studies. Baseline
differences and heterogeneity were addressed using landmark analysis,
time-varying hazard ratios (HRs), frailty Cox models, and
covariate-adjusted restricted mean survival time. The primary outcome was
death with or without unplanned rehospitalization and stroke.
 RESULT(S): Five comparative, risk-adjusted studies (TAVI, 5901;
surgical aortic valve replacement, 12 427) were included. At 48-month
follow-up, TAVI was associated with a higher hazard for adverse events
(HR, 1.62 [95% CI, 1.46-1.79]; P<0.0001 for the composite end point of
death, stroke, or rehospitalization at 48 months); landmark analysis
showed an initial benefit with TAVI, followed by a reversal at 6 months
that was maintained beyond 12 months (12-48 months; P<0.0001).
Time-varying HRs confirmed this trend. Sensitivity analyses, including
frailty Cox models on the full cohort and restricted mean survival time
analysis, supported the robustness of the findings. CONCLUSION(S):
This meta-analysis found limited midterm benefits (ie, 48 months) of TAVI
in bicuspid aortic valve stenosis. These findings should be interpreted
considering patient selection, as younger patients with bicuspid aortic
valve stenosis are increasingly referred for TAVI.

<113>
Accession Number
2044196532
Title
Effects of Transradial Catheterisation on Radial Artery Bypass Graft
Patency: A Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. (no pagination), 2026. Date of Publication:
2026.
Author
Wang Y.; Sharma V.; Vu T.; Marasco S.F.
Institution
(Wang) School of Translational Medicine, Monash University, Melbourne,
VIC, Australia
(Wang, Marasco) Department of Surgery, Monash University, Melbourne, VIC,
Australia
(Sharma) Department of Cardiac Surgery, Austin Health, Heidelberg, VIC,
Australia
(Vu, Marasco) Department of Cardiothoracic Surgery and Transplantation,
The Alfred, Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Background: Transradial catheterisation is the default approach of
coronary angiography, and the radial artery (RA) is a popular conduit
choice for coronary artery bypass grafting (CABG). Whether a previously
catheterised RA (CRA) remains an optimal bypass conduit for CABG is
uncertain. This systematic review and meta-analysis sought to evaluate the
previous CRA bypass graft patency. Method(s): A systematic search is
conducted in MEDLINE, Embase, and Scopus for comparative studies of CRA
versus non-CRA (NCRA) grafts. The primary outcome of this study was RA
graft patency. Random-effects models generated pooled effect sizes with
heterogeneity assessed by I2; small-study effects were examined
with funnel plot/Egger's test, and influence analyses were performed in
the meta-analysis. Result(s): Of the 1,661 studies screened, four
observational studies of 400 patients (175 CRA and 379 NCRA grafts) were
included in the analysis. Across the included studies, the mean time from
catheterisation to CABG was 27.4+/-16.0 days; the mean follow-up imaging
was conducted at 2.06+/-1.88 years. CRA graft patency was lower than NCRA
(73.2% vs 83.9%), and the pooled odds of graft failure were higher with
CRA (odds ratio 1.82; 95% confidence interval 1.26-2.61; p=0.001;
I2=33%). There were no significant small-study biases detected
on planned assessments. Conclusion(s): Prior transradial
catheterisation is associated with reduced patency of RA bypass grafts.
Surgeons should exercise caution when selecting CRA for critical targets,
and prospective controlled data are needed to define patient and
procedural modifiers of risk. Copyright © 2025

<114>
Accession Number
2043729147
Title
Shexiang Baoxin pill in patients with stable coronary artery disease and
reduced eGFR: Subgroup analysis of phase IV randomized trial.
Source
Phytomedicine. 154 (no pagination), 2026. Article Number: 157946. Date of
Publication: 01 May 2026.
Author
Zhou J.; Chen Y.; Shi H.; Jin Y.; Li X.; Wu J.; Pan C.; Qian J.; Wu Y.;
Wang X.; Wang Y.; Lu F.; Ge J.
Institution
(Zhou, Ge) Department of Cardiology, Zhongshan Hospital, Fudan University,
Shanghai, China
(Chen) Shanghai Innovative Engineering Technology Research Center for
Traditional Chinese Medicine Solid Preparations, Shanghai, China
(Shi) Department of Cardiology, Huashan Hospital, Fudan University,
Shanghai, China
(Jin) Department of Cardiology, The Fourth Affiliated Hospital of China
Medical University, Shenyang, China
(Li) Department of Cardiology, Jiangsu Province Hospital, Nanjing, China
(Wu) Department of Cardiology, The Affiliated Hospital of Jiangxi
University of Chinese Medicine, Nanchang, China
(Pan) Department of Cardiology, The First Affiliated Hospital of Guangxi
University of Chinese Medicine, Nanning, China
(Qian) Department of Cardiology, Maanshan General Hospital of Ranger-duree
Healthcare, Maanshan, China
(Wu) Department of Cardiology, Dongfang Hospital, Beijing University of
Chinese Medicine, Beijing, China
(Wang) Department of Cardiology, Shuguang Hospital, Shanghai University of
Traditional Chinese Medicine, Shanghai, China
(Wang) Department of Cardiology, Xiamen Cardiovascular Hospital, Xiamen
University, Xiamen, China
(Lu) Department of Cardiology, The Affiliated Hospital of Shandong
University of Traditional Chinese Medicine, Jinan, China
Publisher
Elsevier GmbH
Abstract
Background : Shexiang Baoxin pill (MUSKARDIA) is a well-known traditional
Chinese medicine that has demonstrated protective effects in coronary
artery disease (CAD). Purpose : To evaluate MUSKARDIA in patients with
stable CAD and reduced estimated glomerular filtration rate (eGFR). Study
Design : This was a subgroup analysis of the multicenter, double-blind,
placebo-controlled phase IV randomized clinical trial (MUST,
ChiCTR-TRC-12,003,513). The MUST trial randomly assigned patients with
stable CAD to MUSKARDIA or placebo group in a 1:1 ratio. The primary
composite efficacy endpoint was the incidence of major adverse
cardiovascular events. The secondary composite efficacy endpoint included
all-cause mortality, non-fatal MI, non-fatal stroke, hospitalization for
unstable angina or heart failure, and coronary revascularization. Methods
This subgroup analysis included patients with reduced baseline eGFR (< 90
ml/min/1.73m2). Results : Among the 1354 participants with reduced
baseline eGFR, there were numerical advantages with MUSKARDIA in improving
the primary (hazard ratio=0.713; 95% CI: 0.379-1.342; p = 0.292) and
secondary (hazard ratio=0.840; 95% CI: 0.608-1.161; p = 0.290) composite
efficacy endpoints. Multivariable adjustment confirmed these benefits. The
primary composite efficacy endpoint showed a trend toward a protective
effect of MUSKARDIA after 12 months. MUSKARDIA significantly improved the
secondary composite efficacy endpoint after 14 months. The profiles of
adverse events were comparable between groups. There were no clinically
meaningful differences in liver and kidney function indicators. Conclusion
Long-term MUSKARDIA shows a protective trend against cardiovascular events
in patients with stable CAD and reduced eGFR, and may be a consideration
for clinical management. Copyright © 2026. Published by Elsevier
GmbH.

<115>
Accession Number
650537462
Title
Intravenous lidocaine reduces systemic inflammation but not myocardial
injury following thoracic surgery for lung cancer: a randomized controlled
trial.
Source
BMC anesthesiology. (no pagination), 2026. Date of Publication: 07 Mar
2026.
Author
Zhang N.; Feng D.; Wu W.; Liu M.; Wu J.; Liu J.; Shi H.
Institution
(Zhang, Feng, Wu, Liu, Wu, Shi) Department of Anesthesiology, Shanghai
Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
(Liu) Department of Anesthesiology, Shanghai Pulmonary Hospital, School of
Medicine, Tongji University, Shanghai, China

<116>
Accession Number
2044193233
Title
A comparative study of the effect of slow and rapid initiation of
cardiopulmonary pump on tissue oxygenation index and ischemic
complications.
Source
Journal of Extra-Corporeal Technology. 58(1) (pp 73-78), 2026. Date of
Publication: 01 Mar 2026.
Author
Bagherinasab M.; Rezaei S.; Moradi A.R.; Jabbari A.; Noori A.; Archer Z.;
Darban N.H.
Institution
(Bagherinasab) Baqiyatallah University of Medical Sciences, Tehran, Iran,
Islamic Republic of
(Rezaei) Student Research Committee, Faculty of Nursing, Tehran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
(Moradi, Noori) Student Research Committee, Faculty of Nursing,
Baqiyatallah University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Jabbari) Golestan University of Medical Science, Gorgan, Iran, Islamic
Republic of
(Archer, Darban) College of Health Sciences, Cardiovascular Science
Program, Glendale, AZ, United States
Publisher
EDP Sciences
Abstract
Introduction: Although the use of the heart-lung machine (HLM) is routine
in cardiac operating theaters, there is still a lack of evidence-based
guidelines concerning the optimal speed to reach full flow during
initiation to reduce critical episodes of cerebral ischemia. Therefore, we
have designed a study to compare two distinct initiation times for the
commencement of cardiopulmonary bypass (CPB). Method(s): We conducted
a randomized, monocentric, double-blind, prospective study to assess the
impact of two different CPB initiation speeds - rapid initiation at 30 s
and slow initiation at 180 s - on cerebral tissue oxygenation (TOI via
NIRS), arterial oxygen pressure, hematocrit (HCT) variation, and the
incidence of postoperative delirium. The target flow rate was set at 2.4
L/min/m2, with adjustments made according to the patient's body
surface area. Result(s): The absolute values of the tissue
oxygenation index (TOI) and HCT showed no differences between the study
during the first 180 s following commencement of CPB. Patients in the fast
group exhibited significantly lower arterial oxygen pressure at the
initiation of the (P < 0.05). Additionally, patients in the fast group
experienced a higher incidence of delirium in the second and third days
following surgery. While clinically relevant, the elevated incidence of
delirium fell short of being statistically significant, with
post-operative days 2 and 3 having P-values of 0.06 and 0.08,
respectively. Conclusion(s): The results of this study indicate that,
despite the absence of a significant difference in TOI between the study
groups, patients in the slow group exhibited a not statistically
significant trend for a lower incidence of delirium, as defined by
CAMICU-7, in comparison to those in the fast group. Copyright ©
The Author(s), published by EDP Sciences, 2026.

<117>
Accession Number
2043903004
Title
Design and rationale of the COMPARE-TAVI 2 trial: An all-comers
head-to-head comparison of Evolut FX+ and Sapien 3 Ultra Resilia
transcatheter heart valves.
Source
American Heart Journal. 297 (no pagination), 2026. Article Number: 107387.
Date of Publication: 01 Jul 2026.
Author
Thim T.; Nissen H.; Niemela M.; Eftekhari A.; Jalanko M.; Savontaus M.;
Jaaskelainen P.; Hensey M.; Jensen R.V.; Norgaard B.L.; Frederiksen C.A.;
Vase H.O.; Pedersen L.; Sorensen H.T.; Christiansen E.H.; Terkelsen C.J.
Institution
(Thim, Jensen, Norgaard, Frederiksen, Vase, Christiansen, Terkelsen)
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
(Thim, Norgaard, Frederiksen, Christiansen, Terkelsen) Department of
Clinical Medicine, Aarhus University, Aarhus, Denmark
(Nissen) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Niemela) Department of Cardiology, Oulu University Hospital, Oulu,
Finland
(Niemela) Research Unit of Biomedicine and Internal Medicine, Medical
Research Center Oulu, University of Oulu, Oulu, Finland
(Eftekhari) Department of Cardiology, Aalborg University Hospital,
Aalborg, Denmark
(Jalanko) Department of Cardiology, Helsinki University Hospital,
Helsinki, Finland
(Savontaus) Heart Center, Turku University Hospital, Turku, Finland
(Jaaskelainen) Heart Center, Kuopio University Hospital, Kuopio, Finland
(Hensey) Department of Cardiology, St James's Hospital, Dublin, Ireland
(Pedersen) Department of Clinical Epidemiology, Aarhus University Hospital
and Aarhus University, Aarhus, Denmark
(Sorensen) Department of Clinical Epidemiology, Center for Population
Medicine, Aarhus University Hospital and Aarhus University, Aarhus,
Denmark
Publisher
Elsevier Inc.
Abstract
Introduction The COMPARE-TAVI trial framework was launched for direct
comparison of transcatheter aortic valve implantation (TAVI) valves. The
COMPARE-TAVI 1 trial, comparing Myval/Myval Octacor versus Sapien 3/Sapien
3 Ultra transcatheter heart valves (THVs), was recently published. Here,
we present the design and rationale for the COMPARE-TAVI 2 trial comparing
the Evolut FX+ self-expandable THV with the Sapien 3 Ultra Resilia
balloon-expandable THV. Methods and analysis In the COMPARE-TAVI 2 trial
(ClinicalTrials.gov NCT06470022), patients will be randomized 1:1 between
the THVs. The trial will test whether the Evolut FX+ self-expandable THV
is noninferior to the Sapien 3 Ultra Resilia balloon-expandable THV in
terms of the combined 1-year primary composite endpoint of all-cause
mortality, stroke, moderate/severe total aortic regurgitation, or
moderate/severe hemodynamic THV deterioration, according to VARC-3
criteria. If noninferiority is proven, superiority analyses may apply.
Based on a power of 80%, alpha level of 0.05, 1-sided test, noninferiority
margin of 4.5%, and expected event rate of 12%, the necessary sample size
has been estimated to be 1,364 patients. Prespecified secondary endpoints,
including long-term follow-up for 10 years, will also be investigated.
Summary The COMPARE-TAVI 2 will provide important information on the
short- and long-term outcomes among patients treated with the Evolut FX+
self-expandable and the Sapien 3 Ultra Resilia balloon-expandable
THVs. Copyright © 2026 The Author(s).

<118>
Accession Number
650540922
Title
Safety and efficacy outcomes of LAAO in patients with prior ICH or
cerebral amyloid angiopathy: A meta-analysis.
Source
European Journal of Neurology. Conference: 11th Congress of the European
Academy of Neurology. Helsinki Finland. 32(Supplement 1) (no pagination),
2025. Date of Publication: 01 Jun 2025.
Author
Mavridis T.; Archontakis-Barakakis P.; Chlorogiannis D.; Charidimou A.
Institution
(Mavridis) Department of Neurology, Tallaght University Hospital (TUH),
Dublin, Ireland
(Archontakis-Barakakis) Redington-Fairview General Hospital, Skowhegan,
ME, United States
(Chlorogiannis) Department of Radiology, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA, United States
(Charidimou) Department of Neurology, Boston University Medical Center,
Boston University School of Medicine, MA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background and aims: Patients under oral anticoagulation for atrial
fibrillation (AF) with a history of intracerebral hemorrhage (ICH) or
cerebral amyloid angiopathy (CAA), have and increased risk of recurrent
ICH. In those high-bleeding risk patients, left atrial appendage occlusion
(LAAO) provided a promising alternative. Limited data from observational
studies have shown that LAAO is safe and feasible with antiplatelet
therapy or short-term OAC post-procedure. This meta-analysis aimed to
provide data regarding the safety and efficacy of LAAO in patients with
prior ICH or CAA. Method(s): PubMed/MEDLINE and EMBASE were s
ystematically reviewed for randomized control trials, observational
studies, and case series reporting stroke (ischemic and hemorrhagic)
events in patients with AF undergoing LAAO who had a history of previous
ICH and/or CAA. Pooled incidence rates (IRs) with corresponding 95%
confidence intervals (CIs) were calculated for primary (post-procedural
stroke and recurrent ICH) and secondary outcomes. Result(s): Fourteen
studies were included in the final analysis including 1,235. The pooled
IRs for recurrent ICH, ischemic stroke, and all-cause mortality were 0.02%
(95%CI: 0.004%-0.03%), 0.02% (95%CI: 0.01%-0.03%), and 0.04% (95%CI:
0.01%-0.08%), respectively (Figures 1-3). Subgroup analyses of patients
with intraparenchymal hemorrhage and/or CAA reported pooled IRs of 0.04%
(95% CI: 0.004-0.1%) for recurrent ICH, 0.04% (95% CI: 0.01-0.08%) for
ischemic stroke, and 0.09% (95% CI: 0.01-0.22%) for all-cause mortality
(Figures 1-3). Conclusion(s): For selected AF patients with a history
of ICH and/ or CAA, LAAO is considered safe and effective, exhibiting low
rates of major cerebrovascular events.

<119>
Accession Number
2044212703
Title
Risk Factor Analysis of Post-TEVAR Distal Aortic Expansion: A Systematic
Review and Meta-Analysis.
Source
Journal of Endovascular Therapy. (no pagination), 2026. Date of
Publication: 2026.
Author
Cui D.; Li X.; Chen Y.; Zhang X.; Huang J.; Bi J.; Dai X.
Institution
(Cui, Li, Zhang, Bi, Dai) Department of Vascular Surgery, Tianjin Medical
University General Hospital, Tianjin, China
(Cui, Li, Chen, Zhang, Bi, Dai) Tianjin Key Laboratory of Precise Vascular
Reconstruction and Organ Function Repair, Tianjin, China
(Chen) Department of Vascular Surgery, The First Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Huang) Dazhangzhuang Town Community Health Service Center, Tianjin, China
Publisher
SAGE Publications Inc.
Abstract
Background: Distal aortic expansion (DAE) after thoracic endovascular
aortic repair (TEVAR) remains a critical long-term outcome-related
determinant. The aim of this study was to identify risk factors for
postoperative DAE through a meta-analysis and meta-regression.
 Method(s): In this systematic review and meta-analysis, the PubMed,
Embase, and the Cochrane Library databases were searched from database
inception to April 1, 2025. The primary outcome was the incidence of
distal aortic expansion (DAE) after TEVAR. Pooled effect estimates were
calculated using random-effects models, and heterogeneity was assessed
with Cochran's Q test and the I2 statistic. Meta-regression was
performed to explore potential predictors of DAE. Publication bias was
evaluated using Egger's test and funnel plots. Result(s): Twenty-four
studies were included, with a pooled DAE incidence of 27% (95% CI:
21%-35%). Meta-regression indicated that male sex (RR = 3.00, p=0.020),
myocardial infarction (RR = 5.98, p<0.001), peripheral vascular disease
(RR = 3.39, p=0.007), malperfusion (RR = 1.52, p=0.050), and postoperative
false lumen expansion (RR = 1.18, p=0.046) were associated with increased
DAE risk. Older age, prior cardiac surgery, congestive heart failure,
residual dissection, and post-false lumen (FL) complete thrombosis
(distal) were protective factors. Conclusion(s): DAE after TEVAR is
determined by a combination of patient comorbidities and aortic remodeling
features. Identifying high-risk profiles-such as male sex, cardiovascular
comorbidities, and persistent false lumen-may help optimize surveillance
and reduce late aortic complications. Clinical Impact: Distal aortic
expansion (DAE) remains a major determinant of late failure after TEVAR
for type B aortic dissection. This study provides a comprehensive
quantitative synthesis of clinical and remodeling-related predictors of
DAE, highlighting high-risk profiles such as male sex, hypertension, prior
myocardial infarction, peripheral vascular disease, and persistent false
lumen patency. By integrating demographic, comorbidity, and morphological
factors, the findings support a risk-adapted surveillance strategy rather
than uniform follow-up protocols. Importantly, the study underscores the
prognostic significance of false lumen dynamics, reinforcing the role of
adjunctive techniques aimed at promoting distal thrombosis. These insights
may facilitate individualized monitoring, earlier intervention, and
improved long-term durability after TEVAR. Copyright © The
Author(s) 2026

<120>
Accession Number
650546826
Title
Rupture and dissection of aortic autograft following the ross procedure: a
systematic review.
Source
Journal of cardiothoracic surgery. (no pagination), 2026. Date of
Publication: 09 Mar 2026.
Author
Ramkaran R.; Briscoe J.; Cameron D.E.; Wang H.
Institution
(Ramkaran) Johns Hopkins University, Baltimore, MD, United States
(Briscoe, Cameron, Wang) Division of Cardiac Surgery, Department of
Surgery, Johns Hopkins School of Medicine, Baltimore, MD, United States

<121>
Accession Number
2043841774
Title
Noninferiority of Ultrasound-Guided Modified Intercostal Block to
Traditional Approach for Analgesia After Minimally Invasive Repair of
Pectus Excavatum in Children: A Randomized Trial.
Source
Pain Research and Management. 2026(1) (no pagination), 2026. Article
Number: 2183328. Date of Publication: 2026.
Author
Yang M.-W.; Duan X.-L.; Cai Y.-Z.; Xia Y.; Sun Y.-Y.; Cheng X.-Q.
Institution
(Yang, Cheng) Department of Anesthesiology, First Affiliated Hospital of
Anhui Medical University, 218 Jixi Road, Anhui, Hefei, China
(Yang, Cai, Xia, Sun) Department of Anesthesiology, Anhui Provincial
Children's Hospital, 39 Wangjiang East Road, Anhui, Hefei, China
(Duan) Department of Pediatric Thoracic Surgery, Anhui Provincial
Children's Hospital, 39 Wangjiang East Road, Anhui, Hefei, China
Publisher
John Wiley and Sons Ltd
Abstract
Background: For pediatric pectus excavatum, the standard treatment is
minimally invasive repair of pectus excavatum (MIRPE). A major challenge,
however, is the severe postoperative pain. Although ultrasound-guided
intercostal nerve block (UINB) offers effective analgesia, the technique's
complexity and associated safety concerns are significant barriers,
deterring its routine use. Modified intercostal nerve block (MINB) is
effective in adult thoracic surgery but unvalidated in pediatric MIRPE.
 Objective(s): To evaluate MINB's noninferiority to UINB for
postoperative analgesia and safety in children undergoing MIRPE.
 Design(s): Single-center randomized noninferiority trial.
 Method(s): Seventy-six ASA I-II pediatric patients (8-18 years)
scheduled for single-bar MIRPE were 1:1 randomized to the MINB or UINB
group. Primary outcome includes 24-h postoperative coughing visual analog
scale (VAS) score (noninferiority margin DELTA = 1.0). Secondary outcomes
include resting/coughing VAS scores at 3, 6, 9, 12, 24, and 48 h
postoperatively; procedure duration; local anesthetic dose; needle
complications; opioid consumption; rescue analgesia; and adverse events.
 Result(s): The mean difference in 24-h coughing VAS (MINB-UINB) score
was -0.02 (95% CI: -0.85 to 0.80), confirming noninferiority of MINB
(upper 95% CI limit 0.80 < noninferiority margin DELTA = 1.0). MINB
reduced procedure time by 65% (4.6 +/- 1.3 vs. 13.2 +/- 1.6 min; p <
0.001), decreased ropivacaine dose by 19% (50.0 +/- 0.0 vs. 61.9 +/- 4.6
mg; p < 0.001), shortened anesthesia duration (119.6 +/- 18.3 vs. 131.8
+/- 14.6 min; p = 0.002), and eliminated vascular injuries (0% vs. 16.2%;
p = 0.025). All other outcomes demonstrated no statistically significant
differences in the comparisons between the groups (p > 0.05).
 Conclusion(s): For children undergoing single-bar MIRPE, MINB
provides noninferior analgesia to UINB with critical advantages: 65%
faster placement, 19% lower ropivacaine dose, reduced anesthesia duration,
and elimination of vascular injuries. These findings suggest that MINB
offers a valuable alternative to UINB for post-MIRPE analgesia, as it
appears to provide a more favorable balance between safety and efficiency.
Trail Registration: Chinese Clinical Trial Registry:
ChiCTR2200057961. Copyright © 2026 ming-Wen Yang et al. Pain
Research and Management published by John Wiley & Sons Ltd.

<122>
Accession Number
2044251282
Title
Beneficial Effects of Canagliflozin in Heart Failure Associated With
Cardiac and Surgical Procedures.
Source
Reviews in Cardiovascular Medicine. 27(2) (no pagination), 2026. Article
Number: 46719. Date of Publication: 01 Feb 2026.
Author
Dong Y.; Zhou F.; Chi L.; Mu J.
Institution
(Dong) Capital Medical University, Beijing, China
(Zhou) Department of Ultrasound, The Third Medical Center of PLA General
Hospital, Beijing, China
(Chi, Mu) Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital
Medical University, Beijing Institute of Heart Lung and Blood Vessel
Diseases, Beijing, China
(Mu) Departemnt of Cardiac Surgery, The Third Affiliated Hospital of
Xinxiang Medical University, Henan, Xinxiang, China
Publisher
IMR Press Limited
Abstract
Heart failure is a significant complication following cardiac surgery.
While sodium-glucose co-transporter-2 (SGLT2) inhibitors show established
benefits in chronic heart failure, their specific role in the
perioperative setting remains poorly defined. This review aims to
consolidate the current evidence on the beneficial effects and underlying
mechanisms of canagliflozin in managing heart failure associated with
cardiac surgery. A narrative review of relevant preclinical animal studies
and clinical trials was conducted to integrate and summarize the existing
data. The evidence demonstrates that canagliflozin confers cardiovascular
protection through multifaceted mechanisms, including improved metabolic
regulation, favorable hemodynamic effects, and potent anti-inflammatory
and anti-fibrotic actions. These mechanisms are highly relevant to
mitigating key pathophysiological insults in the perioperative period.
While current clinical data are limited to observational studies, they
suggest promising benefits for canagliflozin in reducing postoperative
cardiovascular complications. Canagliflozin shows considerable potential
as a therapeutic agent for patients with heart failure related to cardiac
surgery. However, definitive evidence from large-scale, multicenter
randomized controlled trials is warranted to confirm its efficacy and
safety, and to optimize perioperative management strategies. Copyright
© 2026 The Author(s).

EPICORE Embase Updates

Saturday, March 28, 2026

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Followers

Blog Archive

About Me